<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>(Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus - Semlitsch, T - 2020 | Cochrane Library</title> <meta content="(Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus - Semlitsch, T - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005613.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="(Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus - Semlitsch, T - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005613.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD005613.pub4" name="dc.identifier" scheme="DOI"/> <meta content="(Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus" name="citation_title"/> <meta content="Thomas Semlitsch" name="citation_author"/> <meta content="Medical University of Graz" name="citation_author_institution"/> <meta content="thomas.semlitsch@medunigraz.at" name="citation_author_email"/> <meta content="Jennifer Engler" name="citation_author"/> <meta content="Goethe University" name="citation_author_institution"/> <meta content="Andrea Siebenhofer" name="citation_author"/> <meta content="Graz, Austria / Institute of General Practice, Goethe University" name="citation_author_institution"/> <meta content="Klaus Jeitler" name="citation_author"/> <meta content="Medical University of Graz" name="citation_author_institution"/> <meta content="Andrea Berghold" name="citation_author"/> <meta content="Medical University of Graz" name="citation_author_institution"/> <meta content="Karl Horvath" name="citation_author"/> <meta content="Medical University of Graz" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD005613.pub4" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/11/09" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005613.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005613.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005613.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Bias; Diabetes Mellitus, Type 2 [blood, complications, *drug therapy]; Hemoglobin A [metabolism]; Hypoglycemia [chemically induced]; Hypoglycemic Agents [adverse effects, *therapeutic use]; Insulin Detemir [adverse effects, *therapeutic use]; Insulin Glargine [adverse effects, *therapeutic use]; Insulin, Isophane [adverse effects, *therapeutic use]; Insulin, Long-Acting [adverse effects, *therapeutic use]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005613.pub4&amp;doi=10.1002/14651858.CD005613.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005613.pub4&amp;doi=10.1002/14651858.CD005613.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005613.pub4&amp;doi=10.1002/14651858.CD005613.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005613.pub4&amp;doi=10.1002/14651858.CD005613.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005613.pub4&amp;doi=10.1002/14651858.CD005613.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005613.pub4&amp;doi=10.1002/14651858.CD005613.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005613.pub4&amp;doi=10.1002/14651858.CD005613.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005613.pub4&amp;doi=10.1002/14651858.CD005613.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005613.pub4&amp;doi=10.1002/14651858.CD005613.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005613.pub4&amp;doi=10.1002/14651858.CD005613.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005613.pub4&amp;doi=10.1002/14651858.CD005613.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005613.pub4&amp;doi=10.1002/14651858.CD005613.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005613.pub4&amp;doi=10.1002/14651858.CD005613.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005613.pub4&amp;doi=10.1002/14651858.CD005613.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005613.pub4&amp;doi=10.1002/14651858.CD005613.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005613.pub4&amp;doi=10.1002/14651858.CD005613.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005613.pub4&amp;doi=10.1002/14651858.CD005613.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005613.pub4&amp;doi=10.1002/14651858.CD005613.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005613.pub4&amp;doi=10.1002/14651858.CD005613.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005613.pub4&amp;doi=10.1002/14651858.CD005613.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005613.pub4&amp;doi=10.1002/14651858.CD005613.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005613.pub4&amp;doi=10.1002/14651858.CD005613.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005613.pub4&amp;doi=10.1002/14651858.CD005613.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="eLIOL3Be";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD005613\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD005613\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005613\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005613\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","th","ms","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD005613.pub4",title:"(Ultra\\u2010)long\\u2010acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus",firstPublishedDate:"Nov 9, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Metabolic and Endocrine Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=eLIOL3Be&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005613.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005613.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD005613.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD005613.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005613.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD005613.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD005613.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD005613.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD005613.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD005613.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>9053 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD005613.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005613.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005613.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005613.pub4/full#CD005613-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005613.pub4/full#CD005613-sec-0127"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005613.pub4/full#CD005613-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005613.pub4/full#CD005613-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005613.pub4/full#CD005613-sec-0015"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005613.pub4/full#CD005613-sec-0016"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005613.pub4/full#CD005613-sec-0053"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005613.pub4/full#CD005613-sec-0121"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005613.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005613.pub4/appendices#CD005613-sec-0132"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005613.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005613.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/table_n/CD005613StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/table_n/CD005613StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005613.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005613.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005613.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005613.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005613.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD005613.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">(Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005613.pub4/information#CD005613-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Thomas Semlitsch</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005613.pub4/information#CD005613-cr-0005">Jennifer Engler</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005613.pub4/information#CD005613-cr-0006">Andrea Siebenhofer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005613.pub4/information#CD005613-cr-0007">Klaus Jeitler</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005613.pub4/information#CD005613-cr-0008">Andrea Berghold</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005613.pub4/information#CD005613-cr-0009">Karl Horvath</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/information/en#CD005613-sec-0165">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 09 November 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD005613.pub4">https://doi.org/10.1002/14651858.CD005613.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD005613-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005613-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD005613-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD005613-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005613-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005613-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD005613-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD005613-abs-0005">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD005613-abs-0001" lang="en"> <section id="CD005613-sec-0001"> <h3 class="title" id="CD005613-sec-0001">Background</h3> <p>Evidence that antihyperglycaemic therapy is beneficial for people with type 2 diabetes mellitus is conflicting. While the United Kingdom Prospective Diabetes Study (UKPDS) found tighter glycaemic control to be positive, other studies, such as the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, found the effects of an intensive therapy to lower blood glucose to near normal levels to be more harmful than beneficial. Study results also showed different effects for different antihyperglycaemic drugs, regardless of the achieved blood glucose levels. In consequence, firm conclusions on the effect of interventions on patient‐relevant outcomes cannot be drawn from the effect of these interventions on blood glucose concentration alone. In theory, the use of newer insulin analogues may result in fewer macrovascular and microvascular events. </p> </section> <section id="CD005613-sec-0002"> <h3 class="title" id="CD005613-sec-0002">Objectives</h3> <p>To compare the effects of long‐term treatment with (ultra‐)long‐acting insulin analogues (insulin glargine U100 and U300, insulin detemir and insulin degludec) with NPH (neutral protamine Hagedorn) insulin (human isophane insulin) in adults with type 2 diabetes mellitus. </p> </section> <section id="CD005613-sec-0003"> <h3 class="title" id="CD005613-sec-0003">Search methods</h3> <p>For this Cochrane Review update, we searched CENTRAL, MEDLINE, Embase, ICTRP Search Portal and ClinicalTrials.gov. The date of the last search was 5 November 2019, except Embase which was last searched 26 January 2017. We applied no language restrictions. </p> </section> <section id="CD005613-sec-0004"> <h3 class="title" id="CD005613-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) comparing the effects of treatment with (ultra‐)long‐acting insulin analogues to NPH in adults with type 2 diabetes mellitus. </p> </section> <section id="CD005613-sec-0005"> <h3 class="title" id="CD005613-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected trials, assessed risk of bias, extracted data and evaluated the overall certainty of the evidence using GRADE. Trials were pooled using random‐effects meta‐analyses. </p> </section> <section id="CD005613-sec-0006"> <h3 class="title" id="CD005613-sec-0006">Main results</h3> <p>We identified 24 RCTs. Of these, 16 trials compared insulin glargine to NPH insulin and eight trials compared insulin detemir to NPH insulin. In these trials, 3419 people with type 2 diabetes mellitus were randomised to insulin glargine and 1321 people to insulin detemir. The duration of the included trials ranged from 24 weeks to five years. For studies, comparing insulin glargine to NPH insulin, target values ranged from 4.0 mmol/L to 7.8 mmol/L (72 mg/dL to 140 mg/dL) for fasting blood glucose (FBG), from 4.4 mmol/L to 6.6 mmol/L (80 mg/dL to 120 mg/dL) for nocturnal blood glucose and less than 10 mmol/L (180 mg/dL) for postprandial blood glucose, when applicable. Blood glucose and glycosylated haemoglobin A1c (HbA1c) target values for studies comparing insulin detemir to NPH insulin ranged from 4.0 mmol/L to 7.0 mmol/L (72 mg/dL to 126 mg/dL) for FBG, less than 6.7 mmol/L (120 mg/dL) to less than 10 mmol/L (180 mg/dL) for postprandial blood glucose, 4.0 mmol/L to 7.0 mmol/L (72 mg/dL to 126 mg/dL) for nocturnal blood glucose and 5.8% to less than 6.4% HbA1c, when applicable. </p> <p>All trials had an unclear or high risk of bias for several risk of bias domains.</p> <p>Overall, insulin glargine and insulin detemir resulted in fewer participants experiencing hypoglycaemia when compared with NPH insulin. Changes in HbA1c were comparable for long‐acting insulin analogues and NPH insulin. </p> <p>Insulin glargine compared to NPH insulin had a risk ratio (RR) for severe hypoglycaemia of 0.68 (95% confidence interval (CI) 0.46 to 1.01; P = 0.06; absolute risk reduction (ARR) –1.2%, 95% CI –2.0 to 0; 14 trials, 6164 participants; very low‐certainty evidence). The RR for serious hypoglycaemia was 0.75 (95% CI 0.52 to 1.09; P = 0.13; ARR –0.7%, 95% CI –1.3 to 0.2; 10 trials, 4685 participants; low‐certainty evidence). Treatment with insulin glargine reduced the incidence of confirmed hypoglycaemia and confirmed nocturnal hypoglycaemia. </p> <p>Treatment with insulin detemir compared to NPH insulin found an RR for severe hypoglycaemia of 0.45 (95% CI 0.17 to 1.20; P = 0.11; ARR –0.9%, 95% CI –1.4 to 0.4; 5 trials, 1804 participants; very low‐certainty evidence). The Peto odds ratio for serious hypoglycaemia was 0.16, 95% CI 0.04 to 0.61; P = 0.007; ARR –0.9%, 95% CI –1.1 to –0.4; 5 trials, 1777 participants; low‐certainty evidence). Treatment with detemir also reduced the incidence of confirmed hypoglycaemia and confirmed nocturnal hypoglycaemia. </p> <p>Information on patient‐relevant outcomes such as death from any cause, diabetes‐related complications, health‐related quality of life and socioeconomic effects was insufficient or lacking in almost all included trials. For those outcomes for which some data were available, there were no meaningful differences between treatment with glargine or detemir and treatment with NPH. There was no clear difference between insulin‐analogues and NPH insulin in terms of weight gain. </p> <p>The incidence of adverse events was comparable for people treated with glargine or detemir, and people treated with NPH. </p> <p>We found no trials comparing ultra‐long‐acting insulin glargine U300 or insulin degludec with NPH insulin. </p> </section> <section id="CD005613-sec-0007"> <h3 class="title" id="CD005613-sec-0007">Authors' conclusions</h3> <p>While the effects on HbA1c were comparable, treatment with insulin glargine and insulin detemir resulted in fewer participants experiencing hypoglycaemia when compared with NPH insulin. Treatment with insulin detemir also reduced the incidence of serious hypoglycaemia. However, serious hypoglycaemic events were rare and the absolute risk reducing effect was low. Approximately one in 100 people treated with insulin detemir instead of NPH insulin benefited. </p> <p>In the studies, low blood glucose and HbA1c targets, corresponding to near normal or even non‐diabetic blood glucose levels, were set. Therefore, results from the studies are only applicable to people in whom such low blood glucose concentrations are targeted. However, current guidelines recommend less‐intensive blood glucose lowering for most people with type 2 diabetes in daily practice (e.g. people with cardiovascular diseases, a long history of type 2 diabetes, who are susceptible to hypoglycaemia or older people). Additionally, low‐certainty evidence and trial designs that did not conform with current clinical practice meant it remains unclear if the same effects will be observed in daily clinical practice. Most trials did not report patient‐relevant outcomes. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD005613-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005613-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD005613-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD005613-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005613-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005613-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD005613-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/th#CD005613-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD005613-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD005613-abs-0002" lang="en"> <h3>(Ultra‐)long‐acting insulin analogues compared with NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus </h3> <p><b>Introduction</b> </p> <p>Type 2 diabetes mellitus is a progressive condition, meaning that ever more antihyperglycaemic medications are needed to achieve recommended glycosylated haemoglobin A1c (HbA1c) levels with increasing disease duration. The HbA1c test measures blood glucose levels over two to three months. Eventually, many people will require insulin treatment. Insulin treatment is frequently performed by administering human basal insulins once or twice daily. Basal insulins are long‐acting insulins with delayed onset of action covering the basic insulin needs of the body. Fast‐acting insulins are used to cover meals. The most common side effects of insulin treatment are low blood sugar (hypoglycaemia) and weight gain. Newer synthetic insulins, so‐called (ultra‐)long‐acting insulin‐analogues, have been developed with the intention of minimising side effects and allowing better blood glucose control. </p> <p><b>Review question</b> </p> <p>We wanted to compare the effects of treatment with (ultra‐)long‐acting insulin analogues with NPH (neutral protamine Hagedorn) insulin (human isophane insulin). </p> <p><b>Search date</b> </p> <p>The evidence is current to 5 November 2019.</p> <p><b>Background</b> </p> <p>It is unclear if or to what extent (ultra‐)long‐acting insulin analogues show more benefit or less harm compared to NPH insulin. </p> <p><b>Study characteristics</b> </p> <p>All 24 included studies were randomised controlled trials (clinical studies in which people are randomly assigned to one of two or more treatment groups). Sixteen studies compared the long‐acting insulin glargine to NPH insulin and eight studies compared the long‐acting insulin detemir to NPH insulin. In these studies, 3419 people with type 2 diabetes mellitus were randomised to insulin glargine and 1321 people to insulin detemir. The duration of the studies ranged from 24 weeks to 5 years. </p> <p><b>Key results</b> </p> <p>The different insulins reduced HbA1c by about the same amount.</p> <p>Treatment with insulin glargine or insulin detemir instead of NPH insulin resulted in fewer people with hypoglycaemia. Treatment with insulin detemir reduced the risk of serious hypoglycaemia. However, serious hypoglycaemia occurred only rarely in the studies, in fewer than one in 100 people treated with insulin detemir and in about one in 100 people treated with NPH insulin. Approximately one in 100 people treated with insulin detemir instead of NPH insulin benefited. </p> <p>Information on diabetes‐related complications (such as heart disease, renal disease, damage to the retina of the eyes and amputations), death from any cause and health‐related quality of life was scarce. When available, study results did not suggest clear differences between insulin analogues and NPH insulin. </p> <p>There was no clear difference between insulin analogues and NPH insulin for side effects or weight gain. </p> <p>None of the included studies reported on socioeconomic effects (such as costs of the intervention, absence from work, medication consumption). </p> <p><b>Certainty of the evidence</b> </p> <p>In the studies, very low blood glucose and HbA1c target values were set. However, doctors often recommend higher targets for people with a long history of type 2 diabetes, who have had a heart attack or stroke, or who are old. With higher target values, hypoglycaemia occurs less frequently and more people need to be treated with insulin analogues instead of NPH insulin to prevent hypoglycaemia in one person. Therefore, study results are only applicable to people who are treated to such low blood glucose target values. </p> <p>In many studies, an adequate adjustment of NPH insulin was not possible. However, doctors will do that in daily practice. Therefore, a further decrease in the benefit of insulin analogues is expected. </p> <p>Treatment in all but one study lasted for 12 months or less. However, diabetes‐related complications usually only develop over many years. Thus, most studies were unable to answer the important question whether treatment with different insulin preparations has different effects on diabetes‐related complications. This means that potentially important differences between insulin analogues and NPH insulin were not detected. </p> <p>All studies had problems in the way they were conducted.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD005613-sec-0127" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD005613-sec-0127"></div> <h3 class="title" id="CD005613-sec-0128">Implications for practice</h3> <section id="CD005613-sec-0128"> <p>In people with type 2 diabetes mellitus, treatment with insulin detemir reduced the incidence of serious hypoglycaemia, and treatment with insulin glargine or detemir reduced the incidence of confirmed hypoglycaemic and confirmed nocturnal hypoglycaemic events, as compared with NPH insulin, with no substantial difference in glycosylated haemoglobin A1c (HbA1c) lowering. However, serious hypoglycaemic events were rare and the absolute risk reducing effect was low. Approximately one in 100 people treated with insulin detemir instead of NPH insulin benefited. </p> <p>In all studies, low blood glucose and HbA1c targets, corresponding to near normal or even non‐diabetic blood glucose levels, were set. Therefore, results from the studies at hand are only applicable to people in whom such low blood glucose concentrations are targeted. However, current guidelines recommend less intensive blood glucose lowering for the majority of people with type 2 diabetes in daily practice (e.g. people with cardiovascular diseases, with a long history of type 2 diabetes, who are susceptible to hypoglycaemia or elderly people). Additionally, low‐certainty evidence and trial designs that did not conform with current clinical practice meant it remains unclear if the same effects will be observed in daily clinical practice. </p> <p>We found no clear effects of glargine or detemir compared with NPH on diabetes‐related complications. </p> <p>Data on health‐related quality of life and socioeconomic effects were limited or not available. </p> </section> <h3 class="title" id="CD005613-sec-0129">Implications for research</h3> <section id="CD005613-sec-0129"> <p>For most patient‐important outcomes it remains to be clarified if there is a clinically relevant difference between treatment with insulin glargine or detemir and NPH insulin in people with type 2 diabetes mellitus. Furthermore, data are required on socioeconomic effects, as well as from low‐ and middle‐income countries as they were under‐represented in the available trials. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD005613-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD005613-sec-0008"></div> <div class="table" id="CD005613-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Insulin glargine versus NPH insulin for type 2 diabetes mellitus</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Insulin glargine vs NPH insulin for type 2 diabetes mellitus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient:</b> participants with type 2 diabetes mellitus </p> <p><b>Intervention:</b> insulin glargine </p> <p><b>Comparison:</b> NPH insulin (human isophane insulin) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk for NPH insulin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk for insulin glargine</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diabetes‐related complications</b> </p> <p>(1) Fatal MI</p> <p>(2) Fatal stroke</p> <p>(3) Progression in retinopathy</p> <p>(4) Amputations</p> <p>(5) ESRD</p> <p>Follow‐up: 6 months to 36 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>(1) See comment</p> <p>(2) See comment</p> <p><b>(3) 101 per 1000</b> </p> <p>(4) See comment</p> <p>(5) See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>(1) See comment</p> <p>(2) See comment</p> <p><b>(3) 104 per 1000</b> (60 to 178) </p> <p>(4) See comment</p> <p>(5) See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) + (2) See comment</p> <p>(3) <b>RR 1.03</b> </p> <p>(0.60 to 1.77)</p> <p>(4) + (5) See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) 934 (4 RCTs)</p> <p>(2) 934 (4 RCTs)</p> <p>(3) 1947 (5 RCTs)</p> <p>(4) 34 (1 RCT)</p> <p>(5) 34 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) + (2)</p> <p>⊕⊝⊝⊝<br/><b>Very low<sup>a</sup> </b> </p> <p>(3) ⊕⊝⊝⊝<br/><b>Very</b> <b>low<sup>b</sup> </b> </p> <p>(4) + (5) ⊕⊝⊝⊝<br/><b>Very low<sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) 1 trial reported 3/352 participants in the glargine 100 IU group vs 0/349 participants in the NPH group experienced fatal MI; 3 additional trials with 233 participants reported that no fatal MI occurred. </p> <p>(2) No fatal strokes occurred.</p> <p>(3) The 95% prediction interval ranged between 0.22 and 4.83.</p> <p>(4) + (5) 1 trial reported that no amputation or ESRD occurred.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypoglycaemic episodes</b><br/>(1) Severe hypoglycaemia </p> <p>(2) Serious hypoglycaemia</p> <p>(3) Confirmed hypoglycaemia (BG &lt; 75 mg/dL)</p> <p>(4) Confirmed hypoglycaemia (BG &lt; 55 mg/dL)</p> <p>(5) Confirmed nocturnal hypoglycaemia (BG &lt; 75 mg/dL)</p> <p>(6) Confirmed nocturnal hypoglycaemia (BG &lt; 55 mg/dL)</p> <p>Follow‐up: 24 weeks to 5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>(1) <b>37 per 1000</b> </p> <p>(2) <b>27 per 1000</b> </p> <p>(3) <b>572 per 1000</b> </p> <p>(4) <b>180 per 1000</b> </p> <p>(5) <b>351 per 1000</b> </p> <p>(6) <b>115 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>(1) <b>25 per 1000</b> (17 to 37) </p> <p>(2) <b>20 per 1000</b> (14 to 29) </p> <p>(3) <b>526 per 1000</b> (486 to 578) </p> <p>(4) <b>159 per 1000</b> (146 to 173) </p> <p>(5) <b>274 per 1000</b> (239 to 312) </p> <p>(6) <b>85 per 1000</b> (74 to 98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) <b>RR 0.68</b> (0.46 to 1.01) </p> <p>(2) <b>RR 0.75</b> (0.52 to 1.09) </p> <p>(3) <b>RR 0.92</b> (0.85 to 1.01) </p> <p>(4) <b>RR 0.88</b> (0.81 to 0.96) </p> <p>(5) <b>RR 0.78</b> (0.68 to 0.89) </p> <p>(6) <b>RR 0.74</b> (0.64 to 0.85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) 6164 (14 RCTs)</p> <p>(2) 4685 (10 RCTs)</p> <p>(3) 4115 (7 RCTs)</p> <p>(4) 4388 (8 RCTs)</p> <p>(5) 4225 (8 RCTs)</p> <p>(6) 4759 (8 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) ⊕⊝⊝⊝<br/><b>Very low<sup>d</sup> </b> </p> <p>(2) ⊕⊕⊝⊝<br/><b>Low<sup>e</sup> </b> </p> <p>(3) ⊕⊝⊝⊝<br/><b>Very low<sup>f</sup> </b> </p> <p>(4) ⊕⊕⊕⊝<br/><b>Moderate<sup>g</sup> </b> </p> <p>(5) ⊕⊝⊝⊝<br/><b>Very low<sup>f</sup> </b> </p> <p>(6) ⊕⊕⊕⊝<br/><b>Moderate<sup>g</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) The 95% prediction interval ranged between 0.33 and 1.40.</p> <p>(2) The 95% prediction interval ranged between 0.48 and 1.16.</p> <p>(3) The 95% prediction interval ranged between 0.69 and 1.22.</p> <p>(4) The 95% prediction interval ranged between 0.79 and 0.98.</p> <p>(5) The 95% prediction interval ranged between 0.53 and 1.14.</p> <p>(6) The 95% prediction interval ranged between 0.62 and 0.88.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQoL</b> </p> <p>Follow‐up: 28 weeks to 48 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1228 (3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>h</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 trials reported no statically significant differences between glargine groups and NPH groups in HRQoL total scores (W‐BQ22; EQ‐5) or any subscales. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 24 weeks to 5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b> (5 to 15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Peto OR 1.06</b> (0.62 to 1.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6173 (14 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>i</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AEs other than hypoglycaemia</b> </p> <p>(1) SAE</p> <p>(2) Overall AE</p> <p>(3) AE leading to discontinuation</p> <p>Follow‐up: 24 weeks to 5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>(1) <b>135 per 1000</b> </p> <p>(2)<b>662 per 1000</b> </p> <p>(3) <b>17 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>(1) <b>132 per 1000</b> (117 to 148) </p> <p>(2) <b>669 per 1000</b> (649 to 682) </p> <p>(3)<b>20 per 1000</b> (14 to 30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) <b>RR 0.98</b> (0.87 to 1.10) </p> <p>(2) <b>RR 1.01</b> (0.98 to 1.03) </p> <p>(3) <b>RR 1.21</b> (0.84 to 1.76) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) 5499 (13 RCTs)</p> <p>(2) 6170 (14 RCTs)</p> <p>(3) 6149 (13 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) + (2) (+3) ⊕⊕⊕⊝<br/><b>Moderate<sup>j</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) The 95% prediction interval ranged between 0.86 and 1.12.</p> <p>(2) The 95% prediction interval ranged between 0.99 and 1.03.</p> <p>(3) The 95% prediction interval ranged between 0.79 and 1.84.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Socioeconomic effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c</b> </p> <p>Follow‐up: 24 weeks to 5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in HbA1c ranged across control groups from –2.12% to +0.1%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in HbA1c in the intervention groups was <b>0.07% lower</b> </p> <p>(0.18% lower to 0.03% higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5809 (16 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>k</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The 95% prediction interval ranged between –46% and 0.32%.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>AE:</b> adverse event; <b>BG:</b> blood glucose; <b>CI:</b> confidence interval; <b>EQ‐5(D):</b> EuroQol 5 (Dimension); <b>ESRD:</b> end‐stage renal disease; <b>HbA1c:</b> glycosylated haemoglobin A1c; <b>HRQoL:</b> health‐related quality of life; <b>MD:</b> mean difference; <b>MI:</b> myocardial infarction; <b>NPH:</b> neutral protamine Hagedorn; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SAE:</b> serious adverse event; <b>W‐BQ22:</b> Well‐Being Questionnaire (22 items). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded three levels because of risk of bias and serious imprecision (very sparse data) – see <a href="./appendices#CD005613-sec-0133">Appendix 1</a>.<br/><sup>b</sup>Downgraded three levels because of risk of bias, inconsistency and imprecision – see <a href="./appendices#CD005613-sec-0133">Appendix 1</a>.<br/><sup>c</sup>Downgraded three levels because of indirectness and serious imprecision (very sparse data) – see <a href="./appendices#CD005613-sec-0133">Appendix 1</a>.<br/><sup>d</sup>Downgraded three levels because of risk of bias, imprecision and inconsistency – see <a href="./appendices#CD005613-sec-0133">Appendix 1</a>.<br/><sup>e</sup>Downgraded two levels because of risk of bias and imprecision – see <a href="./appendices#CD005613-sec-0133">Appendix 1</a>.<br/><sup>f</sup>Downgraded three levels because of risk of bias, inconsistency and imprecision – see <a href="./appendices#CD005613-sec-0133">Appendix 1</a>.<br/><sup>g</sup>Downgraded one level because of risk of bias – see <a href="./appendices#CD005613-sec-0133">Appendix 1</a>.<br/><sup>h</sup>Downgraded three levels because of risk of bias and serious imprecision – see <a href="./appendices#CD005613-sec-0133">Appendix 1</a>.<br/><sup>i</sup>Downgraded two levels because of risk of bias and imprecision – see <a href="./appendices#CD005613-sec-0133">Appendix 1</a>.<br/><sup>j</sup>Downgraded one level because of imprecision – see <a href="./appendices#CD005613-sec-0133">Appendix 1</a>.<br/><sup>k</sup>Downgraded two levels because of inconsistency and imprecision – see <a href="./appendices#CD005613-sec-0133">Appendix 1</a>. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005613-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Insulin detemir versus NPH insulin for type 2 diabetes mellitus</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Insulin detemir vs NPH insulin for type 2 diabetes mellitus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient:</b> participants with type 2 diabetes mellitus </p> <p><b>Intervention:</b> insulin detemir </p> <p><b>Comparison:</b> NPH insulin (human isophane insulin) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk for NPH insulin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk for insulin detemir</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diabetes‐related complications</b> </p> <p>(1) Fatal MI</p> <p>(2) Fatal stroke</p> <p>(3) Progression in retinopathy</p> <p>(4) Amputations</p> <p>(5) ESRD</p> <p>Follow‐up: 24 weeks to 26 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>(1) + (2) See comment</p> <p><b>(3) 25 per 1000</b> </p> <p>(4) + (5) See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>(1) + (2) See comment</p> <p><b>(3) 37 per 1000</b> (17 to 82) </p> <p>(4) + (5) See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) + (2) See comment</p> <p>(3) <b>RR 1.50</b> </p> <p>(0.68 to 3.32)</p> <p>(4) + (5) See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) + (2) 271 (1 RCT)</p> <p>(3) 972 (2 RCTs)</p> <p>(4) + (5) 271 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) + (2) + (3) + (4) + (5) ⊕⊝⊝⊝<br/><b>Very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) + (2) 1 trial reported that no fatal MI or fatal stroke occurred.</p> <p>(3) –</p> <p>(4) + (5) 1 trial reported that no amputation or ESRD occurred.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypoglycaemic episodes</b> </p> <p>(1) Severe hypoglycaemia</p> <p>(2) Serious hypoglycaemia</p> <p>(3) Confirmed hypoglycaemia (BG &lt; 75 mg/dL)</p> <p>(4) Confirmed hypoglycaemia (BG &lt; 55 mg/dL)</p> <p>(5) Confirmed nocturnal hypoglycaemia (BG &lt; 75 mg/dL)</p> <p>(6) Confirmed nocturnal hypoglycaemia (BG &lt; 55 mg/dL)</p> <p>Follow‐up: 24 weeks to 7 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>(1) <b>17 per 1000</b> </p> <p>(2) <b>11 per 1000</b> </p> <p>(3) <b>562 per 1000</b> </p> <p>(4) <b>493 per 1000</b> </p> <p>(5) <b>309 per 1000</b> </p> <p>(6) <b>40 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>(1) <b>8 per 1000</b> (3 to 21) </p> <p>(2) <b>2 per 1000</b> (0 to 7) </p> <p>(3) <b>410 per 1000</b> (343 to 484) </p> <p>(4) <b>237 per 1000</b> (158 to 350) </p> <p>(5) <b>176 per 1000</b> (145 to 210) </p> <p>(6) <b>13 per 1000</b> (6 to 25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) <b>RR 0.45</b> (0.17 to 1.20) </p> <p>(2) <b>Peto OR 0.16</b> (0.04 to 0.61) </p> <p>(3) <b>RR 0.73</b> (0.61 to 0.86) </p> <p>(4) <b>RR 0.48</b> (0.32 to 0.71) </p> <p>(5) <b>RR 0.57</b> (0.47 to 0.68) </p> <p>(6) <b>RR 0.32</b> (0.16 to 0.63) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) 1804 (5 RCTs)</p> <p>(2) 1777 (5 RCTs)</p> <p>(3) 1718 (4 RCTs)</p> <p>(4) 1718 (4 RCTs)</p> <p>(5) 1718 (4 RCTs)</p> <p>(6) 1718 (4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) ⊕⊝⊝⊝<br/><b>Very low<sup>b</sup> </b> </p> <p>(2) ⊕⊕⊝⊝<br/><b>Low<sup>c</sup> </b> </p> <p>(3) ⊕⊕⊝⊝<br/><b>Low<sup>d</sup> </b> </p> <p>(4) + (5) + (6)<br/>⊕⊕⊝⊝<br/><b>Low<sup>e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) The 95% prediction interval ranged between 0.09 and 2.21.</p> <p>(2) –</p> <p>(3) The 95% prediction interval ranged between 0.36 and 1.48.</p> <p>(4) The 95% prediction interval ranged between 0.20 and 1.13.</p> <p>(5) The 95% prediction interval ranged between 0.39 and 0.84.</p> <p>(6) The 95% prediction interval ranged between 0.07 and 1.42.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> <p>Follow‐up: 26 weeks to 36 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>873 (3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 trials reported no statically significant difference between detemir groups and NPH groups in HRQoL total scores (ITR‐QOLN; DHP‐2; SF‐36) or any subscales. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 24 weeks to 48 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> (1 to 13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Peto OR 0.74</b> (0.20 to 2.65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2328 (8 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>L<b>ow<sup>f</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AEs other than hypoglycaemia</b> </p> <p>(1) SAE</p> <p>(2) Overall AE</p> <p>(3) AE leading to discontinuation</p> <p>Follow‐up: 24 weeks to 48 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>(1) <b>71 per 1000</b> </p> <p>(2)<b>611 per 1000</b> </p> <p>(3) <b>18 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>(1) <b>62 per 1000</b> (45 to 85) </p> <p>(2) <b>629 per 1000</b> (586 to 678) </p> <p>(3)<b>22 per 1000</b> (12 to 40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) <b>RR 0.88</b> </p> <p>(0.64 to 1.20)</p> <p>(2) <b>RR 1.03</b> (0.96 to 1.11) </p> <p>(3) <b>RR 1.22</b> (0.67 to 2.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) 2328 (8 RCTs)</p> <p>(2) 2328 (8 RCTs)</p> <p>(3) 2328 (8 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) + (2) (+3)</p> <p>⊕⊝⊝⊝<br/><b>Moderate<sup>g</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) The 95% prediction interval ranged between 0.60 and 1.30.</p> <p>(2) The 95% prediction interval ranged between 0.94 and 1.13.</p> <p>(3) The 95% prediction interval ranged between 0.57 and 2.62.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Socioeconomic effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c</b> </p> <p>Follow‐up:</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in HbA1c ranged across control groups from –1.9% to –0.32%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in HbA1c in the intervention groups was <b>0.13% higher</b> </p> <p>(0.02% lower to 0.28% higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2233 (7 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>h</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The 95% prediction interval ranged between –0.28% and 0.54%.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>AE:</b> adverse event; <b>BG:</b> blood glucose; <b>CI:</b> confidence interval; <b>DHP‐2:</b> Diabetes Health Profile 2; <b>ESRD: e</b> nd‐stage renal disease; <b>HbA1c:</b> glycosylated haemoglobin A1c; <b>HRQoL:</b> health‐related quality of life; <b>ITR‐QOLN:</b> insulin therapy‐related quality of life at night; <b>MD:</b> mean difference; <b>MI:</b> myocardial infarction; <b>NPH:</b> neutral protamine Hagedorn; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio; <b>SAE:</b> serious adverse event; <b>SF‐36:</b> 36‐item Short Form Health Survey. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded three levels because of risk of bias and serious imprecision (very sparse data) – see <a href="./appendices#CD005613-sec-0134">Appendix 2</a>.<br/><sup>b</sup>Downgraded three levels because of risk of bias and serious imprecision – see <a href="./appendices#CD005613-sec-0134">Appendix 2</a>.<br/><sup>c</sup>Downgraded two levels because of risk of bias and imprecision – see <a href="./appendices#CD005613-sec-0134">Appendix 2</a>.<br/><sup>d</sup>Downgraded two levels because of risk of bias and inconsistency – see <a href="./appendices#CD005613-sec-0134">Appendix 2</a>.<br/><sup>e</sup>Downgraded two levels because risk of bias and imprecision – see <a href="./appendices#CD005613-sec-0134">Appendix 2</a>.<br/><sup>f</sup>Downgraded two levels because of serious imprecision – see <a href="./appendices#CD005613-sec-0134">Appendix 2</a>.<br/><sup>g</sup>Downgraded one level because of imprecision – see <a href="./appendices#CD005613-sec-0134">Appendix 2</a>.<br/><sup>h</sup>Downgraded two levels because of inconsistency and imprecision – see <a href="./appendices#CD005613-sec-0134">Appendix 2</a>. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD005613-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD005613-sec-0009"></div> <section id="CD005613-sec-0010"> <h3 class="title" id="CD005613-sec-0010">Description of the condition</h3> <p>Type 2 diabetes mellitus is a metabolic disorder characterised by relative insulin deficiency resulting from a reduced sensitivity of tissues to insulin, impaired insulin secretion by pancreatic β‐cells, or both (<a href="./references#CD005613-bbs2-0068" title="American Diabetes Association. Introduction: standards of medical care in diabetes. Diabetes Care2020;43:S1-212.">ADA 2020</a>). This in turn leads to chronic hyperglycaemia (i.e. elevated levels of plasma glucose) with disturbances in carbohydrate, fat and protein metabolism (<a href="./references#CD005613-bbs2-0068" title="American Diabetes Association. Introduction: standards of medical care in diabetes. Diabetes Care2020;43:S1-212.">ADA 2020</a>). Long‐term complications of diabetes mellitus include retinopathy, nephropathy, neuropathy and increased risk of cardiovascular disease (CVD) (<a href="./references#CD005613-bbs2-0068" title="American Diabetes Association. Introduction: standards of medical care in diabetes. Diabetes Care2020;43:S1-212.">ADA 2020</a>). </p> </section> <section id="CD005613-sec-0011"> <h3 class="title" id="CD005613-sec-0011">Description of the intervention</h3> <p>Type 2 diabetes mellitus is a progressive disease that causes a decline in pancreatic β‐cell function. Thus, at some point during the course of the disease, treatment with oral glucose‐lowering agents or other non‐insulin glucose‐lowering agents may not suffice, and exogenous insulin will be necessary to achieve the desired glucose levels. At this stage, treatment with intermediate or long‐acting insulins is one of the recommended treatment options (<a href="./references#CD005613-bbs2-0068" title="American Diabetes Association. Introduction: standards of medical care in diabetes. Diabetes Care2020;43:S1-212.">ADA 2020</a>). </p> <p>Historically, intermediate‐ and long‐acting insulin preparations were obtained by crystallising either protamine (NPH type) or zinc (Lente type). Treatment with these basal insulins, however, has drawbacks. Achieving lower blood glucose levels carries an increased risk of hypoglycaemia (<a href="./references#CD005613-bbs2-0071" title="AhrénB . Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vascular Health and Risk Management2013;9:155-63. [PMID: 23637538]">Ahrén 2013</a>). As NPH is associated with a pronounced insulin peak following injection and variable absorption (<a href="./references#CD005613-bbs2-0091" title="HeinemannL , LinkeschovaR , RaveK , HompeschB , SedlakM , HeiseT . Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care2000;23(5):644-9. [PMID: 10834424]">Heinemann 2000</a>; <a href="./references#CD005613-bbs2-0111" title="LeporeM , PampanelliS , FanelliC , PorcellatiF , BartocciL , DiVA , et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes2000;49(12):2142-8. [PMID: 11118018]">Lepore 2000</a>), targeting for lower glycosylated haemoglobin A1c (HbA1c) levels is often difficult and leads to a higher incidence of hypoglycaemic events (<a href="./references#CD005613-bbs2-0071" title="AhrénB . Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vascular Health and Risk Management2013;9:155-63. [PMID: 23637538]">Ahrén 2013</a>). </p> <p>To provide insulin with a more suitable physiological time course to people with diabetes mellitus, so‐called insulin analogues have been developed. Insulin analogues are insulin‐like molecules, engineered on the basis of the molecular structure of human insulin by changing the amino acid sequence and physiochemical properties. Four such (ultra‐)long‐acting insulin analogues – insulin detemir (Levemir), insulin glargine U100 (Lantus), insulin degludec (Tresiba) and insulin glargine U300 (Toujeo) – are currently available on the market. </p> <section id="CD005613-sec-0012"> <h4 class="title">Adverse effects of the intervention</h4> <p>Compared to human insulin, some insulin analogues have shown higher mitogenic potency and insulin‐growth factor binding affinity in vitro and animal studies (<a href="./references#CD005613-bbs2-0089" title="GrantMB , MamesRN , FitzgeraldC , EllisEA , AboufriekhaM , GuyJ . Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor. Diabetologia1993;36(4):282-91. [PMID: 7682976]">Grant 1993</a>; <a href="./references#CD005613-bbs2-0104" title="JorgensenLN , DidriksenLH , DrejerK . Cardinogen effect of the human insulin analogue B10 Asp in female rats. Diabetologia1992;35:A3.">Jorgensen 1992</a>; <a href="./references#CD005613-bbs2-0105" title="KingGL , GoodmanAD , BuzneyS , MosesA , KahnCR . Receptors and growth-promoting effects of insulin and insulinlike growth factors on cells from bovine retinal capillaries and aorta. Journal of Clinical Investigation1985;75(3):1028-36.">King 1985</a>; <a href="./references#CD005613-bbs2-0109" title="KurtzhalsP , SchafferL , SorensenA , KristensenC , JonassenI , SchmidC , et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes2000;49(6):999-1005. [PMID: 10866053]">Kurtzhals 2000</a>). These effects differ depending on the insulin analogue, but results provided in these studies are unable to clarify their relevance for people with diabetes mellitus. The American and European pharmaceutical registration bodies, the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have commented on the mitogenic and carcinogenic potency of long‐acting insulin analogues and concluded that there appear to be few detrimental effects (<a href="./references#CD005613-bbs2-0082" title="European Public Assessment Report (EPAR) on Lantus (Insulin Glargine) – Scientific Discussion (2003). www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000284/WC500036075.pdf (accessed 29 August 2017).">EMA 2003</a>; <a href="./references#CD005613-bbs2-0083" title="European Public Assessment Report (EPAR) on Levemir (Insulin Detemir) – Scientific Discussion (2004). www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000528/WC500036658.pdf (accessed 29 August 2017).">EMA 2004</a>; <a href="./references#CD005613-bbs2-0084" title="Committee for Medicinal Products for Human Use (CHMP) assessment report on Tresiba (Insulin degludec) (2012). www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000284/WC500036075.pdf (accessed 29 August 2017).">EMA 2012</a>; <a href="./references#CD005613-bbs2-0085" title="Center for Drug Evaluation and Research (CDER). Application Number 21-081: Lantus (Insulin Glargine) – Pharmacology Review(s) (2000). www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21081_Lantus_pharmr_P1.pdf and www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21081_Lantus_pharmr_P2.pdf (accessed 29 August 2017).">FDA 2000</a>; <a href="./references#CD005613-bbs2-0086" title="Center for Drug Evaluation and Research (CDER). Application Number 21-536: Levemir (Insulin Detemir) – Pharmacology Review(s) (2005). www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021-536_Levemir_pharmr.PDF (accessed 29 August 2017).">FDA 2005</a>). One cohort study based on data from a large German statutory insurance fund found a dose‐dependent increase in cancer risk for treatment with insulin glargine compared with human insulin (<a href="./references#CD005613-bbs2-0092" title="HemkensLG , GrouvenU , BenderR , GunsterC , GutschmidtS , SelkeGW , et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia2009;52(9):1732-44. [PMID: 19565214]">Hemkens 2009</a>). </p> <p>Epidemiological investigations indicate that higher blood glucose concentrations are associated with a higher risk of developing micro‐ and macrovascular diabetic complications (<a href="./references#CD005613-bbs2-0069" title="AdlerAI , BoykoEJ , AhroniJH , StenselV , ForsbergRC , SmithDG . Risk factors for diabetic peripheral sensory neuropathy. Results of the Seattle Prospective Diabetic Foot Study. Diabetes Care1997;20(7):1162-7. [PMID: 9203456]">Adler 1997</a>; <a href="./references#CD005613-bbs2-0107" title="KleinR . Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care1995;18(2):258-68. [PMID: 7729308]">Klein 1995</a>; <a href="./references#CD005613-bbs2-0129" title="TurnerRC , MillnsH , NeilHA , StrattonIM , ManleySE , MatthewsDR , et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)[. BMJ1998;316(7134):823-8. [PMID: 9549452]">Turner 1998</a>). The United Kingdom Prospective Diabetes Study (UKPDS) showed that lowering blood glucose to near normal levels might reduce microvascular complications (<a href="./references#CD005613-bbs2-0098" title="HolmanRR , PaulSK , BethelMA , MatthewsDR , NeilHA . 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine2008;359:1577-89. [PMID: 18784090]">Holman 2008</a>; <a href="./references#CD005613-bbs2-0130" title="UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352:837-53. [PMID: 9742976]">UKPDS‐33 1998</a>; <a href="./references#CD005613-bbs2-0131" title="UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet1998;352(9131):854-65. [PMID: 9742977]">UKPDS 34 1998</a>). However, evidence that the effects of antihyperglycaemic therapy on macrovascular complications and mortality is positive, is conflicting. Several studies investigating the effects of tight versus less tight glycaemic control have not shown a clear reduction in the risk of macrovascular complications (<a href="./references#CD005613-bbs2-0066" title="Action to Control Cardiovascular Risk in Diabetes Study Group, GersteinHC , MillerME , ByingtonRP , Goff DC Jr, BiggerJT , BuseJB , et al. Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine2008;358:2545-59. [PMID: 18539917]">ACCORD 2008</a>; <a href="./references#CD005613-bbs2-0070" title="Advance Collaborative Group, PatelA , MacMahonS , ChalmersJ , NealB , BillotL , WoodwardM , et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine2008;358:2560-72. [PMID: 18539916]">ADVANCE 2008</a>; <a href="./references#CD005613-bbs2-0081" title="DuckworthW , AbrairaC , MoritzT , RedaD , EmanueleN , ReavenPD , et al. Glucose control and vascular complications in veterans with type 2 diabetes. New England Journal of Medicine2009;360:129-39. [PMID: 19092145]">Duckworth 2009</a>; <a href="./references#CD005613-bbs2-0108" title="KooyA , deJagerJ , LehertP , BetsD , WulffeleMG , DonkerAJ , et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Archives of Internal Medicine2009;169:616-25. [PMID: 19307526]">Kooy 2009</a>). Furthermore, investigations into different pharmacological interventions have shown a reduction in the risk of complications without a significant simultaneous change in blood glucose concentrations (<a href="./references#CD005613-bbs2-0116" title="MarsoSP , DanielsGH , Brown-FrandsenK , KristensenP , MannJF , NauckMA , et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine2016;375:311-22. [PMID: 27295427]">Marso 2016</a>; <a href="./references#CD005613-bbs2-0133" title="ZinmanB , WannerC , LachinJM , FitchettD , BluhmkiE , HantelS , et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine2015;373:2117-28. [PMID: 26378978]">Zinman 2015</a>), while others have reported an increase in the risk of mortality and macrovascular complications despite a substantial decrease in blood glucose levels (<a href="./references#CD005613-bbs2-0066" title="Action to Control Cardiovascular Risk in Diabetes Study Group, GersteinHC , MillerME , ByingtonRP , Goff DC Jr, BiggerJT , BuseJB , et al. Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine2008;358:2545-59. [PMID: 18539917]">ACCORD 2008</a>; <a href="./references#CD005613-bbs2-0127" title="SinghS , LokeYK , FurbergCD . Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA2007;298:1189-95. [PMID: 17848653]">Singh 2007</a>). In consequence, firm conclusions on the effect of interventions on patient‐relevant outcomes cannot be drawn from the effect of these interventions on blood glucose concentrations alone. </p> <p>The new long‐ and ultra‐long‐acting insulins are usually more expensive than NPH insulin. While price differences may not be a problem for health services in high‐income countries, they may be important in low‐ and middle‐income countries. </p> </section> </section> <section id="CD005613-sec-0013"> <h3 class="title" id="CD005613-sec-0013">How the intervention might work</h3> <p>Based on the altered time‐action profiles of insulin analogues, several possible advantages in the therapy of people with type 2 diabetes mellitus have been suggested. For instance, it has been hypothesised that the longer action (lower fasting plasma glucose) and the less pronounced peak (less hypoglycaemia, especially during the night) will enable both HbA1c and the risk of hypoglycaemia to be reduced. It has also been suggested that the use of Insulin glargine or detemir may improve patient's health‐related quality of life and treatment satisfaction. </p> </section> <section id="CD005613-sec-0014"> <h3 class="title" id="CD005613-sec-0014">Why it is important to do this review</h3> <p>The aim of the original Cochrane Review was to systematically review the clinical efficacy and safety of insulin glargine and detemir in the treatment of people with type 2 diabetes mellitus. Although their pharmacokinetic profiles appeared to indicate that long‐acting insulin analogues improved the insulin therapy of people with type 2 diabetes mellitus, their superiority in a clinical setting had still to be confirmed. This is an update of the original Cochrane Review which was necessary because new trials on the topic have been published and new ultra‐long‐acting insulin analogues – insulin degludec and insulin glargine U300 – have been launched on the market since publication of the original review. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD005613-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD005613-sec-0015"></div> <p>To compare the effects of long‐term treatment with (ultra‐)long‐acting insulin analogues (insulin glargine U100 and U300, insulin detemir and insulin degludec) with NPH insulin (human isophane insulin) in adults with type 2 diabetes mellitus. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD005613-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD005613-sec-0016"></div> <section id="CD005613-sec-0017"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD005613-sec-0018"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs).</p> <p>Reports for which no full publication existed were only considered for inclusion in this review if the available information met the publication criteria in the CONSORT statement. </p> </section> <section id="CD005613-sec-0019"> <h4 class="title">Types of participants</h4> <p>Adults (aged 18 years and older) with type 2 diabetes mellitus and not pregnant.</p> </section> <section id="CD005613-sec-0020"> <h4 class="title">Types of interventions</h4> <p>We had intended to compare the following interventions with the comparator.</p> <p>Only trials reporting on subcutaneously administered insulin were considered for inclusion in this review. </p> <section id="CD005613-sec-0021"> <h5 class="title">Intervention</h5> <p> <ul id="CD005613-list-0001"> <li> <p>Long‐acting insulin analogues (insulin glargine U100 or insulin detemir) or ultra‐long‐acting insulin analogues (insulin glargine U300 or insulin degludec). </p> </li> </ul> </p> </section> <section id="CD005613-sec-0022"> <h5 class="title">Comparator</h5> <p> <ul id="CD005613-list-0002"> <li> <p>NPH insulin</p> </li> </ul> </p> <p>Interventions in both intervention and comparator groups had to be the same to enable fair comparisons. </p> </section> <section id="CD005613-sec-0023"> <h5 class="title">Minimum duration of intervention</h5> <p>We considered studies with a minimal duration of 24 weeks. In case of a cross‐over design, each of the periods had to last at least 24 weeks. </p> </section> <section id="CD005613-sec-0024"> <h5 class="title">Minimum duration of follow‐up</h5> <p>Minimal duration of follow‐up was 24 weeks. In case of a cross‐over design, duration of follow‐up for each of the periods had to be at least 24 weeks. </p> <p>We defined extended follow‐up periods (also called open‐label extension studies) as the follow‐up of participants once the original trial as specified in the trial protocol had been terminated. However, such studies are frequently of an observational nature and were only evaluated in case of adverse events (<a href="./references#CD005613-bbs2-0076" title="BuchMH , AletahaD , EmeryP , SmolenJS . Reporting of long-term extension studies: lack of consistency calls for consensus. Annals of the Rheumatic Diseases2011;70(6):886-90. [PMID: 21378403]">Buch 2011</a>; <a href="./references#CD005613-bbs2-0119" title="MeganB , PickeringRM , WeatherallM . Design, objectives, execution and reporting of published open-label extension studies. Journal of Evaluation in Clinical Practice2012;18(2):209-15. [PMID: 21040252]">Megan 2012</a>). </p> </section> </section> <section id="CD005613-sec-0025"> <h4 class="title">Types of outcome measures</h4> <p>We did not exclude trials solely based on their outcome measures. In case none of our primary or secondary outcomes were reported, we planned to provide at least some basic information in an additional table. </p> <section id="CD005613-sec-0026"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD005613-list-0003"> <li> <p>Diabetes‐related complications.</p> </li> <li> <p>Hypoglycaemic episodes.</p> </li> <li> <p>Health‐related quality of life.</p> </li> </ul> </p> </section> <section id="CD005613-sec-0027"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD005613-list-0004"> <li> <p>All‐cause mortality.</p> </li> <li> <p>Adverse events other than hypoglycaemia.</p> </li> <li> <p>Socioeconomic effects.</p> </li> <li> <p>HbA1c.</p> </li> </ul> </p> </section> <section id="CD005613-sec-0028"> <h5 class="title">Method of outcome measurement</h5> <p> <ul id="CD005613-list-0005"> <li> <p>Diabetes‐related complications: such as renal failure, amputation, blindness or deterioration in retinopathy, myocardial infarction, stroke, heart failure, revascularisation procedures. </p> </li> <li> <p>Hypoglycaemic episodes: number of severe (as defined in the studies), serious (as defined in the studies), confirmed (as defined in the studies) and confirmed nocturnal hypoglycaemic episodes (as defined in the studies). </p> </li> <li> <p>Health‐related quality of life: evaluated using a validated instrument such as the 36‐item Short Form (SF‐36) or EuroQol 5 Dimension (EQ‐5D). </p> </li> <li> <p>All‐cause mortality: defined as death from any cause and measured at any time after participants had been randomised to intervention or comparator groups. </p> </li> <li> <p>Adverse events other than hypoglycaemia: such as cancer incidence, skin reactions and measured at any time after participants had been randomised to intervention or comparator groups. </p> </li> <li> <p>Socioeconomic effects: such as direct costs defined as admission or readmission rates, mean length of stay, visits to general practitioner, accident/emergency visits; medication consumption; indirect costs defined as resources lost due to illness by the participant or a family member. </p> </li> <li> <p>HbA1c: measured in % or mmol/mol.</p> </li> </ul> </p> </section> <section id="CD005613-sec-0029"> <h5 class="title">Timing of outcome measurement</h5> <p> <ul id="CD005613-list-0006"> <li> <p>Diabetes‐related complications, hypoglycaemic episodes, all‐cause mortality, adverse events other than hypoglycaemia, socioeconomic effects: measured at any time after participants had been randomised to intervention or comparator groups. </p> </li> <li> <p>Health‐related quality of life: measured at the latest time point of measurement during follow‐up. </p> </li> <li> <p>HbA1c: measured as change between baseline and end of follow‐up.</p> </li> </ul> </p> </section> </section> </section> <section id="CD005613-sec-0030"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD005613-sec-0031"> <h4 class="title">Electronic searches</h4> <p>Searches for the previous review version were conducted to 11 December 2006. For this update, we revised the search strategies. </p> <p>We searched the following sources without restrictions on the language of publication:</p> <p> <ul id="CD005613-list-0007"> <li> <p>from 1 September 2006 to 26 January 2017 (for detailed search strategies, see <a href="./appendices#CD005613-sec-0135">Appendix 3</a>): </p> </li> </ul> </p> <p> <ul class="plain" id="CD005613-list-0008"> <li> <ul id="CD005613-list-0009"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO) (searched 26 January 2017); </p> </li> <li> <p>MEDLINE Ovid (Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present) (searched 26 January 2017); </p> </li> <li> <p>Embase Ovid (1974 to 2017 Week 04) (searched 26 January 2017);</p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) (searched 26 January 2017); </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">www.who.int/trialsearch/</a>) (searched 26 January 2017); </p> </li> </ul> </li> </ul> </p> <p> <ul id="CD005613-list-0010"> <li> <p>from 1 January 2017 to 5 November 2019 (for detailed search strategies, see <a href="./appendices#CD005613-sec-0136">Appendix 4</a>): </p> </li> </ul> </p> <p> <ul class="plain" id="CD005613-list-0011"> <li> <ul id="CD005613-list-0012"> <li> <p>CENTRAL via the CRSO (searched 5 November 2019);</p> </li> <li> <p>MEDLINE Ovid (Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present) (searched 5 November 2019); </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) (searched 5 November 2019); </p> </li> <li> <p>WHO ICTRP (<a href="http://apps.who.int/trialsearch/" target="_blank">www.who.int/trialsearch/</a>) (searched 5 November 2019). </p> </li> </ul> </li> </ul> </p> </section> <section id="CD005613-sec-0032"> <h4 class="title">Searching other resources</h4> <p>We tried to identify other potentially eligible trials or ancillary publications by searching the reference lists of included trials, systematic reviews, meta‐analyses and health technology assessment reports. Inquiries were directed to the two main pharmaceutical companies producing long‐acting insulin analogues (Sanofi, Novo Nordisk). In addition, we contacted authors of potentially relevant and included trials to obtain additional information on the retrieved trials and to determine if further trials existed that we might have missed. </p> <p>We also searched the databases of regulatory agencies (EMA and FDA) (<a href="./references#CD005613-bbs2-0090" title="HartB , LundhA , BeroL . Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses. BMJ2012;344:d7202. [DOI: 10.1136/bmj.d7202]">Hart 2012</a>; <a href="./references#CD005613-bbs2-0125" title="SchrollJB , BeroL . Regulatory agencies hold the key to improving Cochrane Reviews of drugs [editorial]. Cochrane Database of Systematic Reviews2015, Issue 4. [DOI: 10.1002/14651858.ED000098] [PMID: 25904511]">Schroll 2015</a>). </p> <p>We considered additional information based on original trial reports published in a report by the German Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (Institute for Quality and Efficiency in Health Care) (<a href="./references#CD005613-bbs2-0102" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009.">IQWiG 2009</a>), which we defined as grey literature. This report was cited as an additional source. In terms of inconsistency between journal publications and the IQWiG report 2009, data from the IQWiG report were used preferentially, since these data were based on original trial reports and therefore deemed more reliable. </p> <p>We did not use abstracts or conference proceedings for data extraction because this information source does not fulfil the <a href="./references#CD005613-bbs2-0077" title="The CONSORT statement. www.consort-statement.org (accessed 29 August 2017).">CONSORT</a> requirements which is "an evidence‐based, minimum set of recommendations for reporting randomized trials" (<a href="./references#CD005613-bbs2-0077" title="The CONSORT statement. www.consort-statement.org (accessed 29 August 2017).">CONSORT</a>; <a href="./references#CD005613-bbs2-0124" title="SchererRW , MeerpohlJJ , PfeiferN , SchmuckerC , SchwarzerG , vonElmE . Full publication of results initially presented in abstracts. Cochrane Database of Systematic Reviews2018, Issue 11. Art. No: MR000005. [DOI: 10.1002/14651858.MR000005.pub4]">Scherer 2018</a>). </p> </section> </section> <section id="CD005613-sec-0033"> <h3 class="title" id="CD005613-sec-0033">Data collection and analysis</h3> <section id="CD005613-sec-0034"> <h4 class="title">Selection of studies</h4> <p>Two review authors (JE and TS or KH) independently scanned the abstract, title or both, of every record we retrieved in the literature searches, to determine which trials we should assess further. We obtained the full text of all potentially relevant records. We resolved any disagreements through consensus or by recourse to a third review author (JE, KH, TS, KJ). If we could not resolve a disagreement, we categorised the trial as a 'study awaiting classification' and contacted the trial authors for clarification. We present an adapted PRISMA flow diagram to show the process of trial selection (<a href="./references#CD005613-bbs2-0113" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic and meta-analyses of studies that evaluate interventions: explanation and elaboration. PLoS Medicine2009;6(7):1-28. [DOI: 10.1371/journal.pmed.1000100]">Liberati 2009</a>). </p> </section> <section id="CD005613-sec-0035"> <h4 class="title">Data extraction and management</h4> <p>For trials that fulfilled our inclusion criteria, two review authors (JE, KH, TS, KJ) independently extracted key participant and intervention characteristics. We reported data on efficacy outcomes and adverse events using standardised data extraction sheets from the Cochrane Metabolic and Endocrine Disorders (CMED) Group. We resolved any disagreements by discussion or, if required, by consultation with a third review author (JE, KH, TS, KJ) (for details, see <a href="./references#CD005613-sec-0172" title="">Characteristics of included studies</a> table; <a href="#CD005613-tbl-0003">Table 1</a>; <a href="./appendices#CD005613-sec-0137">Appendix 5</a>; <a href="./appendices#CD005613-sec-0138">Appendix 6</a>; <a href="./appendices#CD005613-sec-0139">Appendix 7</a>; <a href="./appendices#CD005613-sec-0140">Appendix 8</a>; <a href="./appendices#CD005613-sec-0141">Appendix 9</a>; <a href="./appendices#CD005613-sec-0142">Appendix 10</a>; <a href="./appendices#CD005613-sec-0143">Appendix 11</a>; <a href="./appendices#CD005613-sec-0144">Appendix 12</a>; <a href="./appendices#CD005613-sec-0145">Appendix 13</a>; <a href="./appendices#CD005613-sec-0146">Appendix 14</a>, <a href="./appendices#CD005613-sec-0147">Appendix 15</a>; <a href="./appendices#CD005613-sec-0148">Appendix 16</a>; <a href="./appendices#CD005613-sec-0149">Appendix 17</a>; <a href="./appendices#CD005613-sec-0150">Appendix 18</a>; <a href="./appendices#CD005613-sec-0151">Appendix 19</a>; <a href="./appendices#CD005613-sec-0133">Appendix 1</a>; <a href="./appendices#CD005613-sec-0134">Appendix 2</a>; <a href="./appendices#CD005613-sec-0152">Appendix 20</a>). </p> <div class="table" id="CD005613-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of trial populations</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Trial ID</b> </p> <p><b>(study design)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention(s) and comparator(s)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Description of power and sample size calculation</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Screened/eligible<br/>(n)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Randomised<br/>(n)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>ITT<br/>(n)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Analysed<br/>(n)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Finishing trial<br/>(n)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Randomised finishing trial<br/>(%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Follow‐up<br/>(extended follow‐up)<sup>a</sup> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0001" title="BerardL , CameronB , WooV , StewartJ . Replacing insulin glargine with neutral protamine Hagedorn (NPH) insulin in a subpopulation of study subjects in the action to control cardiovascular risk in diabetes (ACCORD): effects on blood glucose levels, hypoglycemia and patient satisfaction. Canadian Journal of Diabetes2015;39(4):296-301. [PMID: 25819531]BerardLD , WooVC . Safety and efficacy of NPH after switching from insulin glargine in Canadian patients. Diabetologia2011;54:S430. [EMBASE: 70563203]">Berard 2015</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin glargine once‐daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin once daily or twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>66</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0003" title="EliaschewitzFG , CalvoC , ValbuenaH , RuizM , AschnerP , VillenaJ , et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Archives of Medical Research2006;37(4):495-501. [PMID: 16715577]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Eliaschewitz 2006</a> </p> <p>(parallel RCT, equivalence design)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin glargine at bedtime + glimepiride 4 mg/day in the morning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Based on an equivalence region of 0.5% and an SD of 2.0% for the differences in HbA1c between the groups, equivalence can be demonstrated with a statistical power of 80% with 199 participants per group, based on a 1‐sided α = 0.05. A 1:1 randomisation would require 199 evaluable participants in each group. Based on an expectation that 20% of the participants would not be evaluable, the study required the enrolment of 240 in each group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>918/—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy: 218</p> <p>Safety: 231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>24 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin at bedtime + glimepiride 4 mg/day in the morning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy: 244</p> <p>Safety: 250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>528</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>481</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Efficacy: 462</b> </p> <p><b>Safety: 481</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>462</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>87.5</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0004" title="EUCTR2005-000976-42. A multi-centre, open-labelled, randomised, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime (PREDICTIVE-BMI study) – PREDICTIVE-BMI study. www.clinicaltrialsregister.eu/ctr-search/trial/2005-000976-42/ES (first received 17 May 2006). Fajardo MontañanaC , Hernandez HerreroC , Rivas FernandezM . Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabetic Medicine2008;25(8):916-23. [PMID: 18959604]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00504673. Comparison of insulin detemir versus insulin NPH on weight change in overweight and obese with type 2 diabetes (PREDICTIVE). clinicaltrials.gov/ct2/show/NCT00504673 (first received 20 July 2007). Novo Nordisk A/S. A multi-centre, open-labelled, randomized, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime. (PREDICTIVE-BMI study). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1410&amp;filename=1659-ctr-redacted.pdf (last accessed 3 November 2020). Smith-PalmerJ , Fajardo-MontananaC , PollockRF , EricssonA , ValentineWJ . Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. Journal of Medical Economics2012;15(5):977-86. [PMID: 22563742]">Fajardo Montañana 2008</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin detemir at bedtime</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>272 participants (230 evaluable) were required to detect a difference in weight change of 1.5 kg (SD 4.0) between groups after 26 weeks, using a 2‐sided test with a 0.05 significance level. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>345/293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>26 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin at bedtime</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92.1</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>277</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>271</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>271</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>252</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>91.0</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD005613-bbs2-0005" title="FritscheA , SchweitzerMA , HaringHU , Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Annals of Internal Medicine2003;138(12):952-9. [PMID: 12809451]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Fritsche 2003</a> </p> <p>(parallel RCT, non‐inferiority design)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: insulin glargine in the morning + glimepiride 3 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Based on the assumption of an SD of σ = 2.0%, a difference of Δ = 0.5% for HbA1c reductions among treatment groups can be detected with an α‐error of 0.05 and a β‐error of 0.2. This equates to a statistical power of 80% with 199 participants per group. With use of a 1:1:1 randomisation, 597 participants would be required for this study. Assuming a non‐evaluable rate of 20%, 720 participants (240 per group) would need to be enrolled in this study. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>938/752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>24 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: insulin glargine at bedtime + glimepiride 3 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin at bedtime + glimepiride 3 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.6</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>700</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>695</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>695</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>640</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>91.4</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0006" title="HaakT , TiengoA , DraegerE , SuntumM , WaldhauslW . Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2005;7(1):56-64. [PMID: 15642076]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Haak 2005</a> </p> <p>(parallel RCT, non‐inferiority design)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: detemir once daily at bedtime or twice daily in the morning and at bedtime + mealtime insulin aspart </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The study had sufficient power (85%) to detect a mean difference of 0.4% in HbA1c between groups. A 95% 2‐sided CI was constructed for the difference between the group means (insulin detemir NPH insulin); insulin detemir was deemed non‐inferior if the upper limit of the 95% CI was &lt; 0.4% (absolute). Treatments were considered comparable if the non‐inferiority criterion was fulfilled. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—/—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>26 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: detemir once daily at bedtime or twice daily in the morning and at bedtime + mealtime insulin aspart </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.1</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>505</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>505</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>505</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>471</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>93.3</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0007" title="EUCTR2009-010913-59. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on OHA treatment initiating basal insulin therapy with either insulin glargine or NPH insulin added to therapies with oral hypoglycemic agents (HAPPY) (LANTU_L_04079 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2009-010913-59/results (last accessed 3 May 2017). HermannsN , KulzerB , KohlmannT , JacobS , LandgrafW , TheobaldK , et al. Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial. Health and Quality of Life Outcomes2015;13:77. [PMID: 26055391]NCT00941369. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on oral hypoglycemic agent treatment initiating basal insulin therapy with either insulin glargine or NPH insulin. clinicaltrials.gov/ct2/show/NCT00941369 (first received 17 July 2009). ">Hermanns 2015</a> </p> <p>(cross‐over RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin glargine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>In a previous cross‐sectional study, different effect sizes of insulin glargine compared to NPH insulin in terms of SF‐12 (d = 0.10), PAID (d = 0.22), and ITEQ (d = 0.29) scores were observed. The mean effect size of all 3 scales was d = 0.166. Since the present study had a cross‐over design, in which each participant served as his/her own control, an effect size on the primary endpoint DRQoL of d = 0.20 was expected. Such an effect can be detected with 90% power using a paired t‐test with a significance level of 5% and with 265 participants. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>460/—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>343;<br/>sequence A: 176,<br/>sequence B: 167 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>339;</p> <p>sequence A: 175,<br/>sequence B: 164 </p> <p>229<sup>b</sup>; sequence A: 118,<br/>sequence B: 111 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>296;</p> <p>sequence A: 151,<br/>sequence B: 145 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>86.3;</p> <p>sequence A: 85.8,<br/>sequence B: 86.8 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>48 weeks (efficacy)<br/>49 weeks (safety) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH basal insulin</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>343</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>339</b> </p> <p><b>229<sup>b</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>296</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>86.3</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0008" title="DaileyG , StrangeP , RiddleM . Reconsideration of severe hypoglycemic events in the treat-to-target trial. Diabetes Technology &amp; Therapeutics2009;11(8):477-9. [PMID: 19698059]DaviesMJ , DerezinskiT , PedersenCB , ClausonP . Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Diabetes Technology &amp; Therapeutics2008;10(4):273-7. [PMID: 18715200]HermansenK , DaviesM , DerezinskiT , Martinez RavnG , ClausonP , HomeP . Erratum: A 26-week randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people wih type 2 diabetes (Diabetes Care (2006) 29, (1269-1274)). Diabetes Care2007;30(4):1035. [EMBASE: 46556609]HermansenK , DaviesM , DerezinskiT , MartinezRG , ClausonP , HomeP . A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care2006;29(6):1269-74. [PMID: 16732007]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00604396. Safety and efficacy of insulin detemir in combination with OAD in type 2 diabetes. clinicaltrials.gov/ct2/show/results/NCT00604396 (first received 30 January 2008). ">Hermansen 2006</a> </p> <p>(parallel RCT, non‐inferiority design)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: detemir in the morning and evening</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>A non‐inferiority criterion, defined as a &lt; 0.4% difference in HbA1c, was calculated to require 198 completers per arm for 95% power with a 5% significance level and with a maximum baseline‐adjusted SD of 1.1% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>735/490</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>24 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin in the morning and evening</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.1</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>476</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>475</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>475</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>452</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>95.0</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0009" title='EUCTR2007-006640-22. Superiority of insulin glargine Lantus vs NPH: "Treat to normoglycemia concept". Effect of insulin glargine in comparison to insulin NPH in insulin-naïve people with type 2 diabetes mellitus treated with at least one OAD and not adequately controlled (LANCELOT) (LANTU_C_02762 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2007-006640-22/results (last accessed 19 July 2017). HomePD , BolliGB , MathieuC , DeerochanawongC , LandgrafW , CandelasC , et al. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naive people with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2015;17(1):15-22. [PMID: 24957785]NCT00949442. Lantus versus NPH: comparison in insulin naive people not adequately controlled with at least one oral anti diabetics (OAD) treatment (LANCELOT). clinicaltrials.gov/ct2/show/NCT00949442 (first received 30 July 2009). '>Home 2015</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin glargine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>It was estimated that at least 568 evaluable participants (670 were randomised with 15% not assessable) needed to be randomised to detect a difference in change of HbA1c of 0.3% (3.3 mmol/mol) at the 5% significance level with 90% power.This assumes an SD of change of HbA1c of 1.1% (12 mmol/mol) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1102/—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>36 weeks (efficacy)<br/>37 weeks (safety) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>328</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92.9</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>708</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>701</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>701</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>663</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>93.6</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD005613-bbs2-0010" title="HsiaSH . Comparison of single-dose regimens of insulin glargine versus NPH among inner city ethnic minority type 2 diabetic patients uncontrolled on oral agents. Journal of Investigative Medicine2010;58(1):136. [EMBASE: 70981533]HsiaSH . Insulin glargine compared to NPH among insulin-naive, U.S. inner city, ethnic minority type 2 diabetic patients. Diabetes Research &amp; Clinical Practice2011;91(3):293-9. [PMID: 21146881]NCT00686712. Insulin glargine at bedtime or in AM versus NPH. clinicaltrials.gov/ct2/show/NCT00686712 (first received 7 October 2010). ">Hsia 2011</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: insulin glargine at bedtime</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Based on previously published HbA1c levels in oral agent‐treated participants from the study centre, enrolment of 24 in each of the 3 treatment arms (72 total) would provide 95% power to detect an HbA1c difference of 0.8%, at a 5% significance level. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—/108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.7<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>26 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: insulin glargine in the morning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.0<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin at bedtime</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.7<sup>c</sup> </p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>85</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>85</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>85</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>51</b><sup>c</sup> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>60.0</b><sup>c</sup> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0011" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KawamoriR , IwamotoY , KadowakiT , IwasakiM . Efficacy and safety of insulin glargine in concurrent use with oral hypoglycemic agents for the treatment of type 2 diabetes patients. Rinshoiyaku2003;19(5):445-64. ">Kawamori 2003</a> </p> <p>(parallel RCT, non‐inferiority design)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin glargine once in the morning + OAD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—/400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy: 141</p> <p>Safety: 158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>28 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin once in the morning + OAD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy: 134</p> <p>Safety: 159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79.8</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>335</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>317</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Efficacy: 275</b> </p> <p><b>Safety: 317</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>275</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>82.1</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0012" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. IshiiH , IwamotoY , KakuK , KawamoriR , KobayashiM , TajimaN . Night-time QOL and treatment satisfaction in diabetes mellitus patients treated with insulin detemir used in basal-bolus therapy – randomized multicenter open-label parallel group phase 3 trial compared to NPH insulin. Journal of the Japan Diabetes Society2009;52(8):691-701. [DOI: 10.11213/tonyobyo.52.691]KobayashiM , IwamotoY , KakuK , KawamoriR , TajimaN . Phase 3 clinical trial of insulin detemir for patients with insulin-dependent diabetes during basal-bolus therapy – a study of efficacy and safety with NPH insulin as control. Journal of the Japan Diabetes Society2007;50(9):649-63. [DOI: 10.11213/tonyobyo.50.649]NCT00604344. Efficacy and the safety of insulin detemir in subjects with insulin requiring diabetes. clinicaltrials.gov/ct2/show/NCT00604344 (first received 30 January 2008). Novo Nordisk A/S. A 48-week, randomised, multi-centre, open-labelled, parallel-group trial to compare the efficacy and the safety of NN304 (insulin detemir) and NPH human insulin in subjects with insulin requiring diabetes mellitus on a basal-bolus regimen. https://s3.amazonaws.com/ctr-nvo-7271/NN304-1476/aa9b4da3-1f92-460d-af0a-cc538614c3b2/3f7ed86e-d6e7-4542-ab8f-6cad24b46593/1476-ctr-synopsis-redacted-v2.pdf (last accessed 3 November 2020). ">Kobayashi 2007 A</a> </p> <p>(parallel RCT, non‐inferiority design)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin detemir once daily at bedtime or twice daily in the morning and at bedtime + mealtime insulin aspart </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>454/401<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>48 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin once daily at bedtime or twice daily in the morning and at bedtime + mealtime insulin aspart </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.4</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>105</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>102</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>102</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>97</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>92.4</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0013" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KobayashiM , IwamotoY , KakuK , KawamoriR , TajimaN . Phase 3 clinical trial of insulin detemir for type 2 diabetes patients with insufficient blood sugar control in oral diabetes drug therapy. Journal of the Japan Diabetes Society2007;50(9):665-77. [DOI: 10.11213/tonyobyo.50.665]NCT00604253. Efficacy and safety of insulin detemir in type 2 diabetes inadequately controlled on OHA therapy alone. www.clinicaltrials.gov/ct2/show/results/NCT00604253 (first received 30 January 2008). Novo Nordisk A/S. A 36-week, randomised, multi-centre, open-labelled, parallel-group trial to compare the efficacy and the safety of NN304 and NPH human insulin once daily treatment as add-on to current OHA therapy in subjects with type 2 diabetes mellitus who are inadequately controlled on OHA therapy. http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1397&amp;filename=NN304_1477_ICTRSynopsis_Final_20051101.pdf (last accessed 3 November 2020). ">Kobayashi 2007 B</a> </p> <p>(parallel RCT, non‐inferiority design)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin detemir at bedtime + OAD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>437/371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>36 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin at bedtime + OAD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97.5</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>371</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>363</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>363</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>332</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>89.5</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0014" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. MassiBM , HumburgE , DresslerA , ZiemenM . A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Hormone &amp; Metabolic Research2003;35(3):189-96. [PMID: 12734781]Yki-JarvinenH , DresslerA , ZiemenM . Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care2000;23(8):1130-6. [EMBASE: 2006092604]">Massi 2003</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin glargine once daily at bedtime + OAD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Based on 1:1 randomisation and using a t‐test, a total number of 384 participants (192 for each group) was required to detect a mean difference of 0.5% glycated haemoglobin between insulin glargine and NPH insulin with a significance level of α = 5% and a statistical power of 90%. It was estimated that a total of 480 participants were to be enrolled to have 384 participants evaluable for efficacy analysis, </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>687/—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>52 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin once daily at bedtime + OAD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.4</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>578</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>570</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>570</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>529</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>91.5</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0015" title="NCT00687453. The utility of insulin glargine (Lantus) compared to NPH in ethnic minority type 2 diabetic subjects on combination insulin-oral agent therapy. clinicaltrials.gov/ct2/show/NCT00687453 (first received 30 May 2008). ">NCT00687453</a> </p> <p>(parallel RCT, non‐inferiority design)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin glargine at bedtime</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>27/24 <sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin in the morning and at bedtime</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54<sup>c</sup> </p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>24</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>24</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>24</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>15</b><sup>c</sup> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>62.5</b><sup>c</sup> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0016" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">NN304‐1337</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin detemir once daily at bedtime + metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>24 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin once daily at bedtime + metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.6</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>467</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>467</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>467</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>406</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>86.9</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0017" title="DoucetJ , Le FlochJ , HanaireH , CourregesJ , AlexandreB , BauduceauB . Comparison of safety between detemir and neutral protamine Hagedorn (NPH) in ageing subjects: the '3 L study'. Fundamental and Clinical Pharmacology2011;25:82. [EMBASE: 70653089]EUCTR2006-006589-41-FR. Levemir® in ageing patients with type 2 diabetes A seven-month open-labelled randomised multi-centre two-group parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in the morning in ageing subjects with type 2 diabetes. The 3L Study (Levemir in Late Life) Trial Phase: 4. www.clinicaltrialsregister.eu/ctr-search/trial/2006-006589-41/FR (first received 27 March 2007). NCT00506662. The effect of insulin detemir on glucose control in ageing subjects with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00506662 (first received 25 July 2007). Novo Nordisk A/S. A seven-month, open-labelled, randomised, multicentre, two-group, parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in ageing patients with type 2 diabetes: The 3L Study (Levemir in Later Life) (NN304-1808 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1426&amp;filename=1808-ctr-redacted.pdf (last accessed 3 November 2020). ">NN304‐1808</a> </p> <p>(parallel RCT, non‐inferiority design)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin detemir once daily before breakfast ± metformin at optimal dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>For 80% power and 5% significance level with a baseline‐adjusted SD of 1.1, a total of 238 completers (119 per group) was required. Owing to a 20% maximal expected frequency of participants lost for follow‐up, 286 were to have been included, 143 in each group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>124/—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.3<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>7 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin once daily before breakfast ± metformin at optimal dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.7<sup>c</sup> </p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>86</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>86</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>86</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>41</b><sup>c</sup> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>47.7</b><sup>c</sup> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0018" title="EUCTR2008-003739-19. Ensayo multicéntrico, abierto, aleatorizado, de dos grupos, paralelo para comparar el cambio en la distribución de grasa en sujetos con sobrepeso y obesos con diabetes tipo 2 tras 26 semanas de tratamiento con insulina detemir una vez al día frente a insulina NPH una vez al día, ambas con insulina aspart a la hora de las comidas. www.clinicaltrialsregister.eu/ctr-search/trial/2008-003739-19/ES (first received 19 September 2008). NCT00795600. A multi-centre, open-labelled, randomised, two-group parallel trial comparing the change in fat distribution in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin apart at mealtimes. clinicaltrials.gov/ct2/show/NCT00795600 (first received 21 November 2008). Novo Nordisk A/S. A multi-centre, open-labelled, randomised, two-group parallel trial comparing the change in fat distribution in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart at mealtimes (NN304-3614 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1461&amp;filename=3614-ctr-synopsis-redacted.pdf (last accessed 3 November 2020). TinahonesFJ , Gomez-HuelgasR , Garcia-AlegriaJ , Tapia-GuerreroM , Martos-PerezF . Fat distribution, HbA1c and hypoglycaemia in overweight and obese patients with type 2 diabetes: a comparison of NPH and insulin detemir from a pilot randomised clinical trial. Diabetologia2011;54:S273. [EMBASE: 70562816]TinahonesFJ , Gomez-HuelgasR , GarciaalegriaJ , Tapia-GuerreroMJ , PerezFM . The effect of insulin detemir on fat distribution and weight parameters in overweight and obese subjects with type 2 diabetes. Diabetes2011;60:A309. [EMBASE: 70628891]">NN304‐3614</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin detemir in the evening + insulin aspart each meal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>As the primary objective was to demonstrate a difference of 5% in the primary endpoint, using an analysis of covariance model with 3 factors and 1 covariate and with an SD of 5%, the number of participants needed would be of 23 per group. Assuming a withdrawal rate of 20%, the total number of randomised participants would be 58. With a planned screening failure of 20%, the total number of participants planned would be 73. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>81/—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>26 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin in the evening + insulin aspart each meal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.6</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>60</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>59</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>59</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>52</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>86.7</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0019" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. PanCY , SinnassamyP , ChungKD , KimKW , Group LS . Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Research &amp; Clinical Practice2007;76(1):111-8. [PMID: 17011662]">Pan 2007</a> </p> <p>(parallel RCT, non‐inferiority design)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin glargine in the evening + glimepiride 3 mg in the morning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Assuming an SD of 1.6% for the changes from baseline in HbA1c in the 2 groups, and a maximum difference between the groups to be equivalent to 0.4%, the sample size per group was calculated to provide 80% power. The sample size was adjusted for an evaluation rate of 90%, and a total of 440 participants (220 per group) was thus targeted for randomisation. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>24 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin in the evening + glimepiride 3 mg in the morning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>223<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.5</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>448</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>443</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>443</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>425</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>94.9</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0002" title="BetônicoCC , TitanSM , Correa-GiannellaML , NeryM , QueirozM . Comparison of insulin glargine vs. NPH insulin in basal-bolus therapies in T2DM patients and CKD: preliminary results of a prospective, randomized, open-label trial. Diabetes2016;65:A144-5. [CENTRAL: CN-01450000] BetônicoCC , TitanSM , LiraA , PelaesTS , Correa-GiannellaML , NeryM , et al. Insulin glargine U100 improved glycemic control and reduced nocturnal hypoglycemia in patients with type 2 diabetes mellitus and chronic kidney disease stages 3 and 4. Clinical Therapeutics2019;41(10):2008-20. [PMID: 31383366]NCT02451917. Subcutaneous insulin glargine versus NPH insulin in patients with chronic kidney disease stages III and IV: randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02451917 (first received 22 May 2015). ">Betônico 2019</a> </p> <p>(cross‐over RCT, non‐inferiority design)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin glargine in the morning + insulin lispro at mealtime</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>A sample size of 34 participants provided 90% power to detect a mean difference of 0.7% (7.7 mmol/mol) in the primary endpoint (HbA1c), considering a 15% dropout rate and assuming an SD of 0.85% and a type I error of 5%. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>193/40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Period 1 – glargine/period 2 – NPH: 16</p> <p>Period 1 – NPH/period 2 – glargine: 18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After period 1: 16</p> <p>After period 2: 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After period 1: 16</p> <p>After period 2: 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Period 1 – glargine/period 2 – NPH: 14</p> <p>Period 1 – NPH/period 2 – glargine: 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Period 1 – glargine/period 2 – NPH: 87.5</p> <p>Period 1 – NPH/period 2 – glargine: 83.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Cross‐over trial, 6 months per period</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin 3 times daily + insulin lispro at mealtime</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After period 1: 18</p> <p>After period 2: 14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After period 1: 18</p> <p>After period 2: 14</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>34</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>After period 1: 34</b> </p> <p><b>After period 2: 29</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>After period 1: 34</b> </p> <p><b>After period 2: 29</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>29</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>85.3</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0020" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00653341. Effect of insulin glargine in insulin naïve subjects with type 2 diabetes on oral hypoglycemic agent(s). www.clinicaltrials.gov/ct2/show/results/NCT00653341 (first received 4 April 2008). RiddleMC , RosenstockJ , GerichJ , InsulinG . The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care2003;26(11):3080-6. [PMID: 14578243]">Riddle 2003</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin glargine once at bedtime + OAD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Based on previous data, randomisation of 750 participants had the power to provide an 85% chance of detecting, with α = 5%, a 10% treatment effect for the primary outcome measure </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1381/764</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>372</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>367</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>367</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>334</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>24 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin once at bedtime + OAD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>392</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>389</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>389</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>357</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.1</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>764</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>756</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>756</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>691</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>90.4</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0021" title="FonsecaV , BellDS , BergerS , ThomsonS , MeccaTE . A comparison of bedtime insulin glargine with bedtime neutral protamine Hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. American Journal of the Medical Sciences2004;328(5):274-80. [PMID: 15545844]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. RosenstockJ , SchwartzSL , Clark CM Jr, ParkGD , DonleyDW , EdwardsMB . Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care2001;24(4):631-6. [PMID: 11315821]">Rosenstock 2001</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin glargine once daily at bedtime + premeal regular insulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The study was designed to provide 90% power to detect a mean difference of 0.5% in HbA1c between treatment groups </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>846<sup>g</sup>/— </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>28 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin once at bedtime or twice daily in the morning and at bedtime + premeal regular insulin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.2</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>521</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>518</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>518</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>469</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>90.0</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0022" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00174824. Comparison of insulin glargine and NPH human insulin in progression of diabetic retinopathy in type 2 diabetic patients. clinicaltrials.gov/ct2/show/study/NCT00174824 (first received 15 September 2005). RosenstockJ , FonsecaV , DainMP , RiddleM . Estimating number-needed-to-treat to avoid hypoglycaemic episodes in people with type 2 diabetes: a post-hoc analysis of a prospective randomized controlled trial comparing once-daily insulin glargine with twice-daily NPH insulin. Canadian Journal of Diabetes2009;33(3):185-6. [EMBASE: 70031352]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia2009;52(9):1778-88. [PMID: 19526210]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia2009;52(9):1971-3. [PMID: 19609501]RosenstockJ , FonsecaV , SchinzelS , DainMP , MullinsP , RiddleM . Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: evidence from a long-term controlled trial. Journal of Diabetic Complications2014;28(5):742-9. [PMID: 24856612]">Rosenstock 2009</a> </p> <p>(parallel RCT, non‐inferiority design)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin glargine once daily, generally at bedtime</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Sample size was calculated assuming a 20% 5‐year event rate for a ≥ 3 step progression in diabetic retinopathy on the Early Treatment of Diabetic Retinopathy Study scale from baseline to end of study (based on data from the Diabetes Control and Complications Trial), and a non‐inferiority margin of 10% (half of the expected background rate of 20%) was chosen. Assuming that approximately 40% of the randomised participants would not be evaluable, a sample size of 840 randomised participants (420 per group) was calculated to provide at least 80% power for declaring non‐inferiority </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1413/—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>515</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>513</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>513 (ITT); 514<sup>h</sup> (safety population) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>374</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>5 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin twice daily, generally in the morning and at bedtime</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>509</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>504</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>504 (ITT); 503<sup>h</sup> (safety population) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>364</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.5</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>1024</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>1017</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>1017</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>738</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>72.1</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0023" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. VarewijckAJ , JanssenJA , VahataloM , HoflandLJ , LambertsSW , Yki-JarvinenH . Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. Diabetologia2012;55(4):1186-94. [PMID: 22237688]VarewijckAJ , JanssenJA , VahataloM , LambertsSW , Ki-JarvinenHY . IGF-I bioactivity decreases during insulin therapy in type 2 diabetic patients: comparison of high doses of insulin glargine and NPH insulin in the LANMET study. In: Endocrine Reviews Conference: 93rd Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 32 (3 Meeting Abstracts). 2011. [EMBASE: 70676865]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJA . Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and IGF-I receptor signaling. Diabetes2013;62(7):2539-44. [PMID: 23569175]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJAMJL . Comparison of effects of insulin glargine, its metabolites, IGF-I and human insulin on insulin-and IGF-I receptor signaling in type 2 diabetic patients. In: Endocrine Reviews Conference: 95th Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 34 (3 suppl 1). 2013. [EMBASE: 71784187]Yki-JärvinenH , Kauppinen-MakelinR , TiikkainenM , VahataloM , VirtamoH , Nikkila K et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia2006;49(3):442-51. [PMID: 10937510]">Yki‐Järvinen 2006</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin glargine at bedtime + metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The sample size calculation was based on differences observed in a previous study between 11 insulin‐naive participants treated with NPH and metformin and 12 participants treated with glargine and metformin for 1 year in Helsinki. In this study, HbA1c differed by 0.5% at the end of 1 year; the SDs for the groups were not different and averaged 0.87. The mean HbA1c change for the NPH + metformin group was −0.8 (SE 0.2%) (11 participants), and for the glargine + metformin group it was −1.3 (SE 0.3%) (12 participants) at the end of 1 year. Assuming α = 0.05 and 80% power, the required number of participants per group to observe a difference of 0.5% is 50. To allow for a 10% dropout rate, 110 participants were randomised </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>157/110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>36 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin at bedtime + metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98.0</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>110</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>110</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>110</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>108</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>98.2</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0024" title="YokoyamaH , TadaJ , KamikawaF , KannoS , YokotaY , KuramitsuM . Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Research &amp; Clinical Practice2006;73(1):35-40. [PMID: 16513202]">Yokoyama 2006</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin glargine once at breakfast + aspart/lispro at each meal with or without OADs </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—/—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin daily at bedtime + aspart/lispro at each meal with or without OADs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>62</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Overall total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All comparators</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All interventions and comparators</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8677</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>— denotes not reported.</p> <p><sup>a</sup>Follow‐up under randomised conditions until end of trial or if not available, duration of intervention; extended follow‐up refers to follow‐up of participants once the original study was terminated as specified in the power calculation.<br/><sup>b</sup>Modified ITT set for primary endpoint evaluation (including randomised participants with valid values for DRQoL for both treatment periods).<br/><sup>c</sup>Study prematurely discontinued.<br/><sup>d</sup>Participants with type 1 and type 2 diabetes.<br/><sup>e</sup>3 participants not randomised due to protocol violations.<br/><sup>f</sup>Safety population: 444 participants.<br/><sup>g</sup>According to European Medical Agency report.<br/><sup>h</sup>1 participant who was randomised to receive NPH insulin received insulin glargine throughout the study, and was consequently counted in the ITT population as an NPH participant, but in the safety population as an insulin glargine participant, leading to a discrepancy in the numbers for the ITT and safety populations in both the insulin glargine and NPH insulin arms. </p> <p>C: comparator; CI: confidence interval; DRQoL: diabetes‐related quality of life; HbA1c: glycosylated haemoglobin A1c; I: intervention; ITEQ: Insulin Therapy Experience Questionnaire; ITT: intention‐to‐treat; n: number of participants; NPH: neutral protamine Hagedorn; OAD: oral antihyperglycaemic drug; PAID: Problem Areas In Diabetes; RCT: randomised controlled trial; SD: standard deviation; SE: standard error; SF‐12: 12‐item Short Form Health Survey. </p> </div> </div> <p>We provided information on potentially relevant ongoing trials, including the trial identifier in the <a href="./references#CD005613-sec-0175" title="">Characteristics of ongoing studies</a> table and in <a href="./appendices#CD005613-sec-0142">Appendix 10</a> 'Matrix of trial endpoint (publications and trial documents)'. We tried to find the protocol for each included trial and we reported primary, secondary and other outcomes in comparison with data in publications in <a href="./appendices#CD005613-sec-0142">Appendix 10</a>. </p> <p>We emailed all authors of included trials to enquire whether they would be willing to answer questions on their trials. We presented the results of this survey in <a href="./appendices#CD005613-sec-0151">Appendix 19</a>. We then asked for relevant missing information on the trial from the primary trial author(s), where necessary. </p> <section id="CD005613-sec-0036"> <h5 class="title">Dealing with duplicate and companion publications</h5> <p>In the event of duplicate publications, companion documents or multiple reports of a primary trial, we maximised the information yielded by collating all available data and we used the most complete data set aggregated across all known publications. We listed duplicate publications, companion documents, multiple reports of a primary trial and trial documents of included trials (such as trial registry information) as secondary references under the study identifier (ID) of the included trial. Furthermore, we also listed duplicate publications, companion documents, multiple reports of a trial and trial documents of excluded trials (such as trial registry information) as secondary references under the study ID of the excluded trial. </p> </section> <section id="CD005613-sec-0037"> <h5 class="title">Data from clinical trial registers</h5> <p>If data from included trials were available as study results in clinical trial registers such as <a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> or similar sources, we made full use of this information and extracted the data. If there was also a full publication of the trial, we collated and critically appraised all available data. If an included trial was marked as a completed study in a clinical trial register but no additional information (study results, publication or both) was available, we added this trial to the <a href="./references#CD005613-sec-0173" title="">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD005613-sec-0038"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (JE, KH, TS, KJ) independently assessed the risk of bias for each included trial. We resolved disagreements by consensus or by consulting a third review author (JE, KH, TS, KJ). In the case of disagreement, we consulted the remainder of the review author team and made a judgement based on consensus. If adequate information was unavailable from the study publications, study protocols or other sources, we contacted the study authors for more detail to request missing data on 'Risk of bias' items. </p> <p>We used the Cochrane 'Risk of bias' assessment tool (<a href="./references#CD005613-bbs2-0096" title="HigginsJP , SavovićJ , PageMJ , ElbersRG , SterneJA . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Higgins 2019a</a>), to assign assessments of low, high or unclear risk of bias (for details, see <a href="./appendices#CD005613-sec-0137">Appendix 5</a>; <a href="./appendices#CD005613-sec-0138">Appendix 6</a>). We evaluated individual bias items as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions,</i> according to the criteria and associated categorisations contained therein <i>(</i><a href="./references#CD005613-bbs2-0096" title="HigginsJP , SavovićJ , PageMJ , ElbersRG , SterneJA . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Higgins 2019a</a>). </p> <section id="CD005613-sec-0039"> <h5 class="title">Summary assessment of risk of bias</h5> <p>We presented a 'Risk of bias' graph and a 'Risk of bias' summary figure. We distinguished between self‐reported and investigator‐assessed and adjudicated outcome measures. </p> <p>We considered the following self‐reported outcomes.</p> <p> <ul id="CD005613-list-0013"> <li> <p>Diabetes‐related complications, reported by participants.</p> </li> <li> <p>Hypoglycaemia, when measured by participants.</p> </li> <li> <p>Health‐related quality of life.</p> </li> <li> <p>Adverse events other than hypoglycaemia, as reported by participants.</p> </li> </ul> </p> <p>We considered the following outcomes to be investigator‐assessed.</p> <p> <ul id="CD005613-list-0014"> <li> <p>Diabetes‐related complications, evaluated/as measured by trial personnel.</p> </li> <li> <p>Hypoglycaemia, when measured by trial personnel.</p> </li> <li> <p>All‐cause mortality.</p> </li> <li> <p>Adverse events other than hypoglycaemia, as measured by trial personnel.</p> </li> <li> <p>Socioeconomic effects.</p> </li> <li> <p>HbA1c.</p> </li> </ul> </p> <section id="CD005613-sec-0040"> <h6 class="title">Risk of bias for a study across outcomes</h6> <p>Some risk of bias domains, such as selection bias (sequence generation and allocation sequence concealment), affect the risk of bias across all outcome measures in a study. In case of high risk of selection bias, we marked all endpoints investigated in the associated study as being at high risk. Otherwise, we did not perform a summary assessment of the risk of bias across all outcomes for a study. </p> </section> <section id="CD005613-sec-0041"> <h6 class="title">Risk of bias for an outcome within a study and across domains</h6> <p>We assessed the risk of bias for an outcome measure by including all entries relevant to that outcome (i.e. both study‐level entries and outcome‐specific entries). We considered low risk of bias to denote a low risk of bias for all key domains, unclear risk to denote an unclear risk of bias for one or more key domains and high risk to denote a high risk of bias for one or more key domains. </p> </section> <section id="CD005613-sec-0042"> <h6 class="title">Risk of bias for an outcome across studies and across domains</h6> <p>To facilitate our assessment of the certainty of the evidence for key outcomes, we assessed risk of bias across studies and domains for the outcomes included in the 'Summary of findings' tables. We defined the evidence as being at low risk of bias when most information came from studies at low risk of bias, unclear risk of bias when most information came from studies at low or unclear risk of bias and high risk of bias when a sufficient proportion of information came from studies at high risk of bias. </p> </section> </section> </section> <section id="CD005613-sec-0043"> <h4 class="title">Measures of treatment effect</h4> <p>When at least two included trials were available for a comparison and a given outcome, we tried to express dichotomous data as a risk ratio (RR) or odds ratio (OR) with 95% confidence intervals (CI). For continuous outcomes measured on the same scale (e.g. weight loss in kilograms), we estimated the intervention effect using the mean difference (MD) with 95% CI. For continuous outcomes measuring the same underlying concept (e.g. health‐related quality of life) but using different measurement scales, we intended to calculate the standardised mean difference with 95% CI. We also planned to express time‐to‐event data as a hazard ratio with 95% CI. </p> </section> <section id="CD005613-sec-0044"> <h4 class="title">Unit of analysis issues</h4> <p>We intended to consider the level at which randomisation occurred, such as cross‐over trials, cluster‐randomised trials and multiple observations for the same outcome. If more than one comparison from the same trial was eligible for inclusion in the same meta‐analysis, we either combined groups to create a single pair‐wise comparison or appropriately reduced the sample size so that the same participants did not contribute more than once (splitting the 'shared' group into two or more groups). While the latter approach offers some solution to adjusting the precision of the comparison, it does not account for correlation arising because the same set of participants was included in multiple comparisons (<a href="./references#CD005613-bbs2-0097" title="HigginsJP , LiT , DeeksJJ . Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Higgins 2019b</a>). </p> <p>We planned to reanalyse cluster‐RCTs that had not appropriately adjusted for potential clustering of participants within clusters in their analyses. Variance in the intervention effects would have been inflated by a design effect. Calculation of a design effect would have involved estimation of an intracluster correlation (ICC). We would have obtained estimates of ICCs through contact with authors, or imputed them using estimates from other included trials that reported ICCs, or using external estimates from empirical research (e.g. <a href="./references#CD005613-bbs2-0072" title="BellML , McKenzieJE . Designing psycho-oncology randomised trials and cluster randomised trials: variance components and intra-cluster correlation of commonly used psychosocial measures. Psychooncology2013;22:1738-47. [PMID: 23080401]">Bell 2013</a>). We also planned to examine the impact of clustering using sensitivity analyses. </p> </section> <section id="CD005613-sec-0045"> <h4 class="title">Dealing with missing data</h4> <p>If possible, we obtained missing data from the authors of the included trials. We carefully evaluated important numerical data such as screened, randomly assigned participants as well as intention‐to‐treat (ITT), and as‐treated and per‐protocol populations. We investigated attrition rates (e.g. dropouts, losses to follow‐up, withdrawals), and we critically appraised issues concerning missing data and the use of imputation methods (e.g. last observation carried forward (LOCF)). </p> <p>In trials where the standard deviation (SD) of the outcome was not available at follow‐up or could not be recreated, we standardised using the mean of the pooled baseline SD from those trials in which this information was reported. </p> <p>Where included trials did not report means and SDs for outcomes and we did not receive the necessary information from trial authors, we imputed these values by estimating the mean and variance from the median, range and the size of the sample (<a href="./references#CD005613-bbs2-0099" title="HozoSP , DjulbegovicB , HozoI . Estimating the mean and variance from the median, range, and the size of a sample. BMC Medical Research Methodology2005;5:13. [DOI: 10.1186/1471-2288-5-13]">Hozo 2005</a>). </p> <p>We investigated the impact of imputation on meta‐analyses by performing sensitivity analyses and we reported which trials were included with imputed SDs per outcome. </p> </section> <section id="CD005613-sec-0046"> <h4 class="title">Assessment of heterogeneity</h4> <p>In the event of substantial clinical or methodological heterogeneity, we did not report study results as the pooled effect estimate in a meta‐analysis. </p> <p>We identified heterogeneity (inconsistency) by visually inspecting the forest plots and by using a standard Chi² test with a significance level of α = 0.1 (<a href="./references#CD005613-bbs2-0080" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Deeks 2019</a>). In view of the low power of this test, we also considered the I² statistic – which quantifies inconsistency across studies – to assess the impact of heterogeneity on the meta‐analysis (<a href="./references#CD005613-bbs2-0093" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta-analysis. Statistics in Medicine2002;21(11):1539-58. [PMID: 12111919]">Higgins 2002</a>; <a href="./references#CD005613-bbs2-0094" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analysis. BMJ2003;327:557-60. [PMID: 12958120]">Higgins 2003</a>). When we identified heterogeneity, we attempted to determine possible reasons for this by examining individual characteristics of the study and subgroups. </p> </section> <section id="CD005613-sec-0047"> <h4 class="title">Assessment of reporting biases</h4> <p>If we included 10 or more studies that investigated a particular outcome, we planned to use funnel plots to assess small‐study effects. Several explanations may account for funnel plot asymmetry, including true heterogeneity of effect with respect to study size, poor methodological design (and hence bias of small studies) and selective non‐reporting (<a href="./references#CD005613-bbs2-0106" title="KirkhamJJ , DwanKM , AltmanDG , GambleC , DoddS , SmythR , et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ2010;340:c365. [DOI: 10.1136/bmj.c365]">Kirkham 2010</a>). Therefore, we interpreted the results carefully (<a href="./references#CD005613-bbs2-0128" title="SterneJA , SuttonAJ , IoannidisJP , TerrinN , JonesDR , LauJ , et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ2011;343:d4002. [PMID: 21784880]">Sterne 2011</a>). </p> </section> <section id="CD005613-sec-0048"> <h4 class="title">Data synthesis</h4> <p>We planned to undertake (or display) a meta‐analysis only if participants, interventions, comparisons and outcomes were judged to be sufficiently similar to ensure an answer that was clinically meaningful. For the outcome HbA1c, we used the change between baseline and end of follow‐up for the comparison between the two groups. MDs were calculated using a random‐effects model for the meta‐analysis. In some studies, the mean change and its variance for each group were presented in the published report of the trial. In other cases where these estimates were not reported, we had to calculate appropriate variances, if possible, from other statistics presented. The same approach was used for the outcome weight gain (change in body mass index (BMI)). Furthermore, we looked at different episodes of hypoglycaemia (severe, serious, less than 70 mg/dL to 75 mg/dL, less than 50 mg/dL to 55 mg/dL, nocturnal less than 70 mg/dL to 75 mg/dL, nocturnal less than 50 mg/dL to 55 mg/dL) and serious adverse events. For the meta‐analysis of severe and serious hypoglycaemic episodes, we used Peto's OR method, since the event rates were low. </p> <p>We interpreted random‐effects meta‐analyses with due consideration for the whole distribution of effects and planned to present a prediction interval (<a href="./references#CD005613-bbs2-0073" title="BorensteinM , HigginsJP , HedgesLV , RothsteinHR . Basics of meta-analysis: I² is not an absolute measure of heterogeneity. Research Synthesis Methods2017;8(1):5-18.">Borenstein 2017a</a>; <a href="./references#CD005613-bbs2-0074" title="BorensteinM . Prediction intervals. www.meta-analysis.com/prediction (accessed 3 July 2017).">Borenstein 2017b</a>; <a href="./references#CD005613-bbs2-0095" title="HigginsJP , ThompsonSG , SpiegelhalterDJ . A re-evaluation of random-effects meta-analysis. Journal of the Royal Statistical Society: Series A (Statistics in Society)2009;172(1):137-59.">Higgins 2009</a>). A prediction interval requires at least three studies to be calculated and specifies a predicted range for the true treatment effect in an individual study (<a href="./references#CD005613-bbs2-0122" title="RileyRD , HigginsJP , DeeksJJ . Interpretation of random effects meta-analyses. BMJ2011;342:d549. [PMID: 21310794]">Riley 2011</a>). In addition, we performed statistical analyses according to the statistical guidelines presented in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD005613-bbs2-0080" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Deeks 2019</a>). </p> </section> <section id="CD005613-sec-0049"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We expected the following characteristics to introduce clinical heterogeneity, and planned to carry out the following subgroup analyses for the primary outcomes including investigation of interactions. </p> <p> <ul id="CD005613-list-0015"> <li> <p>Different additional antihyperglycaemic therapy such as oral antidiabetic drugs (OADs) versus insulin. </p> </li> <li> <p>NPH once daily versus NPH twice or three times daily.</p> </li> </ul> </p> </section> <section id="CD005613-sec-0050"> <h4 class="title">Sensitivity analysis</h4> <p>We intended to perform sensitivity analyses for the primary outcomes to explore the influence of the following factors (when applicable) on effect size by restricting analysis to the following: </p> <p> <ul id="CD005613-list-0016"> <li> <p>Published trials.</p> </li> <li> <p>Taking into account risk of bias, as specified in the <a href="#CD005613-sec-0038">Assessment of risk of bias in included studies</a> section. </p> </li> <li> <p>Very long or large trials to establish the extent to which they dominated the results.</p> </li> <li> <p>Trials using the following filters: diagnostic criteria, imputation, language of publication, source of funding (industry versus other) or country. </p> </li> </ul> </p> <p>We also tested the robustness of results by repeating the analyses using different measures of effect size (RR, OR, etc.) and different statistical models (fixed‐effect and random‐effects models). </p> </section> <section id="CD005613-sec-0051"> <h4 class="title">Certainty of the evidence</h4> <p>We present the overall certainty of the evidence for each outcome specified below, according to the GRADE approach, which takes into account issues related to internal validity (risk of bias, inconsistency, imprecision, publication bias) and external validity (such as directness of results)<i>.</i> Two review authors (JE, KH, TS, KJ) independently rated the certainty of the evidence for each outcome. We resolved any differences in assessment by discussion or by consultation with a third review author (JE, KH, TS, KJ). </p> <p>We included appendices entitled 'Checklist to aid consistency and reproducibility of GRADE assessments' (<a href="./appendices#CD005613-sec-0133">Appendix 1</a>; <a href="./appendices#CD005613-sec-0134">Appendix 2</a>), to help with standardisation of the 'Summary of findings' tables (<a href="./references#CD005613-bbs2-0118" title="MeaderN , KingK , LlewellynA , NormanG , BrownJ , RodgersM , et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Systematic Reviews2014;3:82. [PMID: 25056145]">Meader 2014</a>). Alternatively, we planned to use the GRADEpro GDT software and would have presented evidence profile tables as an appendix (<a href="./references#CD005613-bbs2-0088" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version 25 August 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. www.guidelinedevelopment.org.">GRADEpro GDT</a>). If meta‐analysis was not possible, we presented the results in a narrative format in the 'Summary of findings' table. We justified all decisions to downgrade the certainty of the evidence using footnotes, and we made comments to aid the reader's understanding of the Cochrane Review when necessary. </p> <section id="CD005613-sec-0052"> <h5 class="title">'Summary of findings' tables</h5> <p>We presented a summary of the evidence in 'Summary of findings' tables. This provides key information about the best estimate of the magnitude of effect, in relative terms and as absolute differences for each relevant comparison of alternative management strategies; the numbers of participants and studies addressing each important outcome; and a rating of overall confidence in effect estimates for each outcome. We created the 'Summary of findings' tables using the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD005613-bbs2-0126" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing 'Summary of findings' tables and grading the confidence in or quality of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Schünemann 2019</a>), along with Review Manager 5 software (<a href="./references#CD005613-bbs2-0121" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). </p> <p>Interventions presented in the 'Summary of findings' tables were long‐acting insulin analogues (insulin glargine U100 or insulin detemir). The comparator was NPH insulin.<br/>We reported the following outcomes, listed according to priority. </p> <p> <ul id="CD005613-list-0017"> <li> <p>Diabetes‐related complications.</p> </li> <li> <p>Hypoglycaemic episodes.</p> </li> <li> <p>Health‐related quality of life.</p> </li> <li> <p>All‐cause mortality.</p> </li> <li> <p>Adverse events other than hypoglycaemia.</p> </li> <li> <p>Socioeconomic effects.</p> </li> <li> <p>HbA1c.</p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD005613-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD005613-sec-0053"></div> <section id="CD005613-sec-0054"> <h3 class="title">Description of studies</h3> <p>For a detailed description of trials, see <a href="#CD005613-tbl-0003">Table 1</a>, and the <a href="./references#CD005613-sec-0172" title="">Characteristics of included studies</a>, <a href="./references#CD005613-sec-0173" title="">Characteristics of excluded studies</a>, <a href="./references#CD005613-sec-0174" title="">Characteristics of studies awaiting classification</a>, and <a href="./references#CD005613-sec-0175" title="">Characteristics of ongoing studies</a> tables. </p> <section id="CD005613-sec-0055"> <h4 class="title">Results of the search</h4> <p>Using the described strategies, the update searches in 2017 yielded 1969 and in 2019 yielded 2644 results. We identified 92 additional records including the IQWiG report through non‐database sources (<a href="./references#CD005613-bbs2-0102" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009.">IQWiG 2009</a>). After deduplication, 3810 records remained. </p> <p>After reading the 3810 abstracts, we excluded 3721 articles by consensus as irrelevant to the question under review, leaving 89 articles for further examination. We identified 10 additional publications by handsearching the reference lists of included trials, systematic reviews/meta‐analyses and Health Technology Assessment (HTA) reports or databases from regulatory agencies. After screening the full text of the selected 99 publications and after contacting authors of potentially relevant studies, 28 studies (59 articles/records) met the inclusion criteria. Two of these studies (two records) were potentially relevant ongoing trials and three trials (five records) were classified as studies awaiting assessment. Finally, incorporating 15 additional studies with the nine studies from the previous version of the review, in this review update 24 completed trials (63 articles/records) could be included. For further details see flow diagram in <a href="#CD005613-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD005613-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Trial flow diagram; HTA: health technology assessment; RCT: randomised controlled trial." data-id="CD005613-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial flow diagram; HTA: health technology assessment; RCT: randomised controlled trial. </p> </div> </div> </div> </section> <section id="CD005613-sec-0056"> <h4 class="title">Included studies</h4> <p>A detailed description of the characteristics of included trials is presented elsewhere (see <a href="./references#CD005613-sec-0172" title="">Characteristics of included studies</a> table and <a href="./appendices#CD005613-sec-0139">Appendix 7</a>; <a href="./appendices#CD005613-sec-0140">Appendix 8</a>; <a href="./appendices#CD005613-sec-0141">Appendix 9</a>). The following is a short overview. </p> <section id="CD005613-sec-0057"> <h5 class="title">Source of data</h5> <p>The results of 20 trials were at least partially published in scientific journals between 2000 and 2019. For three of the trials, information and results were mostly obtained from entries in ClinicalTrials.gov and from pharmaceutical manufacturers' study reports. For 14 trials, we relied on additional information that was based on the original study reports published in a report by the Institute for Quality and Efficiency in Health Care (<a href="./references#CD005613-bbs2-0102" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009.">IQWiG 2009</a>). For one trial, the IQWiG report was the only available source of data. We contacted authors of all studies that were not included in the IQWiG report to request missing data or clarify issues regarding the methodology of the trial. Nine of the authors replied but only two of them provided information that was relevant to the review. All other authors were contacted during the preparation of the IQWiG report and their replies incorporated in the IQWiG report, where relevant (see <a href="./appendices#CD005613-sec-0151">Appendix 19</a>). </p> </section> <section id="CD005613-sec-0058"> <h5 class="title">Comparisons</h5> <section id="CD005613-sec-0059"> <h6 class="title">Glargine U300 versus NPH</h6> <p>We found no trials comparing glargine U300 with NPH insulin.</p> </section> <section id="CD005613-sec-0060"> <h6 class="title">Glargine versus NPH</h6> <p>Sixteen trials compared NPH to insulin glargine (<a href="./references#CD005613-bbs2-0001" title="BerardL , CameronB , WooV , StewartJ . Replacing insulin glargine with neutral protamine Hagedorn (NPH) insulin in a subpopulation of study subjects in the action to control cardiovascular risk in diabetes (ACCORD): effects on blood glucose levels, hypoglycemia and patient satisfaction. Canadian Journal of Diabetes2015;39(4):296-301. [PMID: 25819531]BerardLD , WooVC . Safety and efficacy of NPH after switching from insulin glargine in Canadian patients. Diabetologia2011;54:S430. [EMBASE: 70563203]">Berard 2015</a>; <a href="./references#CD005613-bbs2-0003" title="EliaschewitzFG , CalvoC , ValbuenaH , RuizM , AschnerP , VillenaJ , et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Archives of Medical Research2006;37(4):495-501. [PMID: 16715577]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Eliaschewitz 2006</a>; <a href="./references#CD005613-bbs2-0005" title="FritscheA , SchweitzerMA , HaringHU , Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Annals of Internal Medicine2003;138(12):952-9. [PMID: 12809451]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Fritsche 2003</a>; <a href="./references#CD005613-bbs2-0007" title="EUCTR2009-010913-59. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on OHA treatment initiating basal insulin therapy with either insulin glargine or NPH insulin added to therapies with oral hypoglycemic agents (HAPPY) (LANTU_L_04079 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2009-010913-59/results (last accessed 3 May 2017). HermannsN , KulzerB , KohlmannT , JacobS , LandgrafW , TheobaldK , et al. Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial. Health and Quality of Life Outcomes2015;13:77. [PMID: 26055391]NCT00941369. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on oral hypoglycemic agent treatment initiating basal insulin therapy with either insulin glargine or NPH insulin. clinicaltrials.gov/ct2/show/NCT00941369 (first received 17 July 2009). ">Hermanns 2015</a>; <a href="./references#CD005613-bbs2-0009" title='EUCTR2007-006640-22. Superiority of insulin glargine Lantus vs NPH: "Treat to normoglycemia concept". Effect of insulin glargine in comparison to insulin NPH in insulin-naïve people with type 2 diabetes mellitus treated with at least one OAD and not adequately controlled (LANCELOT) (LANTU_C_02762 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2007-006640-22/results (last accessed 19 July 2017). HomePD , BolliGB , MathieuC , DeerochanawongC , LandgrafW , CandelasC , et al. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naive people with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2015;17(1):15-22. [PMID: 24957785]NCT00949442. Lantus versus NPH: comparison in insulin naive people not adequately controlled with at least one oral anti diabetics (OAD) treatment (LANCELOT). clinicaltrials.gov/ct2/show/NCT00949442 (first received 30 July 2009). '>Home 2015</a>; <a href="./references#CD005613-bbs2-0010" title="HsiaSH . Comparison of single-dose regimens of insulin glargine versus NPH among inner city ethnic minority type 2 diabetic patients uncontrolled on oral agents. Journal of Investigative Medicine2010;58(1):136. [EMBASE: 70981533]HsiaSH . Insulin glargine compared to NPH among insulin-naive, U.S. inner city, ethnic minority type 2 diabetic patients. Diabetes Research &amp; Clinical Practice2011;91(3):293-9. [PMID: 21146881]NCT00686712. Insulin glargine at bedtime or in AM versus NPH. clinicaltrials.gov/ct2/show/NCT00686712 (first received 7 October 2010). ">Hsia 2011</a>; <a href="./references#CD005613-bbs2-0011" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KawamoriR , IwamotoY , KadowakiT , IwasakiM . Efficacy and safety of insulin glargine in concurrent use with oral hypoglycemic agents for the treatment of type 2 diabetes patients. Rinshoiyaku2003;19(5):445-64. ">Kawamori 2003</a>; <a href="./references#CD005613-bbs2-0014" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. MassiBM , HumburgE , DresslerA , ZiemenM . A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Hormone &amp; Metabolic Research2003;35(3):189-96. [PMID: 12734781]Yki-JarvinenH , DresslerA , ZiemenM . Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care2000;23(8):1130-6. [EMBASE: 2006092604]">Massi 2003</a>; <a href="./references#CD005613-bbs2-0015" title="NCT00687453. The utility of insulin glargine (Lantus) compared to NPH in ethnic minority type 2 diabetic subjects on combination insulin-oral agent therapy. clinicaltrials.gov/ct2/show/NCT00687453 (first received 30 May 2008). ">NCT00687453</a>; <a href="./references#CD005613-bbs2-0019" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. PanCY , SinnassamyP , ChungKD , KimKW , Group LS . Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Research &amp; Clinical Practice2007;76(1):111-8. [PMID: 17011662]">Pan 2007</a>; <a href="./references#CD005613-bbs2-0002" title="BetônicoCC , TitanSM , Correa-GiannellaML , NeryM , QueirozM . Comparison of insulin glargine vs. NPH insulin in basal-bolus therapies in T2DM patients and CKD: preliminary results of a prospective, randomized, open-label trial. Diabetes2016;65:A144-5. [CENTRAL: CN-01450000] BetônicoCC , TitanSM , LiraA , PelaesTS , Correa-GiannellaML , NeryM , et al. Insulin glargine U100 improved glycemic control and reduced nocturnal hypoglycemia in patients with type 2 diabetes mellitus and chronic kidney disease stages 3 and 4. Clinical Therapeutics2019;41(10):2008-20. [PMID: 31383366]NCT02451917. Subcutaneous insulin glargine versus NPH insulin in patients with chronic kidney disease stages III and IV: randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02451917 (first received 22 May 2015). ">Betônico 2019</a>; <a href="./references#CD005613-bbs2-0020" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00653341. Effect of insulin glargine in insulin naïve subjects with type 2 diabetes on oral hypoglycemic agent(s). www.clinicaltrials.gov/ct2/show/results/NCT00653341 (first received 4 April 2008). RiddleMC , RosenstockJ , GerichJ , InsulinG . The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care2003;26(11):3080-6. [PMID: 14578243]">Riddle 2003</a>; <a href="./references#CD005613-bbs2-0021" title="FonsecaV , BellDS , BergerS , ThomsonS , MeccaTE . A comparison of bedtime insulin glargine with bedtime neutral protamine Hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. American Journal of the Medical Sciences2004;328(5):274-80. [PMID: 15545844]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. RosenstockJ , SchwartzSL , Clark CM Jr, ParkGD , DonleyDW , EdwardsMB . Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care2001;24(4):631-6. [PMID: 11315821]">Rosenstock 2001</a>; <a href="./references#CD005613-bbs2-0022" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00174824. Comparison of insulin glargine and NPH human insulin in progression of diabetic retinopathy in type 2 diabetic patients. clinicaltrials.gov/ct2/show/study/NCT00174824 (first received 15 September 2005). RosenstockJ , FonsecaV , DainMP , RiddleM . Estimating number-needed-to-treat to avoid hypoglycaemic episodes in people with type 2 diabetes: a post-hoc analysis of a prospective randomized controlled trial comparing once-daily insulin glargine with twice-daily NPH insulin. Canadian Journal of Diabetes2009;33(3):185-6. [EMBASE: 70031352]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia2009;52(9):1778-88. [PMID: 19526210]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia2009;52(9):1971-3. [PMID: 19609501]RosenstockJ , FonsecaV , SchinzelS , DainMP , MullinsP , RiddleM . Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: evidence from a long-term controlled trial. Journal of Diabetic Complications2014;28(5):742-9. [PMID: 24856612]">Rosenstock 2009</a>; <a href="./references#CD005613-bbs2-0023" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. VarewijckAJ , JanssenJA , VahataloM , HoflandLJ , LambertsSW , Yki-JarvinenH . Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. Diabetologia2012;55(4):1186-94. [PMID: 22237688]VarewijckAJ , JanssenJA , VahataloM , LambertsSW , Ki-JarvinenHY . IGF-I bioactivity decreases during insulin therapy in type 2 diabetic patients: comparison of high doses of insulin glargine and NPH insulin in the LANMET study. In: Endocrine Reviews Conference: 93rd Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 32 (3 Meeting Abstracts). 2011. [EMBASE: 70676865]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJA . Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and IGF-I receptor signaling. Diabetes2013;62(7):2539-44. [PMID: 23569175]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJAMJL . Comparison of effects of insulin glargine, its metabolites, IGF-I and human insulin on insulin-and IGF-I receptor signaling in type 2 diabetic patients. In: Endocrine Reviews Conference: 95th Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 34 (3 suppl 1). 2013. [EMBASE: 71784187]Yki-JärvinenH , Kauppinen-MakelinR , TiikkainenM , VahataloM , VirtamoH , Nikkila K et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia2006;49(3):442-51. [PMID: 10937510]">Yki‐Järvinen 2006</a>; <a href="./references#CD005613-bbs2-0024" title="YokoyamaH , TadaJ , KamikawaF , KannoS , YokotaY , KuramitsuM . Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Research &amp; Clinical Practice2006;73(1):35-40. [PMID: 16513202]">Yokoyama 2006</a>). </p> <p>Glargine was given once daily in all trials and was generally administered shortly before retiring to bed (<a href="./references#CD005613-bbs2-0001" title="BerardL , CameronB , WooV , StewartJ . Replacing insulin glargine with neutral protamine Hagedorn (NPH) insulin in a subpopulation of study subjects in the action to control cardiovascular risk in diabetes (ACCORD): effects on blood glucose levels, hypoglycemia and patient satisfaction. Canadian Journal of Diabetes2015;39(4):296-301. [PMID: 25819531]BerardLD , WooVC . Safety and efficacy of NPH after switching from insulin glargine in Canadian patients. Diabetologia2011;54:S430. [EMBASE: 70563203]">Berard 2015</a>; <a href="./references#CD005613-bbs2-0003" title="EliaschewitzFG , CalvoC , ValbuenaH , RuizM , AschnerP , VillenaJ , et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Archives of Medical Research2006;37(4):495-501. [PMID: 16715577]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Eliaschewitz 2006</a>; <a href="./references#CD005613-bbs2-0009" title='EUCTR2007-006640-22. Superiority of insulin glargine Lantus vs NPH: "Treat to normoglycemia concept". Effect of insulin glargine in comparison to insulin NPH in insulin-naïve people with type 2 diabetes mellitus treated with at least one OAD and not adequately controlled (LANCELOT) (LANTU_C_02762 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2007-006640-22/results (last accessed 19 July 2017). HomePD , BolliGB , MathieuC , DeerochanawongC , LandgrafW , CandelasC , et al. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naive people with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2015;17(1):15-22. [PMID: 24957785]NCT00949442. Lantus versus NPH: comparison in insulin naive people not adequately controlled with at least one oral anti diabetics (OAD) treatment (LANCELOT). clinicaltrials.gov/ct2/show/NCT00949442 (first received 30 July 2009). '>Home 2015</a>; <a href="./references#CD005613-bbs2-0014" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. MassiBM , HumburgE , DresslerA , ZiemenM . A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Hormone &amp; Metabolic Research2003;35(3):189-96. [PMID: 12734781]Yki-JarvinenH , DresslerA , ZiemenM . Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care2000;23(8):1130-6. [EMBASE: 2006092604]">Massi 2003</a>; <a href="./references#CD005613-bbs2-0015" title="NCT00687453. The utility of insulin glargine (Lantus) compared to NPH in ethnic minority type 2 diabetic subjects on combination insulin-oral agent therapy. clinicaltrials.gov/ct2/show/NCT00687453 (first received 30 May 2008). ">NCT00687453</a>; <a href="./references#CD005613-bbs2-0019" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. PanCY , SinnassamyP , ChungKD , KimKW , Group LS . Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Research &amp; Clinical Practice2007;76(1):111-8. [PMID: 17011662]">Pan 2007</a>; <a href="./references#CD005613-bbs2-0020" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00653341. Effect of insulin glargine in insulin naïve subjects with type 2 diabetes on oral hypoglycemic agent(s). www.clinicaltrials.gov/ct2/show/results/NCT00653341 (first received 4 April 2008). RiddleMC , RosenstockJ , GerichJ , InsulinG . The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care2003;26(11):3080-6. [PMID: 14578243]">Riddle 2003</a>; <a href="./references#CD005613-bbs2-0021" title="FonsecaV , BellDS , BergerS , ThomsonS , MeccaTE . A comparison of bedtime insulin glargine with bedtime neutral protamine Hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. American Journal of the Medical Sciences2004;328(5):274-80. [PMID: 15545844]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. RosenstockJ , SchwartzSL , Clark CM Jr, ParkGD , DonleyDW , EdwardsMB . Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care2001;24(4):631-6. [PMID: 11315821]">Rosenstock 2001</a>; <a href="./references#CD005613-bbs2-0022" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00174824. Comparison of insulin glargine and NPH human insulin in progression of diabetic retinopathy in type 2 diabetic patients. clinicaltrials.gov/ct2/show/study/NCT00174824 (first received 15 September 2005). RosenstockJ , FonsecaV , DainMP , RiddleM . Estimating number-needed-to-treat to avoid hypoglycaemic episodes in people with type 2 diabetes: a post-hoc analysis of a prospective randomized controlled trial comparing once-daily insulin glargine with twice-daily NPH insulin. Canadian Journal of Diabetes2009;33(3):185-6. [EMBASE: 70031352]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia2009;52(9):1778-88. [PMID: 19526210]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia2009;52(9):1971-3. [PMID: 19609501]RosenstockJ , FonsecaV , SchinzelS , DainMP , MullinsP , RiddleM . Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: evidence from a long-term controlled trial. Journal of Diabetic Complications2014;28(5):742-9. [PMID: 24856612]">Rosenstock 2009</a>; <a href="./references#CD005613-bbs2-0023" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. VarewijckAJ , JanssenJA , VahataloM , HoflandLJ , LambertsSW , Yki-JarvinenH . Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. Diabetologia2012;55(4):1186-94. [PMID: 22237688]VarewijckAJ , JanssenJA , VahataloM , LambertsSW , Ki-JarvinenHY . IGF-I bioactivity decreases during insulin therapy in type 2 diabetic patients: comparison of high doses of insulin glargine and NPH insulin in the LANMET study. In: Endocrine Reviews Conference: 93rd Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 32 (3 Meeting Abstracts). 2011. [EMBASE: 70676865]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJA . Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and IGF-I receptor signaling. Diabetes2013;62(7):2539-44. [PMID: 23569175]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJAMJL . Comparison of effects of insulin glargine, its metabolites, IGF-I and human insulin on insulin-and IGF-I receptor signaling in type 2 diabetic patients. In: Endocrine Reviews Conference: 95th Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 34 (3 suppl 1). 2013. [EMBASE: 71784187]Yki-JärvinenH , Kauppinen-MakelinR , TiikkainenM , VahataloM , VirtamoH , Nikkila K et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia2006;49(3):442-51. [PMID: 10937510]">Yki‐Järvinen 2006</a>). Three trials administered glargine in the morning (<a href="./references#CD005613-bbs2-0011" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KawamoriR , IwamotoY , KadowakiT , IwasakiM . Efficacy and safety of insulin glargine in concurrent use with oral hypoglycemic agents for the treatment of type 2 diabetes patients. Rinshoiyaku2003;19(5):445-64. ">Kawamori 2003</a>; <a href="./references#CD005613-bbs2-0002" title="BetônicoCC , TitanSM , Correa-GiannellaML , NeryM , QueirozM . Comparison of insulin glargine vs. NPH insulin in basal-bolus therapies in T2DM patients and CKD: preliminary results of a prospective, randomized, open-label trial. Diabetes2016;65:A144-5. [CENTRAL: CN-01450000] BetônicoCC , TitanSM , LiraA , PelaesTS , Correa-GiannellaML , NeryM , et al. Insulin glargine U100 improved glycemic control and reduced nocturnal hypoglycemia in patients with type 2 diabetes mellitus and chronic kidney disease stages 3 and 4. Clinical Therapeutics2019;41(10):2008-20. [PMID: 31383366]NCT02451917. Subcutaneous insulin glargine versus NPH insulin in patients with chronic kidney disease stages III and IV: randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02451917 (first received 22 May 2015). ">Betônico 2019</a>; <a href="./references#CD005613-bbs2-0024" title="YokoyamaH , TadaJ , KamikawaF , KannoS , YokotaY , KuramitsuM . Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Research &amp; Clinical Practice2006;73(1):35-40. [PMID: 16513202]">Yokoyama 2006</a>). Two further trials had two interventional arms, of which one involved taking glargine at bedtime and one in the morning (<a href="./references#CD005613-bbs2-0005" title="FritscheA , SchweitzerMA , HaringHU , Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Annals of Internal Medicine2003;138(12):952-9. [PMID: 12809451]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Fritsche 2003</a>; <a href="./references#CD005613-bbs2-0015" title="NCT00687453. The utility of insulin glargine (Lantus) compared to NPH in ethnic minority type 2 diabetic subjects on combination insulin-oral agent therapy. clinicaltrials.gov/ct2/show/NCT00687453 (first received 30 May 2008). ">NCT00687453</a>). Both intervention arms were compared with NPH. In one trial, glargine could be administered at any time, as long as it was at the same time each day (<a href="./references#CD005613-bbs2-0007" title="EUCTR2009-010913-59. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on OHA treatment initiating basal insulin therapy with either insulin glargine or NPH insulin added to therapies with oral hypoglycemic agents (HAPPY) (LANTU_L_04079 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2009-010913-59/results (last accessed 3 May 2017). HermannsN , KulzerB , KohlmannT , JacobS , LandgrafW , TheobaldK , et al. Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial. Health and Quality of Life Outcomes2015;13:77. [PMID: 26055391]NCT00941369. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on oral hypoglycemic agent treatment initiating basal insulin therapy with either insulin glargine or NPH insulin. clinicaltrials.gov/ct2/show/NCT00941369 (first received 17 July 2009). ">Hermanns 2015</a>). </p> <p>Most trials administered NPH once daily, either shortly before retiring to bed (<a href="./references#CD005613-bbs2-0003" title="EliaschewitzFG , CalvoC , ValbuenaH , RuizM , AschnerP , VillenaJ , et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Archives of Medical Research2006;37(4):495-501. [PMID: 16715577]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Eliaschewitz 2006</a>; <a href="./references#CD005613-bbs2-0005" title="FritscheA , SchweitzerMA , HaringHU , Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Annals of Internal Medicine2003;138(12):952-9. [PMID: 12809451]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Fritsche 2003</a>; <a href="./references#CD005613-bbs2-0009" title='EUCTR2007-006640-22. Superiority of insulin glargine Lantus vs NPH: "Treat to normoglycemia concept". Effect of insulin glargine in comparison to insulin NPH in insulin-naïve people with type 2 diabetes mellitus treated with at least one OAD and not adequately controlled (LANCELOT) (LANTU_C_02762 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2007-006640-22/results (last accessed 19 July 2017). HomePD , BolliGB , MathieuC , DeerochanawongC , LandgrafW , CandelasC , et al. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naive people with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2015;17(1):15-22. [PMID: 24957785]NCT00949442. Lantus versus NPH: comparison in insulin naive people not adequately controlled with at least one oral anti diabetics (OAD) treatment (LANCELOT). clinicaltrials.gov/ct2/show/NCT00949442 (first received 30 July 2009). '>Home 2015</a>; <a href="./references#CD005613-bbs2-0010" title="HsiaSH . Comparison of single-dose regimens of insulin glargine versus NPH among inner city ethnic minority type 2 diabetic patients uncontrolled on oral agents. Journal of Investigative Medicine2010;58(1):136. [EMBASE: 70981533]HsiaSH . Insulin glargine compared to NPH among insulin-naive, U.S. inner city, ethnic minority type 2 diabetic patients. Diabetes Research &amp; Clinical Practice2011;91(3):293-9. [PMID: 21146881]NCT00686712. Insulin glargine at bedtime or in AM versus NPH. clinicaltrials.gov/ct2/show/NCT00686712 (first received 7 October 2010). ">Hsia 2011</a>; <a href="./references#CD005613-bbs2-0014" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. MassiBM , HumburgE , DresslerA , ZiemenM . A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Hormone &amp; Metabolic Research2003;35(3):189-96. [PMID: 12734781]Yki-JarvinenH , DresslerA , ZiemenM . Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care2000;23(8):1130-6. [EMBASE: 2006092604]">Massi 2003</a>; <a href="./references#CD005613-bbs2-0019" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. PanCY , SinnassamyP , ChungKD , KimKW , Group LS . Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Research &amp; Clinical Practice2007;76(1):111-8. [PMID: 17011662]">Pan 2007</a>; <a href="./references#CD005613-bbs2-0020" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00653341. Effect of insulin glargine in insulin naïve subjects with type 2 diabetes on oral hypoglycemic agent(s). www.clinicaltrials.gov/ct2/show/results/NCT00653341 (first received 4 April 2008). RiddleMC , RosenstockJ , GerichJ , InsulinG . The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care2003;26(11):3080-6. [PMID: 14578243]">Riddle 2003</a>; <a href="./references#CD005613-bbs2-0023" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. VarewijckAJ , JanssenJA , VahataloM , HoflandLJ , LambertsSW , Yki-JarvinenH . Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. Diabetologia2012;55(4):1186-94. [PMID: 22237688]VarewijckAJ , JanssenJA , VahataloM , LambertsSW , Ki-JarvinenHY . IGF-I bioactivity decreases during insulin therapy in type 2 diabetic patients: comparison of high doses of insulin glargine and NPH insulin in the LANMET study. In: Endocrine Reviews Conference: 93rd Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 32 (3 Meeting Abstracts). 2011. [EMBASE: 70676865]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJA . Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and IGF-I receptor signaling. Diabetes2013;62(7):2539-44. [PMID: 23569175]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJAMJL . Comparison of effects of insulin glargine, its metabolites, IGF-I and human insulin on insulin-and IGF-I receptor signaling in type 2 diabetic patients. In: Endocrine Reviews Conference: 95th Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 34 (3 suppl 1). 2013. [EMBASE: 71784187]Yki-JärvinenH , Kauppinen-MakelinR , TiikkainenM , VahataloM , VirtamoH , Nikkila K et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia2006;49(3):442-51. [PMID: 10937510]">Yki‐Järvinen 2006</a>; <a href="./references#CD005613-bbs2-0024" title="YokoyamaH , TadaJ , KamikawaF , KannoS , YokotaY , KuramitsuM . Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Research &amp; Clinical Practice2006;73(1):35-40. [PMID: 16513202]">Yokoyama 2006</a>), or in the morning (<a href="./references#CD005613-bbs2-0011" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KawamoriR , IwamotoY , KadowakiT , IwasakiM . Efficacy and safety of insulin glargine in concurrent use with oral hypoglycemic agents for the treatment of type 2 diabetes patients. Rinshoiyaku2003;19(5):445-64. ">Kawamori 2003</a>). Three trials gave NPH once daily at bedtime and once more in the morning if blood glucose targets were not met (<a href="./references#CD005613-bbs2-0001" title="BerardL , CameronB , WooV , StewartJ . Replacing insulin glargine with neutral protamine Hagedorn (NPH) insulin in a subpopulation of study subjects in the action to control cardiovascular risk in diabetes (ACCORD): effects on blood glucose levels, hypoglycemia and patient satisfaction. Canadian Journal of Diabetes2015;39(4):296-301. [PMID: 25819531]BerardLD , WooVC . Safety and efficacy of NPH after switching from insulin glargine in Canadian patients. Diabetologia2011;54:S430. [EMBASE: 70563203]">Berard 2015</a>; <a href="./references#CD005613-bbs2-0007" title="EUCTR2009-010913-59. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on OHA treatment initiating basal insulin therapy with either insulin glargine or NPH insulin added to therapies with oral hypoglycemic agents (HAPPY) (LANTU_L_04079 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2009-010913-59/results (last accessed 3 May 2017). HermannsN , KulzerB , KohlmannT , JacobS , LandgrafW , TheobaldK , et al. Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial. Health and Quality of Life Outcomes2015;13:77. [PMID: 26055391]NCT00941369. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on oral hypoglycemic agent treatment initiating basal insulin therapy with either insulin glargine or NPH insulin. clinicaltrials.gov/ct2/show/NCT00941369 (first received 17 July 2009). ">Hermanns 2015</a>; <a href="./references#CD005613-bbs2-0021" title="FonsecaV , BellDS , BergerS , ThomsonS , MeccaTE . A comparison of bedtime insulin glargine with bedtime neutral protamine Hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. American Journal of the Medical Sciences2004;328(5):274-80. [PMID: 15545844]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. RosenstockJ , SchwartzSL , Clark CM Jr, ParkGD , DonleyDW , EdwardsMB . Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care2001;24(4):631-6. [PMID: 11315821]">Rosenstock 2001</a>). Two trials compared insulin glargine to NPH insulin both at bedtime and in the morning (<a href="./references#CD005613-bbs2-0015" title="NCT00687453. The utility of insulin glargine (Lantus) compared to NPH in ethnic minority type 2 diabetic subjects on combination insulin-oral agent therapy. clinicaltrials.gov/ct2/show/NCT00687453 (first received 30 May 2008). ">NCT00687453</a>; <a href="./references#CD005613-bbs2-0022" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00174824. Comparison of insulin glargine and NPH human insulin in progression of diabetic retinopathy in type 2 diabetic patients. clinicaltrials.gov/ct2/show/study/NCT00174824 (first received 15 September 2005). RosenstockJ , FonsecaV , DainMP , RiddleM . Estimating number-needed-to-treat to avoid hypoglycaemic episodes in people with type 2 diabetes: a post-hoc analysis of a prospective randomized controlled trial comparing once-daily insulin glargine with twice-daily NPH insulin. Canadian Journal of Diabetes2009;33(3):185-6. [EMBASE: 70031352]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia2009;52(9):1778-88. [PMID: 19526210]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia2009;52(9):1971-3. [PMID: 19609501]RosenstockJ , FonsecaV , SchinzelS , DainMP , MullinsP , RiddleM . Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: evidence from a long-term controlled trial. Journal of Diabetic Complications2014;28(5):742-9. [PMID: 24856612]">Rosenstock 2009</a>). One trial administered NPH three times daily, at breakfast, lunch and bedtime (<a href="./references#CD005613-bbs2-0002" title="BetônicoCC , TitanSM , Correa-GiannellaML , NeryM , QueirozM . Comparison of insulin glargine vs. NPH insulin in basal-bolus therapies in T2DM patients and CKD: preliminary results of a prospective, randomized, open-label trial. Diabetes2016;65:A144-5. [CENTRAL: CN-01450000] BetônicoCC , TitanSM , LiraA , PelaesTS , Correa-GiannellaML , NeryM , et al. Insulin glargine U100 improved glycemic control and reduced nocturnal hypoglycemia in patients with type 2 diabetes mellitus and chronic kidney disease stages 3 and 4. Clinical Therapeutics2019;41(10):2008-20. [PMID: 31383366]NCT02451917. Subcutaneous insulin glargine versus NPH insulin in patients with chronic kidney disease stages III and IV: randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02451917 (first received 22 May 2015). ">Betônico 2019</a>). </p> <p>Three trials administered short‐acting insulins (either regular insulin or short‐acting insulin analogues) at mealtimes in addition to glargine and NPH (<a href="./references#CD005613-bbs2-0002" title="BetônicoCC , TitanSM , Correa-GiannellaML , NeryM , QueirozM . Comparison of insulin glargine vs. NPH insulin in basal-bolus therapies in T2DM patients and CKD: preliminary results of a prospective, randomized, open-label trial. Diabetes2016;65:A144-5. [CENTRAL: CN-01450000] BetônicoCC , TitanSM , LiraA , PelaesTS , Correa-GiannellaML , NeryM , et al. Insulin glargine U100 improved glycemic control and reduced nocturnal hypoglycemia in patients with type 2 diabetes mellitus and chronic kidney disease stages 3 and 4. Clinical Therapeutics2019;41(10):2008-20. [PMID: 31383366]NCT02451917. Subcutaneous insulin glargine versus NPH insulin in patients with chronic kidney disease stages III and IV: randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02451917 (first received 22 May 2015). ">Betônico 2019</a>; <a href="./references#CD005613-bbs2-0021" title="FonsecaV , BellDS , BergerS , ThomsonS , MeccaTE . A comparison of bedtime insulin glargine with bedtime neutral protamine Hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. American Journal of the Medical Sciences2004;328(5):274-80. [PMID: 15545844]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. RosenstockJ , SchwartzSL , Clark CM Jr, ParkGD , DonleyDW , EdwardsMB . Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care2001;24(4):631-6. [PMID: 11315821]">Rosenstock 2001</a>; <a href="./references#CD005613-bbs2-0024" title="YokoyamaH , TadaJ , KamikawaF , KannoS , YokotaY , KuramitsuM . Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Research &amp; Clinical Practice2006;73(1):35-40. [PMID: 16513202]">Yokoyama 2006</a>). In nine trials, concomitant medication to lower blood glucose consisted only of OADs (<a href="./references#CD005613-bbs2-0003" title="EliaschewitzFG , CalvoC , ValbuenaH , RuizM , AschnerP , VillenaJ , et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Archives of Medical Research2006;37(4):495-501. [PMID: 16715577]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Eliaschewitz 2006</a>; <a href="./references#CD005613-bbs2-0005" title="FritscheA , SchweitzerMA , HaringHU , Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Annals of Internal Medicine2003;138(12):952-9. [PMID: 12809451]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Fritsche 2003</a>; <a href="./references#CD005613-bbs2-0010" title="HsiaSH . Comparison of single-dose regimens of insulin glargine versus NPH among inner city ethnic minority type 2 diabetic patients uncontrolled on oral agents. Journal of Investigative Medicine2010;58(1):136. [EMBASE: 70981533]HsiaSH . Insulin glargine compared to NPH among insulin-naive, U.S. inner city, ethnic minority type 2 diabetic patients. Diabetes Research &amp; Clinical Practice2011;91(3):293-9. [PMID: 21146881]NCT00686712. Insulin glargine at bedtime or in AM versus NPH. clinicaltrials.gov/ct2/show/NCT00686712 (first received 7 October 2010). ">Hsia 2011</a>; <a href="./references#CD005613-bbs2-0011" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KawamoriR , IwamotoY , KadowakiT , IwasakiM . Efficacy and safety of insulin glargine in concurrent use with oral hypoglycemic agents for the treatment of type 2 diabetes patients. Rinshoiyaku2003;19(5):445-64. ">Kawamori 2003</a>; <a href="./references#CD005613-bbs2-0014" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. MassiBM , HumburgE , DresslerA , ZiemenM . A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Hormone &amp; Metabolic Research2003;35(3):189-96. [PMID: 12734781]Yki-JarvinenH , DresslerA , ZiemenM . Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care2000;23(8):1130-6. [EMBASE: 2006092604]">Massi 2003</a>; <a href="./references#CD005613-bbs2-0015" title="NCT00687453. The utility of insulin glargine (Lantus) compared to NPH in ethnic minority type 2 diabetic subjects on combination insulin-oral agent therapy. clinicaltrials.gov/ct2/show/NCT00687453 (first received 30 May 2008). ">NCT00687453</a>; <a href="./references#CD005613-bbs2-0019" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. PanCY , SinnassamyP , ChungKD , KimKW , Group LS . Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Research &amp; Clinical Practice2007;76(1):111-8. [PMID: 17011662]">Pan 2007</a>; <a href="./references#CD005613-bbs2-0020" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00653341. Effect of insulin glargine in insulin naïve subjects with type 2 diabetes on oral hypoglycemic agent(s). www.clinicaltrials.gov/ct2/show/results/NCT00653341 (first received 4 April 2008). RiddleMC , RosenstockJ , GerichJ , InsulinG . The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care2003;26(11):3080-6. [PMID: 14578243]">Riddle 2003</a>; <a href="./references#CD005613-bbs2-0023" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. VarewijckAJ , JanssenJA , VahataloM , HoflandLJ , LambertsSW , Yki-JarvinenH . Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. Diabetologia2012;55(4):1186-94. [PMID: 22237688]VarewijckAJ , JanssenJA , VahataloM , LambertsSW , Ki-JarvinenHY . IGF-I bioactivity decreases during insulin therapy in type 2 diabetic patients: comparison of high doses of insulin glargine and NPH insulin in the LANMET study. In: Endocrine Reviews Conference: 93rd Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 32 (3 Meeting Abstracts). 2011. [EMBASE: 70676865]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJA . Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and IGF-I receptor signaling. Diabetes2013;62(7):2539-44. [PMID: 23569175]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJAMJL . Comparison of effects of insulin glargine, its metabolites, IGF-I and human insulin on insulin-and IGF-I receptor signaling in type 2 diabetic patients. In: Endocrine Reviews Conference: 95th Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 34 (3 suppl 1). 2013. [EMBASE: 71784187]Yki-JärvinenH , Kauppinen-MakelinR , TiikkainenM , VahataloM , VirtamoH , Nikkila K et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia2006;49(3):442-51. [PMID: 10937510]">Yki‐Järvinen 2006</a>). In the four remaining trials, additional blood glucose lowering medication included OADs and, if necessary, short‐acting insulins (<a href="./references#CD005613-bbs2-0001" title="BerardL , CameronB , WooV , StewartJ . Replacing insulin glargine with neutral protamine Hagedorn (NPH) insulin in a subpopulation of study subjects in the action to control cardiovascular risk in diabetes (ACCORD): effects on blood glucose levels, hypoglycemia and patient satisfaction. Canadian Journal of Diabetes2015;39(4):296-301. [PMID: 25819531]BerardLD , WooVC . Safety and efficacy of NPH after switching from insulin glargine in Canadian patients. Diabetologia2011;54:S430. [EMBASE: 70563203]">Berard 2015</a>; <a href="./references#CD005613-bbs2-0007" title="EUCTR2009-010913-59. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on OHA treatment initiating basal insulin therapy with either insulin glargine or NPH insulin added to therapies with oral hypoglycemic agents (HAPPY) (LANTU_L_04079 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2009-010913-59/results (last accessed 3 May 2017). HermannsN , KulzerB , KohlmannT , JacobS , LandgrafW , TheobaldK , et al. Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial. Health and Quality of Life Outcomes2015;13:77. [PMID: 26055391]NCT00941369. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on oral hypoglycemic agent treatment initiating basal insulin therapy with either insulin glargine or NPH insulin. clinicaltrials.gov/ct2/show/NCT00941369 (first received 17 July 2009). ">Hermanns 2015</a>; <a href="./references#CD005613-bbs2-0022" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00174824. Comparison of insulin glargine and NPH human insulin in progression of diabetic retinopathy in type 2 diabetic patients. clinicaltrials.gov/ct2/show/study/NCT00174824 (first received 15 September 2005). RosenstockJ , FonsecaV , DainMP , RiddleM . Estimating number-needed-to-treat to avoid hypoglycaemic episodes in people with type 2 diabetes: a post-hoc analysis of a prospective randomized controlled trial comparing once-daily insulin glargine with twice-daily NPH insulin. Canadian Journal of Diabetes2009;33(3):185-6. [EMBASE: 70031352]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia2009;52(9):1778-88. [PMID: 19526210]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia2009;52(9):1971-3. [PMID: 19609501]RosenstockJ , FonsecaV , SchinzelS , DainMP , MullinsP , RiddleM . Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: evidence from a long-term controlled trial. Journal of Diabetic Complications2014;28(5):742-9. [PMID: 24856612]">Rosenstock 2009</a>; <a href="./references#CD005613-bbs2-0024" title="YokoyamaH , TadaJ , KamikawaF , KannoS , YokotaY , KuramitsuM . Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Research &amp; Clinical Practice2006;73(1):35-40. [PMID: 16513202]">Yokoyama 2006</a>). </p> <p>All 16 trials used insulin glargine U100.</p> </section> <section id="CD005613-sec-0061"> <h6 class="title">Detemir versus NPH</h6> <p>Eight trials compared NPH insulin to insulin detemir (<a href="./references#CD005613-bbs2-0004" title="EUCTR2005-000976-42. A multi-centre, open-labelled, randomised, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime (PREDICTIVE-BMI study) – PREDICTIVE-BMI study. www.clinicaltrialsregister.eu/ctr-search/trial/2005-000976-42/ES (first received 17 May 2006). Fajardo MontañanaC , Hernandez HerreroC , Rivas FernandezM . Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabetic Medicine2008;25(8):916-23. [PMID: 18959604]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00504673. Comparison of insulin detemir versus insulin NPH on weight change in overweight and obese with type 2 diabetes (PREDICTIVE). clinicaltrials.gov/ct2/show/NCT00504673 (first received 20 July 2007). Novo Nordisk A/S. A multi-centre, open-labelled, randomized, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime. (PREDICTIVE-BMI study). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1410&amp;filename=1659-ctr-redacted.pdf (last accessed 3 November 2020). Smith-PalmerJ , Fajardo-MontananaC , PollockRF , EricssonA , ValentineWJ . Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. Journal of Medical Economics2012;15(5):977-86. [PMID: 22563742]">Fajardo Montañana 2008</a>; <a href="./references#CD005613-bbs2-0006" title="HaakT , TiengoA , DraegerE , SuntumM , WaldhauslW . Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2005;7(1):56-64. [PMID: 15642076]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Haak 2005</a>; <a href="./references#CD005613-bbs2-0008" title="DaileyG , StrangeP , RiddleM . Reconsideration of severe hypoglycemic events in the treat-to-target trial. Diabetes Technology &amp; Therapeutics2009;11(8):477-9. [PMID: 19698059]DaviesMJ , DerezinskiT , PedersenCB , ClausonP . Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Diabetes Technology &amp; Therapeutics2008;10(4):273-7. [PMID: 18715200]HermansenK , DaviesM , DerezinskiT , Martinez RavnG , ClausonP , HomeP . Erratum: A 26-week randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people wih type 2 diabetes (Diabetes Care (2006) 29, (1269-1274)). Diabetes Care2007;30(4):1035. [EMBASE: 46556609]HermansenK , DaviesM , DerezinskiT , MartinezRG , ClausonP , HomeP . A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care2006;29(6):1269-74. [PMID: 16732007]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00604396. Safety and efficacy of insulin detemir in combination with OAD in type 2 diabetes. clinicaltrials.gov/ct2/show/results/NCT00604396 (first received 30 January 2008). ">Hermansen 2006</a>; <a href="./references#CD005613-bbs2-0012" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. IshiiH , IwamotoY , KakuK , KawamoriR , KobayashiM , TajimaN . Night-time QOL and treatment satisfaction in diabetes mellitus patients treated with insulin detemir used in basal-bolus therapy – randomized multicenter open-label parallel group phase 3 trial compared to NPH insulin. Journal of the Japan Diabetes Society2009;52(8):691-701. [DOI: 10.11213/tonyobyo.52.691]KobayashiM , IwamotoY , KakuK , KawamoriR , TajimaN . Phase 3 clinical trial of insulin detemir for patients with insulin-dependent diabetes during basal-bolus therapy – a study of efficacy and safety with NPH insulin as control. Journal of the Japan Diabetes Society2007;50(9):649-63. [DOI: 10.11213/tonyobyo.50.649]NCT00604344. Efficacy and the safety of insulin detemir in subjects with insulin requiring diabetes. clinicaltrials.gov/ct2/show/NCT00604344 (first received 30 January 2008). Novo Nordisk A/S. A 48-week, randomised, multi-centre, open-labelled, parallel-group trial to compare the efficacy and the safety of NN304 (insulin detemir) and NPH human insulin in subjects with insulin requiring diabetes mellitus on a basal-bolus regimen. https://s3.amazonaws.com/ctr-nvo-7271/NN304-1476/aa9b4da3-1f92-460d-af0a-cc538614c3b2/3f7ed86e-d6e7-4542-ab8f-6cad24b46593/1476-ctr-synopsis-redacted-v2.pdf (last accessed 3 November 2020). ">Kobayashi 2007 A</a>; <a href="./references#CD005613-bbs2-0013" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KobayashiM , IwamotoY , KakuK , KawamoriR , TajimaN . Phase 3 clinical trial of insulin detemir for type 2 diabetes patients with insufficient blood sugar control in oral diabetes drug therapy. Journal of the Japan Diabetes Society2007;50(9):665-77. [DOI: 10.11213/tonyobyo.50.665]NCT00604253. Efficacy and safety of insulin detemir in type 2 diabetes inadequately controlled on OHA therapy alone. www.clinicaltrials.gov/ct2/show/results/NCT00604253 (first received 30 January 2008). Novo Nordisk A/S. A 36-week, randomised, multi-centre, open-labelled, parallel-group trial to compare the efficacy and the safety of NN304 and NPH human insulin once daily treatment as add-on to current OHA therapy in subjects with type 2 diabetes mellitus who are inadequately controlled on OHA therapy. http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1397&amp;filename=NN304_1477_ICTRSynopsis_Final_20051101.pdf (last accessed 3 November 2020). ">Kobayashi 2007 B</a>; <a href="./references#CD005613-bbs2-0016" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">NN304‐1337</a>; <a href="./references#CD005613-bbs2-0017" title="DoucetJ , Le FlochJ , HanaireH , CourregesJ , AlexandreB , BauduceauB . Comparison of safety between detemir and neutral protamine Hagedorn (NPH) in ageing subjects: the '3 L study'. Fundamental and Clinical Pharmacology2011;25:82. [EMBASE: 70653089]EUCTR2006-006589-41-FR. Levemir® in ageing patients with type 2 diabetes A seven-month open-labelled randomised multi-centre two-group parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in the morning in ageing subjects with type 2 diabetes. The 3L Study (Levemir in Late Life) Trial Phase: 4. www.clinicaltrialsregister.eu/ctr-search/trial/2006-006589-41/FR (first received 27 March 2007). NCT00506662. The effect of insulin detemir on glucose control in ageing subjects with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00506662 (first received 25 July 2007). Novo Nordisk A/S. A seven-month, open-labelled, randomised, multicentre, two-group, parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in ageing patients with type 2 diabetes: The 3L Study (Levemir in Later Life) (NN304-1808 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1426&amp;filename=1808-ctr-redacted.pdf (last accessed 3 November 2020). ">NN304‐1808</a>; <a href="./references#CD005613-bbs2-0018" title="EUCTR2008-003739-19. Ensayo multicéntrico, abierto, aleatorizado, de dos grupos, paralelo para comparar el cambio en la distribución de grasa en sujetos con sobrepeso y obesos con diabetes tipo 2 tras 26 semanas de tratamiento con insulina detemir una vez al día frente a insulina NPH una vez al día, ambas con insulina aspart a la hora de las comidas. www.clinicaltrialsregister.eu/ctr-search/trial/2008-003739-19/ES (first received 19 September 2008). NCT00795600. A multi-centre, open-labelled, randomised, two-group parallel trial comparing the change in fat distribution in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin apart at mealtimes. clinicaltrials.gov/ct2/show/NCT00795600 (first received 21 November 2008). Novo Nordisk A/S. A multi-centre, open-labelled, randomised, two-group parallel trial comparing the change in fat distribution in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart at mealtimes (NN304-3614 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1461&amp;filename=3614-ctr-synopsis-redacted.pdf (last accessed 3 November 2020). TinahonesFJ , Gomez-HuelgasR , Garcia-AlegriaJ , Tapia-GuerreroM , Martos-PerezF . Fat distribution, HbA1c and hypoglycaemia in overweight and obese patients with type 2 diabetes: a comparison of NPH and insulin detemir from a pilot randomised clinical trial. Diabetologia2011;54:S273. [EMBASE: 70562816]TinahonesFJ , Gomez-HuelgasR , GarciaalegriaJ , Tapia-GuerreroMJ , PerezFM . The effect of insulin detemir on fat distribution and weight parameters in overweight and obese subjects with type 2 diabetes. Diabetes2011;60:A309. [EMBASE: 70628891]">NN304‐3614</a>). </p> <p>Five of these trials administered detemir and NPH once daily, either shortly before retiring to bed (<a href="./references#CD005613-bbs2-0004" title="EUCTR2005-000976-42. A multi-centre, open-labelled, randomised, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime (PREDICTIVE-BMI study) – PREDICTIVE-BMI study. www.clinicaltrialsregister.eu/ctr-search/trial/2005-000976-42/ES (first received 17 May 2006). Fajardo MontañanaC , Hernandez HerreroC , Rivas FernandezM . Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabetic Medicine2008;25(8):916-23. [PMID: 18959604]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00504673. Comparison of insulin detemir versus insulin NPH on weight change in overweight and obese with type 2 diabetes (PREDICTIVE). clinicaltrials.gov/ct2/show/NCT00504673 (first received 20 July 2007). Novo Nordisk A/S. A multi-centre, open-labelled, randomized, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime. (PREDICTIVE-BMI study). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1410&amp;filename=1659-ctr-redacted.pdf (last accessed 3 November 2020). Smith-PalmerJ , Fajardo-MontananaC , PollockRF , EricssonA , ValentineWJ . Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. Journal of Medical Economics2012;15(5):977-86. [PMID: 22563742]">Fajardo Montañana 2008</a>; <a href="./references#CD005613-bbs2-0013" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KobayashiM , IwamotoY , KakuK , KawamoriR , TajimaN . Phase 3 clinical trial of insulin detemir for type 2 diabetes patients with insufficient blood sugar control in oral diabetes drug therapy. Journal of the Japan Diabetes Society2007;50(9):665-77. [DOI: 10.11213/tonyobyo.50.665]NCT00604253. Efficacy and safety of insulin detemir in type 2 diabetes inadequately controlled on OHA therapy alone. www.clinicaltrials.gov/ct2/show/results/NCT00604253 (first received 30 January 2008). Novo Nordisk A/S. A 36-week, randomised, multi-centre, open-labelled, parallel-group trial to compare the efficacy and the safety of NN304 and NPH human insulin once daily treatment as add-on to current OHA therapy in subjects with type 2 diabetes mellitus who are inadequately controlled on OHA therapy. http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1397&amp;filename=NN304_1477_ICTRSynopsis_Final_20051101.pdf (last accessed 3 November 2020). ">Kobayashi 2007 B</a>; <a href="./references#CD005613-bbs2-0016" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">NN304‐1337</a>; <a href="./references#CD005613-bbs2-0018" title="EUCTR2008-003739-19. Ensayo multicéntrico, abierto, aleatorizado, de dos grupos, paralelo para comparar el cambio en la distribución de grasa en sujetos con sobrepeso y obesos con diabetes tipo 2 tras 26 semanas de tratamiento con insulina detemir una vez al día frente a insulina NPH una vez al día, ambas con insulina aspart a la hora de las comidas. www.clinicaltrialsregister.eu/ctr-search/trial/2008-003739-19/ES (first received 19 September 2008). NCT00795600. A multi-centre, open-labelled, randomised, two-group parallel trial comparing the change in fat distribution in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin apart at mealtimes. clinicaltrials.gov/ct2/show/NCT00795600 (first received 21 November 2008). Novo Nordisk A/S. A multi-centre, open-labelled, randomised, two-group parallel trial comparing the change in fat distribution in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart at mealtimes (NN304-3614 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1461&amp;filename=3614-ctr-synopsis-redacted.pdf (last accessed 3 November 2020). TinahonesFJ , Gomez-HuelgasR , Garcia-AlegriaJ , Tapia-GuerreroM , Martos-PerezF . Fat distribution, HbA1c and hypoglycaemia in overweight and obese patients with type 2 diabetes: a comparison of NPH and insulin detemir from a pilot randomised clinical trial. Diabetologia2011;54:S273. [EMBASE: 70562816]TinahonesFJ , Gomez-HuelgasR , GarciaalegriaJ , Tapia-GuerreroMJ , PerezFM . The effect of insulin detemir on fat distribution and weight parameters in overweight and obese subjects with type 2 diabetes. Diabetes2011;60:A309. [EMBASE: 70628891]">NN304‐3614</a>), or in the morning (<a href="./references#CD005613-bbs2-0017" title="DoucetJ , Le FlochJ , HanaireH , CourregesJ , AlexandreB , BauduceauB . Comparison of safety between detemir and neutral protamine Hagedorn (NPH) in ageing subjects: the '3 L study'. Fundamental and Clinical Pharmacology2011;25:82. [EMBASE: 70653089]EUCTR2006-006589-41-FR. Levemir® in ageing patients with type 2 diabetes A seven-month open-labelled randomised multi-centre two-group parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in the morning in ageing subjects with type 2 diabetes. The 3L Study (Levemir in Late Life) Trial Phase: 4. www.clinicaltrialsregister.eu/ctr-search/trial/2006-006589-41/FR (first received 27 March 2007). NCT00506662. The effect of insulin detemir on glucose control in ageing subjects with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00506662 (first received 25 July 2007). Novo Nordisk A/S. A seven-month, open-labelled, randomised, multicentre, two-group, parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in ageing patients with type 2 diabetes: The 3L Study (Levemir in Later Life) (NN304-1808 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1426&amp;filename=1808-ctr-redacted.pdf (last accessed 3 November 2020). ">NN304‐1808</a>). Two trials gave detemir and NPH at bedtime and, if necessary, in the morning (<a href="./references#CD005613-bbs2-0006" title="HaakT , TiengoA , DraegerE , SuntumM , WaldhauslW . Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2005;7(1):56-64. [PMID: 15642076]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Haak 2005</a>; <a href="./references#CD005613-bbs2-0012" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. IshiiH , IwamotoY , KakuK , KawamoriR , KobayashiM , TajimaN . Night-time QOL and treatment satisfaction in diabetes mellitus patients treated with insulin detemir used in basal-bolus therapy – randomized multicenter open-label parallel group phase 3 trial compared to NPH insulin. Journal of the Japan Diabetes Society2009;52(8):691-701. [DOI: 10.11213/tonyobyo.52.691]KobayashiM , IwamotoY , KakuK , KawamoriR , TajimaN . Phase 3 clinical trial of insulin detemir for patients with insulin-dependent diabetes during basal-bolus therapy – a study of efficacy and safety with NPH insulin as control. Journal of the Japan Diabetes Society2007;50(9):649-63. [DOI: 10.11213/tonyobyo.50.649]NCT00604344. Efficacy and the safety of insulin detemir in subjects with insulin requiring diabetes. clinicaltrials.gov/ct2/show/NCT00604344 (first received 30 January 2008). Novo Nordisk A/S. A 48-week, randomised, multi-centre, open-labelled, parallel-group trial to compare the efficacy and the safety of NN304 (insulin detemir) and NPH human insulin in subjects with insulin requiring diabetes mellitus on a basal-bolus regimen. https://s3.amazonaws.com/ctr-nvo-7271/NN304-1476/aa9b4da3-1f92-460d-af0a-cc538614c3b2/3f7ed86e-d6e7-4542-ab8f-6cad24b46593/1476-ctr-synopsis-redacted-v2.pdf (last accessed 3 November 2020). ">Kobayashi 2007 A</a>), and study gave them at bedtime and in the morning (<a href="./references#CD005613-bbs2-0008" title="DaileyG , StrangeP , RiddleM . Reconsideration of severe hypoglycemic events in the treat-to-target trial. Diabetes Technology &amp; Therapeutics2009;11(8):477-9. [PMID: 19698059]DaviesMJ , DerezinskiT , PedersenCB , ClausonP . Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Diabetes Technology &amp; Therapeutics2008;10(4):273-7. [PMID: 18715200]HermansenK , DaviesM , DerezinskiT , Martinez RavnG , ClausonP , HomeP . Erratum: A 26-week randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people wih type 2 diabetes (Diabetes Care (2006) 29, (1269-1274)). Diabetes Care2007;30(4):1035. [EMBASE: 46556609]HermansenK , DaviesM , DerezinskiT , MartinezRG , ClausonP , HomeP . A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care2006;29(6):1269-74. [PMID: 16732007]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00604396. Safety and efficacy of insulin detemir in combination with OAD in type 2 diabetes. clinicaltrials.gov/ct2/show/results/NCT00604396 (first received 30 January 2008). ">Hermansen 2006</a>). </p> <p>Four studies gave OADs as concomitant medication to lower blood glucose (<a href="./references#CD005613-bbs2-0008" title="DaileyG , StrangeP , RiddleM . Reconsideration of severe hypoglycemic events in the treat-to-target trial. Diabetes Technology &amp; Therapeutics2009;11(8):477-9. [PMID: 19698059]DaviesMJ , DerezinskiT , PedersenCB , ClausonP . Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Diabetes Technology &amp; Therapeutics2008;10(4):273-7. [PMID: 18715200]HermansenK , DaviesM , DerezinskiT , Martinez RavnG , ClausonP , HomeP . Erratum: A 26-week randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people wih type 2 diabetes (Diabetes Care (2006) 29, (1269-1274)). Diabetes Care2007;30(4):1035. [EMBASE: 46556609]HermansenK , DaviesM , DerezinskiT , MartinezRG , ClausonP , HomeP . A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care2006;29(6):1269-74. [PMID: 16732007]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00604396. Safety and efficacy of insulin detemir in combination with OAD in type 2 diabetes. clinicaltrials.gov/ct2/show/results/NCT00604396 (first received 30 January 2008). ">Hermansen 2006</a>; <a href="./references#CD005613-bbs2-0013" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KobayashiM , IwamotoY , KakuK , KawamoriR , TajimaN . Phase 3 clinical trial of insulin detemir for type 2 diabetes patients with insufficient blood sugar control in oral diabetes drug therapy. Journal of the Japan Diabetes Society2007;50(9):665-77. [DOI: 10.11213/tonyobyo.50.665]NCT00604253. Efficacy and safety of insulin detemir in type 2 diabetes inadequately controlled on OHA therapy alone. www.clinicaltrials.gov/ct2/show/results/NCT00604253 (first received 30 January 2008). Novo Nordisk A/S. A 36-week, randomised, multi-centre, open-labelled, parallel-group trial to compare the efficacy and the safety of NN304 and NPH human insulin once daily treatment as add-on to current OHA therapy in subjects with type 2 diabetes mellitus who are inadequately controlled on OHA therapy. http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1397&amp;filename=NN304_1477_ICTRSynopsis_Final_20051101.pdf (last accessed 3 November 2020). ">Kobayashi 2007 B</a>; <a href="./references#CD005613-bbs2-0016" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">NN304‐1337</a>; <a href="./references#CD005613-bbs2-0017" title="DoucetJ , Le FlochJ , HanaireH , CourregesJ , AlexandreB , BauduceauB . Comparison of safety between detemir and neutral protamine Hagedorn (NPH) in ageing subjects: the '3 L study'. Fundamental and Clinical Pharmacology2011;25:82. [EMBASE: 70653089]EUCTR2006-006589-41-FR. Levemir® in ageing patients with type 2 diabetes A seven-month open-labelled randomised multi-centre two-group parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in the morning in ageing subjects with type 2 diabetes. The 3L Study (Levemir in Late Life) Trial Phase: 4. www.clinicaltrialsregister.eu/ctr-search/trial/2006-006589-41/FR (first received 27 March 2007). NCT00506662. The effect of insulin detemir on glucose control in ageing subjects with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00506662 (first received 25 July 2007). Novo Nordisk A/S. A seven-month, open-labelled, randomised, multicentre, two-group, parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in ageing patients with type 2 diabetes: The 3L Study (Levemir in Later Life) (NN304-1808 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1426&amp;filename=1808-ctr-redacted.pdf (last accessed 3 November 2020). ">NN304‐1808</a>), three studies gave of insulin aspart at mealtimes (<a href="./references#CD005613-bbs2-0006" title="HaakT , TiengoA , DraegerE , SuntumM , WaldhauslW . Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2005;7(1):56-64. [PMID: 15642076]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Haak 2005</a>; <a href="./references#CD005613-bbs2-0012" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. IshiiH , IwamotoY , KakuK , KawamoriR , KobayashiM , TajimaN . Night-time QOL and treatment satisfaction in diabetes mellitus patients treated with insulin detemir used in basal-bolus therapy – randomized multicenter open-label parallel group phase 3 trial compared to NPH insulin. Journal of the Japan Diabetes Society2009;52(8):691-701. [DOI: 10.11213/tonyobyo.52.691]KobayashiM , IwamotoY , KakuK , KawamoriR , TajimaN . Phase 3 clinical trial of insulin detemir for patients with insulin-dependent diabetes during basal-bolus therapy – a study of efficacy and safety with NPH insulin as control. Journal of the Japan Diabetes Society2007;50(9):649-63. [DOI: 10.11213/tonyobyo.50.649]NCT00604344. Efficacy and the safety of insulin detemir in subjects with insulin requiring diabetes. clinicaltrials.gov/ct2/show/NCT00604344 (first received 30 January 2008). Novo Nordisk A/S. A 48-week, randomised, multi-centre, open-labelled, parallel-group trial to compare the efficacy and the safety of NN304 (insulin detemir) and NPH human insulin in subjects with insulin requiring diabetes mellitus on a basal-bolus regimen. https://s3.amazonaws.com/ctr-nvo-7271/NN304-1476/aa9b4da3-1f92-460d-af0a-cc538614c3b2/3f7ed86e-d6e7-4542-ab8f-6cad24b46593/1476-ctr-synopsis-redacted-v2.pdf (last accessed 3 November 2020). ">Kobayashi 2007 A</a>; <a href="./references#CD005613-bbs2-0018" title="EUCTR2008-003739-19. Ensayo multicéntrico, abierto, aleatorizado, de dos grupos, paralelo para comparar el cambio en la distribución de grasa en sujetos con sobrepeso y obesos con diabetes tipo 2 tras 26 semanas de tratamiento con insulina detemir una vez al día frente a insulina NPH una vez al día, ambas con insulina aspart a la hora de las comidas. www.clinicaltrialsregister.eu/ctr-search/trial/2008-003739-19/ES (first received 19 September 2008). NCT00795600. A multi-centre, open-labelled, randomised, two-group parallel trial comparing the change in fat distribution in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin apart at mealtimes. clinicaltrials.gov/ct2/show/NCT00795600 (first received 21 November 2008). Novo Nordisk A/S. A multi-centre, open-labelled, randomised, two-group parallel trial comparing the change in fat distribution in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart at mealtimes (NN304-3614 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1461&amp;filename=3614-ctr-synopsis-redacted.pdf (last accessed 3 November 2020). TinahonesFJ , Gomez-HuelgasR , Garcia-AlegriaJ , Tapia-GuerreroM , Martos-PerezF . Fat distribution, HbA1c and hypoglycaemia in overweight and obese patients with type 2 diabetes: a comparison of NPH and insulin detemir from a pilot randomised clinical trial. Diabetologia2011;54:S273. [EMBASE: 70562816]TinahonesFJ , Gomez-HuelgasR , GarciaalegriaJ , Tapia-GuerreroMJ , PerezFM . The effect of insulin detemir on fat distribution and weight parameters in overweight and obese subjects with type 2 diabetes. Diabetes2011;60:A309. [EMBASE: 70628891]">NN304‐3614</a>), and one study gave a combination of insulin aspart and OADs (<a href="./references#CD005613-bbs2-0004" title="EUCTR2005-000976-42. A multi-centre, open-labelled, randomised, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime (PREDICTIVE-BMI study) – PREDICTIVE-BMI study. www.clinicaltrialsregister.eu/ctr-search/trial/2005-000976-42/ES (first received 17 May 2006). Fajardo MontañanaC , Hernandez HerreroC , Rivas FernandezM . Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabetic Medicine2008;25(8):916-23. [PMID: 18959604]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00504673. Comparison of insulin detemir versus insulin NPH on weight change in overweight and obese with type 2 diabetes (PREDICTIVE). clinicaltrials.gov/ct2/show/NCT00504673 (first received 20 July 2007). Novo Nordisk A/S. A multi-centre, open-labelled, randomized, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime. (PREDICTIVE-BMI study). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1410&amp;filename=1659-ctr-redacted.pdf (last accessed 3 November 2020). Smith-PalmerJ , Fajardo-MontananaC , PollockRF , EricssonA , ValentineWJ . Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. Journal of Medical Economics2012;15(5):977-86. [PMID: 22563742]">Fajardo Montañana 2008</a>). </p> </section> <section id="CD005613-sec-0062"> <h6 class="title">Deglutec versus NPH</h6> <p>We found no trials comparing insulin degludec with NPH insulin.</p> </section> </section> <section id="CD005613-sec-0063"> <h5 class="title">Overview of trial populations</h5> <section id="CD005613-sec-0064"> <h6 class="title">Glargine versus NPH</h6> <p>Overall, 6330 people with type 2 diabetes mellitus were randomised to the different comparison groups. Individual sample sizes ranged from 24 to 1024 participants per study. Between 60% and 95% of randomised participants finished the trials. </p> </section> <section id="CD005613-sec-0065"> <h6 class="title">Detemir versus NPH</h6> <p>Overall, 2347 people with type 2 diabetes mellitus were randomised to the different comparison groups. Individual sample sizes ranged from 60 to 505 per study. Between 48% and 95% of participants finished the trial. </p> </section> </section> <section id="CD005613-sec-0066"> <h5 class="title">Trial design</h5> <section id="CD005613-sec-0067"> <h6 class="title">Glargine versus NPH</h6> <p>Fourteen trials had a parallel design (<a href="./references#CD005613-bbs2-0001" title="BerardL , CameronB , WooV , StewartJ . Replacing insulin glargine with neutral protamine Hagedorn (NPH) insulin in a subpopulation of study subjects in the action to control cardiovascular risk in diabetes (ACCORD): effects on blood glucose levels, hypoglycemia and patient satisfaction. Canadian Journal of Diabetes2015;39(4):296-301. [PMID: 25819531]BerardLD , WooVC . Safety and efficacy of NPH after switching from insulin glargine in Canadian patients. Diabetologia2011;54:S430. [EMBASE: 70563203]">Berard 2015</a>; <a href="./references#CD005613-bbs2-0003" title="EliaschewitzFG , CalvoC , ValbuenaH , RuizM , AschnerP , VillenaJ , et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Archives of Medical Research2006;37(4):495-501. [PMID: 16715577]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Eliaschewitz 2006</a>; <a href="./references#CD005613-bbs2-0005" title="FritscheA , SchweitzerMA , HaringHU , Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Annals of Internal Medicine2003;138(12):952-9. [PMID: 12809451]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Fritsche 2003</a>; <a href="./references#CD005613-bbs2-0009" title='EUCTR2007-006640-22. Superiority of insulin glargine Lantus vs NPH: "Treat to normoglycemia concept". Effect of insulin glargine in comparison to insulin NPH in insulin-naïve people with type 2 diabetes mellitus treated with at least one OAD and not adequately controlled (LANCELOT) (LANTU_C_02762 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2007-006640-22/results (last accessed 19 July 2017). HomePD , BolliGB , MathieuC , DeerochanawongC , LandgrafW , CandelasC , et al. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naive people with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2015;17(1):15-22. [PMID: 24957785]NCT00949442. Lantus versus NPH: comparison in insulin naive people not adequately controlled with at least one oral anti diabetics (OAD) treatment (LANCELOT). clinicaltrials.gov/ct2/show/NCT00949442 (first received 30 July 2009). '>Home 2015</a>; <a href="./references#CD005613-bbs2-0010" title="HsiaSH . Comparison of single-dose regimens of insulin glargine versus NPH among inner city ethnic minority type 2 diabetic patients uncontrolled on oral agents. Journal of Investigative Medicine2010;58(1):136. [EMBASE: 70981533]HsiaSH . Insulin glargine compared to NPH among insulin-naive, U.S. inner city, ethnic minority type 2 diabetic patients. Diabetes Research &amp; Clinical Practice2011;91(3):293-9. [PMID: 21146881]NCT00686712. Insulin glargine at bedtime or in AM versus NPH. clinicaltrials.gov/ct2/show/NCT00686712 (first received 7 October 2010). ">Hsia 2011</a>; <a href="./references#CD005613-bbs2-0011" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KawamoriR , IwamotoY , KadowakiT , IwasakiM . Efficacy and safety of insulin glargine in concurrent use with oral hypoglycemic agents for the treatment of type 2 diabetes patients. Rinshoiyaku2003;19(5):445-64. ">Kawamori 2003</a>; <a href="./references#CD005613-bbs2-0014" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. MassiBM , HumburgE , DresslerA , ZiemenM . A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Hormone &amp; Metabolic Research2003;35(3):189-96. [PMID: 12734781]Yki-JarvinenH , DresslerA , ZiemenM . Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care2000;23(8):1130-6. [EMBASE: 2006092604]">Massi 2003</a>; <a href="./references#CD005613-bbs2-0015" title="NCT00687453. The utility of insulin glargine (Lantus) compared to NPH in ethnic minority type 2 diabetic subjects on combination insulin-oral agent therapy. clinicaltrials.gov/ct2/show/NCT00687453 (first received 30 May 2008). ">NCT00687453</a>; <a href="./references#CD005613-bbs2-0019" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. PanCY , SinnassamyP , ChungKD , KimKW , Group LS . Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Research &amp; Clinical Practice2007;76(1):111-8. [PMID: 17011662]">Pan 2007</a>; <a href="./references#CD005613-bbs2-0020" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00653341. Effect of insulin glargine in insulin naïve subjects with type 2 diabetes on oral hypoglycemic agent(s). www.clinicaltrials.gov/ct2/show/results/NCT00653341 (first received 4 April 2008). RiddleMC , RosenstockJ , GerichJ , InsulinG . The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care2003;26(11):3080-6. [PMID: 14578243]">Riddle 2003</a>; <a href="./references#CD005613-bbs2-0021" title="FonsecaV , BellDS , BergerS , ThomsonS , MeccaTE . A comparison of bedtime insulin glargine with bedtime neutral protamine Hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. American Journal of the Medical Sciences2004;328(5):274-80. [PMID: 15545844]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. RosenstockJ , SchwartzSL , Clark CM Jr, ParkGD , DonleyDW , EdwardsMB . Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care2001;24(4):631-6. [PMID: 11315821]">Rosenstock 2001</a>; <a href="./references#CD005613-bbs2-0022" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00174824. Comparison of insulin glargine and NPH human insulin in progression of diabetic retinopathy in type 2 diabetic patients. clinicaltrials.gov/ct2/show/study/NCT00174824 (first received 15 September 2005). RosenstockJ , FonsecaV , DainMP , RiddleM . Estimating number-needed-to-treat to avoid hypoglycaemic episodes in people with type 2 diabetes: a post-hoc analysis of a prospective randomized controlled trial comparing once-daily insulin glargine with twice-daily NPH insulin. Canadian Journal of Diabetes2009;33(3):185-6. [EMBASE: 70031352]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia2009;52(9):1778-88. [PMID: 19526210]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia2009;52(9):1971-3. [PMID: 19609501]RosenstockJ , FonsecaV , SchinzelS , DainMP , MullinsP , RiddleM . Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: evidence from a long-term controlled trial. Journal of Diabetic Complications2014;28(5):742-9. [PMID: 24856612]">Rosenstock 2009</a>; <a href="./references#CD005613-bbs2-0023" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. VarewijckAJ , JanssenJA , VahataloM , HoflandLJ , LambertsSW , Yki-JarvinenH . Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. Diabetologia2012;55(4):1186-94. [PMID: 22237688]VarewijckAJ , JanssenJA , VahataloM , LambertsSW , Ki-JarvinenHY . IGF-I bioactivity decreases during insulin therapy in type 2 diabetic patients: comparison of high doses of insulin glargine and NPH insulin in the LANMET study. In: Endocrine Reviews Conference: 93rd Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 32 (3 Meeting Abstracts). 2011. [EMBASE: 70676865]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJA . Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and IGF-I receptor signaling. Diabetes2013;62(7):2539-44. [PMID: 23569175]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJAMJL . Comparison of effects of insulin glargine, its metabolites, IGF-I and human insulin on insulin-and IGF-I receptor signaling in type 2 diabetic patients. In: Endocrine Reviews Conference: 95th Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 34 (3 suppl 1). 2013. [EMBASE: 71784187]Yki-JärvinenH , Kauppinen-MakelinR , TiikkainenM , VahataloM , VirtamoH , Nikkila K et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia2006;49(3):442-51. [PMID: 10937510]">Yki‐Järvinen 2006</a>; <a href="./references#CD005613-bbs2-0024" title="YokoyamaH , TadaJ , KamikawaF , KannoS , YokotaY , KuramitsuM . Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Research &amp; Clinical Practice2006;73(1):35-40. [PMID: 16513202]">Yokoyama 2006</a>), and two had a cross‐over design (<a href="./references#CD005613-bbs2-0007" title="EUCTR2009-010913-59. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on OHA treatment initiating basal insulin therapy with either insulin glargine or NPH insulin added to therapies with oral hypoglycemic agents (HAPPY) (LANTU_L_04079 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2009-010913-59/results (last accessed 3 May 2017). HermannsN , KulzerB , KohlmannT , JacobS , LandgrafW , TheobaldK , et al. Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial. Health and Quality of Life Outcomes2015;13:77. [PMID: 26055391]NCT00941369. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on oral hypoglycemic agent treatment initiating basal insulin therapy with either insulin glargine or NPH insulin. clinicaltrials.gov/ct2/show/NCT00941369 (first received 17 July 2009). ">Hermanns 2015</a>; <a href="./references#CD005613-bbs2-0002" title="BetônicoCC , TitanSM , Correa-GiannellaML , NeryM , QueirozM . Comparison of insulin glargine vs. NPH insulin in basal-bolus therapies in T2DM patients and CKD: preliminary results of a prospective, randomized, open-label trial. Diabetes2016;65:A144-5. [CENTRAL: CN-01450000] BetônicoCC , TitanSM , LiraA , PelaesTS , Correa-GiannellaML , NeryM , et al. Insulin glargine U100 improved glycemic control and reduced nocturnal hypoglycemia in patients with type 2 diabetes mellitus and chronic kidney disease stages 3 and 4. Clinical Therapeutics2019;41(10):2008-20. [PMID: 31383366]NCT02451917. Subcutaneous insulin glargine versus NPH insulin in patients with chronic kidney disease stages III and IV: randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02451917 (first received 22 May 2015). ">Betônico 2019</a>). Seven trials had a superiority design (<a href="./references#CD005613-bbs2-0007" title="EUCTR2009-010913-59. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on OHA treatment initiating basal insulin therapy with either insulin glargine or NPH insulin added to therapies with oral hypoglycemic agents (HAPPY) (LANTU_L_04079 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2009-010913-59/results (last accessed 3 May 2017). HermannsN , KulzerB , KohlmannT , JacobS , LandgrafW , TheobaldK , et al. Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial. Health and Quality of Life Outcomes2015;13:77. [PMID: 26055391]NCT00941369. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on oral hypoglycemic agent treatment initiating basal insulin therapy with either insulin glargine or NPH insulin. clinicaltrials.gov/ct2/show/NCT00941369 (first received 17 July 2009). ">Hermanns 2015</a>; <a href="./references#CD005613-bbs2-0009" title='EUCTR2007-006640-22. Superiority of insulin glargine Lantus vs NPH: "Treat to normoglycemia concept". Effect of insulin glargine in comparison to insulin NPH in insulin-naïve people with type 2 diabetes mellitus treated with at least one OAD and not adequately controlled (LANCELOT) (LANTU_C_02762 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2007-006640-22/results (last accessed 19 July 2017). HomePD , BolliGB , MathieuC , DeerochanawongC , LandgrafW , CandelasC , et al. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naive people with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2015;17(1):15-22. [PMID: 24957785]NCT00949442. Lantus versus NPH: comparison in insulin naive people not adequately controlled with at least one oral anti diabetics (OAD) treatment (LANCELOT). clinicaltrials.gov/ct2/show/NCT00949442 (first received 30 July 2009). '>Home 2015</a>; <a href="./references#CD005613-bbs2-0014" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. MassiBM , HumburgE , DresslerA , ZiemenM . A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Hormone &amp; Metabolic Research2003;35(3):189-96. [PMID: 12734781]Yki-JarvinenH , DresslerA , ZiemenM . Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care2000;23(8):1130-6. [EMBASE: 2006092604]">Massi 2003</a>; <a href="./references#CD005613-bbs2-0020" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00653341. Effect of insulin glargine in insulin naïve subjects with type 2 diabetes on oral hypoglycemic agent(s). www.clinicaltrials.gov/ct2/show/results/NCT00653341 (first received 4 April 2008). RiddleMC , RosenstockJ , GerichJ , InsulinG . The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care2003;26(11):3080-6. [PMID: 14578243]">Riddle 2003</a>; <a href="./references#CD005613-bbs2-0021" title="FonsecaV , BellDS , BergerS , ThomsonS , MeccaTE . A comparison of bedtime insulin glargine with bedtime neutral protamine Hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. American Journal of the Medical Sciences2004;328(5):274-80. [PMID: 15545844]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. RosenstockJ , SchwartzSL , Clark CM Jr, ParkGD , DonleyDW , EdwardsMB . Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care2001;24(4):631-6. [PMID: 11315821]">Rosenstock 2001</a>; <a href="./references#CD005613-bbs2-0023" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. VarewijckAJ , JanssenJA , VahataloM , HoflandLJ , LambertsSW , Yki-JarvinenH . Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. Diabetologia2012;55(4):1186-94. [PMID: 22237688]VarewijckAJ , JanssenJA , VahataloM , LambertsSW , Ki-JarvinenHY . IGF-I bioactivity decreases during insulin therapy in type 2 diabetic patients: comparison of high doses of insulin glargine and NPH insulin in the LANMET study. In: Endocrine Reviews Conference: 93rd Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 32 (3 Meeting Abstracts). 2011. [EMBASE: 70676865]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJA . Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and IGF-I receptor signaling. Diabetes2013;62(7):2539-44. [PMID: 23569175]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJAMJL . Comparison of effects of insulin glargine, its metabolites, IGF-I and human insulin on insulin-and IGF-I receptor signaling in type 2 diabetic patients. In: Endocrine Reviews Conference: 95th Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 34 (3 suppl 1). 2013. [EMBASE: 71784187]Yki-JärvinenH , Kauppinen-MakelinR , TiikkainenM , VahataloM , VirtamoH , Nikkila K et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia2006;49(3):442-51. [PMID: 10937510]">Yki‐Järvinen 2006</a>; <a href="./references#CD005613-bbs2-0024" title="YokoyamaH , TadaJ , KamikawaF , KannoS , YokotaY , KuramitsuM . Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Research &amp; Clinical Practice2006;73(1):35-40. [PMID: 16513202]">Yokoyama 2006</a>), and seven trials had an equivalence/non‐inferiority design (<a href="./references#CD005613-bbs2-0003" title="EliaschewitzFG , CalvoC , ValbuenaH , RuizM , AschnerP , VillenaJ , et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Archives of Medical Research2006;37(4):495-501. [PMID: 16715577]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Eliaschewitz 2006</a>; <a href="./references#CD005613-bbs2-0005" title="FritscheA , SchweitzerMA , HaringHU , Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Annals of Internal Medicine2003;138(12):952-9. [PMID: 12809451]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Fritsche 2003</a>; <a href="./references#CD005613-bbs2-0011" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KawamoriR , IwamotoY , KadowakiT , IwasakiM . Efficacy and safety of insulin glargine in concurrent use with oral hypoglycemic agents for the treatment of type 2 diabetes patients. Rinshoiyaku2003;19(5):445-64. ">Kawamori 2003</a>; <a href="./references#CD005613-bbs2-0015" title="NCT00687453. The utility of insulin glargine (Lantus) compared to NPH in ethnic minority type 2 diabetic subjects on combination insulin-oral agent therapy. clinicaltrials.gov/ct2/show/NCT00687453 (first received 30 May 2008). ">NCT00687453</a>; <a href="./references#CD005613-bbs2-0019" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. PanCY , SinnassamyP , ChungKD , KimKW , Group LS . Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Research &amp; Clinical Practice2007;76(1):111-8. [PMID: 17011662]">Pan 2007</a>; <a href="./references#CD005613-bbs2-0002" title="BetônicoCC , TitanSM , Correa-GiannellaML , NeryM , QueirozM . Comparison of insulin glargine vs. NPH insulin in basal-bolus therapies in T2DM patients and CKD: preliminary results of a prospective, randomized, open-label trial. Diabetes2016;65:A144-5. [CENTRAL: CN-01450000] BetônicoCC , TitanSM , LiraA , PelaesTS , Correa-GiannellaML , NeryM , et al. Insulin glargine U100 improved glycemic control and reduced nocturnal hypoglycemia in patients with type 2 diabetes mellitus and chronic kidney disease stages 3 and 4. Clinical Therapeutics2019;41(10):2008-20. [PMID: 31383366]NCT02451917. Subcutaneous insulin glargine versus NPH insulin in patients with chronic kidney disease stages III and IV: randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02451917 (first received 22 May 2015). ">Betônico 2019</a>; <a href="./references#CD005613-bbs2-0022" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00174824. Comparison of insulin glargine and NPH human insulin in progression of diabetic retinopathy in type 2 diabetic patients. clinicaltrials.gov/ct2/show/study/NCT00174824 (first received 15 September 2005). RosenstockJ , FonsecaV , DainMP , RiddleM . Estimating number-needed-to-treat to avoid hypoglycaemic episodes in people with type 2 diabetes: a post-hoc analysis of a prospective randomized controlled trial comparing once-daily insulin glargine with twice-daily NPH insulin. Canadian Journal of Diabetes2009;33(3):185-6. [EMBASE: 70031352]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia2009;52(9):1778-88. [PMID: 19526210]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia2009;52(9):1971-3. [PMID: 19609501]RosenstockJ , FonsecaV , SchinzelS , DainMP , MullinsP , RiddleM . Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: evidence from a long-term controlled trial. Journal of Diabetic Complications2014;28(5):742-9. [PMID: 24856612]">Rosenstock 2009</a>). The latter was unclear in two trials (<a href="./references#CD005613-bbs2-0001" title="BerardL , CameronB , WooV , StewartJ . Replacing insulin glargine with neutral protamine Hagedorn (NPH) insulin in a subpopulation of study subjects in the action to control cardiovascular risk in diabetes (ACCORD): effects on blood glucose levels, hypoglycemia and patient satisfaction. Canadian Journal of Diabetes2015;39(4):296-301. [PMID: 25819531]BerardLD , WooVC . Safety and efficacy of NPH after switching from insulin glargine in Canadian patients. Diabetologia2011;54:S430. [EMBASE: 70563203]">Berard 2015</a>; <a href="./references#CD005613-bbs2-0010" title="HsiaSH . Comparison of single-dose regimens of insulin glargine versus NPH among inner city ethnic minority type 2 diabetic patients uncontrolled on oral agents. Journal of Investigative Medicine2010;58(1):136. [EMBASE: 70981533]HsiaSH . Insulin glargine compared to NPH among insulin-naive, U.S. inner city, ethnic minority type 2 diabetic patients. Diabetes Research &amp; Clinical Practice2011;91(3):293-9. [PMID: 21146881]NCT00686712. Insulin glargine at bedtime or in AM versus NPH. clinicaltrials.gov/ct2/show/NCT00686712 (first received 7 October 2010). ">Hsia 2011</a>). </p> <p>Eleven trials had a multicentre design with the number of centres ranging from seven to 111 (<a href="./references#CD005613-bbs2-0003" title="EliaschewitzFG , CalvoC , ValbuenaH , RuizM , AschnerP , VillenaJ , et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Archives of Medical Research2006;37(4):495-501. [PMID: 16715577]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Eliaschewitz 2006</a>; <a href="./references#CD005613-bbs2-0005" title="FritscheA , SchweitzerMA , HaringHU , Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Annals of Internal Medicine2003;138(12):952-9. [PMID: 12809451]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Fritsche 2003</a>; <a href="./references#CD005613-bbs2-0007" title="EUCTR2009-010913-59. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on OHA treatment initiating basal insulin therapy with either insulin glargine or NPH insulin added to therapies with oral hypoglycemic agents (HAPPY) (LANTU_L_04079 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2009-010913-59/results (last accessed 3 May 2017). HermannsN , KulzerB , KohlmannT , JacobS , LandgrafW , TheobaldK , et al. Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial. Health and Quality of Life Outcomes2015;13:77. [PMID: 26055391]NCT00941369. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on oral hypoglycemic agent treatment initiating basal insulin therapy with either insulin glargine or NPH insulin. clinicaltrials.gov/ct2/show/NCT00941369 (first received 17 July 2009). ">Hermanns 2015</a>; <a href="./references#CD005613-bbs2-0009" title='EUCTR2007-006640-22. Superiority of insulin glargine Lantus vs NPH: "Treat to normoglycemia concept". Effect of insulin glargine in comparison to insulin NPH in insulin-naïve people with type 2 diabetes mellitus treated with at least one OAD and not adequately controlled (LANCELOT) (LANTU_C_02762 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2007-006640-22/results (last accessed 19 July 2017). HomePD , BolliGB , MathieuC , DeerochanawongC , LandgrafW , CandelasC , et al. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naive people with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2015;17(1):15-22. [PMID: 24957785]NCT00949442. Lantus versus NPH: comparison in insulin naive people not adequately controlled with at least one oral anti diabetics (OAD) treatment (LANCELOT). clinicaltrials.gov/ct2/show/NCT00949442 (first received 30 July 2009). '>Home 2015</a>; <a href="./references#CD005613-bbs2-0011" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KawamoriR , IwamotoY , KadowakiT , IwasakiM . Efficacy and safety of insulin glargine in concurrent use with oral hypoglycemic agents for the treatment of type 2 diabetes patients. Rinshoiyaku2003;19(5):445-64. ">Kawamori 2003</a>; <a href="./references#CD005613-bbs2-0014" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. MassiBM , HumburgE , DresslerA , ZiemenM . A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Hormone &amp; Metabolic Research2003;35(3):189-96. [PMID: 12734781]Yki-JarvinenH , DresslerA , ZiemenM . Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care2000;23(8):1130-6. [EMBASE: 2006092604]">Massi 2003</a>; <a href="./references#CD005613-bbs2-0019" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. PanCY , SinnassamyP , ChungKD , KimKW , Group LS . Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Research &amp; Clinical Practice2007;76(1):111-8. [PMID: 17011662]">Pan 2007</a>; <a href="./references#CD005613-bbs2-0020" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00653341. Effect of insulin glargine in insulin naïve subjects with type 2 diabetes on oral hypoglycemic agent(s). www.clinicaltrials.gov/ct2/show/results/NCT00653341 (first received 4 April 2008). RiddleMC , RosenstockJ , GerichJ , InsulinG . The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care2003;26(11):3080-6. [PMID: 14578243]">Riddle 2003</a>; <a href="./references#CD005613-bbs2-0021" title="FonsecaV , BellDS , BergerS , ThomsonS , MeccaTE . A comparison of bedtime insulin glargine with bedtime neutral protamine Hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. American Journal of the Medical Sciences2004;328(5):274-80. [PMID: 15545844]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. RosenstockJ , SchwartzSL , Clark CM Jr, ParkGD , DonleyDW , EdwardsMB . Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care2001;24(4):631-6. [PMID: 11315821]">Rosenstock 2001</a>; <a href="./references#CD005613-bbs2-0022" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00174824. Comparison of insulin glargine and NPH human insulin in progression of diabetic retinopathy in type 2 diabetic patients. clinicaltrials.gov/ct2/show/study/NCT00174824 (first received 15 September 2005). RosenstockJ , FonsecaV , DainMP , RiddleM . Estimating number-needed-to-treat to avoid hypoglycaemic episodes in people with type 2 diabetes: a post-hoc analysis of a prospective randomized controlled trial comparing once-daily insulin glargine with twice-daily NPH insulin. Canadian Journal of Diabetes2009;33(3):185-6. [EMBASE: 70031352]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia2009;52(9):1778-88. [PMID: 19526210]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia2009;52(9):1971-3. [PMID: 19609501]RosenstockJ , FonsecaV , SchinzelS , DainMP , MullinsP , RiddleM . Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: evidence from a long-term controlled trial. Journal of Diabetic Complications2014;28(5):742-9. [PMID: 24856612]">Rosenstock 2009</a>; <a href="./references#CD005613-bbs2-0023" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. VarewijckAJ , JanssenJA , VahataloM , HoflandLJ , LambertsSW , Yki-JarvinenH . Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. Diabetologia2012;55(4):1186-94. [PMID: 22237688]VarewijckAJ , JanssenJA , VahataloM , LambertsSW , Ki-JarvinenHY . IGF-I bioactivity decreases during insulin therapy in type 2 diabetic patients: comparison of high doses of insulin glargine and NPH insulin in the LANMET study. In: Endocrine Reviews Conference: 93rd Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 32 (3 Meeting Abstracts). 2011. [EMBASE: 70676865]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJA . Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and IGF-I receptor signaling. Diabetes2013;62(7):2539-44. [PMID: 23569175]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJAMJL . Comparison of effects of insulin glargine, its metabolites, IGF-I and human insulin on insulin-and IGF-I receptor signaling in type 2 diabetic patients. In: Endocrine Reviews Conference: 95th Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 34 (3 suppl 1). 2013. [EMBASE: 71784187]Yki-JärvinenH , Kauppinen-MakelinR , TiikkainenM , VahataloM , VirtamoH , Nikkila K et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia2006;49(3):442-51. [PMID: 10937510]">Yki‐Järvinen 2006</a>). Eight trials involved more than 50 centres (<a href="./references#CD005613-bbs2-0003" title="EliaschewitzFG , CalvoC , ValbuenaH , RuizM , AschnerP , VillenaJ , et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Archives of Medical Research2006;37(4):495-501. [PMID: 16715577]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Eliaschewitz 2006</a>; <a href="./references#CD005613-bbs2-0005" title="FritscheA , SchweitzerMA , HaringHU , Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Annals of Internal Medicine2003;138(12):952-9. [PMID: 12809451]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Fritsche 2003</a>; <a href="./references#CD005613-bbs2-0009" title='EUCTR2007-006640-22. Superiority of insulin glargine Lantus vs NPH: "Treat to normoglycemia concept". Effect of insulin glargine in comparison to insulin NPH in insulin-naïve people with type 2 diabetes mellitus treated with at least one OAD and not adequately controlled (LANCELOT) (LANTU_C_02762 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2007-006640-22/results (last accessed 19 July 2017). HomePD , BolliGB , MathieuC , DeerochanawongC , LandgrafW , CandelasC , et al. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naive people with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2015;17(1):15-22. [PMID: 24957785]NCT00949442. Lantus versus NPH: comparison in insulin naive people not adequately controlled with at least one oral anti diabetics (OAD) treatment (LANCELOT). clinicaltrials.gov/ct2/show/NCT00949442 (first received 30 July 2009). '>Home 2015</a>; <a href="./references#CD005613-bbs2-0011" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KawamoriR , IwamotoY , KadowakiT , IwasakiM . Efficacy and safety of insulin glargine in concurrent use with oral hypoglycemic agents for the treatment of type 2 diabetes patients. Rinshoiyaku2003;19(5):445-64. ">Kawamori 2003</a>; <a href="./references#CD005613-bbs2-0014" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. MassiBM , HumburgE , DresslerA , ZiemenM . A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Hormone &amp; Metabolic Research2003;35(3):189-96. [PMID: 12734781]Yki-JarvinenH , DresslerA , ZiemenM . Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care2000;23(8):1130-6. [EMBASE: 2006092604]">Massi 2003</a>; <a href="./references#CD005613-bbs2-0020" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00653341. Effect of insulin glargine in insulin naïve subjects with type 2 diabetes on oral hypoglycemic agent(s). www.clinicaltrials.gov/ct2/show/results/NCT00653341 (first received 4 April 2008). RiddleMC , RosenstockJ , GerichJ , InsulinG . The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care2003;26(11):3080-6. [PMID: 14578243]">Riddle 2003</a>; <a href="./references#CD005613-bbs2-0021" title="FonsecaV , BellDS , BergerS , ThomsonS , MeccaTE . A comparison of bedtime insulin glargine with bedtime neutral protamine Hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. American Journal of the Medical Sciences2004;328(5):274-80. [PMID: 15545844]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. RosenstockJ , SchwartzSL , Clark CM Jr, ParkGD , DonleyDW , EdwardsMB . Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care2001;24(4):631-6. [PMID: 11315821]">Rosenstock 2001</a>; <a href="./references#CD005613-bbs2-0022" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00174824. Comparison of insulin glargine and NPH human insulin in progression of diabetic retinopathy in type 2 diabetic patients. clinicaltrials.gov/ct2/show/study/NCT00174824 (first received 15 September 2005). RosenstockJ , FonsecaV , DainMP , RiddleM . Estimating number-needed-to-treat to avoid hypoglycaemic episodes in people with type 2 diabetes: a post-hoc analysis of a prospective randomized controlled trial comparing once-daily insulin glargine with twice-daily NPH insulin. Canadian Journal of Diabetes2009;33(3):185-6. [EMBASE: 70031352]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia2009;52(9):1778-88. [PMID: 19526210]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia2009;52(9):1971-3. [PMID: 19609501]RosenstockJ , FonsecaV , SchinzelS , DainMP , MullinsP , RiddleM . Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: evidence from a long-term controlled trial. Journal of Diabetic Complications2014;28(5):742-9. [PMID: 24856612]">Rosenstock 2009</a>). </p> <p>Neither participants nor study personnel or outcome assessors were reported to be blinded in any of the trials. </p> <p>Trials were performed between 1997 and 2016. This information was not available for seven trials (<a href="./references#CD005613-bbs2-0001" title="BerardL , CameronB , WooV , StewartJ . Replacing insulin glargine with neutral protamine Hagedorn (NPH) insulin in a subpopulation of study subjects in the action to control cardiovascular risk in diabetes (ACCORD): effects on blood glucose levels, hypoglycemia and patient satisfaction. Canadian Journal of Diabetes2015;39(4):296-301. [PMID: 25819531]BerardLD , WooVC . Safety and efficacy of NPH after switching from insulin glargine in Canadian patients. Diabetologia2011;54:S430. [EMBASE: 70563203]">Berard 2015</a>; <a href="./references#CD005613-bbs2-0003" title="EliaschewitzFG , CalvoC , ValbuenaH , RuizM , AschnerP , VillenaJ , et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Archives of Medical Research2006;37(4):495-501. [PMID: 16715577]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Eliaschewitz 2006</a>; <a href="./references#CD005613-bbs2-0011" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KawamoriR , IwamotoY , KadowakiT , IwasakiM . Efficacy and safety of insulin glargine in concurrent use with oral hypoglycemic agents for the treatment of type 2 diabetes patients. Rinshoiyaku2003;19(5):445-64. ">Kawamori 2003</a>; <a href="./references#CD005613-bbs2-0019" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. PanCY , SinnassamyP , ChungKD , KimKW , Group LS . Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Research &amp; Clinical Practice2007;76(1):111-8. [PMID: 17011662]">Pan 2007</a>; <a href="./references#CD005613-bbs2-0021" title="FonsecaV , BellDS , BergerS , ThomsonS , MeccaTE . A comparison of bedtime insulin glargine with bedtime neutral protamine Hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. American Journal of the Medical Sciences2004;328(5):274-80. [PMID: 15545844]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. RosenstockJ , SchwartzSL , Clark CM Jr, ParkGD , DonleyDW , EdwardsMB . Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care2001;24(4):631-6. [PMID: 11315821]">Rosenstock 2001</a>; <a href="./references#CD005613-bbs2-0023" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. VarewijckAJ , JanssenJA , VahataloM , HoflandLJ , LambertsSW , Yki-JarvinenH . Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. Diabetologia2012;55(4):1186-94. [PMID: 22237688]VarewijckAJ , JanssenJA , VahataloM , LambertsSW , Ki-JarvinenHY . IGF-I bioactivity decreases during insulin therapy in type 2 diabetic patients: comparison of high doses of insulin glargine and NPH insulin in the LANMET study. In: Endocrine Reviews Conference: 93rd Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 32 (3 Meeting Abstracts). 2011. [EMBASE: 70676865]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJA . Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and IGF-I receptor signaling. Diabetes2013;62(7):2539-44. [PMID: 23569175]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJAMJL . Comparison of effects of insulin glargine, its metabolites, IGF-I and human insulin on insulin-and IGF-I receptor signaling in type 2 diabetic patients. In: Endocrine Reviews Conference: 95th Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 34 (3 suppl 1). 2013. [EMBASE: 71784187]Yki-JärvinenH , Kauppinen-MakelinR , TiikkainenM , VahataloM , VirtamoH , Nikkila K et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia2006;49(3):442-51. [PMID: 10937510]">Yki‐Järvinen 2006</a>; <a href="./references#CD005613-bbs2-0024" title="YokoyamaH , TadaJ , KamikawaF , KannoS , YokotaY , KuramitsuM . Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Research &amp; Clinical Practice2006;73(1):35-40. [PMID: 16513202]">Yokoyama 2006</a>). </p> <p>The mean duration of intervention was identical to the mean duration of follow‐up in all trials and ranged from six to 60 months. </p> <p>Seven trials had formal run‐in periods ranging from two to 12 weeks (<a href="./references#CD005613-bbs2-0005" title="FritscheA , SchweitzerMA , HaringHU , Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Annals of Internal Medicine2003;138(12):952-9. [PMID: 12809451]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Fritsche 2003</a>; <a href="./references#CD005613-bbs2-0009" title='EUCTR2007-006640-22. Superiority of insulin glargine Lantus vs NPH: "Treat to normoglycemia concept". Effect of insulin glargine in comparison to insulin NPH in insulin-naïve people with type 2 diabetes mellitus treated with at least one OAD and not adequately controlled (LANCELOT) (LANTU_C_02762 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2007-006640-22/results (last accessed 19 July 2017). HomePD , BolliGB , MathieuC , DeerochanawongC , LandgrafW , CandelasC , et al. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naive people with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2015;17(1):15-22. [PMID: 24957785]NCT00949442. Lantus versus NPH: comparison in insulin naive people not adequately controlled with at least one oral anti diabetics (OAD) treatment (LANCELOT). clinicaltrials.gov/ct2/show/NCT00949442 (first received 30 July 2009). '>Home 2015</a>; <a href="./references#CD005613-bbs2-0010" title="HsiaSH . Comparison of single-dose regimens of insulin glargine versus NPH among inner city ethnic minority type 2 diabetic patients uncontrolled on oral agents. Journal of Investigative Medicine2010;58(1):136. [EMBASE: 70981533]HsiaSH . Insulin glargine compared to NPH among insulin-naive, U.S. inner city, ethnic minority type 2 diabetic patients. Diabetes Research &amp; Clinical Practice2011;91(3):293-9. [PMID: 21146881]NCT00686712. Insulin glargine at bedtime or in AM versus NPH. clinicaltrials.gov/ct2/show/NCT00686712 (first received 7 October 2010). ">Hsia 2011</a>; <a href="./references#CD005613-bbs2-0015" title="NCT00687453. The utility of insulin glargine (Lantus) compared to NPH in ethnic minority type 2 diabetic subjects on combination insulin-oral agent therapy. clinicaltrials.gov/ct2/show/NCT00687453 (first received 30 May 2008). ">NCT00687453</a>; <a href="./references#CD005613-bbs2-0020" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00653341. Effect of insulin glargine in insulin naïve subjects with type 2 diabetes on oral hypoglycemic agent(s). www.clinicaltrials.gov/ct2/show/results/NCT00653341 (first received 4 April 2008). RiddleMC , RosenstockJ , GerichJ , InsulinG . The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care2003;26(11):3080-6. [PMID: 14578243]">Riddle 2003</a>; <a href="./references#CD005613-bbs2-0023" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. VarewijckAJ , JanssenJA , VahataloM , HoflandLJ , LambertsSW , Yki-JarvinenH . Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. Diabetologia2012;55(4):1186-94. [PMID: 22237688]VarewijckAJ , JanssenJA , VahataloM , LambertsSW , Ki-JarvinenHY . IGF-I bioactivity decreases during insulin therapy in type 2 diabetic patients: comparison of high doses of insulin glargine and NPH insulin in the LANMET study. In: Endocrine Reviews Conference: 93rd Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 32 (3 Meeting Abstracts). 2011. [EMBASE: 70676865]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJA . Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and IGF-I receptor signaling. Diabetes2013;62(7):2539-44. [PMID: 23569175]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJAMJL . Comparison of effects of insulin glargine, its metabolites, IGF-I and human insulin on insulin-and IGF-I receptor signaling in type 2 diabetic patients. In: Endocrine Reviews Conference: 95th Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 34 (3 suppl 1). 2013. [EMBASE: 71784187]Yki-JärvinenH , Kauppinen-MakelinR , TiikkainenM , VahataloM , VirtamoH , Nikkila K et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia2006;49(3):442-51. [PMID: 10937510]">Yki‐Järvinen 2006</a>; <a href="./references#CD005613-bbs2-0024" title="YokoyamaH , TadaJ , KamikawaF , KannoS , YokotaY , KuramitsuM . Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Research &amp; Clinical Practice2006;73(1):35-40. [PMID: 16513202]">Yokoyama 2006</a>). </p> <p>Two trials were terminated early, one because of a lack of funding (<a href="./references#CD005613-bbs2-0010" title="HsiaSH . Comparison of single-dose regimens of insulin glargine versus NPH among inner city ethnic minority type 2 diabetic patients uncontrolled on oral agents. Journal of Investigative Medicine2010;58(1):136. [EMBASE: 70981533]HsiaSH . Insulin glargine compared to NPH among insulin-naive, U.S. inner city, ethnic minority type 2 diabetic patients. Diabetes Research &amp; Clinical Practice2011;91(3):293-9. [PMID: 21146881]NCT00686712. Insulin glargine at bedtime or in AM versus NPH. clinicaltrials.gov/ct2/show/NCT00686712 (first received 7 October 2010). ">Hsia 2011</a>), and one for unspecified reasons (<a href="./references#CD005613-bbs2-0015" title="NCT00687453. The utility of insulin glargine (Lantus) compared to NPH in ethnic minority type 2 diabetic subjects on combination insulin-oral agent therapy. clinicaltrials.gov/ct2/show/NCT00687453 (first received 30 May 2008). ">NCT00687453</a>). </p> </section> <section id="CD005613-sec-0068"> <h6 class="title">Detemir versus NPH</h6> <p>All trials had a parallel design and all but three had a non‐inferiority design. Of these three trials, two had a superiority design (<a href="./references#CD005613-bbs2-0004" title="EUCTR2005-000976-42. A multi-centre, open-labelled, randomised, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime (PREDICTIVE-BMI study) – PREDICTIVE-BMI study. www.clinicaltrialsregister.eu/ctr-search/trial/2005-000976-42/ES (first received 17 May 2006). Fajardo MontañanaC , Hernandez HerreroC , Rivas FernandezM . Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabetic Medicine2008;25(8):916-23. [PMID: 18959604]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00504673. Comparison of insulin detemir versus insulin NPH on weight change in overweight and obese with type 2 diabetes (PREDICTIVE). clinicaltrials.gov/ct2/show/NCT00504673 (first received 20 July 2007). Novo Nordisk A/S. A multi-centre, open-labelled, randomized, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime. (PREDICTIVE-BMI study). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1410&amp;filename=1659-ctr-redacted.pdf (last accessed 3 November 2020). Smith-PalmerJ , Fajardo-MontananaC , PollockRF , EricssonA , ValentineWJ . Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. Journal of Medical Economics2012;15(5):977-86. [PMID: 22563742]">Fajardo Montañana 2008</a>; <a href="./references#CD005613-bbs2-0018" title="EUCTR2008-003739-19. Ensayo multicéntrico, abierto, aleatorizado, de dos grupos, paralelo para comparar el cambio en la distribución de grasa en sujetos con sobrepeso y obesos con diabetes tipo 2 tras 26 semanas de tratamiento con insulina detemir una vez al día frente a insulina NPH una vez al día, ambas con insulina aspart a la hora de las comidas. www.clinicaltrialsregister.eu/ctr-search/trial/2008-003739-19/ES (first received 19 September 2008). NCT00795600. A multi-centre, open-labelled, randomised, two-group parallel trial comparing the change in fat distribution in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin apart at mealtimes. clinicaltrials.gov/ct2/show/NCT00795600 (first received 21 November 2008). Novo Nordisk A/S. A multi-centre, open-labelled, randomised, two-group parallel trial comparing the change in fat distribution in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart at mealtimes (NN304-3614 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1461&amp;filename=3614-ctr-synopsis-redacted.pdf (last accessed 3 November 2020). TinahonesFJ , Gomez-HuelgasR , Garcia-AlegriaJ , Tapia-GuerreroM , Martos-PerezF . Fat distribution, HbA1c and hypoglycaemia in overweight and obese patients with type 2 diabetes: a comparison of NPH and insulin detemir from a pilot randomised clinical trial. Diabetologia2011;54:S273. [EMBASE: 70562816]TinahonesFJ , Gomez-HuelgasR , GarciaalegriaJ , Tapia-GuerreroMJ , PerezFM . The effect of insulin detemir on fat distribution and weight parameters in overweight and obese subjects with type 2 diabetes. Diabetes2011;60:A309. [EMBASE: 70628891]">NN304‐3614</a>), and in one trial, the design was unclear (<a href="./references#CD005613-bbs2-0016" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">NN304‐1337</a>). </p> <p>Seven trials were multicentre where the number ranged from five to 65. For one trial, no information on the number of trial centres was available (<a href="./references#CD005613-bbs2-0016" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">NN304‐1337</a>). </p> <p>Neither participants nor study personnel or outcome assessors were reported to be blinded in any of the trials. </p> <p>Trials were performed between 2003 and 2010. For two trials, no information on when the trials were performed was available (<a href="./references#CD005613-bbs2-0006" title="HaakT , TiengoA , DraegerE , SuntumM , WaldhauslW . Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2005;7(1):56-64. [PMID: 15642076]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Haak 2005</a>; <a href="./references#CD005613-bbs2-0016" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">NN304‐1337</a>). </p> <p>The mean duration of intervention was similar to the mean duration of follow‐up in all trials and ranged from 24 to 48 weeks. </p> <p>One trial had a formal run‐in period of two weeks' duration (<a href="./references#CD005613-bbs2-0016" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">NN304‐1337</a>). </p> <p><a href="./references#CD005613-bbs2-0017" title="DoucetJ , Le FlochJ , HanaireH , CourregesJ , AlexandreB , BauduceauB . Comparison of safety between detemir and neutral protamine Hagedorn (NPH) in ageing subjects: the '3 L study'. Fundamental and Clinical Pharmacology2011;25:82. [EMBASE: 70653089]EUCTR2006-006589-41-FR. Levemir® in ageing patients with type 2 diabetes A seven-month open-labelled randomised multi-centre two-group parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in the morning in ageing subjects with type 2 diabetes. The 3L Study (Levemir in Late Life) Trial Phase: 4. www.clinicaltrialsregister.eu/ctr-search/trial/2006-006589-41/FR (first received 27 March 2007). NCT00506662. The effect of insulin detemir on glucose control in ageing subjects with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00506662 (first received 25 July 2007). Novo Nordisk A/S. A seven-month, open-labelled, randomised, multicentre, two-group, parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in ageing patients with type 2 diabetes: The 3L Study (Levemir in Later Life) (NN304-1808 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1426&amp;filename=1808-ctr-redacted.pdf (last accessed 3 November 2020). ">NN304‐1808</a> was discontinued prematurely because of recruitment problems. </p> </section> </section> <section id="CD005613-sec-0069"> <h5 class="title">Settings</h5> <section id="CD005613-sec-0070"> <h6 class="title">Glargine versus NPH</h6> <p>Some information on settings was available for six trials: two trials were conducted in a speciality primary care clinic (<a href="./references#CD005613-bbs2-0010" title="HsiaSH . Comparison of single-dose regimens of insulin glargine versus NPH among inner city ethnic minority type 2 diabetic patients uncontrolled on oral agents. Journal of Investigative Medicine2010;58(1):136. [EMBASE: 70981533]HsiaSH . Insulin glargine compared to NPH among insulin-naive, U.S. inner city, ethnic minority type 2 diabetic patients. Diabetes Research &amp; Clinical Practice2011;91(3):293-9. [PMID: 21146881]NCT00686712. Insulin glargine at bedtime or in AM versus NPH. clinicaltrials.gov/ct2/show/NCT00686712 (first received 7 October 2010). ">Hsia 2011</a>; <a href="./references#CD005613-bbs2-0015" title="NCT00687453. The utility of insulin glargine (Lantus) compared to NPH in ethnic minority type 2 diabetic subjects on combination insulin-oral agent therapy. clinicaltrials.gov/ct2/show/NCT00687453 (first received 30 May 2008). ">NCT00687453</a>), one in university hospital facilities (<a href="./references#CD005613-bbs2-0002" title="BetônicoCC , TitanSM , Correa-GiannellaML , NeryM , QueirozM . Comparison of insulin glargine vs. NPH insulin in basal-bolus therapies in T2DM patients and CKD: preliminary results of a prospective, randomized, open-label trial. Diabetes2016;65:A144-5. [CENTRAL: CN-01450000] BetônicoCC , TitanSM , LiraA , PelaesTS , Correa-GiannellaML , NeryM , et al. Insulin glargine U100 improved glycemic control and reduced nocturnal hypoglycemia in patients with type 2 diabetes mellitus and chronic kidney disease stages 3 and 4. Clinical Therapeutics2019;41(10):2008-20. [PMID: 31383366]NCT02451917. Subcutaneous insulin glargine versus NPH insulin in patients with chronic kidney disease stages III and IV: randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02451917 (first received 22 May 2015). ">Betônico 2019</a>), two in outpatient facilities (<a href="./references#CD005613-bbs2-0007" title="EUCTR2009-010913-59. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on OHA treatment initiating basal insulin therapy with either insulin glargine or NPH insulin added to therapies with oral hypoglycemic agents (HAPPY) (LANTU_L_04079 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2009-010913-59/results (last accessed 3 May 2017). HermannsN , KulzerB , KohlmannT , JacobS , LandgrafW , TheobaldK , et al. Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial. Health and Quality of Life Outcomes2015;13:77. [PMID: 26055391]NCT00941369. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on oral hypoglycemic agent treatment initiating basal insulin therapy with either insulin glargine or NPH insulin. clinicaltrials.gov/ct2/show/NCT00941369 (first received 17 July 2009). ">Hermanns 2015</a>; <a href="./references#CD005613-bbs2-0024" title="YokoyamaH , TadaJ , KamikawaF , KannoS , YokotaY , KuramitsuM . Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Research &amp; Clinical Practice2006;73(1):35-40. [PMID: 16513202]">Yokoyama 2006</a>), and one in an inpatient and outpatient care facility (<a href="./references#CD005613-bbs2-0011" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KawamoriR , IwamotoY , KadowakiT , IwasakiM . Efficacy and safety of insulin glargine in concurrent use with oral hypoglycemic agents for the treatment of type 2 diabetes patients. Rinshoiyaku2003;19(5):445-64. ">Kawamori 2003</a>). </p> </section> <section id="CD005613-sec-0071"> <h6 class="title">Detemir versus NPH</h6> <p>No information was available for any of the trials.</p> </section> </section> <section id="CD005613-sec-0072"> <h5 class="title">Participants</h5> <section id="CD005613-sec-0073"> <h6 class="title">Glargine versus NPH</h6> <p>Only people with type 2 diabetes mellitus were included. Major exclusion criteria were insulin therapy before the initiation of the trial in six trials (<a href="./references#CD005613-bbs2-0003" title="EliaschewitzFG , CalvoC , ValbuenaH , RuizM , AschnerP , VillenaJ , et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Archives of Medical Research2006;37(4):495-501. [PMID: 16715577]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Eliaschewitz 2006</a>; <a href="./references#CD005613-bbs2-0005" title="FritscheA , SchweitzerMA , HaringHU , Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Annals of Internal Medicine2003;138(12):952-9. [PMID: 12809451]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Fritsche 2003</a>; <a href="./references#CD005613-bbs2-0007" title="EUCTR2009-010913-59. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on OHA treatment initiating basal insulin therapy with either insulin glargine or NPH insulin added to therapies with oral hypoglycemic agents (HAPPY) (LANTU_L_04079 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2009-010913-59/results (last accessed 3 May 2017). HermannsN , KulzerB , KohlmannT , JacobS , LandgrafW , TheobaldK , et al. Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial. Health and Quality of Life Outcomes2015;13:77. [PMID: 26055391]NCT00941369. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on oral hypoglycemic agent treatment initiating basal insulin therapy with either insulin glargine or NPH insulin. clinicaltrials.gov/ct2/show/NCT00941369 (first received 17 July 2009). ">Hermanns 2015</a>; <a href="./references#CD005613-bbs2-0014" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. MassiBM , HumburgE , DresslerA , ZiemenM . A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Hormone &amp; Metabolic Research2003;35(3):189-96. [PMID: 12734781]Yki-JarvinenH , DresslerA , ZiemenM . Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care2000;23(8):1130-6. [EMBASE: 2006092604]">Massi 2003</a>; <a href="./references#CD005613-bbs2-0020" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00653341. Effect of insulin glargine in insulin naïve subjects with type 2 diabetes on oral hypoglycemic agent(s). www.clinicaltrials.gov/ct2/show/results/NCT00653341 (first received 4 April 2008). RiddleMC , RosenstockJ , GerichJ , InsulinG . The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care2003;26(11):3080-6. [PMID: 14578243]">Riddle 2003</a>; <a href="./references#CD005613-bbs2-0023" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. VarewijckAJ , JanssenJA , VahataloM , HoflandLJ , LambertsSW , Yki-JarvinenH . Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. Diabetologia2012;55(4):1186-94. [PMID: 22237688]VarewijckAJ , JanssenJA , VahataloM , LambertsSW , Ki-JarvinenHY . IGF-I bioactivity decreases during insulin therapy in type 2 diabetic patients: comparison of high doses of insulin glargine and NPH insulin in the LANMET study. In: Endocrine Reviews Conference: 93rd Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 32 (3 Meeting Abstracts). 2011. [EMBASE: 70676865]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJA . Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and IGF-I receptor signaling. Diabetes2013;62(7):2539-44. [PMID: 23569175]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJAMJL . Comparison of effects of insulin glargine, its metabolites, IGF-I and human insulin on insulin-and IGF-I receptor signaling in type 2 diabetic patients. In: Endocrine Reviews Conference: 95th Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 34 (3 suppl 1). 2013. [EMBASE: 71784187]Yki-JärvinenH , Kauppinen-MakelinR , TiikkainenM , VahataloM , VirtamoH , Nikkila K et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia2006;49(3):442-51. [PMID: 10937510]">Yki‐Järvinen 2006</a>), use of insulin analogues in one trial (<a href="./references#CD005613-bbs2-0022" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00174824. Comparison of insulin glargine and NPH human insulin in progression of diabetic retinopathy in type 2 diabetic patients. clinicaltrials.gov/ct2/show/study/NCT00174824 (first received 15 September 2005). RosenstockJ , FonsecaV , DainMP , RiddleM . Estimating number-needed-to-treat to avoid hypoglycaemic episodes in people with type 2 diabetes: a post-hoc analysis of a prospective randomized controlled trial comparing once-daily insulin glargine with twice-daily NPH insulin. Canadian Journal of Diabetes2009;33(3):185-6. [EMBASE: 70031352]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia2009;52(9):1778-88. [PMID: 19526210]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia2009;52(9):1971-3. [PMID: 19609501]RosenstockJ , FonsecaV , SchinzelS , DainMP , MullinsP , RiddleM . Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: evidence from a long-term controlled trial. Journal of Diabetic Complications2014;28(5):742-9. [PMID: 24856612]">Rosenstock 2009</a>), and severe diabetic retinopathy in eight trials (<a href="./references#CD005613-bbs2-0009" title='EUCTR2007-006640-22. Superiority of insulin glargine Lantus vs NPH: "Treat to normoglycemia concept". Effect of insulin glargine in comparison to insulin NPH in insulin-naïve people with type 2 diabetes mellitus treated with at least one OAD and not adequately controlled (LANCELOT) (LANTU_C_02762 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2007-006640-22/results (last accessed 19 July 2017). HomePD , BolliGB , MathieuC , DeerochanawongC , LandgrafW , CandelasC , et al. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naive people with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2015;17(1):15-22. [PMID: 24957785]NCT00949442. Lantus versus NPH: comparison in insulin naive people not adequately controlled with at least one oral anti diabetics (OAD) treatment (LANCELOT). clinicaltrials.gov/ct2/show/NCT00949442 (first received 30 July 2009). '>Home 2015</a>; <a href="./references#CD005613-bbs2-0010" title="HsiaSH . Comparison of single-dose regimens of insulin glargine versus NPH among inner city ethnic minority type 2 diabetic patients uncontrolled on oral agents. Journal of Investigative Medicine2010;58(1):136. [EMBASE: 70981533]HsiaSH . Insulin glargine compared to NPH among insulin-naive, U.S. inner city, ethnic minority type 2 diabetic patients. Diabetes Research &amp; Clinical Practice2011;91(3):293-9. [PMID: 21146881]NCT00686712. Insulin glargine at bedtime or in AM versus NPH. clinicaltrials.gov/ct2/show/NCT00686712 (first received 7 October 2010). ">Hsia 2011</a>; <a href="./references#CD005613-bbs2-0011" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KawamoriR , IwamotoY , KadowakiT , IwasakiM . Efficacy and safety of insulin glargine in concurrent use with oral hypoglycemic agents for the treatment of type 2 diabetes patients. Rinshoiyaku2003;19(5):445-64. ">Kawamori 2003</a>; <a href="./references#CD005613-bbs2-0014" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. MassiBM , HumburgE , DresslerA , ZiemenM . A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Hormone &amp; Metabolic Research2003;35(3):189-96. [PMID: 12734781]Yki-JarvinenH , DresslerA , ZiemenM . Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care2000;23(8):1130-6. [EMBASE: 2006092604]">Massi 2003</a>; <a href="./references#CD005613-bbs2-0015" title="NCT00687453. The utility of insulin glargine (Lantus) compared to NPH in ethnic minority type 2 diabetic subjects on combination insulin-oral agent therapy. clinicaltrials.gov/ct2/show/NCT00687453 (first received 30 May 2008). ">NCT00687453</a>; <a href="./references#CD005613-bbs2-0019" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. PanCY , SinnassamyP , ChungKD , KimKW , Group LS . Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Research &amp; Clinical Practice2007;76(1):111-8. [PMID: 17011662]">Pan 2007</a>; <a href="./references#CD005613-bbs2-0022" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00174824. Comparison of insulin glargine and NPH human insulin in progression of diabetic retinopathy in type 2 diabetic patients. clinicaltrials.gov/ct2/show/study/NCT00174824 (first received 15 September 2005). RosenstockJ , FonsecaV , DainMP , RiddleM . Estimating number-needed-to-treat to avoid hypoglycaemic episodes in people with type 2 diabetes: a post-hoc analysis of a prospective randomized controlled trial comparing once-daily insulin glargine with twice-daily NPH insulin. Canadian Journal of Diabetes2009;33(3):185-6. [EMBASE: 70031352]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia2009;52(9):1778-88. [PMID: 19526210]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia2009;52(9):1971-3. [PMID: 19609501]RosenstockJ , FonsecaV , SchinzelS , DainMP , MullinsP , RiddleM . Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: evidence from a long-term controlled trial. Journal of Diabetic Complications2014;28(5):742-9. [PMID: 24856612]">Rosenstock 2009</a>; <a href="./references#CD005613-bbs2-0023" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. VarewijckAJ , JanssenJA , VahataloM , HoflandLJ , LambertsSW , Yki-JarvinenH . Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. Diabetologia2012;55(4):1186-94. [PMID: 22237688]VarewijckAJ , JanssenJA , VahataloM , LambertsSW , Ki-JarvinenHY . IGF-I bioactivity decreases during insulin therapy in type 2 diabetic patients: comparison of high doses of insulin glargine and NPH insulin in the LANMET study. In: Endocrine Reviews Conference: 93rd Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 32 (3 Meeting Abstracts). 2011. [EMBASE: 70676865]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJA . Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and IGF-I receptor signaling. Diabetes2013;62(7):2539-44. [PMID: 23569175]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJAMJL . Comparison of effects of insulin glargine, its metabolites, IGF-I and human insulin on insulin-and IGF-I receptor signaling in type 2 diabetic patients. In: Endocrine Reviews Conference: 95th Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 34 (3 suppl 1). 2013. [EMBASE: 71784187]Yki-JärvinenH , Kauppinen-MakelinR , TiikkainenM , VahataloM , VirtamoH , Nikkila K et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia2006;49(3):442-51. [PMID: 10937510]">Yki‐Järvinen 2006</a>). The mean duration of diabetes at baseline ranged from eight to 19 years. Participants were mostly of white ethnicity (for those publications with no information on the ethnic composition of the study population, it was inferred from the study locations), with mean age ranging from 50 to 62 years. The proportion of women in the comparison groups varied between 25% and 77%. Most participants were overweight, with mean BMI ranging from 23 kg/m² to 35 kg/m². None of the trials were performed on pharmaco‐naive people (i.e. people whose treatment consisted only of dietary changes, exercise or both). Metabolic control in participants ranged from 6.9% (51 mmol/mol) to 9.6% (81 mmol/mol) HbA1c at baseline. Two trials including 515 participants were conducted in low‐ and middle‐income countries (<a href="./references#CD005613-bbs2-0003" title="EliaschewitzFG , CalvoC , ValbuenaH , RuizM , AschnerP , VillenaJ , et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Archives of Medical Research2006;37(4):495-501. [PMID: 16715577]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Eliaschewitz 2006</a>; <a href="./references#CD005613-bbs2-0002" title="BetônicoCC , TitanSM , Correa-GiannellaML , NeryM , QueirozM . Comparison of insulin glargine vs. NPH insulin in basal-bolus therapies in T2DM patients and CKD: preliminary results of a prospective, randomized, open-label trial. Diabetes2016;65:A144-5. [CENTRAL: CN-01450000] BetônicoCC , TitanSM , LiraA , PelaesTS , Correa-GiannellaML , NeryM , et al. Insulin glargine U100 improved glycemic control and reduced nocturnal hypoglycemia in patients with type 2 diabetes mellitus and chronic kidney disease stages 3 and 4. Clinical Therapeutics2019;41(10):2008-20. [PMID: 31383366]NCT02451917. Subcutaneous insulin glargine versus NPH insulin in patients with chronic kidney disease stages III and IV: randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02451917 (first received 22 May 2015). ">Betônico 2019</a>). In addition, three further trials had study centres in low‐ and middle‐income countries (<a href="./references#CD005613-bbs2-0009" title='EUCTR2007-006640-22. Superiority of insulin glargine Lantus vs NPH: "Treat to normoglycemia concept". Effect of insulin glargine in comparison to insulin NPH in insulin-naïve people with type 2 diabetes mellitus treated with at least one OAD and not adequately controlled (LANCELOT) (LANTU_C_02762 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2007-006640-22/results (last accessed 19 July 2017). HomePD , BolliGB , MathieuC , DeerochanawongC , LandgrafW , CandelasC , et al. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naive people with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2015;17(1):15-22. [PMID: 24957785]NCT00949442. Lantus versus NPH: comparison in insulin naive people not adequately controlled with at least one oral anti diabetics (OAD) treatment (LANCELOT). clinicaltrials.gov/ct2/show/NCT00949442 (first received 30 July 2009). '>Home 2015</a>; <a href="./references#CD005613-bbs2-0014" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. MassiBM , HumburgE , DresslerA , ZiemenM . A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Hormone &amp; Metabolic Research2003;35(3):189-96. [PMID: 12734781]Yki-JarvinenH , DresslerA , ZiemenM . Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care2000;23(8):1130-6. [EMBASE: 2006092604]">Massi 2003</a>; <a href="./references#CD005613-bbs2-0019" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. PanCY , SinnassamyP , ChungKD , KimKW , Group LS . Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Research &amp; Clinical Practice2007;76(1):111-8. [PMID: 17011662]">Pan 2007</a>). Two trials conducted in the USA were specifically designed to investigate the effects of glargine versus NPH in low‐income inner‐city ethnic minorities (<a href="./references#CD005613-bbs2-0010" title="HsiaSH . Comparison of single-dose regimens of insulin glargine versus NPH among inner city ethnic minority type 2 diabetic patients uncontrolled on oral agents. Journal of Investigative Medicine2010;58(1):136. [EMBASE: 70981533]HsiaSH . Insulin glargine compared to NPH among insulin-naive, U.S. inner city, ethnic minority type 2 diabetic patients. Diabetes Research &amp; Clinical Practice2011;91(3):293-9. [PMID: 21146881]NCT00686712. Insulin glargine at bedtime or in AM versus NPH. clinicaltrials.gov/ct2/show/NCT00686712 (first received 7 October 2010). ">Hsia 2011</a>; <a href="./references#CD005613-bbs2-0015" title="NCT00687453. The utility of insulin glargine (Lantus) compared to NPH in ethnic minority type 2 diabetic subjects on combination insulin-oral agent therapy. clinicaltrials.gov/ct2/show/NCT00687453 (first received 30 May 2008). ">NCT00687453</a>). </p> </section> <section id="CD005613-sec-0074"> <h6 class="title">Detemir versus NPH</h6> <p>Only people with type 2 diabetes mellitus were included. Major exclusion criteria were severe retinopathy (<a href="./references#CD005613-bbs2-0004" title="EUCTR2005-000976-42. A multi-centre, open-labelled, randomised, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime (PREDICTIVE-BMI study) – PREDICTIVE-BMI study. www.clinicaltrialsregister.eu/ctr-search/trial/2005-000976-42/ES (first received 17 May 2006). Fajardo MontañanaC , Hernandez HerreroC , Rivas FernandezM . Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabetic Medicine2008;25(8):916-23. [PMID: 18959604]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00504673. Comparison of insulin detemir versus insulin NPH on weight change in overweight and obese with type 2 diabetes (PREDICTIVE). clinicaltrials.gov/ct2/show/NCT00504673 (first received 20 July 2007). Novo Nordisk A/S. A multi-centre, open-labelled, randomized, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime. (PREDICTIVE-BMI study). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1410&amp;filename=1659-ctr-redacted.pdf (last accessed 3 November 2020). Smith-PalmerJ , Fajardo-MontananaC , PollockRF , EricssonA , ValentineWJ . Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. Journal of Medical Economics2012;15(5):977-86. [PMID: 22563742]">Fajardo Montañana 2008</a>; <a href="./references#CD005613-bbs2-0006" title="HaakT , TiengoA , DraegerE , SuntumM , WaldhauslW . Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2005;7(1):56-64. [PMID: 15642076]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Haak 2005</a>; <a href="./references#CD005613-bbs2-0008" title="DaileyG , StrangeP , RiddleM . Reconsideration of severe hypoglycemic events in the treat-to-target trial. Diabetes Technology &amp; Therapeutics2009;11(8):477-9. [PMID: 19698059]DaviesMJ , DerezinskiT , PedersenCB , ClausonP . Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Diabetes Technology &amp; Therapeutics2008;10(4):273-7. [PMID: 18715200]HermansenK , DaviesM , DerezinskiT , Martinez RavnG , ClausonP , HomeP . Erratum: A 26-week randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people wih type 2 diabetes (Diabetes Care (2006) 29, (1269-1274)). Diabetes Care2007;30(4):1035. [EMBASE: 46556609]HermansenK , DaviesM , DerezinskiT , MartinezRG , ClausonP , HomeP . A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care2006;29(6):1269-74. [PMID: 16732007]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00604396. Safety and efficacy of insulin detemir in combination with OAD in type 2 diabetes. clinicaltrials.gov/ct2/show/results/NCT00604396 (first received 30 January 2008). ">Hermansen 2006</a>; <a href="./references#CD005613-bbs2-0012" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. IshiiH , IwamotoY , KakuK , KawamoriR , KobayashiM , TajimaN . Night-time QOL and treatment satisfaction in diabetes mellitus patients treated with insulin detemir used in basal-bolus therapy – randomized multicenter open-label parallel group phase 3 trial compared to NPH insulin. Journal of the Japan Diabetes Society2009;52(8):691-701. [DOI: 10.11213/tonyobyo.52.691]KobayashiM , IwamotoY , KakuK , KawamoriR , TajimaN . Phase 3 clinical trial of insulin detemir for patients with insulin-dependent diabetes during basal-bolus therapy – a study of efficacy and safety with NPH insulin as control. Journal of the Japan Diabetes Society2007;50(9):649-63. [DOI: 10.11213/tonyobyo.50.649]NCT00604344. Efficacy and the safety of insulin detemir in subjects with insulin requiring diabetes. clinicaltrials.gov/ct2/show/NCT00604344 (first received 30 January 2008). Novo Nordisk A/S. A 48-week, randomised, multi-centre, open-labelled, parallel-group trial to compare the efficacy and the safety of NN304 (insulin detemir) and NPH human insulin in subjects with insulin requiring diabetes mellitus on a basal-bolus regimen. https://s3.amazonaws.com/ctr-nvo-7271/NN304-1476/aa9b4da3-1f92-460d-af0a-cc538614c3b2/3f7ed86e-d6e7-4542-ab8f-6cad24b46593/1476-ctr-synopsis-redacted-v2.pdf (last accessed 3 November 2020). ">Kobayashi 2007 A</a>; <a href="./references#CD005613-bbs2-0016" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">NN304‐1337</a>; <a href="./references#CD005613-bbs2-0017" title="DoucetJ , Le FlochJ , HanaireH , CourregesJ , AlexandreB , BauduceauB . Comparison of safety between detemir and neutral protamine Hagedorn (NPH) in ageing subjects: the '3 L study'. Fundamental and Clinical Pharmacology2011;25:82. [EMBASE: 70653089]EUCTR2006-006589-41-FR. Levemir® in ageing patients with type 2 diabetes A seven-month open-labelled randomised multi-centre two-group parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in the morning in ageing subjects with type 2 diabetes. The 3L Study (Levemir in Late Life) Trial Phase: 4. www.clinicaltrialsregister.eu/ctr-search/trial/2006-006589-41/FR (first received 27 March 2007). NCT00506662. The effect of insulin detemir on glucose control in ageing subjects with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00506662 (first received 25 July 2007). Novo Nordisk A/S. A seven-month, open-labelled, randomised, multicentre, two-group, parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in ageing patients with type 2 diabetes: The 3L Study (Levemir in Later Life) (NN304-1808 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1426&amp;filename=1808-ctr-redacted.pdf (last accessed 3 November 2020). ">NN304‐1808</a>; <a href="./references#CD005613-bbs2-0018" title="EUCTR2008-003739-19. Ensayo multicéntrico, abierto, aleatorizado, de dos grupos, paralelo para comparar el cambio en la distribución de grasa en sujetos con sobrepeso y obesos con diabetes tipo 2 tras 26 semanas de tratamiento con insulina detemir una vez al día frente a insulina NPH una vez al día, ambas con insulina aspart a la hora de las comidas. www.clinicaltrialsregister.eu/ctr-search/trial/2008-003739-19/ES (first received 19 September 2008). NCT00795600. A multi-centre, open-labelled, randomised, two-group parallel trial comparing the change in fat distribution in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin apart at mealtimes. clinicaltrials.gov/ct2/show/NCT00795600 (first received 21 November 2008). Novo Nordisk A/S. A multi-centre, open-labelled, randomised, two-group parallel trial comparing the change in fat distribution in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart at mealtimes (NN304-3614 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1461&amp;filename=3614-ctr-synopsis-redacted.pdf (last accessed 3 November 2020). TinahonesFJ , Gomez-HuelgasR , Garcia-AlegriaJ , Tapia-GuerreroM , Martos-PerezF . Fat distribution, HbA1c and hypoglycaemia in overweight and obese patients with type 2 diabetes: a comparison of NPH and insulin detemir from a pilot randomised clinical trial. Diabetologia2011;54:S273. [EMBASE: 70562816]TinahonesFJ , Gomez-HuelgasR , GarciaalegriaJ , Tapia-GuerreroMJ , PerezFM . The effect of insulin detemir on fat distribution and weight parameters in overweight and obese subjects with type 2 diabetes. Diabetes2011;60:A309. [EMBASE: 70628891]">NN304‐3614</a>), and recurrent major hypoglycaemia (<a href="./references#CD005613-bbs2-0006" title="HaakT , TiengoA , DraegerE , SuntumM , WaldhauslW . Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2005;7(1):56-64. [PMID: 15642076]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Haak 2005</a>; <a href="./references#CD005613-bbs2-0008" title="DaileyG , StrangeP , RiddleM . Reconsideration of severe hypoglycemic events in the treat-to-target trial. Diabetes Technology &amp; Therapeutics2009;11(8):477-9. [PMID: 19698059]DaviesMJ , DerezinskiT , PedersenCB , ClausonP . Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Diabetes Technology &amp; Therapeutics2008;10(4):273-7. [PMID: 18715200]HermansenK , DaviesM , DerezinskiT , Martinez RavnG , ClausonP , HomeP . Erratum: A 26-week randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people wih type 2 diabetes (Diabetes Care (2006) 29, (1269-1274)). Diabetes Care2007;30(4):1035. [EMBASE: 46556609]HermansenK , DaviesM , DerezinskiT , MartinezRG , ClausonP , HomeP . A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care2006;29(6):1269-74. [PMID: 16732007]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00604396. Safety and efficacy of insulin detemir in combination with OAD in type 2 diabetes. clinicaltrials.gov/ct2/show/results/NCT00604396 (first received 30 January 2008). ">Hermansen 2006</a>; <a href="./references#CD005613-bbs2-0012" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. IshiiH , IwamotoY , KakuK , KawamoriR , KobayashiM , TajimaN . Night-time QOL and treatment satisfaction in diabetes mellitus patients treated with insulin detemir used in basal-bolus therapy – randomized multicenter open-label parallel group phase 3 trial compared to NPH insulin. Journal of the Japan Diabetes Society2009;52(8):691-701. [DOI: 10.11213/tonyobyo.52.691]KobayashiM , IwamotoY , KakuK , KawamoriR , TajimaN . Phase 3 clinical trial of insulin detemir for patients with insulin-dependent diabetes during basal-bolus therapy – a study of efficacy and safety with NPH insulin as control. Journal of the Japan Diabetes Society2007;50(9):649-63. [DOI: 10.11213/tonyobyo.50.649]NCT00604344. Efficacy and the safety of insulin detemir in subjects with insulin requiring diabetes. clinicaltrials.gov/ct2/show/NCT00604344 (first received 30 January 2008). Novo Nordisk A/S. A 48-week, randomised, multi-centre, open-labelled, parallel-group trial to compare the efficacy and the safety of NN304 (insulin detemir) and NPH human insulin in subjects with insulin requiring diabetes mellitus on a basal-bolus regimen. https://s3.amazonaws.com/ctr-nvo-7271/NN304-1476/aa9b4da3-1f92-460d-af0a-cc538614c3b2/3f7ed86e-d6e7-4542-ab8f-6cad24b46593/1476-ctr-synopsis-redacted-v2.pdf (last accessed 3 November 2020). ">Kobayashi 2007 A</a>; <a href="./references#CD005613-bbs2-0016" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">NN304‐1337</a>; <a href="./references#CD005613-bbs2-0017" title="DoucetJ , Le FlochJ , HanaireH , CourregesJ , AlexandreB , BauduceauB . Comparison of safety between detemir and neutral protamine Hagedorn (NPH) in ageing subjects: the '3 L study'. Fundamental and Clinical Pharmacology2011;25:82. [EMBASE: 70653089]EUCTR2006-006589-41-FR. Levemir® in ageing patients with type 2 diabetes A seven-month open-labelled randomised multi-centre two-group parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in the morning in ageing subjects with type 2 diabetes. The 3L Study (Levemir in Late Life) Trial Phase: 4. www.clinicaltrialsregister.eu/ctr-search/trial/2006-006589-41/FR (first received 27 March 2007). NCT00506662. The effect of insulin detemir on glucose control in ageing subjects with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00506662 (first received 25 July 2007). Novo Nordisk A/S. A seven-month, open-labelled, randomised, multicentre, two-group, parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in ageing patients with type 2 diabetes: The 3L Study (Levemir in Later Life) (NN304-1808 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1426&amp;filename=1808-ctr-redacted.pdf (last accessed 3 November 2020). ">NN304‐1808</a>). Mean duration of diabetes ranged from about 10 to 17 years. Participants were mostly of white or Asian ethnicity (for those publications with no information on the ethnic composition of the study population, it was inferred from the study locations), with mean age ranging from 55 to 78 years in the various comparison groups. Most participants were overweight, with BMI ranging from 22 kg/m² to 32 kg/m². The proportion of women varied from 29% to 62% in the different comparison groups. None of the studies were performed on pharmaco‐naive people. Metabolic control in participants ranged from 7.6% to 9.5% HbA1c at baseline. One trial was partly conducted in a low‐income country, in Puerto Rico as well as the USA (<a href="./references#CD005613-bbs2-0016" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">NN304‐1337</a>). All other trials were carried out in Europe and Japan. </p> </section> </section> <section id="CD005613-sec-0075"> <h5 class="title">Diagnosis</h5> <section id="CD005613-sec-0076"> <h6 class="title">Glargine versus NPH</h6> <p>In one trial, the diagnosis of type 2 diabetes was made according to American Diabetes Association (ADA) criteria valid at the time (<a href="./references#CD005613-bbs2-0002" title="BetônicoCC , TitanSM , Correa-GiannellaML , NeryM , QueirozM . Comparison of insulin glargine vs. NPH insulin in basal-bolus therapies in T2DM patients and CKD: preliminary results of a prospective, randomized, open-label trial. Diabetes2016;65:A144-5. [CENTRAL: CN-01450000] BetônicoCC , TitanSM , LiraA , PelaesTS , Correa-GiannellaML , NeryM , et al. Insulin glargine U100 improved glycemic control and reduced nocturnal hypoglycemia in patients with type 2 diabetes mellitus and chronic kidney disease stages 3 and 4. Clinical Therapeutics2019;41(10):2008-20. [PMID: 31383366]NCT02451917. Subcutaneous insulin glargine versus NPH insulin in patients with chronic kidney disease stages III and IV: randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02451917 (first received 22 May 2015). ">Betônico 2019</a>), and in one further trial in accordance with WHO criteria (<a href="./references#CD005613-bbs2-0019" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. PanCY , SinnassamyP , ChungKD , KimKW , Group LS . Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Research &amp; Clinical Practice2007;76(1):111-8. [PMID: 17011662]">Pan 2007</a>). For all other trials, the exact criteria used to diagnose type 2 diabetes mellitus were unclear. </p> </section> <section id="CD005613-sec-0077"> <h6 class="title">Detemir versus NPH</h6> <p>In two trials, the diagnosis of type 2 diabetes was made in accordance with the ADA criteria valid at the time (<a href="./references#CD005613-bbs2-0006" title="HaakT , TiengoA , DraegerE , SuntumM , WaldhauslW . Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2005;7(1):56-64. [PMID: 15642076]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Haak 2005</a>; <a href="./references#CD005613-bbs2-0017" title="DoucetJ , Le FlochJ , HanaireH , CourregesJ , AlexandreB , BauduceauB . Comparison of safety between detemir and neutral protamine Hagedorn (NPH) in ageing subjects: the '3 L study'. Fundamental and Clinical Pharmacology2011;25:82. [EMBASE: 70653089]EUCTR2006-006589-41-FR. Levemir® in ageing patients with type 2 diabetes A seven-month open-labelled randomised multi-centre two-group parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in the morning in ageing subjects with type 2 diabetes. The 3L Study (Levemir in Late Life) Trial Phase: 4. www.clinicaltrialsregister.eu/ctr-search/trial/2006-006589-41/FR (first received 27 March 2007). NCT00506662. The effect of insulin detemir on glucose control in ageing subjects with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00506662 (first received 25 July 2007). Novo Nordisk A/S. A seven-month, open-labelled, randomised, multicentre, two-group, parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in ageing patients with type 2 diabetes: The 3L Study (Levemir in Later Life) (NN304-1808 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1426&amp;filename=1808-ctr-redacted.pdf (last accessed 3 November 2020). ">NN304‐1808</a>). For all other trials, the exact diagnostic criteria used to diagnose type 2 diabetes mellitus were unclear. </p> </section> </section> <section id="CD005613-sec-0078"> <h5 class="title">Interventions</h5> <section id="CD005613-sec-0079"> <h6 class="title">Glargine versus NPH</h6> <p>All insulins were administered subcutaneously in all included trials. Dosages of investigative drugs and concomitant medications varied between trials and participants. None of the included trials were placebo controlled. </p> <p>While administering glargine once daily is adequate, usage instructions recommend adapting the number of daily injections for NPH as necessary, as is common in clinical practice. Thus, for studies limiting NPH to a single daily injection, the comparator could not be considered adequate (<a href="./references#CD005613-bbs2-0003" title="EliaschewitzFG , CalvoC , ValbuenaH , RuizM , AschnerP , VillenaJ , et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Archives of Medical Research2006;37(4):495-501. [PMID: 16715577]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Eliaschewitz 2006</a>; <a href="./references#CD005613-bbs2-0005" title="FritscheA , SchweitzerMA , HaringHU , Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Annals of Internal Medicine2003;138(12):952-9. [PMID: 12809451]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Fritsche 2003</a>; <a href="./references#CD005613-bbs2-0009" title='EUCTR2007-006640-22. Superiority of insulin glargine Lantus vs NPH: "Treat to normoglycemia concept". Effect of insulin glargine in comparison to insulin NPH in insulin-naïve people with type 2 diabetes mellitus treated with at least one OAD and not adequately controlled (LANCELOT) (LANTU_C_02762 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2007-006640-22/results (last accessed 19 July 2017). HomePD , BolliGB , MathieuC , DeerochanawongC , LandgrafW , CandelasC , et al. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naive people with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2015;17(1):15-22. [PMID: 24957785]NCT00949442. Lantus versus NPH: comparison in insulin naive people not adequately controlled with at least one oral anti diabetics (OAD) treatment (LANCELOT). clinicaltrials.gov/ct2/show/NCT00949442 (first received 30 July 2009). '>Home 2015</a>; <a href="./references#CD005613-bbs2-0010" title="HsiaSH . Comparison of single-dose regimens of insulin glargine versus NPH among inner city ethnic minority type 2 diabetic patients uncontrolled on oral agents. Journal of Investigative Medicine2010;58(1):136. [EMBASE: 70981533]HsiaSH . Insulin glargine compared to NPH among insulin-naive, U.S. inner city, ethnic minority type 2 diabetic patients. Diabetes Research &amp; Clinical Practice2011;91(3):293-9. [PMID: 21146881]NCT00686712. Insulin glargine at bedtime or in AM versus NPH. clinicaltrials.gov/ct2/show/NCT00686712 (first received 7 October 2010). ">Hsia 2011</a>; <a href="./references#CD005613-bbs2-0011" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KawamoriR , IwamotoY , KadowakiT , IwasakiM . Efficacy and safety of insulin glargine in concurrent use with oral hypoglycemic agents for the treatment of type 2 diabetes patients. Rinshoiyaku2003;19(5):445-64. ">Kawamori 2003</a>; <a href="./references#CD005613-bbs2-0014" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. MassiBM , HumburgE , DresslerA , ZiemenM . A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Hormone &amp; Metabolic Research2003;35(3):189-96. [PMID: 12734781]Yki-JarvinenH , DresslerA , ZiemenM . Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care2000;23(8):1130-6. [EMBASE: 2006092604]">Massi 2003</a>; <a href="./references#CD005613-bbs2-0019" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. PanCY , SinnassamyP , ChungKD , KimKW , Group LS . Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Research &amp; Clinical Practice2007;76(1):111-8. [PMID: 17011662]">Pan 2007</a>; <a href="./references#CD005613-bbs2-0020" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00653341. Effect of insulin glargine in insulin naïve subjects with type 2 diabetes on oral hypoglycemic agent(s). www.clinicaltrials.gov/ct2/show/results/NCT00653341 (first received 4 April 2008). RiddleMC , RosenstockJ , GerichJ , InsulinG . The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care2003;26(11):3080-6. [PMID: 14578243]">Riddle 2003</a>; <a href="./references#CD005613-bbs2-0023" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. VarewijckAJ , JanssenJA , VahataloM , HoflandLJ , LambertsSW , Yki-JarvinenH . Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. Diabetologia2012;55(4):1186-94. [PMID: 22237688]VarewijckAJ , JanssenJA , VahataloM , LambertsSW , Ki-JarvinenHY . IGF-I bioactivity decreases during insulin therapy in type 2 diabetic patients: comparison of high doses of insulin glargine and NPH insulin in the LANMET study. In: Endocrine Reviews Conference: 93rd Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 32 (3 Meeting Abstracts). 2011. [EMBASE: 70676865]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJA . Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and IGF-I receptor signaling. Diabetes2013;62(7):2539-44. [PMID: 23569175]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJAMJL . Comparison of effects of insulin glargine, its metabolites, IGF-I and human insulin on insulin-and IGF-I receptor signaling in type 2 diabetic patients. In: Endocrine Reviews Conference: 95th Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 34 (3 suppl 1). 2013. [EMBASE: 71784187]Yki-JärvinenH , Kauppinen-MakelinR , TiikkainenM , VahataloM , VirtamoH , Nikkila K et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia2006;49(3):442-51. [PMID: 10937510]">Yki‐Järvinen 2006</a>; <a href="./references#CD005613-bbs2-0024" title="YokoyamaH , TadaJ , KamikawaF , KannoS , YokotaY , KuramitsuM . Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Research &amp; Clinical Practice2006;73(1):35-40. [PMID: 16513202]">Yokoyama 2006</a>). </p> <p>Target values for fasting blood glucose concentration ranged from 4.0 mmol/L to 7.8 mmol/L (72 mg/dL to 140 mg/dL) (<a href="./references#CD005613-bbs2-0003" title="EliaschewitzFG , CalvoC , ValbuenaH , RuizM , AschnerP , VillenaJ , et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Archives of Medical Research2006;37(4):495-501. [PMID: 16715577]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Eliaschewitz 2006</a>; <a href="./references#CD005613-bbs2-0005" title="FritscheA , SchweitzerMA , HaringHU , Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Annals of Internal Medicine2003;138(12):952-9. [PMID: 12809451]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Fritsche 2003</a>; <a href="./references#CD005613-bbs2-0009" title='EUCTR2007-006640-22. Superiority of insulin glargine Lantus vs NPH: "Treat to normoglycemia concept". Effect of insulin glargine in comparison to insulin NPH in insulin-naïve people with type 2 diabetes mellitus treated with at least one OAD and not adequately controlled (LANCELOT) (LANTU_C_02762 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2007-006640-22/results (last accessed 19 July 2017). HomePD , BolliGB , MathieuC , DeerochanawongC , LandgrafW , CandelasC , et al. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naive people with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2015;17(1):15-22. [PMID: 24957785]NCT00949442. Lantus versus NPH: comparison in insulin naive people not adequately controlled with at least one oral anti diabetics (OAD) treatment (LANCELOT). clinicaltrials.gov/ct2/show/NCT00949442 (first received 30 July 2009). '>Home 2015</a>; <a href="./references#CD005613-bbs2-0010" title="HsiaSH . Comparison of single-dose regimens of insulin glargine versus NPH among inner city ethnic minority type 2 diabetic patients uncontrolled on oral agents. Journal of Investigative Medicine2010;58(1):136. [EMBASE: 70981533]HsiaSH . Insulin glargine compared to NPH among insulin-naive, U.S. inner city, ethnic minority type 2 diabetic patients. Diabetes Research &amp; Clinical Practice2011;91(3):293-9. [PMID: 21146881]NCT00686712. Insulin glargine at bedtime or in AM versus NPH. clinicaltrials.gov/ct2/show/NCT00686712 (first received 7 October 2010). ">Hsia 2011</a>; <a href="./references#CD005613-bbs2-0011" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KawamoriR , IwamotoY , KadowakiT , IwasakiM . Efficacy and safety of insulin glargine in concurrent use with oral hypoglycemic agents for the treatment of type 2 diabetes patients. Rinshoiyaku2003;19(5):445-64. ">Kawamori 2003</a>; <a href="./references#CD005613-bbs2-0014" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. MassiBM , HumburgE , DresslerA , ZiemenM . A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Hormone &amp; Metabolic Research2003;35(3):189-96. [PMID: 12734781]Yki-JarvinenH , DresslerA , ZiemenM . Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care2000;23(8):1130-6. [EMBASE: 2006092604]">Massi 2003</a>; <a href="./references#CD005613-bbs2-0019" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. PanCY , SinnassamyP , ChungKD , KimKW , Group LS . Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Research &amp; Clinical Practice2007;76(1):111-8. [PMID: 17011662]">Pan 2007</a>; <a href="./references#CD005613-bbs2-0002" title="BetônicoCC , TitanSM , Correa-GiannellaML , NeryM , QueirozM . Comparison of insulin glargine vs. NPH insulin in basal-bolus therapies in T2DM patients and CKD: preliminary results of a prospective, randomized, open-label trial. Diabetes2016;65:A144-5. [CENTRAL: CN-01450000] BetônicoCC , TitanSM , LiraA , PelaesTS , Correa-GiannellaML , NeryM , et al. Insulin glargine U100 improved glycemic control and reduced nocturnal hypoglycemia in patients with type 2 diabetes mellitus and chronic kidney disease stages 3 and 4. Clinical Therapeutics2019;41(10):2008-20. [PMID: 31383366]NCT02451917. Subcutaneous insulin glargine versus NPH insulin in patients with chronic kidney disease stages III and IV: randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02451917 (first received 22 May 2015). ">Betônico 2019</a>; <a href="./references#CD005613-bbs2-0020" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00653341. Effect of insulin glargine in insulin naïve subjects with type 2 diabetes on oral hypoglycemic agent(s). www.clinicaltrials.gov/ct2/show/results/NCT00653341 (first received 4 April 2008). RiddleMC , RosenstockJ , GerichJ , InsulinG . The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care2003;26(11):3080-6. [PMID: 14578243]">Riddle 2003</a>; <a href="./references#CD005613-bbs2-0021" title="FonsecaV , BellDS , BergerS , ThomsonS , MeccaTE . A comparison of bedtime insulin glargine with bedtime neutral protamine Hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. American Journal of the Medical Sciences2004;328(5):274-80. [PMID: 15545844]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. RosenstockJ , SchwartzSL , Clark CM Jr, ParkGD , DonleyDW , EdwardsMB . Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care2001;24(4):631-6. [PMID: 11315821]">Rosenstock 2001</a>; <a href="./references#CD005613-bbs2-0022" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00174824. Comparison of insulin glargine and NPH human insulin in progression of diabetic retinopathy in type 2 diabetic patients. clinicaltrials.gov/ct2/show/study/NCT00174824 (first received 15 September 2005). RosenstockJ , FonsecaV , DainMP , RiddleM . Estimating number-needed-to-treat to avoid hypoglycaemic episodes in people with type 2 diabetes: a post-hoc analysis of a prospective randomized controlled trial comparing once-daily insulin glargine with twice-daily NPH insulin. Canadian Journal of Diabetes2009;33(3):185-6. [EMBASE: 70031352]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia2009;52(9):1778-88. [PMID: 19526210]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia2009;52(9):1971-3. [PMID: 19609501]RosenstockJ , FonsecaV , SchinzelS , DainMP , MullinsP , RiddleM . Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: evidence from a long-term controlled trial. Journal of Diabetic Complications2014;28(5):742-9. [PMID: 24856612]">Rosenstock 2009</a>; <a href="./references#CD005613-bbs2-0023" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. VarewijckAJ , JanssenJA , VahataloM , HoflandLJ , LambertsSW , Yki-JarvinenH . Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. Diabetologia2012;55(4):1186-94. [PMID: 22237688]VarewijckAJ , JanssenJA , VahataloM , LambertsSW , Ki-JarvinenHY . IGF-I bioactivity decreases during insulin therapy in type 2 diabetic patients: comparison of high doses of insulin glargine and NPH insulin in the LANMET study. In: Endocrine Reviews Conference: 93rd Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 32 (3 Meeting Abstracts). 2011. [EMBASE: 70676865]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJA . Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and IGF-I receptor signaling. Diabetes2013;62(7):2539-44. [PMID: 23569175]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJAMJL . Comparison of effects of insulin glargine, its metabolites, IGF-I and human insulin on insulin-and IGF-I receptor signaling in type 2 diabetic patients. In: Endocrine Reviews Conference: 95th Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 34 (3 suppl 1). 2013. [EMBASE: 71784187]Yki-JärvinenH , Kauppinen-MakelinR , TiikkainenM , VahataloM , VirtamoH , Nikkila K et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia2006;49(3):442-51. [PMID: 10937510]">Yki‐Järvinen 2006</a>). Two studies set nocturnal blood glucose targets ranging from 4.4 mmol/L to 6.6 mmol/L (80 mg/dL to 120 mg/dL) (<a href="./references#CD005613-bbs2-0009" title='EUCTR2007-006640-22. Superiority of insulin glargine Lantus vs NPH: "Treat to normoglycemia concept". Effect of insulin glargine in comparison to insulin NPH in insulin-naïve people with type 2 diabetes mellitus treated with at least one OAD and not adequately controlled (LANCELOT) (LANTU_C_02762 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2007-006640-22/results (last accessed 19 July 2017). HomePD , BolliGB , MathieuC , DeerochanawongC , LandgrafW , CandelasC , et al. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naive people with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2015;17(1):15-22. [PMID: 24957785]NCT00949442. Lantus versus NPH: comparison in insulin naive people not adequately controlled with at least one oral anti diabetics (OAD) treatment (LANCELOT). clinicaltrials.gov/ct2/show/NCT00949442 (first received 30 July 2009). '>Home 2015</a>; <a href="./references#CD005613-bbs2-0002" title="BetônicoCC , TitanSM , Correa-GiannellaML , NeryM , QueirozM . Comparison of insulin glargine vs. NPH insulin in basal-bolus therapies in T2DM patients and CKD: preliminary results of a prospective, randomized, open-label trial. Diabetes2016;65:A144-5. [CENTRAL: CN-01450000] BetônicoCC , TitanSM , LiraA , PelaesTS , Correa-GiannellaML , NeryM , et al. Insulin glargine U100 improved glycemic control and reduced nocturnal hypoglycemia in patients with type 2 diabetes mellitus and chronic kidney disease stages 3 and 4. Clinical Therapeutics2019;41(10):2008-20. [PMID: 31383366]NCT02451917. Subcutaneous insulin glargine versus NPH insulin in patients with chronic kidney disease stages III and IV: randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02451917 (first received 22 May 2015). ">Betônico 2019</a>). One study prespecified an additional target for postprandial blood glucose concentration below 10 mmol/L (180 mg/dL) (<a href="./references#CD005613-bbs2-0002" title="BetônicoCC , TitanSM , Correa-GiannellaML , NeryM , QueirozM . Comparison of insulin glargine vs. NPH insulin in basal-bolus therapies in T2DM patients and CKD: preliminary results of a prospective, randomized, open-label trial. Diabetes2016;65:A144-5. [CENTRAL: CN-01450000] BetônicoCC , TitanSM , LiraA , PelaesTS , Correa-GiannellaML , NeryM , et al. Insulin glargine U100 improved glycemic control and reduced nocturnal hypoglycemia in patients with type 2 diabetes mellitus and chronic kidney disease stages 3 and 4. Clinical Therapeutics2019;41(10):2008-20. [PMID: 31383366]NCT02451917. Subcutaneous insulin glargine versus NPH insulin in patients with chronic kidney disease stages III and IV: randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02451917 (first received 22 May 2015). ">Betônico 2019</a>). For four studies target values remained unclear (<a href="./references#CD005613-bbs2-0001" title="BerardL , CameronB , WooV , StewartJ . Replacing insulin glargine with neutral protamine Hagedorn (NPH) insulin in a subpopulation of study subjects in the action to control cardiovascular risk in diabetes (ACCORD): effects on blood glucose levels, hypoglycemia and patient satisfaction. Canadian Journal of Diabetes2015;39(4):296-301. [PMID: 25819531]BerardLD , WooVC . Safety and efficacy of NPH after switching from insulin glargine in Canadian patients. Diabetologia2011;54:S430. [EMBASE: 70563203]">Berard 2015</a>; <a href="./references#CD005613-bbs2-0007" title="EUCTR2009-010913-59. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on OHA treatment initiating basal insulin therapy with either insulin glargine or NPH insulin added to therapies with oral hypoglycemic agents (HAPPY) (LANTU_L_04079 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2009-010913-59/results (last accessed 3 May 2017). HermannsN , KulzerB , KohlmannT , JacobS , LandgrafW , TheobaldK , et al. Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial. Health and Quality of Life Outcomes2015;13:77. [PMID: 26055391]NCT00941369. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on oral hypoglycemic agent treatment initiating basal insulin therapy with either insulin glargine or NPH insulin. clinicaltrials.gov/ct2/show/NCT00941369 (first received 17 July 2009). ">Hermanns 2015</a>; <a href="./references#CD005613-bbs2-0015" title="NCT00687453. The utility of insulin glargine (Lantus) compared to NPH in ethnic minority type 2 diabetic subjects on combination insulin-oral agent therapy. clinicaltrials.gov/ct2/show/NCT00687453 (first received 30 May 2008). ">NCT00687453</a>; <a href="./references#CD005613-bbs2-0024" title="YokoyamaH , TadaJ , KamikawaF , KannoS , YokotaY , KuramitsuM . Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Research &amp; Clinical Practice2006;73(1):35-40. [PMID: 16513202]">Yokoyama 2006</a>). </p> <p>The design of the investigation by <a href="./references#CD005613-bbs2-0024" title="YokoyamaH , TadaJ , KamikawaF , KannoS , YokotaY , KuramitsuM . Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Research &amp; Clinical Practice2006;73(1):35-40. [PMID: 16513202]">Yokoyama 2006</a> required upward titration of insulin glargine with the aim of basal insulin making up 50% of the total daily insulin requirement. In contrast to this, the percentage of NPH in the total daily insulin requirement was left unchanged, thus introducing a difference in the treatments of the two comparison groups. This made the trial unfit to identify substance‐specific differences between insulin glargine and NPH insulin. Even though this was the case, we were unable to formally exclude this trial on the basis of our prespecified exclusion criteria. When appropriate, therefore, we conducted a sensitivity analysis that excluded this study. </p> </section> <section id="CD005613-sec-0080"> <h6 class="title">Detemir versus NPH</h6> <p>All insulins were administered subcutaneously in all included trials. Dosages of investigative drugs and concomitant medications varied among trials and participants. None of the included trials were placebo controlled. </p> <p>In accordance with usage instructions and common clinical practice, the number of daily injections of NPH should be adjusted as necessary. Thus, the comparator could not be considered adequate in studies limiting NPH to a single daily injection (<a href="./references#CD005613-bbs2-0004" title="EUCTR2005-000976-42. A multi-centre, open-labelled, randomised, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime (PREDICTIVE-BMI study) – PREDICTIVE-BMI study. www.clinicaltrialsregister.eu/ctr-search/trial/2005-000976-42/ES (first received 17 May 2006). Fajardo MontañanaC , Hernandez HerreroC , Rivas FernandezM . Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabetic Medicine2008;25(8):916-23. [PMID: 18959604]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00504673. Comparison of insulin detemir versus insulin NPH on weight change in overweight and obese with type 2 diabetes (PREDICTIVE). clinicaltrials.gov/ct2/show/NCT00504673 (first received 20 July 2007). Novo Nordisk A/S. A multi-centre, open-labelled, randomized, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime. (PREDICTIVE-BMI study). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1410&amp;filename=1659-ctr-redacted.pdf (last accessed 3 November 2020). Smith-PalmerJ , Fajardo-MontananaC , PollockRF , EricssonA , ValentineWJ . Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. Journal of Medical Economics2012;15(5):977-86. [PMID: 22563742]">Fajardo Montañana 2008</a>; <a href="./references#CD005613-bbs2-0013" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KobayashiM , IwamotoY , KakuK , KawamoriR , TajimaN . Phase 3 clinical trial of insulin detemir for type 2 diabetes patients with insufficient blood sugar control in oral diabetes drug therapy. Journal of the Japan Diabetes Society2007;50(9):665-77. [DOI: 10.11213/tonyobyo.50.665]NCT00604253. Efficacy and safety of insulin detemir in type 2 diabetes inadequately controlled on OHA therapy alone. www.clinicaltrials.gov/ct2/show/results/NCT00604253 (first received 30 January 2008). Novo Nordisk A/S. A 36-week, randomised, multi-centre, open-labelled, parallel-group trial to compare the efficacy and the safety of NN304 and NPH human insulin once daily treatment as add-on to current OHA therapy in subjects with type 2 diabetes mellitus who are inadequately controlled on OHA therapy. http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1397&amp;filename=NN304_1477_ICTRSynopsis_Final_20051101.pdf (last accessed 3 November 2020). ">Kobayashi 2007 B</a>; <a href="./references#CD005613-bbs2-0016" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">NN304‐1337</a>; <a href="./references#CD005613-bbs2-0017" title="DoucetJ , Le FlochJ , HanaireH , CourregesJ , AlexandreB , BauduceauB . Comparison of safety between detemir and neutral protamine Hagedorn (NPH) in ageing subjects: the '3 L study'. Fundamental and Clinical Pharmacology2011;25:82. [EMBASE: 70653089]EUCTR2006-006589-41-FR. Levemir® in ageing patients with type 2 diabetes A seven-month open-labelled randomised multi-centre two-group parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in the morning in ageing subjects with type 2 diabetes. The 3L Study (Levemir in Late Life) Trial Phase: 4. www.clinicaltrialsregister.eu/ctr-search/trial/2006-006589-41/FR (first received 27 March 2007). NCT00506662. The effect of insulin detemir on glucose control in ageing subjects with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00506662 (first received 25 July 2007). Novo Nordisk A/S. A seven-month, open-labelled, randomised, multicentre, two-group, parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in ageing patients with type 2 diabetes: The 3L Study (Levemir in Later Life) (NN304-1808 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1426&amp;filename=1808-ctr-redacted.pdf (last accessed 3 November 2020). ">NN304‐1808</a>; <a href="./references#CD005613-bbs2-0018" title="EUCTR2008-003739-19. Ensayo multicéntrico, abierto, aleatorizado, de dos grupos, paralelo para comparar el cambio en la distribución de grasa en sujetos con sobrepeso y obesos con diabetes tipo 2 tras 26 semanas de tratamiento con insulina detemir una vez al día frente a insulina NPH una vez al día, ambas con insulina aspart a la hora de las comidas. www.clinicaltrialsregister.eu/ctr-search/trial/2008-003739-19/ES (first received 19 September 2008). NCT00795600. A multi-centre, open-labelled, randomised, two-group parallel trial comparing the change in fat distribution in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin apart at mealtimes. clinicaltrials.gov/ct2/show/NCT00795600 (first received 21 November 2008). Novo Nordisk A/S. A multi-centre, open-labelled, randomised, two-group parallel trial comparing the change in fat distribution in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart at mealtimes (NN304-3614 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1461&amp;filename=3614-ctr-synopsis-redacted.pdf (last accessed 3 November 2020). TinahonesFJ , Gomez-HuelgasR , Garcia-AlegriaJ , Tapia-GuerreroM , Martos-PerezF . Fat distribution, HbA1c and hypoglycaemia in overweight and obese patients with type 2 diabetes: a comparison of NPH and insulin detemir from a pilot randomised clinical trial. Diabetologia2011;54:S273. [EMBASE: 70562816]TinahonesFJ , Gomez-HuelgasR , GarciaalegriaJ , Tapia-GuerreroMJ , PerezFM . The effect of insulin detemir on fat distribution and weight parameters in overweight and obese subjects with type 2 diabetes. Diabetes2011;60:A309. [EMBASE: 70628891]">NN304‐3614</a>). </p> <p>Target values for fasting blood glucose concentration ranged from 4.0 mmol/L to 7.0 mmol/L (72 mg/dL to 126 mg/dL) (<a href="./references#CD005613-bbs2-0004" title="EUCTR2005-000976-42. A multi-centre, open-labelled, randomised, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime (PREDICTIVE-BMI study) – PREDICTIVE-BMI study. www.clinicaltrialsregister.eu/ctr-search/trial/2005-000976-42/ES (first received 17 May 2006). Fajardo MontañanaC , Hernandez HerreroC , Rivas FernandezM . Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabetic Medicine2008;25(8):916-23. [PMID: 18959604]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00504673. Comparison of insulin detemir versus insulin NPH on weight change in overweight and obese with type 2 diabetes (PREDICTIVE). clinicaltrials.gov/ct2/show/NCT00504673 (first received 20 July 2007). Novo Nordisk A/S. A multi-centre, open-labelled, randomized, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime. (PREDICTIVE-BMI study). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1410&amp;filename=1659-ctr-redacted.pdf (last accessed 3 November 2020). Smith-PalmerJ , Fajardo-MontananaC , PollockRF , EricssonA , ValentineWJ . Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. Journal of Medical Economics2012;15(5):977-86. [PMID: 22563742]">Fajardo Montañana 2008</a>; <a href="./references#CD005613-bbs2-0006" title="HaakT , TiengoA , DraegerE , SuntumM , WaldhauslW . Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2005;7(1):56-64. [PMID: 15642076]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Haak 2005</a>; <a href="./references#CD005613-bbs2-0008" title="DaileyG , StrangeP , RiddleM . Reconsideration of severe hypoglycemic events in the treat-to-target trial. Diabetes Technology &amp; Therapeutics2009;11(8):477-9. [PMID: 19698059]DaviesMJ , DerezinskiT , PedersenCB , ClausonP . Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Diabetes Technology &amp; Therapeutics2008;10(4):273-7. [PMID: 18715200]HermansenK , DaviesM , DerezinskiT , Martinez RavnG , ClausonP , HomeP . Erratum: A 26-week randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people wih type 2 diabetes (Diabetes Care (2006) 29, (1269-1274)). Diabetes Care2007;30(4):1035. [EMBASE: 46556609]HermansenK , DaviesM , DerezinskiT , MartinezRG , ClausonP , HomeP . A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care2006;29(6):1269-74. [PMID: 16732007]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00604396. Safety and efficacy of insulin detemir in combination with OAD in type 2 diabetes. clinicaltrials.gov/ct2/show/results/NCT00604396 (first received 30 January 2008). ">Hermansen 2006</a>; <a href="./references#CD005613-bbs2-0012" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. IshiiH , IwamotoY , KakuK , KawamoriR , KobayashiM , TajimaN . Night-time QOL and treatment satisfaction in diabetes mellitus patients treated with insulin detemir used in basal-bolus therapy – randomized multicenter open-label parallel group phase 3 trial compared to NPH insulin. Journal of the Japan Diabetes Society2009;52(8):691-701. [DOI: 10.11213/tonyobyo.52.691]KobayashiM , IwamotoY , KakuK , KawamoriR , TajimaN . Phase 3 clinical trial of insulin detemir for patients with insulin-dependent diabetes during basal-bolus therapy – a study of efficacy and safety with NPH insulin as control. Journal of the Japan Diabetes Society2007;50(9):649-63. [DOI: 10.11213/tonyobyo.50.649]NCT00604344. Efficacy and the safety of insulin detemir in subjects with insulin requiring diabetes. clinicaltrials.gov/ct2/show/NCT00604344 (first received 30 January 2008). Novo Nordisk A/S. A 48-week, randomised, multi-centre, open-labelled, parallel-group trial to compare the efficacy and the safety of NN304 (insulin detemir) and NPH human insulin in subjects with insulin requiring diabetes mellitus on a basal-bolus regimen. https://s3.amazonaws.com/ctr-nvo-7271/NN304-1476/aa9b4da3-1f92-460d-af0a-cc538614c3b2/3f7ed86e-d6e7-4542-ab8f-6cad24b46593/1476-ctr-synopsis-redacted-v2.pdf (last accessed 3 November 2020). ">Kobayashi 2007 A</a>; <a href="./references#CD005613-bbs2-0013" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KobayashiM , IwamotoY , KakuK , KawamoriR , TajimaN . Phase 3 clinical trial of insulin detemir for type 2 diabetes patients with insufficient blood sugar control in oral diabetes drug therapy. Journal of the Japan Diabetes Society2007;50(9):665-77. [DOI: 10.11213/tonyobyo.50.665]NCT00604253. Efficacy and safety of insulin detemir in type 2 diabetes inadequately controlled on OHA therapy alone. www.clinicaltrials.gov/ct2/show/results/NCT00604253 (first received 30 January 2008). Novo Nordisk A/S. A 36-week, randomised, multi-centre, open-labelled, parallel-group trial to compare the efficacy and the safety of NN304 and NPH human insulin once daily treatment as add-on to current OHA therapy in subjects with type 2 diabetes mellitus who are inadequately controlled on OHA therapy. http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1397&amp;filename=NN304_1477_ICTRSynopsis_Final_20051101.pdf (last accessed 3 November 2020). ">Kobayashi 2007 B</a>; <a href="./references#CD005613-bbs2-0016" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">NN304‐1337</a>). A nocturnal blood glucose target was set in one study ranging from 4.0 mmol/L to 7.0 mmol/L (72 mmol/L to 126 mg/dL) (<a href="./references#CD005613-bbs2-0006" title="HaakT , TiengoA , DraegerE , SuntumM , WaldhauslW . Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2005;7(1):56-64. [PMID: 15642076]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Haak 2005</a>). Four studies prespecified an additional target for postprandial blood glucose concentration ranging between below 6.7 mmol/L (120 mg/dL) to below 10 mmol/L (180 mg/dL) (<a href="./references#CD005613-bbs2-0004" title="EUCTR2005-000976-42. A multi-centre, open-labelled, randomised, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime (PREDICTIVE-BMI study) – PREDICTIVE-BMI study. www.clinicaltrialsregister.eu/ctr-search/trial/2005-000976-42/ES (first received 17 May 2006). Fajardo MontañanaC , Hernandez HerreroC , Rivas FernandezM . Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabetic Medicine2008;25(8):916-23. [PMID: 18959604]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00504673. Comparison of insulin detemir versus insulin NPH on weight change in overweight and obese with type 2 diabetes (PREDICTIVE). clinicaltrials.gov/ct2/show/NCT00504673 (first received 20 July 2007). Novo Nordisk A/S. A multi-centre, open-labelled, randomized, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime. (PREDICTIVE-BMI study). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1410&amp;filename=1659-ctr-redacted.pdf (last accessed 3 November 2020). Smith-PalmerJ , Fajardo-MontananaC , PollockRF , EricssonA , ValentineWJ . Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. Journal of Medical Economics2012;15(5):977-86. [PMID: 22563742]">Fajardo Montañana 2008</a>; <a href="./references#CD005613-bbs2-0006" title="HaakT , TiengoA , DraegerE , SuntumM , WaldhauslW . Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2005;7(1):56-64. [PMID: 15642076]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Haak 2005</a>; <a href="./references#CD005613-bbs2-0012" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. IshiiH , IwamotoY , KakuK , KawamoriR , KobayashiM , TajimaN . Night-time QOL and treatment satisfaction in diabetes mellitus patients treated with insulin detemir used in basal-bolus therapy – randomized multicenter open-label parallel group phase 3 trial compared to NPH insulin. Journal of the Japan Diabetes Society2009;52(8):691-701. [DOI: 10.11213/tonyobyo.52.691]KobayashiM , IwamotoY , KakuK , KawamoriR , TajimaN . Phase 3 clinical trial of insulin detemir for patients with insulin-dependent diabetes during basal-bolus therapy – a study of efficacy and safety with NPH insulin as control. Journal of the Japan Diabetes Society2007;50(9):649-63. [DOI: 10.11213/tonyobyo.50.649]NCT00604344. Efficacy and the safety of insulin detemir in subjects with insulin requiring diabetes. clinicaltrials.gov/ct2/show/NCT00604344 (first received 30 January 2008). Novo Nordisk A/S. A 48-week, randomised, multi-centre, open-labelled, parallel-group trial to compare the efficacy and the safety of NN304 (insulin detemir) and NPH human insulin in subjects with insulin requiring diabetes mellitus on a basal-bolus regimen. https://s3.amazonaws.com/ctr-nvo-7271/NN304-1476/aa9b4da3-1f92-460d-af0a-cc538614c3b2/3f7ed86e-d6e7-4542-ab8f-6cad24b46593/1476-ctr-synopsis-redacted-v2.pdf (last accessed 3 November 2020). ">Kobayashi 2007 A</a>; <a href="./references#CD005613-bbs2-0013" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KobayashiM , IwamotoY , KakuK , KawamoriR , TajimaN . Phase 3 clinical trial of insulin detemir for type 2 diabetes patients with insufficient blood sugar control in oral diabetes drug therapy. Journal of the Japan Diabetes Society2007;50(9):665-77. [DOI: 10.11213/tonyobyo.50.665]NCT00604253. Efficacy and safety of insulin detemir in type 2 diabetes inadequately controlled on OHA therapy alone. www.clinicaltrials.gov/ct2/show/results/NCT00604253 (first received 30 January 2008). Novo Nordisk A/S. A 36-week, randomised, multi-centre, open-labelled, parallel-group trial to compare the efficacy and the safety of NN304 and NPH human insulin once daily treatment as add-on to current OHA therapy in subjects with type 2 diabetes mellitus who are inadequately controlled on OHA therapy. http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1397&amp;filename=NN304_1477_ICTRSynopsis_Final_20051101.pdf (last accessed 3 November 2020). ">Kobayashi 2007 B</a>). In <a href="./references#CD005613-bbs2-0008" title="DaileyG , StrangeP , RiddleM . Reconsideration of severe hypoglycemic events in the treat-to-target trial. Diabetes Technology &amp; Therapeutics2009;11(8):477-9. [PMID: 19698059]DaviesMJ , DerezinskiT , PedersenCB , ClausonP . Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Diabetes Technology &amp; Therapeutics2008;10(4):273-7. [PMID: 18715200]HermansenK , DaviesM , DerezinskiT , Martinez RavnG , ClausonP , HomeP . Erratum: A 26-week randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people wih type 2 diabetes (Diabetes Care (2006) 29, (1269-1274)). Diabetes Care2007;30(4):1035. [EMBASE: 46556609]HermansenK , DaviesM , DerezinskiT , MartinezRG , ClausonP , HomeP . A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care2006;29(6):1269-74. [PMID: 16732007]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00604396. Safety and efficacy of insulin detemir in combination with OAD in type 2 diabetes. clinicaltrials.gov/ct2/show/results/NCT00604396 (first received 30 January 2008). ">Hermansen 2006</a>, a predinner blood glucose target of 6.0 mmol/L (108 mg/dL) or below was also set. For two studies, target values remained unclear (<a href="./references#CD005613-bbs2-0017" title="DoucetJ , Le FlochJ , HanaireH , CourregesJ , AlexandreB , BauduceauB . Comparison of safety between detemir and neutral protamine Hagedorn (NPH) in ageing subjects: the '3 L study'. Fundamental and Clinical Pharmacology2011;25:82. [EMBASE: 70653089]EUCTR2006-006589-41-FR. Levemir® in ageing patients with type 2 diabetes A seven-month open-labelled randomised multi-centre two-group parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in the morning in ageing subjects with type 2 diabetes. The 3L Study (Levemir in Late Life) Trial Phase: 4. www.clinicaltrialsregister.eu/ctr-search/trial/2006-006589-41/FR (first received 27 March 2007). NCT00506662. The effect of insulin detemir on glucose control in ageing subjects with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00506662 (first received 25 July 2007). Novo Nordisk A/S. A seven-month, open-labelled, randomised, multicentre, two-group, parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in ageing patients with type 2 diabetes: The 3L Study (Levemir in Later Life) (NN304-1808 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1426&amp;filename=1808-ctr-redacted.pdf (last accessed 3 November 2020). ">NN304‐1808</a>; <a href="./references#CD005613-bbs2-0018" title="EUCTR2008-003739-19. Ensayo multicéntrico, abierto, aleatorizado, de dos grupos, paralelo para comparar el cambio en la distribución de grasa en sujetos con sobrepeso y obesos con diabetes tipo 2 tras 26 semanas de tratamiento con insulina detemir una vez al día frente a insulina NPH una vez al día, ambas con insulina aspart a la hora de las comidas. www.clinicaltrialsregister.eu/ctr-search/trial/2008-003739-19/ES (first received 19 September 2008). NCT00795600. A multi-centre, open-labelled, randomised, two-group parallel trial comparing the change in fat distribution in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin apart at mealtimes. clinicaltrials.gov/ct2/show/NCT00795600 (first received 21 November 2008). Novo Nordisk A/S. A multi-centre, open-labelled, randomised, two-group parallel trial comparing the change in fat distribution in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart at mealtimes (NN304-3614 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1461&amp;filename=3614-ctr-synopsis-redacted.pdf (last accessed 3 November 2020). TinahonesFJ , Gomez-HuelgasR , Garcia-AlegriaJ , Tapia-GuerreroM , Martos-PerezF . Fat distribution, HbA1c and hypoglycaemia in overweight and obese patients with type 2 diabetes: a comparison of NPH and insulin detemir from a pilot randomised clinical trial. Diabetologia2011;54:S273. [EMBASE: 70562816]TinahonesFJ , Gomez-HuelgasR , GarciaalegriaJ , Tapia-GuerreroMJ , PerezFM . The effect of insulin detemir on fat distribution and weight parameters in overweight and obese subjects with type 2 diabetes. Diabetes2011;60:A309. [EMBASE: 70628891]">NN304‐3614</a>). </p> <p>In trials comparing glargine or detemir to NPH, reported target blood glucose levels used in the adjustment of blood glucose lowering medications were consistent with the target range recommended by ADA for most non‐pregnant adults with diabetes (<a href="./references#CD005613-bbs2-0068" title="American Diabetes Association. Introduction: standards of medical care in diabetes. Diabetes Care2020;43:S1-212.">ADA 2020</a>), but they were generally at the lower end of the recommended target range. Furthermore, they did not take into account ADA's recommendation that the goals be adjusted individually, depending on the duration of diabetes, known CVD and other factors. In the included trials, the participants had diabetes for eight to 19 years at the start of the trial. In current clinical practice, blood glucose targets for many of the trials' participants would probably have been raised. This also casts doubt on the adequacy of the interventions and comparators. </p> </section> </section> <section id="CD005613-sec-0081"> <h5 class="title">Outcomes</h5> <section id="CD005613-sec-0082"> <h6 class="title">Glargine versus NPH</h6> <p>HbA1c was the defined primary outcome in all but four trials (<a href="./references#CD005613-bbs2-0001" title="BerardL , CameronB , WooV , StewartJ . Replacing insulin glargine with neutral protamine Hagedorn (NPH) insulin in a subpopulation of study subjects in the action to control cardiovascular risk in diabetes (ACCORD): effects on blood glucose levels, hypoglycemia and patient satisfaction. Canadian Journal of Diabetes2015;39(4):296-301. [PMID: 25819531]BerardLD , WooVC . Safety and efficacy of NPH after switching from insulin glargine in Canadian patients. Diabetologia2011;54:S430. [EMBASE: 70563203]">Berard 2015</a>; <a href="./references#CD005613-bbs2-0007" title="EUCTR2009-010913-59. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on OHA treatment initiating basal insulin therapy with either insulin glargine or NPH insulin added to therapies with oral hypoglycemic agents (HAPPY) (LANTU_L_04079 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2009-010913-59/results (last accessed 3 May 2017). HermannsN , KulzerB , KohlmannT , JacobS , LandgrafW , TheobaldK , et al. Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial. Health and Quality of Life Outcomes2015;13:77. [PMID: 26055391]NCT00941369. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on oral hypoglycemic agent treatment initiating basal insulin therapy with either insulin glargine or NPH insulin. clinicaltrials.gov/ct2/show/NCT00941369 (first received 17 July 2009). ">Hermanns 2015</a>; <a href="./references#CD005613-bbs2-0022" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00174824. Comparison of insulin glargine and NPH human insulin in progression of diabetic retinopathy in type 2 diabetic patients. clinicaltrials.gov/ct2/show/study/NCT00174824 (first received 15 September 2005). RosenstockJ , FonsecaV , DainMP , RiddleM . Estimating number-needed-to-treat to avoid hypoglycaemic episodes in people with type 2 diabetes: a post-hoc analysis of a prospective randomized controlled trial comparing once-daily insulin glargine with twice-daily NPH insulin. Canadian Journal of Diabetes2009;33(3):185-6. [EMBASE: 70031352]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia2009;52(9):1778-88. [PMID: 19526210]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia2009;52(9):1971-3. [PMID: 19609501]RosenstockJ , FonsecaV , SchinzelS , DainMP , MullinsP , RiddleM . Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: evidence from a long-term controlled trial. Journal of Diabetic Complications2014;28(5):742-9. [PMID: 24856612]">Rosenstock 2009</a>; <a href="./references#CD005613-bbs2-0024" title="YokoyamaH , TadaJ , KamikawaF , KannoS , YokotaY , KuramitsuM . Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Research &amp; Clinical Practice2006;73(1):35-40. [PMID: 16513202]">Yokoyama 2006</a>). Further defined primary outcomes were progression of retinopathy in one trial (<a href="./references#CD005613-bbs2-0022" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00174824. Comparison of insulin glargine and NPH human insulin in progression of diabetic retinopathy in type 2 diabetic patients. clinicaltrials.gov/ct2/show/study/NCT00174824 (first received 15 September 2005). RosenstockJ , FonsecaV , DainMP , RiddleM . Estimating number-needed-to-treat to avoid hypoglycaemic episodes in people with type 2 diabetes: a post-hoc analysis of a prospective randomized controlled trial comparing once-daily insulin glargine with twice-daily NPH insulin. Canadian Journal of Diabetes2009;33(3):185-6. [EMBASE: 70031352]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia2009;52(9):1778-88. [PMID: 19526210]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia2009;52(9):1971-3. [PMID: 19609501]RosenstockJ , FonsecaV , SchinzelS , DainMP , MullinsP , RiddleM . Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: evidence from a long-term controlled trial. Journal of Diabetic Complications2014;28(5):742-9. [PMID: 24856612]">Rosenstock 2009</a>), and health‐related quality of life in another (<a href="./references#CD005613-bbs2-0007" title="EUCTR2009-010913-59. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on OHA treatment initiating basal insulin therapy with either insulin glargine or NPH insulin added to therapies with oral hypoglycemic agents (HAPPY) (LANTU_L_04079 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2009-010913-59/results (last accessed 3 May 2017). HermannsN , KulzerB , KohlmannT , JacobS , LandgrafW , TheobaldK , et al. Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial. Health and Quality of Life Outcomes2015;13:77. [PMID: 26055391]NCT00941369. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on oral hypoglycemic agent treatment initiating basal insulin therapy with either insulin glargine or NPH insulin. clinicaltrials.gov/ct2/show/NCT00941369 (first received 17 July 2009). ">Hermanns 2015</a>). For two trials, the primary outcome remained unclear (<a href="./references#CD005613-bbs2-0001" title="BerardL , CameronB , WooV , StewartJ . Replacing insulin glargine with neutral protamine Hagedorn (NPH) insulin in a subpopulation of study subjects in the action to control cardiovascular risk in diabetes (ACCORD): effects on blood glucose levels, hypoglycemia and patient satisfaction. Canadian Journal of Diabetes2015;39(4):296-301. [PMID: 25819531]BerardLD , WooVC . Safety and efficacy of NPH after switching from insulin glargine in Canadian patients. Diabetologia2011;54:S430. [EMBASE: 70563203]">Berard 2015</a>; <a href="./references#CD005613-bbs2-0024" title="YokoyamaH , TadaJ , KamikawaF , KannoS , YokotaY , KuramitsuM . Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Research &amp; Clinical Practice2006;73(1):35-40. [PMID: 16513202]">Yokoyama 2006</a>). For all but two trials (<a href="./references#CD005613-bbs2-0001" title="BerardL , CameronB , WooV , StewartJ . Replacing insulin glargine with neutral protamine Hagedorn (NPH) insulin in a subpopulation of study subjects in the action to control cardiovascular risk in diabetes (ACCORD): effects on blood glucose levels, hypoglycemia and patient satisfaction. Canadian Journal of Diabetes2015;39(4):296-301. [PMID: 25819531]BerardLD , WooVC . Safety and efficacy of NPH after switching from insulin glargine in Canadian patients. Diabetologia2011;54:S430. [EMBASE: 70563203]">Berard 2015</a>; <a href="./references#CD005613-bbs2-0024" title="YokoyamaH , TadaJ , KamikawaF , KannoS , YokotaY , KuramitsuM . Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Research &amp; Clinical Practice2006;73(1):35-40. [PMID: 16513202]">Yokoyama 2006</a>), information on adverse events was reported. Reports on late diabetes complications were available for eight trials (<a href="./references#CD005613-bbs2-0009" title='EUCTR2007-006640-22. Superiority of insulin glargine Lantus vs NPH: "Treat to normoglycemia concept". Effect of insulin glargine in comparison to insulin NPH in insulin-naïve people with type 2 diabetes mellitus treated with at least one OAD and not adequately controlled (LANCELOT) (LANTU_C_02762 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2007-006640-22/results (last accessed 19 July 2017). HomePD , BolliGB , MathieuC , DeerochanawongC , LandgrafW , CandelasC , et al. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naive people with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2015;17(1):15-22. [PMID: 24957785]NCT00949442. Lantus versus NPH: comparison in insulin naive people not adequately controlled with at least one oral anti diabetics (OAD) treatment (LANCELOT). clinicaltrials.gov/ct2/show/NCT00949442 (first received 30 July 2009). '>Home 2015</a>; <a href="./references#CD005613-bbs2-0010" title="HsiaSH . Comparison of single-dose regimens of insulin glargine versus NPH among inner city ethnic minority type 2 diabetic patients uncontrolled on oral agents. Journal of Investigative Medicine2010;58(1):136. [EMBASE: 70981533]HsiaSH . Insulin glargine compared to NPH among insulin-naive, U.S. inner city, ethnic minority type 2 diabetic patients. Diabetes Research &amp; Clinical Practice2011;91(3):293-9. [PMID: 21146881]NCT00686712. Insulin glargine at bedtime or in AM versus NPH. clinicaltrials.gov/ct2/show/NCT00686712 (first received 7 October 2010). ">Hsia 2011</a>; <a href="./references#CD005613-bbs2-0014" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. MassiBM , HumburgE , DresslerA , ZiemenM . A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Hormone &amp; Metabolic Research2003;35(3):189-96. [PMID: 12734781]Yki-JarvinenH , DresslerA , ZiemenM . Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care2000;23(8):1130-6. [EMBASE: 2006092604]">Massi 2003</a>; <a href="./references#CD005613-bbs2-0015" title="NCT00687453. The utility of insulin glargine (Lantus) compared to NPH in ethnic minority type 2 diabetic subjects on combination insulin-oral agent therapy. clinicaltrials.gov/ct2/show/NCT00687453 (first received 30 May 2008). ">NCT00687453</a>; <a href="./references#CD005613-bbs2-0002" title="BetônicoCC , TitanSM , Correa-GiannellaML , NeryM , QueirozM . Comparison of insulin glargine vs. NPH insulin in basal-bolus therapies in T2DM patients and CKD: preliminary results of a prospective, randomized, open-label trial. Diabetes2016;65:A144-5. [CENTRAL: CN-01450000] BetônicoCC , TitanSM , LiraA , PelaesTS , Correa-GiannellaML , NeryM , et al. Insulin glargine U100 improved glycemic control and reduced nocturnal hypoglycemia in patients with type 2 diabetes mellitus and chronic kidney disease stages 3 and 4. Clinical Therapeutics2019;41(10):2008-20. [PMID: 31383366]NCT02451917. Subcutaneous insulin glargine versus NPH insulin in patients with chronic kidney disease stages III and IV: randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02451917 (first received 22 May 2015). ">Betônico 2019</a>; <a href="./references#CD005613-bbs2-0021" title="FonsecaV , BellDS , BergerS , ThomsonS , MeccaTE . A comparison of bedtime insulin glargine with bedtime neutral protamine Hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. American Journal of the Medical Sciences2004;328(5):274-80. [PMID: 15545844]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. RosenstockJ , SchwartzSL , Clark CM Jr, ParkGD , DonleyDW , EdwardsMB . Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care2001;24(4):631-6. [PMID: 11315821]">Rosenstock 2001</a>; <a href="./references#CD005613-bbs2-0022" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00174824. Comparison of insulin glargine and NPH human insulin in progression of diabetic retinopathy in type 2 diabetic patients. clinicaltrials.gov/ct2/show/study/NCT00174824 (first received 15 September 2005). RosenstockJ , FonsecaV , DainMP , RiddleM . Estimating number-needed-to-treat to avoid hypoglycaemic episodes in people with type 2 diabetes: a post-hoc analysis of a prospective randomized controlled trial comparing once-daily insulin glargine with twice-daily NPH insulin. Canadian Journal of Diabetes2009;33(3):185-6. [EMBASE: 70031352]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia2009;52(9):1778-88. [PMID: 19526210]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia2009;52(9):1971-3. [PMID: 19609501]RosenstockJ , FonsecaV , SchinzelS , DainMP , MullinsP , RiddleM . Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: evidence from a long-term controlled trial. Journal of Diabetic Complications2014;28(5):742-9. [PMID: 24856612]">Rosenstock 2009</a>; <a href="./references#CD005613-bbs2-0023" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. VarewijckAJ , JanssenJA , VahataloM , HoflandLJ , LambertsSW , Yki-JarvinenH . Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. Diabetologia2012;55(4):1186-94. [PMID: 22237688]VarewijckAJ , JanssenJA , VahataloM , LambertsSW , Ki-JarvinenHY . IGF-I bioactivity decreases during insulin therapy in type 2 diabetic patients: comparison of high doses of insulin glargine and NPH insulin in the LANMET study. In: Endocrine Reviews Conference: 93rd Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 32 (3 Meeting Abstracts). 2011. [EMBASE: 70676865]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJA . Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and IGF-I receptor signaling. Diabetes2013;62(7):2539-44. [PMID: 23569175]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJAMJL . Comparison of effects of insulin glargine, its metabolites, IGF-I and human insulin on insulin-and IGF-I receptor signaling in type 2 diabetic patients. In: Endocrine Reviews Conference: 95th Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 34 (3 suppl 1). 2013. [EMBASE: 71784187]Yki-JärvinenH , Kauppinen-MakelinR , TiikkainenM , VahataloM , VirtamoH , Nikkila K et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia2006;49(3):442-51. [PMID: 10937510]">Yki‐Järvinen 2006</a>). Fourteen trials either reported mortality directly, or it could be deduced from provided information (<a href="./references#CD005613-bbs2-0003" title="EliaschewitzFG , CalvoC , ValbuenaH , RuizM , AschnerP , VillenaJ , et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Archives of Medical Research2006;37(4):495-501. [PMID: 16715577]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Eliaschewitz 2006</a>; <a href="./references#CD005613-bbs2-0005" title="FritscheA , SchweitzerMA , HaringHU , Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Annals of Internal Medicine2003;138(12):952-9. [PMID: 12809451]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Fritsche 2003</a>; <a href="./references#CD005613-bbs2-0007" title="EUCTR2009-010913-59. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on OHA treatment initiating basal insulin therapy with either insulin glargine or NPH insulin added to therapies with oral hypoglycemic agents (HAPPY) (LANTU_L_04079 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2009-010913-59/results (last accessed 3 May 2017). HermannsN , KulzerB , KohlmannT , JacobS , LandgrafW , TheobaldK , et al. Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial. Health and Quality of Life Outcomes2015;13:77. [PMID: 26055391]NCT00941369. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on oral hypoglycemic agent treatment initiating basal insulin therapy with either insulin glargine or NPH insulin. clinicaltrials.gov/ct2/show/NCT00941369 (first received 17 July 2009). ">Hermanns 2015</a>; <a href="./references#CD005613-bbs2-0009" title='EUCTR2007-006640-22. Superiority of insulin glargine Lantus vs NPH: "Treat to normoglycemia concept". Effect of insulin glargine in comparison to insulin NPH in insulin-naïve people with type 2 diabetes mellitus treated with at least one OAD and not adequately controlled (LANCELOT) (LANTU_C_02762 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2007-006640-22/results (last accessed 19 July 2017). HomePD , BolliGB , MathieuC , DeerochanawongC , LandgrafW , CandelasC , et al. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naive people with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2015;17(1):15-22. [PMID: 24957785]NCT00949442. Lantus versus NPH: comparison in insulin naive people not adequately controlled with at least one oral anti diabetics (OAD) treatment (LANCELOT). clinicaltrials.gov/ct2/show/NCT00949442 (first received 30 July 2009). '>Home 2015</a>; <a href="./references#CD005613-bbs2-0010" title="HsiaSH . Comparison of single-dose regimens of insulin glargine versus NPH among inner city ethnic minority type 2 diabetic patients uncontrolled on oral agents. Journal of Investigative Medicine2010;58(1):136. [EMBASE: 70981533]HsiaSH . Insulin glargine compared to NPH among insulin-naive, U.S. inner city, ethnic minority type 2 diabetic patients. Diabetes Research &amp; Clinical Practice2011;91(3):293-9. [PMID: 21146881]NCT00686712. Insulin glargine at bedtime or in AM versus NPH. clinicaltrials.gov/ct2/show/NCT00686712 (first received 7 October 2010). ">Hsia 2011</a>; <a href="./references#CD005613-bbs2-0011" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KawamoriR , IwamotoY , KadowakiT , IwasakiM . Efficacy and safety of insulin glargine in concurrent use with oral hypoglycemic agents for the treatment of type 2 diabetes patients. Rinshoiyaku2003;19(5):445-64. ">Kawamori 2003</a>; <a href="./references#CD005613-bbs2-0014" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. MassiBM , HumburgE , DresslerA , ZiemenM . A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Hormone &amp; Metabolic Research2003;35(3):189-96. [PMID: 12734781]Yki-JarvinenH , DresslerA , ZiemenM . Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care2000;23(8):1130-6. [EMBASE: 2006092604]">Massi 2003</a>; <a href="./references#CD005613-bbs2-0015" title="NCT00687453. The utility of insulin glargine (Lantus) compared to NPH in ethnic minority type 2 diabetic subjects on combination insulin-oral agent therapy. clinicaltrials.gov/ct2/show/NCT00687453 (first received 30 May 2008). ">NCT00687453</a>; <a href="./references#CD005613-bbs2-0019" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. PanCY , SinnassamyP , ChungKD , KimKW , Group LS . Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Research &amp; Clinical Practice2007;76(1):111-8. [PMID: 17011662]">Pan 2007</a>; <a href="./references#CD005613-bbs2-0002" title="BetônicoCC , TitanSM , Correa-GiannellaML , NeryM , QueirozM . Comparison of insulin glargine vs. NPH insulin in basal-bolus therapies in T2DM patients and CKD: preliminary results of a prospective, randomized, open-label trial. Diabetes2016;65:A144-5. [CENTRAL: CN-01450000] BetônicoCC , TitanSM , LiraA , PelaesTS , Correa-GiannellaML , NeryM , et al. Insulin glargine U100 improved glycemic control and reduced nocturnal hypoglycemia in patients with type 2 diabetes mellitus and chronic kidney disease stages 3 and 4. Clinical Therapeutics2019;41(10):2008-20. [PMID: 31383366]NCT02451917. Subcutaneous insulin glargine versus NPH insulin in patients with chronic kidney disease stages III and IV: randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02451917 (first received 22 May 2015). ">Betônico 2019</a>; <a href="./references#CD005613-bbs2-0020" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00653341. Effect of insulin glargine in insulin naïve subjects with type 2 diabetes on oral hypoglycemic agent(s). www.clinicaltrials.gov/ct2/show/results/NCT00653341 (first received 4 April 2008). RiddleMC , RosenstockJ , GerichJ , InsulinG . The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care2003;26(11):3080-6. [PMID: 14578243]">Riddle 2003</a>; <a href="./references#CD005613-bbs2-0021" title="FonsecaV , BellDS , BergerS , ThomsonS , MeccaTE . A comparison of bedtime insulin glargine with bedtime neutral protamine Hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. American Journal of the Medical Sciences2004;328(5):274-80. [PMID: 15545844]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. RosenstockJ , SchwartzSL , Clark CM Jr, ParkGD , DonleyDW , EdwardsMB . Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care2001;24(4):631-6. [PMID: 11315821]">Rosenstock 2001</a>; <a href="./references#CD005613-bbs2-0022" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00174824. Comparison of insulin glargine and NPH human insulin in progression of diabetic retinopathy in type 2 diabetic patients. clinicaltrials.gov/ct2/show/study/NCT00174824 (first received 15 September 2005). RosenstockJ , FonsecaV , DainMP , RiddleM . Estimating number-needed-to-treat to avoid hypoglycaemic episodes in people with type 2 diabetes: a post-hoc analysis of a prospective randomized controlled trial comparing once-daily insulin glargine with twice-daily NPH insulin. Canadian Journal of Diabetes2009;33(3):185-6. [EMBASE: 70031352]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia2009;52(9):1778-88. [PMID: 19526210]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia2009;52(9):1971-3. [PMID: 19609501]RosenstockJ , FonsecaV , SchinzelS , DainMP , MullinsP , RiddleM . Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: evidence from a long-term controlled trial. Journal of Diabetic Complications2014;28(5):742-9. [PMID: 24856612]">Rosenstock 2009</a>; <a href="./references#CD005613-bbs2-0023" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. VarewijckAJ , JanssenJA , VahataloM , HoflandLJ , LambertsSW , Yki-JarvinenH . Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. Diabetologia2012;55(4):1186-94. [PMID: 22237688]VarewijckAJ , JanssenJA , VahataloM , LambertsSW , Ki-JarvinenHY . IGF-I bioactivity decreases during insulin therapy in type 2 diabetic patients: comparison of high doses of insulin glargine and NPH insulin in the LANMET study. In: Endocrine Reviews Conference: 93rd Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 32 (3 Meeting Abstracts). 2011. [EMBASE: 70676865]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJA . Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and IGF-I receptor signaling. Diabetes2013;62(7):2539-44. [PMID: 23569175]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJAMJL . Comparison of effects of insulin glargine, its metabolites, IGF-I and human insulin on insulin-and IGF-I receptor signaling in type 2 diabetic patients. In: Endocrine Reviews Conference: 95th Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 34 (3 suppl 1). 2013. [EMBASE: 71784187]Yki-JärvinenH , Kauppinen-MakelinR , TiikkainenM , VahataloM , VirtamoH , Nikkila K et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia2006;49(3):442-51. [PMID: 10937510]">Yki‐Järvinen 2006</a>). Three trials did not report information on health‐related quality of life (<a href="./references#CD005613-bbs2-0007" title="EUCTR2009-010913-59. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on OHA treatment initiating basal insulin therapy with either insulin glargine or NPH insulin added to therapies with oral hypoglycemic agents (HAPPY) (LANTU_L_04079 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2009-010913-59/results (last accessed 3 May 2017). HermannsN , KulzerB , KohlmannT , JacobS , LandgrafW , TheobaldK , et al. Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial. Health and Quality of Life Outcomes2015;13:77. [PMID: 26055391]NCT00941369. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on oral hypoglycemic agent treatment initiating basal insulin therapy with either insulin glargine or NPH insulin. clinicaltrials.gov/ct2/show/NCT00941369 (first received 17 July 2009). ">Hermanns 2015</a>; <a href="./references#CD005613-bbs2-0014" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. MassiBM , HumburgE , DresslerA , ZiemenM . A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Hormone &amp; Metabolic Research2003;35(3):189-96. [PMID: 12734781]Yki-JarvinenH , DresslerA , ZiemenM . Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care2000;23(8):1130-6. [EMBASE: 2006092604]">Massi 2003</a>; <a href="./references#CD005613-bbs2-0021" title="FonsecaV , BellDS , BergerS , ThomsonS , MeccaTE . A comparison of bedtime insulin glargine with bedtime neutral protamine Hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. American Journal of the Medical Sciences2004;328(5):274-80. [PMID: 15545844]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. RosenstockJ , SchwartzSL , Clark CM Jr, ParkGD , DonleyDW , EdwardsMB . Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care2001;24(4):631-6. [PMID: 11315821]">Rosenstock 2001</a>). No trial provided information on socioeconomic effects. </p> </section> <section id="CD005613-sec-0083"> <h6 class="title">Detemir versus NPH</h6> <p>HbA1c was the defined primary outcome in six trials (<a href="./references#CD005613-bbs2-0006" title="HaakT , TiengoA , DraegerE , SuntumM , WaldhauslW . Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2005;7(1):56-64. [PMID: 15642076]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Haak 2005</a>; <a href="./references#CD005613-bbs2-0008" title="DaileyG , StrangeP , RiddleM . Reconsideration of severe hypoglycemic events in the treat-to-target trial. Diabetes Technology &amp; Therapeutics2009;11(8):477-9. [PMID: 19698059]DaviesMJ , DerezinskiT , PedersenCB , ClausonP . Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Diabetes Technology &amp; Therapeutics2008;10(4):273-7. [PMID: 18715200]HermansenK , DaviesM , DerezinskiT , Martinez RavnG , ClausonP , HomeP . Erratum: A 26-week randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people wih type 2 diabetes (Diabetes Care (2006) 29, (1269-1274)). Diabetes Care2007;30(4):1035. [EMBASE: 46556609]HermansenK , DaviesM , DerezinskiT , MartinezRG , ClausonP , HomeP . A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care2006;29(6):1269-74. [PMID: 16732007]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00604396. Safety and efficacy of insulin detemir in combination with OAD in type 2 diabetes. clinicaltrials.gov/ct2/show/results/NCT00604396 (first received 30 January 2008). ">Hermansen 2006</a>; <a href="./references#CD005613-bbs2-0012" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. IshiiH , IwamotoY , KakuK , KawamoriR , KobayashiM , TajimaN . Night-time QOL and treatment satisfaction in diabetes mellitus patients treated with insulin detemir used in basal-bolus therapy – randomized multicenter open-label parallel group phase 3 trial compared to NPH insulin. Journal of the Japan Diabetes Society2009;52(8):691-701. [DOI: 10.11213/tonyobyo.52.691]KobayashiM , IwamotoY , KakuK , KawamoriR , TajimaN . Phase 3 clinical trial of insulin detemir for patients with insulin-dependent diabetes during basal-bolus therapy – a study of efficacy and safety with NPH insulin as control. Journal of the Japan Diabetes Society2007;50(9):649-63. [DOI: 10.11213/tonyobyo.50.649]NCT00604344. Efficacy and the safety of insulin detemir in subjects with insulin requiring diabetes. clinicaltrials.gov/ct2/show/NCT00604344 (first received 30 January 2008). Novo Nordisk A/S. A 48-week, randomised, multi-centre, open-labelled, parallel-group trial to compare the efficacy and the safety of NN304 (insulin detemir) and NPH human insulin in subjects with insulin requiring diabetes mellitus on a basal-bolus regimen. https://s3.amazonaws.com/ctr-nvo-7271/NN304-1476/aa9b4da3-1f92-460d-af0a-cc538614c3b2/3f7ed86e-d6e7-4542-ab8f-6cad24b46593/1476-ctr-synopsis-redacted-v2.pdf (last accessed 3 November 2020). ">Kobayashi 2007 A</a>; <a href="./references#CD005613-bbs2-0013" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KobayashiM , IwamotoY , KakuK , KawamoriR , TajimaN . Phase 3 clinical trial of insulin detemir for type 2 diabetes patients with insufficient blood sugar control in oral diabetes drug therapy. Journal of the Japan Diabetes Society2007;50(9):665-77. [DOI: 10.11213/tonyobyo.50.665]NCT00604253. Efficacy and safety of insulin detemir in type 2 diabetes inadequately controlled on OHA therapy alone. www.clinicaltrials.gov/ct2/show/results/NCT00604253 (first received 30 January 2008). Novo Nordisk A/S. A 36-week, randomised, multi-centre, open-labelled, parallel-group trial to compare the efficacy and the safety of NN304 and NPH human insulin once daily treatment as add-on to current OHA therapy in subjects with type 2 diabetes mellitus who are inadequately controlled on OHA therapy. http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1397&amp;filename=NN304_1477_ICTRSynopsis_Final_20051101.pdf (last accessed 3 November 2020). ">Kobayashi 2007 B</a>; <a href="./references#CD005613-bbs2-0016" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">NN304‐1337</a>; <a href="./references#CD005613-bbs2-0017" title="DoucetJ , Le FlochJ , HanaireH , CourregesJ , AlexandreB , BauduceauB . Comparison of safety between detemir and neutral protamine Hagedorn (NPH) in ageing subjects: the '3 L study'. Fundamental and Clinical Pharmacology2011;25:82. [EMBASE: 70653089]EUCTR2006-006589-41-FR. Levemir® in ageing patients with type 2 diabetes A seven-month open-labelled randomised multi-centre two-group parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in the morning in ageing subjects with type 2 diabetes. The 3L Study (Levemir in Late Life) Trial Phase: 4. www.clinicaltrialsregister.eu/ctr-search/trial/2006-006589-41/FR (first received 27 March 2007). NCT00506662. The effect of insulin detemir on glucose control in ageing subjects with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00506662 (first received 25 July 2007). Novo Nordisk A/S. A seven-month, open-labelled, randomised, multicentre, two-group, parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in ageing patients with type 2 diabetes: The 3L Study (Levemir in Later Life) (NN304-1808 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1426&amp;filename=1808-ctr-redacted.pdf (last accessed 3 November 2020). ">NN304‐1808</a>). Further defined primary outcomes were weight loss (<a href="./references#CD005613-bbs2-0004" title="EUCTR2005-000976-42. A multi-centre, open-labelled, randomised, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime (PREDICTIVE-BMI study) – PREDICTIVE-BMI study. www.clinicaltrialsregister.eu/ctr-search/trial/2005-000976-42/ES (first received 17 May 2006). Fajardo MontañanaC , Hernandez HerreroC , Rivas FernandezM . Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabetic Medicine2008;25(8):916-23. [PMID: 18959604]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00504673. Comparison of insulin detemir versus insulin NPH on weight change in overweight and obese with type 2 diabetes (PREDICTIVE). clinicaltrials.gov/ct2/show/NCT00504673 (first received 20 July 2007). Novo Nordisk A/S. A multi-centre, open-labelled, randomized, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime. (PREDICTIVE-BMI study). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1410&amp;filename=1659-ctr-redacted.pdf (last accessed 3 November 2020). Smith-PalmerJ , Fajardo-MontananaC , PollockRF , EricssonA , ValentineWJ . Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. Journal of Medical Economics2012;15(5):977-86. [PMID: 22563742]">Fajardo Montañana 2008</a>) and changes in trunk fat mass (<a href="./references#CD005613-bbs2-0018" title="EUCTR2008-003739-19. Ensayo multicéntrico, abierto, aleatorizado, de dos grupos, paralelo para comparar el cambio en la distribución de grasa en sujetos con sobrepeso y obesos con diabetes tipo 2 tras 26 semanas de tratamiento con insulina detemir una vez al día frente a insulina NPH una vez al día, ambas con insulina aspart a la hora de las comidas. www.clinicaltrialsregister.eu/ctr-search/trial/2008-003739-19/ES (first received 19 September 2008). NCT00795600. A multi-centre, open-labelled, randomised, two-group parallel trial comparing the change in fat distribution in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin apart at mealtimes. clinicaltrials.gov/ct2/show/NCT00795600 (first received 21 November 2008). Novo Nordisk A/S. A multi-centre, open-labelled, randomised, two-group parallel trial comparing the change in fat distribution in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart at mealtimes (NN304-3614 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1461&amp;filename=3614-ctr-synopsis-redacted.pdf (last accessed 3 November 2020). TinahonesFJ , Gomez-HuelgasR , Garcia-AlegriaJ , Tapia-GuerreroM , Martos-PerezF . Fat distribution, HbA1c and hypoglycaemia in overweight and obese patients with type 2 diabetes: a comparison of NPH and insulin detemir from a pilot randomised clinical trial. Diabetologia2011;54:S273. [EMBASE: 70562816]TinahonesFJ , Gomez-HuelgasR , GarciaalegriaJ , Tapia-GuerreroMJ , PerezFM . The effect of insulin detemir on fat distribution and weight parameters in overweight and obese subjects with type 2 diabetes. Diabetes2011;60:A309. [EMBASE: 70628891]">NN304‐3614</a>). </p> <p>All trials reported information on adverse events. All trials either reported on mortality, or it could be deduced from the information provided. </p> <p>Reports on late diabetes complications were available in five trials (<a href="./references#CD005613-bbs2-0004" title="EUCTR2005-000976-42. A multi-centre, open-labelled, randomised, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime (PREDICTIVE-BMI study) – PREDICTIVE-BMI study. www.clinicaltrialsregister.eu/ctr-search/trial/2005-000976-42/ES (first received 17 May 2006). Fajardo MontañanaC , Hernandez HerreroC , Rivas FernandezM . Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabetic Medicine2008;25(8):916-23. [PMID: 18959604]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00504673. Comparison of insulin detemir versus insulin NPH on weight change in overweight and obese with type 2 diabetes (PREDICTIVE). clinicaltrials.gov/ct2/show/NCT00504673 (first received 20 July 2007). Novo Nordisk A/S. A multi-centre, open-labelled, randomized, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime. (PREDICTIVE-BMI study). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1410&amp;filename=1659-ctr-redacted.pdf (last accessed 3 November 2020). Smith-PalmerJ , Fajardo-MontananaC , PollockRF , EricssonA , ValentineWJ . Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. Journal of Medical Economics2012;15(5):977-86. [PMID: 22563742]">Fajardo Montañana 2008</a>; <a href="./references#CD005613-bbs2-0006" title="HaakT , TiengoA , DraegerE , SuntumM , WaldhauslW . Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2005;7(1):56-64. [PMID: 15642076]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Haak 2005</a>; <a href="./references#CD005613-bbs2-0013" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KobayashiM , IwamotoY , KakuK , KawamoriR , TajimaN . Phase 3 clinical trial of insulin detemir for type 2 diabetes patients with insufficient blood sugar control in oral diabetes drug therapy. Journal of the Japan Diabetes Society2007;50(9):665-77. [DOI: 10.11213/tonyobyo.50.665]NCT00604253. Efficacy and safety of insulin detemir in type 2 diabetes inadequately controlled on OHA therapy alone. www.clinicaltrials.gov/ct2/show/results/NCT00604253 (first received 30 January 2008). Novo Nordisk A/S. A 36-week, randomised, multi-centre, open-labelled, parallel-group trial to compare the efficacy and the safety of NN304 and NPH human insulin once daily treatment as add-on to current OHA therapy in subjects with type 2 diabetes mellitus who are inadequately controlled on OHA therapy. http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1397&amp;filename=NN304_1477_ICTRSynopsis_Final_20051101.pdf (last accessed 3 November 2020). ">Kobayashi 2007 B</a>; <a href="./references#CD005613-bbs2-0016" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">NN304‐1337</a>; <a href="./references#CD005613-bbs2-0017" title="DoucetJ , Le FlochJ , HanaireH , CourregesJ , AlexandreB , BauduceauB . Comparison of safety between detemir and neutral protamine Hagedorn (NPH) in ageing subjects: the '3 L study'. Fundamental and Clinical Pharmacology2011;25:82. [EMBASE: 70653089]EUCTR2006-006589-41-FR. Levemir® in ageing patients with type 2 diabetes A seven-month open-labelled randomised multi-centre two-group parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in the morning in ageing subjects with type 2 diabetes. The 3L Study (Levemir in Late Life) Trial Phase: 4. www.clinicaltrialsregister.eu/ctr-search/trial/2006-006589-41/FR (first received 27 March 2007). NCT00506662. The effect of insulin detemir on glucose control in ageing subjects with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00506662 (first received 25 July 2007). Novo Nordisk A/S. A seven-month, open-labelled, randomised, multicentre, two-group, parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in ageing patients with type 2 diabetes: The 3L Study (Levemir in Later Life) (NN304-1808 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1426&amp;filename=1808-ctr-redacted.pdf (last accessed 3 November 2020). ">NN304‐1808</a>). </p> <p>Three trials reported information on health‐related quality of life (<a href="./references#CD005613-bbs2-0004" title="EUCTR2005-000976-42. A multi-centre, open-labelled, randomised, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime (PREDICTIVE-BMI study) – PREDICTIVE-BMI study. www.clinicaltrialsregister.eu/ctr-search/trial/2005-000976-42/ES (first received 17 May 2006). Fajardo MontañanaC , Hernandez HerreroC , Rivas FernandezM . Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabetic Medicine2008;25(8):916-23. [PMID: 18959604]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00504673. Comparison of insulin detemir versus insulin NPH on weight change in overweight and obese with type 2 diabetes (PREDICTIVE). clinicaltrials.gov/ct2/show/NCT00504673 (first received 20 July 2007). Novo Nordisk A/S. A multi-centre, open-labelled, randomized, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime. (PREDICTIVE-BMI study). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1410&amp;filename=1659-ctr-redacted.pdf (last accessed 3 November 2020). Smith-PalmerJ , Fajardo-MontananaC , PollockRF , EricssonA , ValentineWJ . Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. Journal of Medical Economics2012;15(5):977-86. [PMID: 22563742]">Fajardo Montañana 2008</a>; <a href="./references#CD005613-bbs2-0006" title="HaakT , TiengoA , DraegerE , SuntumM , WaldhauslW . Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2005;7(1):56-64. [PMID: 15642076]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Haak 2005</a>; <a href="./references#CD005613-bbs2-0012" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. IshiiH , IwamotoY , KakuK , KawamoriR , KobayashiM , TajimaN . Night-time QOL and treatment satisfaction in diabetes mellitus patients treated with insulin detemir used in basal-bolus therapy – randomized multicenter open-label parallel group phase 3 trial compared to NPH insulin. Journal of the Japan Diabetes Society2009;52(8):691-701. [DOI: 10.11213/tonyobyo.52.691]KobayashiM , IwamotoY , KakuK , KawamoriR , TajimaN . Phase 3 clinical trial of insulin detemir for patients with insulin-dependent diabetes during basal-bolus therapy – a study of efficacy and safety with NPH insulin as control. Journal of the Japan Diabetes Society2007;50(9):649-63. [DOI: 10.11213/tonyobyo.50.649]NCT00604344. Efficacy and the safety of insulin detemir in subjects with insulin requiring diabetes. clinicaltrials.gov/ct2/show/NCT00604344 (first received 30 January 2008). Novo Nordisk A/S. A 48-week, randomised, multi-centre, open-labelled, parallel-group trial to compare the efficacy and the safety of NN304 (insulin detemir) and NPH human insulin in subjects with insulin requiring diabetes mellitus on a basal-bolus regimen. https://s3.amazonaws.com/ctr-nvo-7271/NN304-1476/aa9b4da3-1f92-460d-af0a-cc538614c3b2/3f7ed86e-d6e7-4542-ab8f-6cad24b46593/1476-ctr-synopsis-redacted-v2.pdf (last accessed 3 November 2020). ">Kobayashi 2007 A</a>). No trial provided information on socioeconomic effects. </p> </section> </section> </section> <section id="CD005613-sec-0084"> <h4 class="title">Excluded studies</h4> <p>Full‐text evaluation in the study selection process of this review update resulted in the exclusion of 36 trials (40 articles/records). The main reasons for exclusion were that the study was a systematic review (meta‐analysis/HTA report), that the comparison was not adequate, and that the study was not a RCT (see <a href="#CD005613-fig-0001">Figure 1</a>). For details see <a href="./references#CD005613-sec-0173" title="">Characteristics of excluded studies</a> table. </p> <section id="CD005613-sec-0085"> <h5 class="title">Studies awaiting classification</h5> <p>We classified three trials with five references as awaiting classification (see <a href="./references#CD005613-sec-0174" title="">Characteristics of studies awaiting classification</a> table). All three trials with an estimated total of 140 participants were listed in ClinicalTrials.gov as having been completed (<a href="./references#CD005613-bbs2-0061" title="EUCTR2007-003085-17-GB. The effect of insulin detemir on energy balance, postprandial nutrient handling, body fat distribution, and adipose tissue metabolism and gene expression in patients with type 2 diabetes. www.clinicaltrialsregister.eu/ctr-search/trial/2007-003085-17/GB (first received 26 November 2007). ISRCTN72730583. The effect of insulin detemir on energy balance, postprandial nutrient handling, body fat distribution and adipose tissue metabolism and gene expression in patients with type 2 diabetes. www.isrctn.com/ISRCTN72730583 (first received 30 July 2010). NCT00788840. A 24-week, national, single-centre, open-labelled, randomised, parallel-group trial comparing energy expenditure with insulin detemir versus NPH insulin using a vasal-volus regimen with insulin aspart as the mealtime insulin in subjects with type 2 diabetes. www.clinicaltrials.gov/ct2/show/study/NCT00788840 (first received 11 November 2008). ">NCT00788840</a>; <a href="./references#CD005613-bbs2-0062" title="NCT01310452. A multi-centre, open-labeled, randomized, parallel study on liver fat content and visceral fat mass in overweight and obese type 2 diabetes patients after 26 weeks treatment with insulin detemir once daily versus insulin NPH once daily. www.clinicaltrials.gov/ct2/show/study/NCT01310452 (first received 8 March 2011). ">NCT01310452</a>; <a href="./references#CD005613-bbs2-0063" title="NCT01500850. Establishing cardiovascular biomarkers to define preferred lantus use. www.clinicaltrials.gov/ct2/show/record/NCT01500850 (first received 29 December 2011). ">NCT01500850</a>), but no study results were reported and no publications were available. We contacted the investigators for each trial, but none of them replied. </p> </section> <section id="CD005613-sec-0086"> <h5 class="title">Ongoing trials</h5> <p>We found two potentially relevant ongoing RCTs. One trial investigated the ultra‐long‐acting insulin analogue insulin degludec in comparison to insulin detemir, insulin glargine or NPH insulin in adults aged 60 to 75 years with type 2 diabetes mellitus who were at high risk of developing Alzheimer's disease (<a href="./references#CD005613-bbs2-0064" title="EUCTR2017-004454-42-ES. An interventional study to arrest the progression of cognitive decline in diabetic patients at high risk of developing Alzheimer's disease by reducing hypoglycemic events (low blood glucose). www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-004454-42 (first received 25 January 2018). ">EUCTR2017‐004454‐42‐ES</a>). The estimated number of participants in this trial is 188. The trial will assess the rate of hypoglycaemic events and blood glucose measures which are primary and secondary outcomes in our review. The estimated completion date for the trial is not stated. The second trial investigates the ultra‐long‐acting insulin analogue insulin glargine U‐300 in comparison to NPH insulin in insulin‐naive adults with type 2 diabetes mellitus who were suboptimally controlled on their previous antidiabetic treatment (<a href="./references#CD005613-bbs2-0065" title="NCT03389490. A pilot study to describe the glycaemic variability of insulin glargine 300U/ml versus NPH (neutral protamine Hagedorn) in the insulin-naïve type 2 diabetes patients following a patient-adjusted insulin algorithm in Hong Kong. www.clinicaltrials.gov/ct2/show/NCT03389490 (first received 3 January 2018). ">NCT03389490</a>). The estimated number of participants is 50. Changes in HbA1c and the incidence of hypoglycaemia, which are primary and secondary outcomes in our review, are predefined secondary outcomes in this trial. For further details see <a href="./references#CD005613-sec-0175" title="">Characteristics of ongoing studies</a> table. </p> </section> </section> </section> <section id="CD005613-sec-0087"> <h3 class="title">Risk of bias in included studies</h3> <p>For details on the risk of bias in the included trials, see <a href="./references#CD005613-sec-0172" title="">Characteristics of included studies</a> table. </p> <p>For an overview of assessments of each risk of bias item for individual trials and across all trials see <a href="#CD005613-fig-0002">Figure 2</a> and <a href="#CD005613-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD005613-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials (blank cells indicate that the particular outcome was not measured in some trials)." data-id="CD005613-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials (blank cells indicate that the particular outcome was not measured in some trials). </p> </div> </div> </div> <div class="figure" id="CD005613-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included trial (blank cells indicate that the particular outcome was not measured in the trial)" data-id="CD005613-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included trial (blank cells indicate that the particular outcome was not measured in the trial) </p> </div> </div> </div> <section id="CD005613-sec-0088"> <h4 class="title">Allocation</h4> <p>All included studies were RCTs. Regarding method of randomisation and allocation concealment, we judged seven trials to have a low risk of bias based on the information from journal publications (<a href="./references#CD005613-bbs2-0004" title="EUCTR2005-000976-42. A multi-centre, open-labelled, randomised, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime (PREDICTIVE-BMI study) – PREDICTIVE-BMI study. www.clinicaltrialsregister.eu/ctr-search/trial/2005-000976-42/ES (first received 17 May 2006). Fajardo MontañanaC , Hernandez HerreroC , Rivas FernandezM . Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabetic Medicine2008;25(8):916-23. [PMID: 18959604]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00504673. Comparison of insulin detemir versus insulin NPH on weight change in overweight and obese with type 2 diabetes (PREDICTIVE). clinicaltrials.gov/ct2/show/NCT00504673 (first received 20 July 2007). Novo Nordisk A/S. A multi-centre, open-labelled, randomized, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime. (PREDICTIVE-BMI study). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1410&amp;filename=1659-ctr-redacted.pdf (last accessed 3 November 2020). Smith-PalmerJ , Fajardo-MontananaC , PollockRF , EricssonA , ValentineWJ . Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. Journal of Medical Economics2012;15(5):977-86. [PMID: 22563742]">Fajardo Montañana 2008</a>; <a href="./references#CD005613-bbs2-0005" title="FritscheA , SchweitzerMA , HaringHU , Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Annals of Internal Medicine2003;138(12):952-9. [PMID: 12809451]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Fritsche 2003</a>; <a href="./references#CD005613-bbs2-0008" title="DaileyG , StrangeP , RiddleM . Reconsideration of severe hypoglycemic events in the treat-to-target trial. Diabetes Technology &amp; Therapeutics2009;11(8):477-9. [PMID: 19698059]DaviesMJ , DerezinskiT , PedersenCB , ClausonP . Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Diabetes Technology &amp; Therapeutics2008;10(4):273-7. [PMID: 18715200]HermansenK , DaviesM , DerezinskiT , Martinez RavnG , ClausonP , HomeP . Erratum: A 26-week randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people wih type 2 diabetes (Diabetes Care (2006) 29, (1269-1274)). Diabetes Care2007;30(4):1035. [EMBASE: 46556609]HermansenK , DaviesM , DerezinskiT , MartinezRG , ClausonP , HomeP . A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care2006;29(6):1269-74. [PMID: 16732007]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00604396. Safety and efficacy of insulin detemir in combination with OAD in type 2 diabetes. clinicaltrials.gov/ct2/show/results/NCT00604396 (first received 30 January 2008). ">Hermansen 2006</a>; <a href="./references#CD005613-bbs2-0009" title='EUCTR2007-006640-22. Superiority of insulin glargine Lantus vs NPH: "Treat to normoglycemia concept". Effect of insulin glargine in comparison to insulin NPH in insulin-naïve people with type 2 diabetes mellitus treated with at least one OAD and not adequately controlled (LANCELOT) (LANTU_C_02762 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2007-006640-22/results (last accessed 19 July 2017). HomePD , BolliGB , MathieuC , DeerochanawongC , LandgrafW , CandelasC , et al. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naive people with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2015;17(1):15-22. [PMID: 24957785]NCT00949442. Lantus versus NPH: comparison in insulin naive people not adequately controlled with at least one oral anti diabetics (OAD) treatment (LANCELOT). clinicaltrials.gov/ct2/show/NCT00949442 (first received 30 July 2009). '>Home 2015</a>; <a href="./references#CD005613-bbs2-0014" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. MassiBM , HumburgE , DresslerA , ZiemenM . A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Hormone &amp; Metabolic Research2003;35(3):189-96. [PMID: 12734781]Yki-JarvinenH , DresslerA , ZiemenM . Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care2000;23(8):1130-6. [EMBASE: 2006092604]">Massi 2003</a>; <a href="./references#CD005613-bbs2-0017" title="DoucetJ , Le FlochJ , HanaireH , CourregesJ , AlexandreB , BauduceauB . Comparison of safety between detemir and neutral protamine Hagedorn (NPH) in ageing subjects: the '3 L study'. Fundamental and Clinical Pharmacology2011;25:82. [EMBASE: 70653089]EUCTR2006-006589-41-FR. Levemir® in ageing patients with type 2 diabetes A seven-month open-labelled randomised multi-centre two-group parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in the morning in ageing subjects with type 2 diabetes. The 3L Study (Levemir in Late Life) Trial Phase: 4. www.clinicaltrialsregister.eu/ctr-search/trial/2006-006589-41/FR (first received 27 March 2007). NCT00506662. The effect of insulin detemir on glucose control in ageing subjects with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00506662 (first received 25 July 2007). Novo Nordisk A/S. A seven-month, open-labelled, randomised, multicentre, two-group, parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in ageing patients with type 2 diabetes: The 3L Study (Levemir in Later Life) (NN304-1808 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1426&amp;filename=1808-ctr-redacted.pdf (last accessed 3 November 2020). ">NN304‐1808</a>; <a href="./references#CD005613-bbs2-0020" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00653341. Effect of insulin glargine in insulin naïve subjects with type 2 diabetes on oral hypoglycemic agent(s). www.clinicaltrials.gov/ct2/show/results/NCT00653341 (first received 4 April 2008). RiddleMC , RosenstockJ , GerichJ , InsulinG . The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care2003;26(11):3080-6. [PMID: 14578243]">Riddle 2003</a>). In six additional trials, randomisation and allocation concealment were considered adequate in the IQWiG report 2009 (<a href="./references#CD005613-bbs2-0003" title="EliaschewitzFG , CalvoC , ValbuenaH , RuizM , AschnerP , VillenaJ , et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Archives of Medical Research2006;37(4):495-501. [PMID: 16715577]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Eliaschewitz 2006</a>; <a href="./references#CD005613-bbs2-0006" title="HaakT , TiengoA , DraegerE , SuntumM , WaldhauslW . Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2005;7(1):56-64. [PMID: 15642076]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Haak 2005</a>; <a href="./references#CD005613-bbs2-0016" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">NN304‐1337</a>; <a href="./references#CD005613-bbs2-0019" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. PanCY , SinnassamyP , ChungKD , KimKW , Group LS . Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Research &amp; Clinical Practice2007;76(1):111-8. [PMID: 17011662]">Pan 2007</a>; <a href="./references#CD005613-bbs2-0021" title="FonsecaV , BellDS , BergerS , ThomsonS , MeccaTE . A comparison of bedtime insulin glargine with bedtime neutral protamine Hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. American Journal of the Medical Sciences2004;328(5):274-80. [PMID: 15545844]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. RosenstockJ , SchwartzSL , Clark CM Jr, ParkGD , DonleyDW , EdwardsMB . Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care2001;24(4):631-6. [PMID: 11315821]">Rosenstock 2001</a>; <a href="./references#CD005613-bbs2-0022" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00174824. Comparison of insulin glargine and NPH human insulin in progression of diabetic retinopathy in type 2 diabetic patients. clinicaltrials.gov/ct2/show/study/NCT00174824 (first received 15 September 2005). RosenstockJ , FonsecaV , DainMP , RiddleM . Estimating number-needed-to-treat to avoid hypoglycaemic episodes in people with type 2 diabetes: a post-hoc analysis of a prospective randomized controlled trial comparing once-daily insulin glargine with twice-daily NPH insulin. Canadian Journal of Diabetes2009;33(3):185-6. [EMBASE: 70031352]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia2009;52(9):1778-88. [PMID: 19526210]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia2009;52(9):1971-3. [PMID: 19609501]RosenstockJ , FonsecaV , SchinzelS , DainMP , MullinsP , RiddleM . Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: evidence from a long-term controlled trial. Journal of Diabetic Complications2014;28(5):742-9. [PMID: 24856612]">Rosenstock 2009</a>; <a href="./references#CD005613-bbs2-0023" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. VarewijckAJ , JanssenJA , VahataloM , HoflandLJ , LambertsSW , Yki-JarvinenH . Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. Diabetologia2012;55(4):1186-94. [PMID: 22237688]VarewijckAJ , JanssenJA , VahataloM , LambertsSW , Ki-JarvinenHY . IGF-I bioactivity decreases during insulin therapy in type 2 diabetic patients: comparison of high doses of insulin glargine and NPH insulin in the LANMET study. In: Endocrine Reviews Conference: 93rd Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 32 (3 Meeting Abstracts). 2011. [EMBASE: 70676865]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJA . Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and IGF-I receptor signaling. Diabetes2013;62(7):2539-44. [PMID: 23569175]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJAMJL . Comparison of effects of insulin glargine, its metabolites, IGF-I and human insulin on insulin-and IGF-I receptor signaling in type 2 diabetic patients. In: Endocrine Reviews Conference: 95th Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 34 (3 suppl 1). 2013. [EMBASE: 71784187]Yki-JärvinenH , Kauppinen-MakelinR , TiikkainenM , VahataloM , VirtamoH , Nikkila K et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia2006;49(3):442-51. [PMID: 10937510]">Yki‐Järvinen 2006</a>) (<a href="./references#CD005613-bbs2-0102" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009.">IQWiG 2009</a>), while in one trial randomisation was adequate but allocation concealment unclear (<a href="./references#CD005613-bbs2-0011" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KawamoriR , IwamotoY , KadowakiT , IwasakiM . Efficacy and safety of insulin glargine in concurrent use with oral hypoglycemic agents for the treatment of type 2 diabetes patients. Rinshoiyaku2003;19(5):445-64. ">Kawamori 2003</a>). For another trial, detailed information was only available for allocation concealment, while the randomisation method was unclear (<a href="./references#CD005613-bbs2-0007" title="EUCTR2009-010913-59. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on OHA treatment initiating basal insulin therapy with either insulin glargine or NPH insulin added to therapies with oral hypoglycemic agents (HAPPY) (LANTU_L_04079 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2009-010913-59/results (last accessed 3 May 2017). HermannsN , KulzerB , KohlmannT , JacobS , LandgrafW , TheobaldK , et al. Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial. Health and Quality of Life Outcomes2015;13:77. [PMID: 26055391]NCT00941369. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on oral hypoglycemic agent treatment initiating basal insulin therapy with either insulin glargine or NPH insulin. clinicaltrials.gov/ct2/show/NCT00941369 (first received 17 July 2009). ">Hermanns 2015</a>). The remaining eight trials only reported that participants were randomised without providing any information on the method used (<a href="./references#CD005613-bbs2-0001" title="BerardL , CameronB , WooV , StewartJ . Replacing insulin glargine with neutral protamine Hagedorn (NPH) insulin in a subpopulation of study subjects in the action to control cardiovascular risk in diabetes (ACCORD): effects on blood glucose levels, hypoglycemia and patient satisfaction. Canadian Journal of Diabetes2015;39(4):296-301. [PMID: 25819531]BerardLD , WooVC . Safety and efficacy of NPH after switching from insulin glargine in Canadian patients. Diabetologia2011;54:S430. [EMBASE: 70563203]">Berard 2015</a>; <a href="./references#CD005613-bbs2-0010" title="HsiaSH . Comparison of single-dose regimens of insulin glargine versus NPH among inner city ethnic minority type 2 diabetic patients uncontrolled on oral agents. Journal of Investigative Medicine2010;58(1):136. [EMBASE: 70981533]HsiaSH . Insulin glargine compared to NPH among insulin-naive, U.S. inner city, ethnic minority type 2 diabetic patients. Diabetes Research &amp; Clinical Practice2011;91(3):293-9. [PMID: 21146881]NCT00686712. Insulin glargine at bedtime or in AM versus NPH. clinicaltrials.gov/ct2/show/NCT00686712 (first received 7 October 2010). ">Hsia 2011</a>; <a href="./references#CD005613-bbs2-0012" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. IshiiH , IwamotoY , KakuK , KawamoriR , KobayashiM , TajimaN . Night-time QOL and treatment satisfaction in diabetes mellitus patients treated with insulin detemir used in basal-bolus therapy – randomized multicenter open-label parallel group phase 3 trial compared to NPH insulin. Journal of the Japan Diabetes Society2009;52(8):691-701. [DOI: 10.11213/tonyobyo.52.691]KobayashiM , IwamotoY , KakuK , KawamoriR , TajimaN . Phase 3 clinical trial of insulin detemir for patients with insulin-dependent diabetes during basal-bolus therapy – a study of efficacy and safety with NPH insulin as control. Journal of the Japan Diabetes Society2007;50(9):649-63. [DOI: 10.11213/tonyobyo.50.649]NCT00604344. Efficacy and the safety of insulin detemir in subjects with insulin requiring diabetes. clinicaltrials.gov/ct2/show/NCT00604344 (first received 30 January 2008). Novo Nordisk A/S. A 48-week, randomised, multi-centre, open-labelled, parallel-group trial to compare the efficacy and the safety of NN304 (insulin detemir) and NPH human insulin in subjects with insulin requiring diabetes mellitus on a basal-bolus regimen. https://s3.amazonaws.com/ctr-nvo-7271/NN304-1476/aa9b4da3-1f92-460d-af0a-cc538614c3b2/3f7ed86e-d6e7-4542-ab8f-6cad24b46593/1476-ctr-synopsis-redacted-v2.pdf (last accessed 3 November 2020). ">Kobayashi 2007 A</a>; <a href="./references#CD005613-bbs2-0013" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KobayashiM , IwamotoY , KakuK , KawamoriR , TajimaN . Phase 3 clinical trial of insulin detemir for type 2 diabetes patients with insufficient blood sugar control in oral diabetes drug therapy. Journal of the Japan Diabetes Society2007;50(9):665-77. [DOI: 10.11213/tonyobyo.50.665]NCT00604253. Efficacy and safety of insulin detemir in type 2 diabetes inadequately controlled on OHA therapy alone. www.clinicaltrials.gov/ct2/show/results/NCT00604253 (first received 30 January 2008). Novo Nordisk A/S. A 36-week, randomised, multi-centre, open-labelled, parallel-group trial to compare the efficacy and the safety of NN304 and NPH human insulin once daily treatment as add-on to current OHA therapy in subjects with type 2 diabetes mellitus who are inadequately controlled on OHA therapy. http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1397&amp;filename=NN304_1477_ICTRSynopsis_Final_20051101.pdf (last accessed 3 November 2020). ">Kobayashi 2007 B</a>; <a href="./references#CD005613-bbs2-0015" title="NCT00687453. The utility of insulin glargine (Lantus) compared to NPH in ethnic minority type 2 diabetic subjects on combination insulin-oral agent therapy. clinicaltrials.gov/ct2/show/NCT00687453 (first received 30 May 2008). ">NCT00687453</a>; <a href="./references#CD005613-bbs2-0018" title="EUCTR2008-003739-19. Ensayo multicéntrico, abierto, aleatorizado, de dos grupos, paralelo para comparar el cambio en la distribución de grasa en sujetos con sobrepeso y obesos con diabetes tipo 2 tras 26 semanas de tratamiento con insulina detemir una vez al día frente a insulina NPH una vez al día, ambas con insulina aspart a la hora de las comidas. www.clinicaltrialsregister.eu/ctr-search/trial/2008-003739-19/ES (first received 19 September 2008). NCT00795600. A multi-centre, open-labelled, randomised, two-group parallel trial comparing the change in fat distribution in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin apart at mealtimes. clinicaltrials.gov/ct2/show/NCT00795600 (first received 21 November 2008). Novo Nordisk A/S. A multi-centre, open-labelled, randomised, two-group parallel trial comparing the change in fat distribution in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart at mealtimes (NN304-3614 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1461&amp;filename=3614-ctr-synopsis-redacted.pdf (last accessed 3 November 2020). TinahonesFJ , Gomez-HuelgasR , Garcia-AlegriaJ , Tapia-GuerreroM , Martos-PerezF . Fat distribution, HbA1c and hypoglycaemia in overweight and obese patients with type 2 diabetes: a comparison of NPH and insulin detemir from a pilot randomised clinical trial. Diabetologia2011;54:S273. [EMBASE: 70562816]TinahonesFJ , Gomez-HuelgasR , GarciaalegriaJ , Tapia-GuerreroMJ , PerezFM . The effect of insulin detemir on fat distribution and weight parameters in overweight and obese subjects with type 2 diabetes. Diabetes2011;60:A309. [EMBASE: 70628891]">NN304‐3614</a>; <a href="./references#CD005613-bbs2-0002" title="BetônicoCC , TitanSM , Correa-GiannellaML , NeryM , QueirozM . Comparison of insulin glargine vs. NPH insulin in basal-bolus therapies in T2DM patients and CKD: preliminary results of a prospective, randomized, open-label trial. Diabetes2016;65:A144-5. [CENTRAL: CN-01450000] BetônicoCC , TitanSM , LiraA , PelaesTS , Correa-GiannellaML , NeryM , et al. Insulin glargine U100 improved glycemic control and reduced nocturnal hypoglycemia in patients with type 2 diabetes mellitus and chronic kidney disease stages 3 and 4. Clinical Therapeutics2019;41(10):2008-20. [PMID: 31383366]NCT02451917. Subcutaneous insulin glargine versus NPH insulin in patients with chronic kidney disease stages III and IV: randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02451917 (first received 22 May 2015). ">Betônico 2019</a>; <a href="./references#CD005613-bbs2-0024" title="YokoyamaH , TadaJ , KamikawaF , KannoS , YokotaY , KuramitsuM . Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Research &amp; Clinical Practice2006;73(1):35-40. [PMID: 16513202]">Yokoyama 2006</a>). Therefore, we considered these trials to have an unclear risk of bias with regard to randomisation and allocation concealment. </p> </section> <section id="CD005613-sec-0089"> <h4 class="title">Blinding</h4> <p>Participants or carers were not blinded to the interventions in any of the included trials. Even if blinding is difficult in such trials because glargine and detemir are clear solutions while NPH is milky in appearance, the fact remains that an open design, especially with no blinded outcome assessment and poor or unclear concealment of allocation, carries an increased risk of bias. </p> <p>None of the trials provided explicit information on a blinded outcome assessment. Where measured, all primary and secondary outcomes in this review, except HbA1c, were participant reported, investigator assessed or both. Thirteen trials conducted assessment of HbA1c in central laboratories (<a href="./references#CD005613-bbs2-0003" title="EliaschewitzFG , CalvoC , ValbuenaH , RuizM , AschnerP , VillenaJ , et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Archives of Medical Research2006;37(4):495-501. [PMID: 16715577]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Eliaschewitz 2006</a>; <a href="./references#CD005613-bbs2-0004" title="EUCTR2005-000976-42. A multi-centre, open-labelled, randomised, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime (PREDICTIVE-BMI study) – PREDICTIVE-BMI study. www.clinicaltrialsregister.eu/ctr-search/trial/2005-000976-42/ES (first received 17 May 2006). Fajardo MontañanaC , Hernandez HerreroC , Rivas FernandezM . Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabetic Medicine2008;25(8):916-23. [PMID: 18959604]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00504673. Comparison of insulin detemir versus insulin NPH on weight change in overweight and obese with type 2 diabetes (PREDICTIVE). clinicaltrials.gov/ct2/show/NCT00504673 (first received 20 July 2007). Novo Nordisk A/S. A multi-centre, open-labelled, randomized, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime. (PREDICTIVE-BMI study). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1410&amp;filename=1659-ctr-redacted.pdf (last accessed 3 November 2020). Smith-PalmerJ , Fajardo-MontananaC , PollockRF , EricssonA , ValentineWJ . Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. Journal of Medical Economics2012;15(5):977-86. [PMID: 22563742]">Fajardo Montañana 2008</a>; <a href="./references#CD005613-bbs2-0005" title="FritscheA , SchweitzerMA , HaringHU , Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Annals of Internal Medicine2003;138(12):952-9. [PMID: 12809451]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Fritsche 2003</a>; <a href="./references#CD005613-bbs2-0006" title="HaakT , TiengoA , DraegerE , SuntumM , WaldhauslW . Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2005;7(1):56-64. [PMID: 15642076]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Haak 2005</a>; <a href="./references#CD005613-bbs2-0007" title="EUCTR2009-010913-59. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on OHA treatment initiating basal insulin therapy with either insulin glargine or NPH insulin added to therapies with oral hypoglycemic agents (HAPPY) (LANTU_L_04079 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2009-010913-59/results (last accessed 3 May 2017). HermannsN , KulzerB , KohlmannT , JacobS , LandgrafW , TheobaldK , et al. Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial. Health and Quality of Life Outcomes2015;13:77. [PMID: 26055391]NCT00941369. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on oral hypoglycemic agent treatment initiating basal insulin therapy with either insulin glargine or NPH insulin. clinicaltrials.gov/ct2/show/NCT00941369 (first received 17 July 2009). ">Hermanns 2015</a>; <a href="./references#CD005613-bbs2-0008" title="DaileyG , StrangeP , RiddleM . Reconsideration of severe hypoglycemic events in the treat-to-target trial. Diabetes Technology &amp; Therapeutics2009;11(8):477-9. [PMID: 19698059]DaviesMJ , DerezinskiT , PedersenCB , ClausonP . Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Diabetes Technology &amp; Therapeutics2008;10(4):273-7. [PMID: 18715200]HermansenK , DaviesM , DerezinskiT , Martinez RavnG , ClausonP , HomeP . Erratum: A 26-week randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people wih type 2 diabetes (Diabetes Care (2006) 29, (1269-1274)). Diabetes Care2007;30(4):1035. [EMBASE: 46556609]HermansenK , DaviesM , DerezinskiT , MartinezRG , ClausonP , HomeP . A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care2006;29(6):1269-74. [PMID: 16732007]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00604396. Safety and efficacy of insulin detemir in combination with OAD in type 2 diabetes. clinicaltrials.gov/ct2/show/results/NCT00604396 (first received 30 January 2008). ">Hermansen 2006</a>; <a href="./references#CD005613-bbs2-0009" title='EUCTR2007-006640-22. Superiority of insulin glargine Lantus vs NPH: "Treat to normoglycemia concept". Effect of insulin glargine in comparison to insulin NPH in insulin-naïve people with type 2 diabetes mellitus treated with at least one OAD and not adequately controlled (LANCELOT) (LANTU_C_02762 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2007-006640-22/results (last accessed 19 July 2017). HomePD , BolliGB , MathieuC , DeerochanawongC , LandgrafW , CandelasC , et al. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naive people with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2015;17(1):15-22. [PMID: 24957785]NCT00949442. Lantus versus NPH: comparison in insulin naive people not adequately controlled with at least one oral anti diabetics (OAD) treatment (LANCELOT). clinicaltrials.gov/ct2/show/NCT00949442 (first received 30 July 2009). '>Home 2015</a>; <a href="./references#CD005613-bbs2-0010" title="HsiaSH . Comparison of single-dose regimens of insulin glargine versus NPH among inner city ethnic minority type 2 diabetic patients uncontrolled on oral agents. Journal of Investigative Medicine2010;58(1):136. [EMBASE: 70981533]HsiaSH . Insulin glargine compared to NPH among insulin-naive, U.S. inner city, ethnic minority type 2 diabetic patients. Diabetes Research &amp; Clinical Practice2011;91(3):293-9. [PMID: 21146881]NCT00686712. Insulin glargine at bedtime or in AM versus NPH. clinicaltrials.gov/ct2/show/NCT00686712 (first received 7 October 2010). ">Hsia 2011</a>; <a href="./references#CD005613-bbs2-0014" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. MassiBM , HumburgE , DresslerA , ZiemenM . A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Hormone &amp; Metabolic Research2003;35(3):189-96. [PMID: 12734781]Yki-JarvinenH , DresslerA , ZiemenM . Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care2000;23(8):1130-6. [EMBASE: 2006092604]">Massi 2003</a>; <a href="./references#CD005613-bbs2-0016" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">NN304‐1337</a>; <a href="./references#CD005613-bbs2-0020" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00653341. Effect of insulin glargine in insulin naïve subjects with type 2 diabetes on oral hypoglycemic agent(s). www.clinicaltrials.gov/ct2/show/results/NCT00653341 (first received 4 April 2008). RiddleMC , RosenstockJ , GerichJ , InsulinG . The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care2003;26(11):3080-6. [PMID: 14578243]">Riddle 2003</a>; <a href="./references#CD005613-bbs2-0021" title="FonsecaV , BellDS , BergerS , ThomsonS , MeccaTE . A comparison of bedtime insulin glargine with bedtime neutral protamine Hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. American Journal of the Medical Sciences2004;328(5):274-80. [PMID: 15545844]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. RosenstockJ , SchwartzSL , Clark CM Jr, ParkGD , DonleyDW , EdwardsMB . Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care2001;24(4):631-6. [PMID: 11315821]">Rosenstock 2001</a>; <a href="./references#CD005613-bbs2-0022" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00174824. Comparison of insulin glargine and NPH human insulin in progression of diabetic retinopathy in type 2 diabetic patients. clinicaltrials.gov/ct2/show/study/NCT00174824 (first received 15 September 2005). RosenstockJ , FonsecaV , DainMP , RiddleM . Estimating number-needed-to-treat to avoid hypoglycaemic episodes in people with type 2 diabetes: a post-hoc analysis of a prospective randomized controlled trial comparing once-daily insulin glargine with twice-daily NPH insulin. Canadian Journal of Diabetes2009;33(3):185-6. [EMBASE: 70031352]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia2009;52(9):1778-88. [PMID: 19526210]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia2009;52(9):1971-3. [PMID: 19609501]RosenstockJ , FonsecaV , SchinzelS , DainMP , MullinsP , RiddleM . Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: evidence from a long-term controlled trial. Journal of Diabetic Complications2014;28(5):742-9. [PMID: 24856612]">Rosenstock 2009</a>). A blinded outcome assessment can therefore be assumed and we considered these studies to carry a low risk of performance and detection bias for this outcome measure. Non‐serious adverse events and diabetes‐related complications were participant‐reported or investigator assessed in all but one trial and were, therefore, considered unclear risk of performance and detection bias. One trial described an adjudicated outcome measurement for diabetic retinopathy with treatment‐group‐masked grading of fundus photographs, and, therefore, carried a low risk of detection bias for this outcome (<a href="./references#CD005613-bbs2-0022" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00174824. Comparison of insulin glargine and NPH human insulin in progression of diabetic retinopathy in type 2 diabetic patients. clinicaltrials.gov/ct2/show/study/NCT00174824 (first received 15 September 2005). RosenstockJ , FonsecaV , DainMP , RiddleM . Estimating number-needed-to-treat to avoid hypoglycaemic episodes in people with type 2 diabetes: a post-hoc analysis of a prospective randomized controlled trial comparing once-daily insulin glargine with twice-daily NPH insulin. Canadian Journal of Diabetes2009;33(3):185-6. [EMBASE: 70031352]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia2009;52(9):1778-88. [PMID: 19526210]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia2009;52(9):1971-3. [PMID: 19609501]RosenstockJ , FonsecaV , SchinzelS , DainMP , MullinsP , RiddleM . Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: evidence from a long-term controlled trial. Journal of Diabetic Complications2014;28(5):742-9. [PMID: 24856612]">Rosenstock 2009</a>). Health‐related quality of life measurements and non‐severe or severe hypoglycaemia were exclusively participant‐reported in the included trials. As blood glucose was self‐measured in all trials, including confirmed hypoglycaemic events, an increased risk of subjective influence existed. Therefore, these outcomes carried a high risk of performance and detection bias. We considered serious hypoglycaemia, fulfilling at least one criterion of a serious adverse event, serious adverse events themselves and mortality, to carry a low risk of performance and detection bias, since the possibility of subjective interference is minimal for these outcome measures. </p> </section> <section id="CD005613-sec-0090"> <h4 class="title">Incomplete outcome data</h4> <p>Twenty‐two trials reported the number of participants who were randomised and who finished the trial (<a href="./references#CD005613-bbs2-0003" title="EliaschewitzFG , CalvoC , ValbuenaH , RuizM , AschnerP , VillenaJ , et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Archives of Medical Research2006;37(4):495-501. [PMID: 16715577]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Eliaschewitz 2006</a>; <a href="./references#CD005613-bbs2-0004" title="EUCTR2005-000976-42. A multi-centre, open-labelled, randomised, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime (PREDICTIVE-BMI study) – PREDICTIVE-BMI study. www.clinicaltrialsregister.eu/ctr-search/trial/2005-000976-42/ES (first received 17 May 2006). Fajardo MontañanaC , Hernandez HerreroC , Rivas FernandezM . Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabetic Medicine2008;25(8):916-23. [PMID: 18959604]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00504673. Comparison of insulin detemir versus insulin NPH on weight change in overweight and obese with type 2 diabetes (PREDICTIVE). clinicaltrials.gov/ct2/show/NCT00504673 (first received 20 July 2007). Novo Nordisk A/S. A multi-centre, open-labelled, randomized, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime. (PREDICTIVE-BMI study). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1410&amp;filename=1659-ctr-redacted.pdf (last accessed 3 November 2020). Smith-PalmerJ , Fajardo-MontananaC , PollockRF , EricssonA , ValentineWJ . Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. Journal of Medical Economics2012;15(5):977-86. [PMID: 22563742]">Fajardo Montañana 2008</a>; <a href="./references#CD005613-bbs2-0005" title="FritscheA , SchweitzerMA , HaringHU , Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Annals of Internal Medicine2003;138(12):952-9. [PMID: 12809451]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Fritsche 2003</a>; <a href="./references#CD005613-bbs2-0006" title="HaakT , TiengoA , DraegerE , SuntumM , WaldhauslW . Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2005;7(1):56-64. [PMID: 15642076]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Haak 2005</a>; <a href="./references#CD005613-bbs2-0007" title="EUCTR2009-010913-59. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on OHA treatment initiating basal insulin therapy with either insulin glargine or NPH insulin added to therapies with oral hypoglycemic agents (HAPPY) (LANTU_L_04079 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2009-010913-59/results (last accessed 3 May 2017). HermannsN , KulzerB , KohlmannT , JacobS , LandgrafW , TheobaldK , et al. Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial. Health and Quality of Life Outcomes2015;13:77. [PMID: 26055391]NCT00941369. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on oral hypoglycemic agent treatment initiating basal insulin therapy with either insulin glargine or NPH insulin. clinicaltrials.gov/ct2/show/NCT00941369 (first received 17 July 2009). ">Hermanns 2015</a>; <a href="./references#CD005613-bbs2-0008" title="DaileyG , StrangeP , RiddleM . Reconsideration of severe hypoglycemic events in the treat-to-target trial. Diabetes Technology &amp; Therapeutics2009;11(8):477-9. [PMID: 19698059]DaviesMJ , DerezinskiT , PedersenCB , ClausonP . Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Diabetes Technology &amp; Therapeutics2008;10(4):273-7. [PMID: 18715200]HermansenK , DaviesM , DerezinskiT , Martinez RavnG , ClausonP , HomeP . Erratum: A 26-week randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people wih type 2 diabetes (Diabetes Care (2006) 29, (1269-1274)). Diabetes Care2007;30(4):1035. [EMBASE: 46556609]HermansenK , DaviesM , DerezinskiT , MartinezRG , ClausonP , HomeP . A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care2006;29(6):1269-74. [PMID: 16732007]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00604396. Safety and efficacy of insulin detemir in combination with OAD in type 2 diabetes. clinicaltrials.gov/ct2/show/results/NCT00604396 (first received 30 January 2008). ">Hermansen 2006</a>; <a href="./references#CD005613-bbs2-0009" title='EUCTR2007-006640-22. Superiority of insulin glargine Lantus vs NPH: "Treat to normoglycemia concept". Effect of insulin glargine in comparison to insulin NPH in insulin-naïve people with type 2 diabetes mellitus treated with at least one OAD and not adequately controlled (LANCELOT) (LANTU_C_02762 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2007-006640-22/results (last accessed 19 July 2017). HomePD , BolliGB , MathieuC , DeerochanawongC , LandgrafW , CandelasC , et al. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naive people with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2015;17(1):15-22. [PMID: 24957785]NCT00949442. Lantus versus NPH: comparison in insulin naive people not adequately controlled with at least one oral anti diabetics (OAD) treatment (LANCELOT). clinicaltrials.gov/ct2/show/NCT00949442 (first received 30 July 2009). '>Home 2015</a>; <a href="./references#CD005613-bbs2-0010" title="HsiaSH . Comparison of single-dose regimens of insulin glargine versus NPH among inner city ethnic minority type 2 diabetic patients uncontrolled on oral agents. Journal of Investigative Medicine2010;58(1):136. [EMBASE: 70981533]HsiaSH . Insulin glargine compared to NPH among insulin-naive, U.S. inner city, ethnic minority type 2 diabetic patients. Diabetes Research &amp; Clinical Practice2011;91(3):293-9. [PMID: 21146881]NCT00686712. Insulin glargine at bedtime or in AM versus NPH. clinicaltrials.gov/ct2/show/NCT00686712 (first received 7 October 2010). ">Hsia 2011</a>; <a href="./references#CD005613-bbs2-0011" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KawamoriR , IwamotoY , KadowakiT , IwasakiM . Efficacy and safety of insulin glargine in concurrent use with oral hypoglycemic agents for the treatment of type 2 diabetes patients. Rinshoiyaku2003;19(5):445-64. ">Kawamori 2003</a>; <a href="./references#CD005613-bbs2-0012" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. IshiiH , IwamotoY , KakuK , KawamoriR , KobayashiM , TajimaN . Night-time QOL and treatment satisfaction in diabetes mellitus patients treated with insulin detemir used in basal-bolus therapy – randomized multicenter open-label parallel group phase 3 trial compared to NPH insulin. Journal of the Japan Diabetes Society2009;52(8):691-701. [DOI: 10.11213/tonyobyo.52.691]KobayashiM , IwamotoY , KakuK , KawamoriR , TajimaN . Phase 3 clinical trial of insulin detemir for patients with insulin-dependent diabetes during basal-bolus therapy – a study of efficacy and safety with NPH insulin as control. Journal of the Japan Diabetes Society2007;50(9):649-63. [DOI: 10.11213/tonyobyo.50.649]NCT00604344. Efficacy and the safety of insulin detemir in subjects with insulin requiring diabetes. clinicaltrials.gov/ct2/show/NCT00604344 (first received 30 January 2008). Novo Nordisk A/S. A 48-week, randomised, multi-centre, open-labelled, parallel-group trial to compare the efficacy and the safety of NN304 (insulin detemir) and NPH human insulin in subjects with insulin requiring diabetes mellitus on a basal-bolus regimen. https://s3.amazonaws.com/ctr-nvo-7271/NN304-1476/aa9b4da3-1f92-460d-af0a-cc538614c3b2/3f7ed86e-d6e7-4542-ab8f-6cad24b46593/1476-ctr-synopsis-redacted-v2.pdf (last accessed 3 November 2020). ">Kobayashi 2007 A</a>; <a href="./references#CD005613-bbs2-0013" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KobayashiM , IwamotoY , KakuK , KawamoriR , TajimaN . Phase 3 clinical trial of insulin detemir for type 2 diabetes patients with insufficient blood sugar control in oral diabetes drug therapy. Journal of the Japan Diabetes Society2007;50(9):665-77. [DOI: 10.11213/tonyobyo.50.665]NCT00604253. Efficacy and safety of insulin detemir in type 2 diabetes inadequately controlled on OHA therapy alone. www.clinicaltrials.gov/ct2/show/results/NCT00604253 (first received 30 January 2008). Novo Nordisk A/S. A 36-week, randomised, multi-centre, open-labelled, parallel-group trial to compare the efficacy and the safety of NN304 and NPH human insulin once daily treatment as add-on to current OHA therapy in subjects with type 2 diabetes mellitus who are inadequately controlled on OHA therapy. http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1397&amp;filename=NN304_1477_ICTRSynopsis_Final_20051101.pdf (last accessed 3 November 2020). ">Kobayashi 2007 B</a>; <a href="./references#CD005613-bbs2-0014" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. MassiBM , HumburgE , DresslerA , ZiemenM . A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Hormone &amp; Metabolic Research2003;35(3):189-96. [PMID: 12734781]Yki-JarvinenH , DresslerA , ZiemenM . Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care2000;23(8):1130-6. [EMBASE: 2006092604]">Massi 2003</a>; <a href="./references#CD005613-bbs2-0015" title="NCT00687453. The utility of insulin glargine (Lantus) compared to NPH in ethnic minority type 2 diabetic subjects on combination insulin-oral agent therapy. clinicaltrials.gov/ct2/show/NCT00687453 (first received 30 May 2008). ">NCT00687453</a>; <a href="./references#CD005613-bbs2-0016" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">NN304‐1337</a>; <a href="./references#CD005613-bbs2-0017" title="DoucetJ , Le FlochJ , HanaireH , CourregesJ , AlexandreB , BauduceauB . Comparison of safety between detemir and neutral protamine Hagedorn (NPH) in ageing subjects: the '3 L study'. Fundamental and Clinical Pharmacology2011;25:82. [EMBASE: 70653089]EUCTR2006-006589-41-FR. Levemir® in ageing patients with type 2 diabetes A seven-month open-labelled randomised multi-centre two-group parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in the morning in ageing subjects with type 2 diabetes. The 3L Study (Levemir in Late Life) Trial Phase: 4. www.clinicaltrialsregister.eu/ctr-search/trial/2006-006589-41/FR (first received 27 March 2007). NCT00506662. The effect of insulin detemir on glucose control in ageing subjects with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00506662 (first received 25 July 2007). Novo Nordisk A/S. A seven-month, open-labelled, randomised, multicentre, two-group, parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in ageing patients with type 2 diabetes: The 3L Study (Levemir in Later Life) (NN304-1808 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1426&amp;filename=1808-ctr-redacted.pdf (last accessed 3 November 2020). ">NN304‐1808</a>; <a href="./references#CD005613-bbs2-0018" title="EUCTR2008-003739-19. Ensayo multicéntrico, abierto, aleatorizado, de dos grupos, paralelo para comparar el cambio en la distribución de grasa en sujetos con sobrepeso y obesos con diabetes tipo 2 tras 26 semanas de tratamiento con insulina detemir una vez al día frente a insulina NPH una vez al día, ambas con insulina aspart a la hora de las comidas. www.clinicaltrialsregister.eu/ctr-search/trial/2008-003739-19/ES (first received 19 September 2008). NCT00795600. A multi-centre, open-labelled, randomised, two-group parallel trial comparing the change in fat distribution in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin apart at mealtimes. clinicaltrials.gov/ct2/show/NCT00795600 (first received 21 November 2008). Novo Nordisk A/S. A multi-centre, open-labelled, randomised, two-group parallel trial comparing the change in fat distribution in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart at mealtimes (NN304-3614 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1461&amp;filename=3614-ctr-synopsis-redacted.pdf (last accessed 3 November 2020). TinahonesFJ , Gomez-HuelgasR , Garcia-AlegriaJ , Tapia-GuerreroM , Martos-PerezF . Fat distribution, HbA1c and hypoglycaemia in overweight and obese patients with type 2 diabetes: a comparison of NPH and insulin detemir from a pilot randomised clinical trial. Diabetologia2011;54:S273. [EMBASE: 70562816]TinahonesFJ , Gomez-HuelgasR , GarciaalegriaJ , Tapia-GuerreroMJ , PerezFM . The effect of insulin detemir on fat distribution and weight parameters in overweight and obese subjects with type 2 diabetes. Diabetes2011;60:A309. [EMBASE: 70628891]">NN304‐3614</a>; <a href="./references#CD005613-bbs2-0019" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. PanCY , SinnassamyP , ChungKD , KimKW , Group LS . Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Research &amp; Clinical Practice2007;76(1):111-8. [PMID: 17011662]">Pan 2007</a>; <a href="./references#CD005613-bbs2-0002" title="BetônicoCC , TitanSM , Correa-GiannellaML , NeryM , QueirozM . Comparison of insulin glargine vs. NPH insulin in basal-bolus therapies in T2DM patients and CKD: preliminary results of a prospective, randomized, open-label trial. Diabetes2016;65:A144-5. [CENTRAL: CN-01450000] BetônicoCC , TitanSM , LiraA , PelaesTS , Correa-GiannellaML , NeryM , et al. Insulin glargine U100 improved glycemic control and reduced nocturnal hypoglycemia in patients with type 2 diabetes mellitus and chronic kidney disease stages 3 and 4. Clinical Therapeutics2019;41(10):2008-20. [PMID: 31383366]NCT02451917. Subcutaneous insulin glargine versus NPH insulin in patients with chronic kidney disease stages III and IV: randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02451917 (first received 22 May 2015). ">Betônico 2019</a>; <a href="./references#CD005613-bbs2-0020" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00653341. Effect of insulin glargine in insulin naïve subjects with type 2 diabetes on oral hypoglycemic agent(s). www.clinicaltrials.gov/ct2/show/results/NCT00653341 (first received 4 April 2008). RiddleMC , RosenstockJ , GerichJ , InsulinG . The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care2003;26(11):3080-6. [PMID: 14578243]">Riddle 2003</a>; <a href="./references#CD005613-bbs2-0021" title="FonsecaV , BellDS , BergerS , ThomsonS , MeccaTE . A comparison of bedtime insulin glargine with bedtime neutral protamine Hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. American Journal of the Medical Sciences2004;328(5):274-80. [PMID: 15545844]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. RosenstockJ , SchwartzSL , Clark CM Jr, ParkGD , DonleyDW , EdwardsMB . Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care2001;24(4):631-6. [PMID: 11315821]">Rosenstock 2001</a>; <a href="./references#CD005613-bbs2-0022" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00174824. Comparison of insulin glargine and NPH human insulin in progression of diabetic retinopathy in type 2 diabetic patients. clinicaltrials.gov/ct2/show/study/NCT00174824 (first received 15 September 2005). RosenstockJ , FonsecaV , DainMP , RiddleM . Estimating number-needed-to-treat to avoid hypoglycaemic episodes in people with type 2 diabetes: a post-hoc analysis of a prospective randomized controlled trial comparing once-daily insulin glargine with twice-daily NPH insulin. Canadian Journal of Diabetes2009;33(3):185-6. [EMBASE: 70031352]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia2009;52(9):1778-88. [PMID: 19526210]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia2009;52(9):1971-3. [PMID: 19609501]RosenstockJ , FonsecaV , SchinzelS , DainMP , MullinsP , RiddleM . Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: evidence from a long-term controlled trial. Journal of Diabetic Complications2014;28(5):742-9. [PMID: 24856612]">Rosenstock 2009</a>; <a href="./references#CD005613-bbs2-0023" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. VarewijckAJ , JanssenJA , VahataloM , HoflandLJ , LambertsSW , Yki-JarvinenH . Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. Diabetologia2012;55(4):1186-94. [PMID: 22237688]VarewijckAJ , JanssenJA , VahataloM , LambertsSW , Ki-JarvinenHY . IGF-I bioactivity decreases during insulin therapy in type 2 diabetic patients: comparison of high doses of insulin glargine and NPH insulin in the LANMET study. In: Endocrine Reviews Conference: 93rd Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 32 (3 Meeting Abstracts). 2011. [EMBASE: 70676865]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJA . Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and IGF-I receptor signaling. Diabetes2013;62(7):2539-44. [PMID: 23569175]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJAMJL . Comparison of effects of insulin glargine, its metabolites, IGF-I and human insulin on insulin-and IGF-I receptor signaling in type 2 diabetic patients. In: Endocrine Reviews Conference: 95th Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 34 (3 suppl 1). 2013. [EMBASE: 71784187]Yki-JärvinenH , Kauppinen-MakelinR , TiikkainenM , VahataloM , VirtamoH , Nikkila K et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia2006;49(3):442-51. [PMID: 10937510]">Yki‐Järvinen 2006</a>). The percentage of randomised participants completing their respective trials ranged from 48% to 98%. The remaining two trials only stated the number of randomised participants (<a href="./references#CD005613-bbs2-0001" title="BerardL , CameronB , WooV , StewartJ . Replacing insulin glargine with neutral protamine Hagedorn (NPH) insulin in a subpopulation of study subjects in the action to control cardiovascular risk in diabetes (ACCORD): effects on blood glucose levels, hypoglycemia and patient satisfaction. Canadian Journal of Diabetes2015;39(4):296-301. [PMID: 25819531]BerardLD , WooVC . Safety and efficacy of NPH after switching from insulin glargine in Canadian patients. Diabetologia2011;54:S430. [EMBASE: 70563203]">Berard 2015</a>; <a href="./references#CD005613-bbs2-0024" title="YokoyamaH , TadaJ , KamikawaF , KannoS , YokotaY , KuramitsuM . Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Research &amp; Clinical Practice2006;73(1):35-40. [PMID: 16513202]">Yokoyama 2006</a>). </p> <p>Nineteen trials used an ITT approach for efficacy outcomes and 22 trials for safety outcomes. Even though none of the trials included all randomised participants in the analyses (so that they were not, in a strict sense, ITT analyses), the difference between randomised and analysed participants was small in all but three trials (<a href="./references#CD005613-bbs2-0010" title="HsiaSH . Comparison of single-dose regimens of insulin glargine versus NPH among inner city ethnic minority type 2 diabetic patients uncontrolled on oral agents. Journal of Investigative Medicine2010;58(1):136. [EMBASE: 70981533]HsiaSH . Insulin glargine compared to NPH among insulin-naive, U.S. inner city, ethnic minority type 2 diabetic patients. Diabetes Research &amp; Clinical Practice2011;91(3):293-9. [PMID: 21146881]NCT00686712. Insulin glargine at bedtime or in AM versus NPH. clinicaltrials.gov/ct2/show/NCT00686712 (first received 7 October 2010). ">Hsia 2011</a>; <a href="./references#CD005613-bbs2-0015" title="NCT00687453. The utility of insulin glargine (Lantus) compared to NPH in ethnic minority type 2 diabetic subjects on combination insulin-oral agent therapy. clinicaltrials.gov/ct2/show/NCT00687453 (first received 30 May 2008). ">NCT00687453</a>; <a href="./references#CD005613-bbs2-0017" title="DoucetJ , Le FlochJ , HanaireH , CourregesJ , AlexandreB , BauduceauB . Comparison of safety between detemir and neutral protamine Hagedorn (NPH) in ageing subjects: the '3 L study'. Fundamental and Clinical Pharmacology2011;25:82. [EMBASE: 70653089]EUCTR2006-006589-41-FR. Levemir® in ageing patients with type 2 diabetes A seven-month open-labelled randomised multi-centre two-group parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in the morning in ageing subjects with type 2 diabetes. The 3L Study (Levemir in Late Life) Trial Phase: 4. www.clinicaltrialsregister.eu/ctr-search/trial/2006-006589-41/FR (first received 27 March 2007). NCT00506662. The effect of insulin detemir on glucose control in ageing subjects with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00506662 (first received 25 July 2007). Novo Nordisk A/S. A seven-month, open-labelled, randomised, multicentre, two-group, parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in ageing patients with type 2 diabetes: The 3L Study (Levemir in Later Life) (NN304-1808 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1426&amp;filename=1808-ctr-redacted.pdf (last accessed 3 November 2020). ">NN304‐1808</a>), so we judged this as no substantial problem. One trial reported a per‐protocol analysis of efficacy outcomes with an equivalence design (<a href="./references#CD005613-bbs2-0003" title="EliaschewitzFG , CalvoC , ValbuenaH , RuizM , AschnerP , VillenaJ , et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Archives of Medical Research2006;37(4):495-501. [PMID: 16715577]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Eliaschewitz 2006</a>), and in another one with a non‐inferiority design (<a href="./references#CD005613-bbs2-0011" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KawamoriR , IwamotoY , KadowakiT , IwasakiM . Efficacy and safety of insulin glargine in concurrent use with oral hypoglycemic agents for the treatment of type 2 diabetes patients. Rinshoiyaku2003;19(5):445-64. ">Kawamori 2003</a>). </p> <p>Seventeen trials used LOCF in the analyses for missing data (<a href="./references#CD005613-bbs2-0003" title="EliaschewitzFG , CalvoC , ValbuenaH , RuizM , AschnerP , VillenaJ , et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Archives of Medical Research2006;37(4):495-501. [PMID: 16715577]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Eliaschewitz 2006</a>; <a href="./references#CD005613-bbs2-0004" title="EUCTR2005-000976-42. A multi-centre, open-labelled, randomised, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime (PREDICTIVE-BMI study) – PREDICTIVE-BMI study. www.clinicaltrialsregister.eu/ctr-search/trial/2005-000976-42/ES (first received 17 May 2006). Fajardo MontañanaC , Hernandez HerreroC , Rivas FernandezM . Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabetic Medicine2008;25(8):916-23. [PMID: 18959604]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00504673. Comparison of insulin detemir versus insulin NPH on weight change in overweight and obese with type 2 diabetes (PREDICTIVE). clinicaltrials.gov/ct2/show/NCT00504673 (first received 20 July 2007). Novo Nordisk A/S. A multi-centre, open-labelled, randomized, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime. (PREDICTIVE-BMI study). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1410&amp;filename=1659-ctr-redacted.pdf (last accessed 3 November 2020). Smith-PalmerJ , Fajardo-MontananaC , PollockRF , EricssonA , ValentineWJ . Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. Journal of Medical Economics2012;15(5):977-86. [PMID: 22563742]">Fajardo Montañana 2008</a>; <a href="./references#CD005613-bbs2-0005" title="FritscheA , SchweitzerMA , HaringHU , Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Annals of Internal Medicine2003;138(12):952-9. [PMID: 12809451]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Fritsche 2003</a>; <a href="./references#CD005613-bbs2-0006" title="HaakT , TiengoA , DraegerE , SuntumM , WaldhauslW . Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2005;7(1):56-64. [PMID: 15642076]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Haak 2005</a>; <a href="./references#CD005613-bbs2-0007" title="EUCTR2009-010913-59. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on OHA treatment initiating basal insulin therapy with either insulin glargine or NPH insulin added to therapies with oral hypoglycemic agents (HAPPY) (LANTU_L_04079 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2009-010913-59/results (last accessed 3 May 2017). HermannsN , KulzerB , KohlmannT , JacobS , LandgrafW , TheobaldK , et al. Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial. Health and Quality of Life Outcomes2015;13:77. [PMID: 26055391]NCT00941369. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on oral hypoglycemic agent treatment initiating basal insulin therapy with either insulin glargine or NPH insulin. clinicaltrials.gov/ct2/show/NCT00941369 (first received 17 July 2009). ">Hermanns 2015</a>; <a href="./references#CD005613-bbs2-0008" title="DaileyG , StrangeP , RiddleM . Reconsideration of severe hypoglycemic events in the treat-to-target trial. Diabetes Technology &amp; Therapeutics2009;11(8):477-9. [PMID: 19698059]DaviesMJ , DerezinskiT , PedersenCB , ClausonP . Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Diabetes Technology &amp; Therapeutics2008;10(4):273-7. [PMID: 18715200]HermansenK , DaviesM , DerezinskiT , Martinez RavnG , ClausonP , HomeP . Erratum: A 26-week randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people wih type 2 diabetes (Diabetes Care (2006) 29, (1269-1274)). Diabetes Care2007;30(4):1035. [EMBASE: 46556609]HermansenK , DaviesM , DerezinskiT , MartinezRG , ClausonP , HomeP . A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care2006;29(6):1269-74. [PMID: 16732007]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00604396. Safety and efficacy of insulin detemir in combination with OAD in type 2 diabetes. clinicaltrials.gov/ct2/show/results/NCT00604396 (first received 30 January 2008). ">Hermansen 2006</a>; <a href="./references#CD005613-bbs2-0009" title='EUCTR2007-006640-22. Superiority of insulin glargine Lantus vs NPH: "Treat to normoglycemia concept". Effect of insulin glargine in comparison to insulin NPH in insulin-naïve people with type 2 diabetes mellitus treated with at least one OAD and not adequately controlled (LANCELOT) (LANTU_C_02762 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2007-006640-22/results (last accessed 19 July 2017). HomePD , BolliGB , MathieuC , DeerochanawongC , LandgrafW , CandelasC , et al. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naive people with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2015;17(1):15-22. [PMID: 24957785]NCT00949442. Lantus versus NPH: comparison in insulin naive people not adequately controlled with at least one oral anti diabetics (OAD) treatment (LANCELOT). clinicaltrials.gov/ct2/show/NCT00949442 (first received 30 July 2009). '>Home 2015</a>; <a href="./references#CD005613-bbs2-0010" title="HsiaSH . Comparison of single-dose regimens of insulin glargine versus NPH among inner city ethnic minority type 2 diabetic patients uncontrolled on oral agents. Journal of Investigative Medicine2010;58(1):136. [EMBASE: 70981533]HsiaSH . Insulin glargine compared to NPH among insulin-naive, U.S. inner city, ethnic minority type 2 diabetic patients. Diabetes Research &amp; Clinical Practice2011;91(3):293-9. [PMID: 21146881]NCT00686712. Insulin glargine at bedtime or in AM versus NPH. clinicaltrials.gov/ct2/show/NCT00686712 (first received 7 October 2010). ">Hsia 2011</a>; <a href="./references#CD005613-bbs2-0012" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. IshiiH , IwamotoY , KakuK , KawamoriR , KobayashiM , TajimaN . Night-time QOL and treatment satisfaction in diabetes mellitus patients treated with insulin detemir used in basal-bolus therapy – randomized multicenter open-label parallel group phase 3 trial compared to NPH insulin. Journal of the Japan Diabetes Society2009;52(8):691-701. [DOI: 10.11213/tonyobyo.52.691]KobayashiM , IwamotoY , KakuK , KawamoriR , TajimaN . Phase 3 clinical trial of insulin detemir for patients with insulin-dependent diabetes during basal-bolus therapy – a study of efficacy and safety with NPH insulin as control. Journal of the Japan Diabetes Society2007;50(9):649-63. [DOI: 10.11213/tonyobyo.50.649]NCT00604344. Efficacy and the safety of insulin detemir in subjects with insulin requiring diabetes. clinicaltrials.gov/ct2/show/NCT00604344 (first received 30 January 2008). Novo Nordisk A/S. A 48-week, randomised, multi-centre, open-labelled, parallel-group trial to compare the efficacy and the safety of NN304 (insulin detemir) and NPH human insulin in subjects with insulin requiring diabetes mellitus on a basal-bolus regimen. https://s3.amazonaws.com/ctr-nvo-7271/NN304-1476/aa9b4da3-1f92-460d-af0a-cc538614c3b2/3f7ed86e-d6e7-4542-ab8f-6cad24b46593/1476-ctr-synopsis-redacted-v2.pdf (last accessed 3 November 2020). ">Kobayashi 2007 A</a>; <a href="./references#CD005613-bbs2-0013" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KobayashiM , IwamotoY , KakuK , KawamoriR , TajimaN . Phase 3 clinical trial of insulin detemir for type 2 diabetes patients with insufficient blood sugar control in oral diabetes drug therapy. Journal of the Japan Diabetes Society2007;50(9):665-77. [DOI: 10.11213/tonyobyo.50.665]NCT00604253. Efficacy and safety of insulin detemir in type 2 diabetes inadequately controlled on OHA therapy alone. www.clinicaltrials.gov/ct2/show/results/NCT00604253 (first received 30 January 2008). Novo Nordisk A/S. A 36-week, randomised, multi-centre, open-labelled, parallel-group trial to compare the efficacy and the safety of NN304 and NPH human insulin once daily treatment as add-on to current OHA therapy in subjects with type 2 diabetes mellitus who are inadequately controlled on OHA therapy. http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1397&amp;filename=NN304_1477_ICTRSynopsis_Final_20051101.pdf (last accessed 3 November 2020). ">Kobayashi 2007 B</a>; <a href="./references#CD005613-bbs2-0015" title="NCT00687453. The utility of insulin glargine (Lantus) compared to NPH in ethnic minority type 2 diabetic subjects on combination insulin-oral agent therapy. clinicaltrials.gov/ct2/show/NCT00687453 (first received 30 May 2008). ">NCT00687453</a>; <a href="./references#CD005613-bbs2-0016" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">NN304‐1337</a>; <a href="./references#CD005613-bbs2-0017" title="DoucetJ , Le FlochJ , HanaireH , CourregesJ , AlexandreB , BauduceauB . Comparison of safety between detemir and neutral protamine Hagedorn (NPH) in ageing subjects: the '3 L study'. Fundamental and Clinical Pharmacology2011;25:82. [EMBASE: 70653089]EUCTR2006-006589-41-FR. Levemir® in ageing patients with type 2 diabetes A seven-month open-labelled randomised multi-centre two-group parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in the morning in ageing subjects with type 2 diabetes. The 3L Study (Levemir in Late Life) Trial Phase: 4. www.clinicaltrialsregister.eu/ctr-search/trial/2006-006589-41/FR (first received 27 March 2007). NCT00506662. The effect of insulin detemir on glucose control in ageing subjects with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00506662 (first received 25 July 2007). Novo Nordisk A/S. A seven-month, open-labelled, randomised, multicentre, two-group, parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in ageing patients with type 2 diabetes: The 3L Study (Levemir in Later Life) (NN304-1808 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1426&amp;filename=1808-ctr-redacted.pdf (last accessed 3 November 2020). ">NN304‐1808</a>; <a href="./references#CD005613-bbs2-0018" title="EUCTR2008-003739-19. Ensayo multicéntrico, abierto, aleatorizado, de dos grupos, paralelo para comparar el cambio en la distribución de grasa en sujetos con sobrepeso y obesos con diabetes tipo 2 tras 26 semanas de tratamiento con insulina detemir una vez al día frente a insulina NPH una vez al día, ambas con insulina aspart a la hora de las comidas. www.clinicaltrialsregister.eu/ctr-search/trial/2008-003739-19/ES (first received 19 September 2008). NCT00795600. A multi-centre, open-labelled, randomised, two-group parallel trial comparing the change in fat distribution in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin apart at mealtimes. clinicaltrials.gov/ct2/show/NCT00795600 (first received 21 November 2008). Novo Nordisk A/S. A multi-centre, open-labelled, randomised, two-group parallel trial comparing the change in fat distribution in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart at mealtimes (NN304-3614 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1461&amp;filename=3614-ctr-synopsis-redacted.pdf (last accessed 3 November 2020). TinahonesFJ , Gomez-HuelgasR , Garcia-AlegriaJ , Tapia-GuerreroM , Martos-PerezF . Fat distribution, HbA1c and hypoglycaemia in overweight and obese patients with type 2 diabetes: a comparison of NPH and insulin detemir from a pilot randomised clinical trial. Diabetologia2011;54:S273. [EMBASE: 70562816]TinahonesFJ , Gomez-HuelgasR , GarciaalegriaJ , Tapia-GuerreroMJ , PerezFM . The effect of insulin detemir on fat distribution and weight parameters in overweight and obese subjects with type 2 diabetes. Diabetes2011;60:A309. [EMBASE: 70628891]">NN304‐3614</a>; <a href="./references#CD005613-bbs2-0020" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00653341. Effect of insulin glargine in insulin naïve subjects with type 2 diabetes on oral hypoglycemic agent(s). www.clinicaltrials.gov/ct2/show/results/NCT00653341 (first received 4 April 2008). RiddleMC , RosenstockJ , GerichJ , InsulinG . The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care2003;26(11):3080-6. [PMID: 14578243]">Riddle 2003</a>; <a href="./references#CD005613-bbs2-0021" title="FonsecaV , BellDS , BergerS , ThomsonS , MeccaTE . A comparison of bedtime insulin glargine with bedtime neutral protamine Hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. American Journal of the Medical Sciences2004;328(5):274-80. [PMID: 15545844]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. RosenstockJ , SchwartzSL , Clark CM Jr, ParkGD , DonleyDW , EdwardsMB . Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care2001;24(4):631-6. [PMID: 11315821]">Rosenstock 2001</a>; <a href="./references#CD005613-bbs2-0022" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00174824. Comparison of insulin glargine and NPH human insulin in progression of diabetic retinopathy in type 2 diabetic patients. clinicaltrials.gov/ct2/show/study/NCT00174824 (first received 15 September 2005). RosenstockJ , FonsecaV , DainMP , RiddleM . Estimating number-needed-to-treat to avoid hypoglycaemic episodes in people with type 2 diabetes: a post-hoc analysis of a prospective randomized controlled trial comparing once-daily insulin glargine with twice-daily NPH insulin. Canadian Journal of Diabetes2009;33(3):185-6. [EMBASE: 70031352]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia2009;52(9):1778-88. [PMID: 19526210]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia2009;52(9):1971-3. [PMID: 19609501]RosenstockJ , FonsecaV , SchinzelS , DainMP , MullinsP , RiddleM . Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: evidence from a long-term controlled trial. Journal of Diabetic Complications2014;28(5):742-9. [PMID: 24856612]">Rosenstock 2009</a>). It was unclear how the remaining seven investigations treated missing data in the analyses (<a href="./references#CD005613-bbs2-0001" title="BerardL , CameronB , WooV , StewartJ . Replacing insulin glargine with neutral protamine Hagedorn (NPH) insulin in a subpopulation of study subjects in the action to control cardiovascular risk in diabetes (ACCORD): effects on blood glucose levels, hypoglycemia and patient satisfaction. Canadian Journal of Diabetes2015;39(4):296-301. [PMID: 25819531]BerardLD , WooVC . Safety and efficacy of NPH after switching from insulin glargine in Canadian patients. Diabetologia2011;54:S430. [EMBASE: 70563203]">Berard 2015</a>; <a href="./references#CD005613-bbs2-0011" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KawamoriR , IwamotoY , KadowakiT , IwasakiM . Efficacy and safety of insulin glargine in concurrent use with oral hypoglycemic agents for the treatment of type 2 diabetes patients. Rinshoiyaku2003;19(5):445-64. ">Kawamori 2003</a>; <a href="./references#CD005613-bbs2-0014" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. MassiBM , HumburgE , DresslerA , ZiemenM . A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Hormone &amp; Metabolic Research2003;35(3):189-96. [PMID: 12734781]Yki-JarvinenH , DresslerA , ZiemenM . Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care2000;23(8):1130-6. [EMBASE: 2006092604]">Massi 2003</a>; <a href="./references#CD005613-bbs2-0019" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. PanCY , SinnassamyP , ChungKD , KimKW , Group LS . Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Research &amp; Clinical Practice2007;76(1):111-8. [PMID: 17011662]">Pan 2007</a>; <a href="./references#CD005613-bbs2-0002" title="BetônicoCC , TitanSM , Correa-GiannellaML , NeryM , QueirozM . Comparison of insulin glargine vs. NPH insulin in basal-bolus therapies in T2DM patients and CKD: preliminary results of a prospective, randomized, open-label trial. Diabetes2016;65:A144-5. [CENTRAL: CN-01450000] BetônicoCC , TitanSM , LiraA , PelaesTS , Correa-GiannellaML , NeryM , et al. Insulin glargine U100 improved glycemic control and reduced nocturnal hypoglycemia in patients with type 2 diabetes mellitus and chronic kidney disease stages 3 and 4. Clinical Therapeutics2019;41(10):2008-20. [PMID: 31383366]NCT02451917. Subcutaneous insulin glargine versus NPH insulin in patients with chronic kidney disease stages III and IV: randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02451917 (first received 22 May 2015). ">Betônico 2019</a>; <a href="./references#CD005613-bbs2-0023" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. VarewijckAJ , JanssenJA , VahataloM , HoflandLJ , LambertsSW , Yki-JarvinenH . Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. Diabetologia2012;55(4):1186-94. [PMID: 22237688]VarewijckAJ , JanssenJA , VahataloM , LambertsSW , Ki-JarvinenHY . IGF-I bioactivity decreases during insulin therapy in type 2 diabetic patients: comparison of high doses of insulin glargine and NPH insulin in the LANMET study. In: Endocrine Reviews Conference: 93rd Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 32 (3 Meeting Abstracts). 2011. [EMBASE: 70676865]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJA . Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and IGF-I receptor signaling. Diabetes2013;62(7):2539-44. [PMID: 23569175]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJAMJL . Comparison of effects of insulin glargine, its metabolites, IGF-I and human insulin on insulin-and IGF-I receptor signaling in type 2 diabetic patients. In: Endocrine Reviews Conference: 95th Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 34 (3 suppl 1). 2013. [EMBASE: 71784187]Yki-JärvinenH , Kauppinen-MakelinR , TiikkainenM , VahataloM , VirtamoH , Nikkila K et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia2006;49(3):442-51. [PMID: 10937510]">Yki‐Järvinen 2006</a>; <a href="./references#CD005613-bbs2-0024" title="YokoyamaH , TadaJ , KamikawaF , KannoS , YokotaY , KuramitsuM . Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Research &amp; Clinical Practice2006;73(1):35-40. [PMID: 16513202]">Yokoyama 2006</a>). </p> <p>Twenty‐two trials described discontinuing participants and provided at least some details on the reasons for terminating the trial. Two trials reported neither the number of discontinuing participants nor the reasons for withdrawal (<a href="./references#CD005613-bbs2-0001" title="BerardL , CameronB , WooV , StewartJ . Replacing insulin glargine with neutral protamine Hagedorn (NPH) insulin in a subpopulation of study subjects in the action to control cardiovascular risk in diabetes (ACCORD): effects on blood glucose levels, hypoglycemia and patient satisfaction. Canadian Journal of Diabetes2015;39(4):296-301. [PMID: 25819531]BerardLD , WooVC . Safety and efficacy of NPH after switching from insulin glargine in Canadian patients. Diabetologia2011;54:S430. [EMBASE: 70563203]">Berard 2015</a>; <a href="./references#CD005613-bbs2-0024" title="YokoyamaH , TadaJ , KamikawaF , KannoS , YokotaY , KuramitsuM . Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Research &amp; Clinical Practice2006;73(1):35-40. [PMID: 16513202]">Yokoyama 2006</a>). </p> <p>Three trials were at high risk of incomplete outcome data for all outcomes of relevance for this review. The trials with completion rates of only 48% (<a href="./references#CD005613-bbs2-0017" title="DoucetJ , Le FlochJ , HanaireH , CourregesJ , AlexandreB , BauduceauB . Comparison of safety between detemir and neutral protamine Hagedorn (NPH) in ageing subjects: the '3 L study'. Fundamental and Clinical Pharmacology2011;25:82. [EMBASE: 70653089]EUCTR2006-006589-41-FR. Levemir® in ageing patients with type 2 diabetes A seven-month open-labelled randomised multi-centre two-group parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in the morning in ageing subjects with type 2 diabetes. The 3L Study (Levemir in Late Life) Trial Phase: 4. www.clinicaltrialsregister.eu/ctr-search/trial/2006-006589-41/FR (first received 27 March 2007). NCT00506662. The effect of insulin detemir on glucose control in ageing subjects with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00506662 (first received 25 July 2007). Novo Nordisk A/S. A seven-month, open-labelled, randomised, multicentre, two-group, parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in ageing patients with type 2 diabetes: The 3L Study (Levemir in Later Life) (NN304-1808 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1426&amp;filename=1808-ctr-redacted.pdf (last accessed 3 November 2020). ">NN304‐1808</a>), 60% (<a href="./references#CD005613-bbs2-0010" title="HsiaSH . Comparison of single-dose regimens of insulin glargine versus NPH among inner city ethnic minority type 2 diabetic patients uncontrolled on oral agents. Journal of Investigative Medicine2010;58(1):136. [EMBASE: 70981533]HsiaSH . Insulin glargine compared to NPH among insulin-naive, U.S. inner city, ethnic minority type 2 diabetic patients. Diabetes Research &amp; Clinical Practice2011;91(3):293-9. [PMID: 21146881]NCT00686712. Insulin glargine at bedtime or in AM versus NPH. clinicaltrials.gov/ct2/show/NCT00686712 (first received 7 October 2010). ">Hsia 2011</a>), and 63% (<a href="./references#CD005613-bbs2-0015" title="NCT00687453. The utility of insulin glargine (Lantus) compared to NPH in ethnic minority type 2 diabetic subjects on combination insulin-oral agent therapy. clinicaltrials.gov/ct2/show/NCT00687453 (first received 30 May 2008). ">NCT00687453</a>) were prematurely discontinued. Two trials stated the reasons for discontinuation, which were recruitment problems (<a href="./references#CD005613-bbs2-0017" title="DoucetJ , Le FlochJ , HanaireH , CourregesJ , AlexandreB , BauduceauB . Comparison of safety between detemir and neutral protamine Hagedorn (NPH) in ageing subjects: the '3 L study'. Fundamental and Clinical Pharmacology2011;25:82. [EMBASE: 70653089]EUCTR2006-006589-41-FR. Levemir® in ageing patients with type 2 diabetes A seven-month open-labelled randomised multi-centre two-group parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in the morning in ageing subjects with type 2 diabetes. The 3L Study (Levemir in Late Life) Trial Phase: 4. www.clinicaltrialsregister.eu/ctr-search/trial/2006-006589-41/FR (first received 27 March 2007). NCT00506662. The effect of insulin detemir on glucose control in ageing subjects with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00506662 (first received 25 July 2007). Novo Nordisk A/S. A seven-month, open-labelled, randomised, multicentre, two-group, parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in ageing patients with type 2 diabetes: The 3L Study (Levemir in Later Life) (NN304-1808 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1426&amp;filename=1808-ctr-redacted.pdf (last accessed 3 November 2020). ">NN304‐1808</a>) and funding limits (<a href="./references#CD005613-bbs2-0010" title="HsiaSH . Comparison of single-dose regimens of insulin glargine versus NPH among inner city ethnic minority type 2 diabetic patients uncontrolled on oral agents. Journal of Investigative Medicine2010;58(1):136. [EMBASE: 70981533]HsiaSH . Insulin glargine compared to NPH among insulin-naive, U.S. inner city, ethnic minority type 2 diabetic patients. Diabetes Research &amp; Clinical Practice2011;91(3):293-9. [PMID: 21146881]NCT00686712. Insulin glargine at bedtime or in AM versus NPH. clinicaltrials.gov/ct2/show/NCT00686712 (first received 7 October 2010). ">Hsia 2011</a>). We considered two trials to have incomplete outcome data for the primary outcome health‐related quality of life (<a href="./references#CD005613-bbs2-0012" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. IshiiH , IwamotoY , KakuK , KawamoriR , KobayashiM , TajimaN . Night-time QOL and treatment satisfaction in diabetes mellitus patients treated with insulin detemir used in basal-bolus therapy – randomized multicenter open-label parallel group phase 3 trial compared to NPH insulin. Journal of the Japan Diabetes Society2009;52(8):691-701. [DOI: 10.11213/tonyobyo.52.691]KobayashiM , IwamotoY , KakuK , KawamoriR , TajimaN . Phase 3 clinical trial of insulin detemir for patients with insulin-dependent diabetes during basal-bolus therapy – a study of efficacy and safety with NPH insulin as control. Journal of the Japan Diabetes Society2007;50(9):649-63. [DOI: 10.11213/tonyobyo.50.649]NCT00604344. Efficacy and the safety of insulin detemir in subjects with insulin requiring diabetes. clinicaltrials.gov/ct2/show/NCT00604344 (first received 30 January 2008). Novo Nordisk A/S. A 48-week, randomised, multi-centre, open-labelled, parallel-group trial to compare the efficacy and the safety of NN304 (insulin detemir) and NPH human insulin in subjects with insulin requiring diabetes mellitus on a basal-bolus regimen. https://s3.amazonaws.com/ctr-nvo-7271/NN304-1476/aa9b4da3-1f92-460d-af0a-cc538614c3b2/3f7ed86e-d6e7-4542-ab8f-6cad24b46593/1476-ctr-synopsis-redacted-v2.pdf (last accessed 3 November 2020). ">Kobayashi 2007 A</a>; <a href="./references#CD005613-bbs2-0014" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. MassiBM , HumburgE , DresslerA , ZiemenM . A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Hormone &amp; Metabolic Research2003;35(3):189-96. [PMID: 12734781]Yki-JarvinenH , DresslerA , ZiemenM . Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care2000;23(8):1130-6. [EMBASE: 2006092604]">Massi 2003</a>). In one trial, 8% (glargine) and 23% (NPH) of the trial population were not included in health‐related quality of life analyses (<a href="./references#CD005613-bbs2-0012" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. IshiiH , IwamotoY , KakuK , KawamoriR , KobayashiM , TajimaN . Night-time QOL and treatment satisfaction in diabetes mellitus patients treated with insulin detemir used in basal-bolus therapy – randomized multicenter open-label parallel group phase 3 trial compared to NPH insulin. Journal of the Japan Diabetes Society2009;52(8):691-701. [DOI: 10.11213/tonyobyo.52.691]KobayashiM , IwamotoY , KakuK , KawamoriR , TajimaN . Phase 3 clinical trial of insulin detemir for patients with insulin-dependent diabetes during basal-bolus therapy – a study of efficacy and safety with NPH insulin as control. Journal of the Japan Diabetes Society2007;50(9):649-63. [DOI: 10.11213/tonyobyo.50.649]NCT00604344. Efficacy and the safety of insulin detemir in subjects with insulin requiring diabetes. clinicaltrials.gov/ct2/show/NCT00604344 (first received 30 January 2008). Novo Nordisk A/S. A 48-week, randomised, multi-centre, open-labelled, parallel-group trial to compare the efficacy and the safety of NN304 (insulin detemir) and NPH human insulin in subjects with insulin requiring diabetes mellitus on a basal-bolus regimen. https://s3.amazonaws.com/ctr-nvo-7271/NN304-1476/aa9b4da3-1f92-460d-af0a-cc538614c3b2/3f7ed86e-d6e7-4542-ab8f-6cad24b46593/1476-ctr-synopsis-redacted-v2.pdf (last accessed 3 November 2020). ">Kobayashi 2007 A</a>). In the other trial, 12% (glargine) and 15% (NPH) of the trial population were not included in health‐related quality of life analyses because validated questionnaires were not available in all languages (<a href="./references#CD005613-bbs2-0014" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. MassiBM , HumburgE , DresslerA , ZiemenM . A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Hormone &amp; Metabolic Research2003;35(3):189-96. [PMID: 12734781]Yki-JarvinenH , DresslerA , ZiemenM . Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care2000;23(8):1130-6. [EMBASE: 2006092604]">Massi 2003</a>). In one trial, only per‐protocol analysis was available for HbA1c measurement, with missing data of 16% in the glargine group and 20% in the NPH group (<a href="./references#CD005613-bbs2-0011" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KawamoriR , IwamotoY , KadowakiT , IwasakiM . Efficacy and safety of insulin glargine in concurrent use with oral hypoglycemic agents for the treatment of type 2 diabetes patients. Rinshoiyaku2003;19(5):445-64. ">Kawamori 2003</a>). Therefore, this trial was at high risk of reporting incomplete outcome data for this secondary outcome. </p> </section> <section id="CD005613-sec-0091"> <h4 class="title">Selective reporting</h4> <p>Four trials have not yet been published in peer‐review journals (<a href="./references#CD005613-bbs2-0015" title="NCT00687453. The utility of insulin glargine (Lantus) compared to NPH in ethnic minority type 2 diabetic subjects on combination insulin-oral agent therapy. clinicaltrials.gov/ct2/show/NCT00687453 (first received 30 May 2008). ">NCT00687453</a>; <a href="./references#CD005613-bbs2-0016" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">NN304‐1337</a>; <a href="./references#CD005613-bbs2-0017" title="DoucetJ , Le FlochJ , HanaireH , CourregesJ , AlexandreB , BauduceauB . Comparison of safety between detemir and neutral protamine Hagedorn (NPH) in ageing subjects: the '3 L study'. Fundamental and Clinical Pharmacology2011;25:82. [EMBASE: 70653089]EUCTR2006-006589-41-FR. Levemir® in ageing patients with type 2 diabetes A seven-month open-labelled randomised multi-centre two-group parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in the morning in ageing subjects with type 2 diabetes. The 3L Study (Levemir in Late Life) Trial Phase: 4. www.clinicaltrialsregister.eu/ctr-search/trial/2006-006589-41/FR (first received 27 March 2007). NCT00506662. The effect of insulin detemir on glucose control in ageing subjects with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00506662 (first received 25 July 2007). Novo Nordisk A/S. A seven-month, open-labelled, randomised, multicentre, two-group, parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in ageing patients with type 2 diabetes: The 3L Study (Levemir in Later Life) (NN304-1808 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1426&amp;filename=1808-ctr-redacted.pdf (last accessed 3 November 2020). ">NN304‐1808</a>; <a href="./references#CD005613-bbs2-0018" title="EUCTR2008-003739-19. Ensayo multicéntrico, abierto, aleatorizado, de dos grupos, paralelo para comparar el cambio en la distribución de grasa en sujetos con sobrepeso y obesos con diabetes tipo 2 tras 26 semanas de tratamiento con insulina detemir una vez al día frente a insulina NPH una vez al día, ambas con insulina aspart a la hora de las comidas. www.clinicaltrialsregister.eu/ctr-search/trial/2008-003739-19/ES (first received 19 September 2008). NCT00795600. A multi-centre, open-labelled, randomised, two-group parallel trial comparing the change in fat distribution in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin apart at mealtimes. clinicaltrials.gov/ct2/show/NCT00795600 (first received 21 November 2008). Novo Nordisk A/S. A multi-centre, open-labelled, randomised, two-group parallel trial comparing the change in fat distribution in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart at mealtimes (NN304-3614 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1461&amp;filename=3614-ctr-synopsis-redacted.pdf (last accessed 3 November 2020). TinahonesFJ , Gomez-HuelgasR , Garcia-AlegriaJ , Tapia-GuerreroM , Martos-PerezF . Fat distribution, HbA1c and hypoglycaemia in overweight and obese patients with type 2 diabetes: a comparison of NPH and insulin detemir from a pilot randomised clinical trial. Diabetologia2011;54:S273. [EMBASE: 70562816]TinahonesFJ , Gomez-HuelgasR , GarciaalegriaJ , Tapia-GuerreroMJ , PerezFM . The effect of insulin detemir on fat distribution and weight parameters in overweight and obese subjects with type 2 diabetes. Diabetes2011;60:A309. [EMBASE: 70628891]">NN304‐3614</a>), and information was only obtained from pharmaceutical manufacturers' study reports, ClinicalTrials.gov entries, the IQWiG report or correspondence with the study investigator. Six trials had a high risk of reporting bias on one or more of the outcomes of relevance for this review (<a href="./references#CD005613-bbs2-0001" title="BerardL , CameronB , WooV , StewartJ . Replacing insulin glargine with neutral protamine Hagedorn (NPH) insulin in a subpopulation of study subjects in the action to control cardiovascular risk in diabetes (ACCORD): effects on blood glucose levels, hypoglycemia and patient satisfaction. Canadian Journal of Diabetes2015;39(4):296-301. [PMID: 25819531]BerardLD , WooVC . Safety and efficacy of NPH after switching from insulin glargine in Canadian patients. Diabetologia2011;54:S430. [EMBASE: 70563203]">Berard 2015</a>; <a href="./references#CD005613-bbs2-0009" title='EUCTR2007-006640-22. Superiority of insulin glargine Lantus vs NPH: "Treat to normoglycemia concept". Effect of insulin glargine in comparison to insulin NPH in insulin-naïve people with type 2 diabetes mellitus treated with at least one OAD and not adequately controlled (LANCELOT) (LANTU_C_02762 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2007-006640-22/results (last accessed 19 July 2017). HomePD , BolliGB , MathieuC , DeerochanawongC , LandgrafW , CandelasC , et al. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naive people with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2015;17(1):15-22. [PMID: 24957785]NCT00949442. Lantus versus NPH: comparison in insulin naive people not adequately controlled with at least one oral anti diabetics (OAD) treatment (LANCELOT). clinicaltrials.gov/ct2/show/NCT00949442 (first received 30 July 2009). '>Home 2015</a>; <a href="./references#CD005613-bbs2-0012" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. IshiiH , IwamotoY , KakuK , KawamoriR , KobayashiM , TajimaN . Night-time QOL and treatment satisfaction in diabetes mellitus patients treated with insulin detemir used in basal-bolus therapy – randomized multicenter open-label parallel group phase 3 trial compared to NPH insulin. Journal of the Japan Diabetes Society2009;52(8):691-701. [DOI: 10.11213/tonyobyo.52.691]KobayashiM , IwamotoY , KakuK , KawamoriR , TajimaN . Phase 3 clinical trial of insulin detemir for patients with insulin-dependent diabetes during basal-bolus therapy – a study of efficacy and safety with NPH insulin as control. Journal of the Japan Diabetes Society2007;50(9):649-63. [DOI: 10.11213/tonyobyo.50.649]NCT00604344. Efficacy and the safety of insulin detemir in subjects with insulin requiring diabetes. clinicaltrials.gov/ct2/show/NCT00604344 (first received 30 January 2008). Novo Nordisk A/S. A 48-week, randomised, multi-centre, open-labelled, parallel-group trial to compare the efficacy and the safety of NN304 (insulin detemir) and NPH human insulin in subjects with insulin requiring diabetes mellitus on a basal-bolus regimen. https://s3.amazonaws.com/ctr-nvo-7271/NN304-1476/aa9b4da3-1f92-460d-af0a-cc538614c3b2/3f7ed86e-d6e7-4542-ab8f-6cad24b46593/1476-ctr-synopsis-redacted-v2.pdf (last accessed 3 November 2020). ">Kobayashi 2007 A</a>; <a href="./references#CD005613-bbs2-0015" title="NCT00687453. The utility of insulin glargine (Lantus) compared to NPH in ethnic minority type 2 diabetic subjects on combination insulin-oral agent therapy. clinicaltrials.gov/ct2/show/NCT00687453 (first received 30 May 2008). ">NCT00687453</a>; <a href="./references#CD005613-bbs2-0017" title="DoucetJ , Le FlochJ , HanaireH , CourregesJ , AlexandreB , BauduceauB . Comparison of safety between detemir and neutral protamine Hagedorn (NPH) in ageing subjects: the '3 L study'. Fundamental and Clinical Pharmacology2011;25:82. [EMBASE: 70653089]EUCTR2006-006589-41-FR. Levemir® in ageing patients with type 2 diabetes A seven-month open-labelled randomised multi-centre two-group parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in the morning in ageing subjects with type 2 diabetes. The 3L Study (Levemir in Late Life) Trial Phase: 4. www.clinicaltrialsregister.eu/ctr-search/trial/2006-006589-41/FR (first received 27 March 2007). NCT00506662. The effect of insulin detemir on glucose control in ageing subjects with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00506662 (first received 25 July 2007). Novo Nordisk A/S. A seven-month, open-labelled, randomised, multicentre, two-group, parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in ageing patients with type 2 diabetes: The 3L Study (Levemir in Later Life) (NN304-1808 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1426&amp;filename=1808-ctr-redacted.pdf (last accessed 3 November 2020). ">NN304‐1808</a>; <a href="./references#CD005613-bbs2-0024" title="YokoyamaH , TadaJ , KamikawaF , KannoS , YokotaY , KuramitsuM . Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Research &amp; Clinical Practice2006;73(1):35-40. [PMID: 16513202]">Yokoyama 2006</a>). Two trials had an unclear risk of reporting bias (<a href="./references#CD005613-bbs2-0007" title="EUCTR2009-010913-59. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on OHA treatment initiating basal insulin therapy with either insulin glargine or NPH insulin added to therapies with oral hypoglycemic agents (HAPPY) (LANTU_L_04079 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2009-010913-59/results (last accessed 3 May 2017). HermannsN , KulzerB , KohlmannT , JacobS , LandgrafW , TheobaldK , et al. Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial. Health and Quality of Life Outcomes2015;13:77. [PMID: 26055391]NCT00941369. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on oral hypoglycemic agent treatment initiating basal insulin therapy with either insulin glargine or NPH insulin. clinicaltrials.gov/ct2/show/NCT00941369 (first received 17 July 2009). ">Hermanns 2015</a>; <a href="./references#CD005613-bbs2-0019" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. PanCY , SinnassamyP , ChungKD , KimKW , Group LS . Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Research &amp; Clinical Practice2007;76(1):111-8. [PMID: 17011662]">Pan 2007</a>). The risk of reporting bias was low in all other trials. For details, see <a href="./appendices#CD005613-sec-0142">Appendix 10</a> and <a href="./appendices#CD005613-sec-0143">Appendix 11</a>. </p> </section> <section id="CD005613-sec-0092"> <h4 class="title">Other potential sources of bias</h4> <p>We judged three trials at high risk in the 'other bias' section because of their premature termination (<a href="./references#CD005613-bbs2-0010" title="HsiaSH . Comparison of single-dose regimens of insulin glargine versus NPH among inner city ethnic minority type 2 diabetic patients uncontrolled on oral agents. Journal of Investigative Medicine2010;58(1):136. [EMBASE: 70981533]HsiaSH . Insulin glargine compared to NPH among insulin-naive, U.S. inner city, ethnic minority type 2 diabetic patients. Diabetes Research &amp; Clinical Practice2011;91(3):293-9. [PMID: 21146881]NCT00686712. Insulin glargine at bedtime or in AM versus NPH. clinicaltrials.gov/ct2/show/NCT00686712 (first received 7 October 2010). ">Hsia 2011</a>; <a href="./references#CD005613-bbs2-0015" title="NCT00687453. The utility of insulin glargine (Lantus) compared to NPH in ethnic minority type 2 diabetic subjects on combination insulin-oral agent therapy. clinicaltrials.gov/ct2/show/NCT00687453 (first received 30 May 2008). ">NCT00687453</a>; <a href="./references#CD005613-bbs2-0017" title="DoucetJ , Le FlochJ , HanaireH , CourregesJ , AlexandreB , BauduceauB . Comparison of safety between detemir and neutral protamine Hagedorn (NPH) in ageing subjects: the '3 L study'. Fundamental and Clinical Pharmacology2011;25:82. [EMBASE: 70653089]EUCTR2006-006589-41-FR. Levemir® in ageing patients with type 2 diabetes A seven-month open-labelled randomised multi-centre two-group parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in the morning in ageing subjects with type 2 diabetes. The 3L Study (Levemir in Late Life) Trial Phase: 4. www.clinicaltrialsregister.eu/ctr-search/trial/2006-006589-41/FR (first received 27 March 2007). NCT00506662. The effect of insulin detemir on glucose control in ageing subjects with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00506662 (first received 25 July 2007). Novo Nordisk A/S. A seven-month, open-labelled, randomised, multicentre, two-group, parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in ageing patients with type 2 diabetes: The 3L Study (Levemir in Later Life) (NN304-1808 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1426&amp;filename=1808-ctr-redacted.pdf (last accessed 3 November 2020). ">NN304‐1808</a>). With the exception of one (<a href="./references#CD005613-bbs2-0002" title="BetônicoCC , TitanSM , Correa-GiannellaML , NeryM , QueirozM . Comparison of insulin glargine vs. NPH insulin in basal-bolus therapies in T2DM patients and CKD: preliminary results of a prospective, randomized, open-label trial. Diabetes2016;65:A144-5. [CENTRAL: CN-01450000] BetônicoCC , TitanSM , LiraA , PelaesTS , Correa-GiannellaML , NeryM , et al. Insulin glargine U100 improved glycemic control and reduced nocturnal hypoglycemia in patients with type 2 diabetes mellitus and chronic kidney disease stages 3 and 4. Clinical Therapeutics2019;41(10):2008-20. [PMID: 31383366]NCT02451917. Subcutaneous insulin glargine versus NPH insulin in patients with chronic kidney disease stages III and IV: randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02451917 (first received 22 May 2015). ">Betônico 2019</a>), all other trials had an unclear risk in this section, either because they had received funding from a pharmaceutical company (<a href="./references#CD005613-bbs2-0001" title="BerardL , CameronB , WooV , StewartJ . Replacing insulin glargine with neutral protamine Hagedorn (NPH) insulin in a subpopulation of study subjects in the action to control cardiovascular risk in diabetes (ACCORD): effects on blood glucose levels, hypoglycemia and patient satisfaction. Canadian Journal of Diabetes2015;39(4):296-301. [PMID: 25819531]BerardLD , WooVC . Safety and efficacy of NPH after switching from insulin glargine in Canadian patients. Diabetologia2011;54:S430. [EMBASE: 70563203]">Berard 2015</a>; <a href="./references#CD005613-bbs2-0003" title="EliaschewitzFG , CalvoC , ValbuenaH , RuizM , AschnerP , VillenaJ , et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Archives of Medical Research2006;37(4):495-501. [PMID: 16715577]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Eliaschewitz 2006</a>; <a href="./references#CD005613-bbs2-0004" title="EUCTR2005-000976-42. A multi-centre, open-labelled, randomised, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime (PREDICTIVE-BMI study) – PREDICTIVE-BMI study. www.clinicaltrialsregister.eu/ctr-search/trial/2005-000976-42/ES (first received 17 May 2006). Fajardo MontañanaC , Hernandez HerreroC , Rivas FernandezM . Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabetic Medicine2008;25(8):916-23. [PMID: 18959604]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00504673. Comparison of insulin detemir versus insulin NPH on weight change in overweight and obese with type 2 diabetes (PREDICTIVE). clinicaltrials.gov/ct2/show/NCT00504673 (first received 20 July 2007). Novo Nordisk A/S. A multi-centre, open-labelled, randomized, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime. (PREDICTIVE-BMI study). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1410&amp;filename=1659-ctr-redacted.pdf (last accessed 3 November 2020). Smith-PalmerJ , Fajardo-MontananaC , PollockRF , EricssonA , ValentineWJ . Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. Journal of Medical Economics2012;15(5):977-86. [PMID: 22563742]">Fajardo Montañana 2008</a>; <a href="./references#CD005613-bbs2-0005" title="FritscheA , SchweitzerMA , HaringHU , Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Annals of Internal Medicine2003;138(12):952-9. [PMID: 12809451]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Fritsche 2003</a>; <a href="./references#CD005613-bbs2-0007" title="EUCTR2009-010913-59. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on OHA treatment initiating basal insulin therapy with either insulin glargine or NPH insulin added to therapies with oral hypoglycemic agents (HAPPY) (LANTU_L_04079 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2009-010913-59/results (last accessed 3 May 2017). HermannsN , KulzerB , KohlmannT , JacobS , LandgrafW , TheobaldK , et al. Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial. Health and Quality of Life Outcomes2015;13:77. [PMID: 26055391]NCT00941369. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on oral hypoglycemic agent treatment initiating basal insulin therapy with either insulin glargine or NPH insulin. clinicaltrials.gov/ct2/show/NCT00941369 (first received 17 July 2009). ">Hermanns 2015</a>; <a href="./references#CD005613-bbs2-0008" title="DaileyG , StrangeP , RiddleM . Reconsideration of severe hypoglycemic events in the treat-to-target trial. Diabetes Technology &amp; Therapeutics2009;11(8):477-9. [PMID: 19698059]DaviesMJ , DerezinskiT , PedersenCB , ClausonP . Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Diabetes Technology &amp; Therapeutics2008;10(4):273-7. [PMID: 18715200]HermansenK , DaviesM , DerezinskiT , Martinez RavnG , ClausonP , HomeP . Erratum: A 26-week randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people wih type 2 diabetes (Diabetes Care (2006) 29, (1269-1274)). Diabetes Care2007;30(4):1035. [EMBASE: 46556609]HermansenK , DaviesM , DerezinskiT , MartinezRG , ClausonP , HomeP . A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care2006;29(6):1269-74. [PMID: 16732007]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00604396. Safety and efficacy of insulin detemir in combination with OAD in type 2 diabetes. clinicaltrials.gov/ct2/show/results/NCT00604396 (first received 30 January 2008). ">Hermansen 2006</a>; <a href="./references#CD005613-bbs2-0009" title='EUCTR2007-006640-22. Superiority of insulin glargine Lantus vs NPH: "Treat to normoglycemia concept". Effect of insulin glargine in comparison to insulin NPH in insulin-naïve people with type 2 diabetes mellitus treated with at least one OAD and not adequately controlled (LANCELOT) (LANTU_C_02762 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2007-006640-22/results (last accessed 19 July 2017). HomePD , BolliGB , MathieuC , DeerochanawongC , LandgrafW , CandelasC , et al. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naive people with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2015;17(1):15-22. [PMID: 24957785]NCT00949442. Lantus versus NPH: comparison in insulin naive people not adequately controlled with at least one oral anti diabetics (OAD) treatment (LANCELOT). clinicaltrials.gov/ct2/show/NCT00949442 (first received 30 July 2009). '>Home 2015</a>; <a href="./references#CD005613-bbs2-0011" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KawamoriR , IwamotoY , KadowakiT , IwasakiM . Efficacy and safety of insulin glargine in concurrent use with oral hypoglycemic agents for the treatment of type 2 diabetes patients. Rinshoiyaku2003;19(5):445-64. ">Kawamori 2003</a>; <a href="./references#CD005613-bbs2-0012" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. IshiiH , IwamotoY , KakuK , KawamoriR , KobayashiM , TajimaN . Night-time QOL and treatment satisfaction in diabetes mellitus patients treated with insulin detemir used in basal-bolus therapy – randomized multicenter open-label parallel group phase 3 trial compared to NPH insulin. Journal of the Japan Diabetes Society2009;52(8):691-701. [DOI: 10.11213/tonyobyo.52.691]KobayashiM , IwamotoY , KakuK , KawamoriR , TajimaN . Phase 3 clinical trial of insulin detemir for patients with insulin-dependent diabetes during basal-bolus therapy – a study of efficacy and safety with NPH insulin as control. Journal of the Japan Diabetes Society2007;50(9):649-63. [DOI: 10.11213/tonyobyo.50.649]NCT00604344. Efficacy and the safety of insulin detemir in subjects with insulin requiring diabetes. clinicaltrials.gov/ct2/show/NCT00604344 (first received 30 January 2008). Novo Nordisk A/S. A 48-week, randomised, multi-centre, open-labelled, parallel-group trial to compare the efficacy and the safety of NN304 (insulin detemir) and NPH human insulin in subjects with insulin requiring diabetes mellitus on a basal-bolus regimen. https://s3.amazonaws.com/ctr-nvo-7271/NN304-1476/aa9b4da3-1f92-460d-af0a-cc538614c3b2/3f7ed86e-d6e7-4542-ab8f-6cad24b46593/1476-ctr-synopsis-redacted-v2.pdf (last accessed 3 November 2020). ">Kobayashi 2007 A</a>; <a href="./references#CD005613-bbs2-0013" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KobayashiM , IwamotoY , KakuK , KawamoriR , TajimaN . Phase 3 clinical trial of insulin detemir for type 2 diabetes patients with insufficient blood sugar control in oral diabetes drug therapy. Journal of the Japan Diabetes Society2007;50(9):665-77. [DOI: 10.11213/tonyobyo.50.665]NCT00604253. Efficacy and safety of insulin detemir in type 2 diabetes inadequately controlled on OHA therapy alone. www.clinicaltrials.gov/ct2/show/results/NCT00604253 (first received 30 January 2008). Novo Nordisk A/S. A 36-week, randomised, multi-centre, open-labelled, parallel-group trial to compare the efficacy and the safety of NN304 and NPH human insulin once daily treatment as add-on to current OHA therapy in subjects with type 2 diabetes mellitus who are inadequately controlled on OHA therapy. http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1397&amp;filename=NN304_1477_ICTRSynopsis_Final_20051101.pdf (last accessed 3 November 2020). ">Kobayashi 2007 B</a>; <a href="./references#CD005613-bbs2-0014" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. MassiBM , HumburgE , DresslerA , ZiemenM . A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Hormone &amp; Metabolic Research2003;35(3):189-96. [PMID: 12734781]Yki-JarvinenH , DresslerA , ZiemenM . Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care2000;23(8):1130-6. [EMBASE: 2006092604]">Massi 2003</a>; <a href="./references#CD005613-bbs2-0016" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">NN304‐1337</a>; <a href="./references#CD005613-bbs2-0018" title="EUCTR2008-003739-19. Ensayo multicéntrico, abierto, aleatorizado, de dos grupos, paralelo para comparar el cambio en la distribución de grasa en sujetos con sobrepeso y obesos con diabetes tipo 2 tras 26 semanas de tratamiento con insulina detemir una vez al día frente a insulina NPH una vez al día, ambas con insulina aspart a la hora de las comidas. www.clinicaltrialsregister.eu/ctr-search/trial/2008-003739-19/ES (first received 19 September 2008). NCT00795600. A multi-centre, open-labelled, randomised, two-group parallel trial comparing the change in fat distribution in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin apart at mealtimes. clinicaltrials.gov/ct2/show/NCT00795600 (first received 21 November 2008). Novo Nordisk A/S. A multi-centre, open-labelled, randomised, two-group parallel trial comparing the change in fat distribution in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart at mealtimes (NN304-3614 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1461&amp;filename=3614-ctr-synopsis-redacted.pdf (last accessed 3 November 2020). TinahonesFJ , Gomez-HuelgasR , Garcia-AlegriaJ , Tapia-GuerreroM , Martos-PerezF . Fat distribution, HbA1c and hypoglycaemia in overweight and obese patients with type 2 diabetes: a comparison of NPH and insulin detemir from a pilot randomised clinical trial. Diabetologia2011;54:S273. [EMBASE: 70562816]TinahonesFJ , Gomez-HuelgasR , GarciaalegriaJ , Tapia-GuerreroMJ , PerezFM . The effect of insulin detemir on fat distribution and weight parameters in overweight and obese subjects with type 2 diabetes. Diabetes2011;60:A309. [EMBASE: 70628891]">NN304‐3614</a>; <a href="./references#CD005613-bbs2-0019" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. PanCY , SinnassamyP , ChungKD , KimKW , Group LS . Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Research &amp; Clinical Practice2007;76(1):111-8. [PMID: 17011662]">Pan 2007</a>; <a href="./references#CD005613-bbs2-0020" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00653341. Effect of insulin glargine in insulin naïve subjects with type 2 diabetes on oral hypoglycemic agent(s). www.clinicaltrials.gov/ct2/show/results/NCT00653341 (first received 4 April 2008). RiddleMC , RosenstockJ , GerichJ , InsulinG . The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care2003;26(11):3080-6. [PMID: 14578243]">Riddle 2003</a>; <a href="./references#CD005613-bbs2-0021" title="FonsecaV , BellDS , BergerS , ThomsonS , MeccaTE . A comparison of bedtime insulin glargine with bedtime neutral protamine Hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. American Journal of the Medical Sciences2004;328(5):274-80. [PMID: 15545844]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. RosenstockJ , SchwartzSL , Clark CM Jr, ParkGD , DonleyDW , EdwardsMB . Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care2001;24(4):631-6. [PMID: 11315821]">Rosenstock 2001</a>; <a href="./references#CD005613-bbs2-0022" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00174824. Comparison of insulin glargine and NPH human insulin in progression of diabetic retinopathy in type 2 diabetic patients. clinicaltrials.gov/ct2/show/study/NCT00174824 (first received 15 September 2005). RosenstockJ , FonsecaV , DainMP , RiddleM . Estimating number-needed-to-treat to avoid hypoglycaemic episodes in people with type 2 diabetes: a post-hoc analysis of a prospective randomized controlled trial comparing once-daily insulin glargine with twice-daily NPH insulin. Canadian Journal of Diabetes2009;33(3):185-6. [EMBASE: 70031352]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia2009;52(9):1778-88. [PMID: 19526210]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia2009;52(9):1971-3. [PMID: 19609501]RosenstockJ , FonsecaV , SchinzelS , DainMP , MullinsP , RiddleM . Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: evidence from a long-term controlled trial. Journal of Diabetic Complications2014;28(5):742-9. [PMID: 24856612]">Rosenstock 2009</a>; <a href="./references#CD005613-bbs2-0023" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. VarewijckAJ , JanssenJA , VahataloM , HoflandLJ , LambertsSW , Yki-JarvinenH . Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. Diabetologia2012;55(4):1186-94. [PMID: 22237688]VarewijckAJ , JanssenJA , VahataloM , LambertsSW , Ki-JarvinenHY . IGF-I bioactivity decreases during insulin therapy in type 2 diabetic patients: comparison of high doses of insulin glargine and NPH insulin in the LANMET study. In: Endocrine Reviews Conference: 93rd Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 32 (3 Meeting Abstracts). 2011. [EMBASE: 70676865]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJA . Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and IGF-I receptor signaling. Diabetes2013;62(7):2539-44. [PMID: 23569175]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJAMJL . Comparison of effects of insulin glargine, its metabolites, IGF-I and human insulin on insulin-and IGF-I receptor signaling in type 2 diabetic patients. In: Endocrine Reviews Conference: 95th Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 34 (3 suppl 1). 2013. [EMBASE: 71784187]Yki-JärvinenH , Kauppinen-MakelinR , TiikkainenM , VahataloM , VirtamoH , Nikkila K et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia2006;49(3):442-51. [PMID: 10937510]">Yki‐Järvinen 2006</a>), or did not report their funding source (<a href="./references#CD005613-bbs2-0006" title="HaakT , TiengoA , DraegerE , SuntumM , WaldhauslW . Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2005;7(1):56-64. [PMID: 15642076]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Haak 2005</a>; <a href="./references#CD005613-bbs2-0024" title="YokoyamaH , TadaJ , KamikawaF , KannoS , YokotaY , KuramitsuM . Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Research &amp; Clinical Practice2006;73(1):35-40. [PMID: 16513202]">Yokoyama 2006</a>). </p> </section> </section> <section id="CD005613-sec-0093"> <h3 class="title" id="CD005613-sec-0093">Effects of interventions</h3> <p>See: <a href="./full#CD005613-tbl-0001"><b>Summary of findings 1</b> Insulin glargine versus NPH insulin for type 2 diabetes mellitus</a>; <a href="./full#CD005613-tbl-0002"><b>Summary of findings 2</b> Insulin detemir versus NPH insulin for type 2 diabetes mellitus</a> </p> <section id="CD005613-sec-0094"> <h4 class="title">Baseline characteristics</h4> <p>For details of baseline characteristics, see <a href="./appendices#CD005613-sec-0140">Appendix 8</a> and <a href="./appendices#CD005613-sec-0141">Appendix 9</a>. </p> </section> <section id="CD005613-sec-0095"> <h4 class="title">Long‐acting insulin analogue glargine versus NPH insulin</h4> <p>As it is not possible to include a comparison group twice in the same meta‐analysis, we could not consider all treatment arms from two trials in the meta‐analyses (<a href="./references#CD005613-bbs2-0005" title="FritscheA , SchweitzerMA , HaringHU , Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Annals of Internal Medicine2003;138(12):952-9. [PMID: 12809451]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Fritsche 2003</a>; <a href="./references#CD005613-bbs2-0010" title="HsiaSH . Comparison of single-dose regimens of insulin glargine versus NPH among inner city ethnic minority type 2 diabetic patients uncontrolled on oral agents. Journal of Investigative Medicine2010;58(1):136. [EMBASE: 70981533]HsiaSH . Insulin glargine compared to NPH among insulin-naive, U.S. inner city, ethnic minority type 2 diabetic patients. Diabetes Research &amp; Clinical Practice2011;91(3):293-9. [PMID: 21146881]NCT00686712. Insulin glargine at bedtime or in AM versus NPH. clinicaltrials.gov/ct2/show/NCT00686712 (first received 7 October 2010). ">Hsia 2011</a>). For reasons of homogeneity, only the comparison of glargine in the evening versus NPH in the evening was included in our analyses. </p> <p>In case of cross‐over studies, we considered only the results from the first period for continuous outcomes, but from both periods for dichotomous outcomes (<a href="./references#CD005613-bbs2-0007" title="EUCTR2009-010913-59. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on OHA treatment initiating basal insulin therapy with either insulin glargine or NPH insulin added to therapies with oral hypoglycemic agents (HAPPY) (LANTU_L_04079 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2009-010913-59/results (last accessed 3 May 2017). HermannsN , KulzerB , KohlmannT , JacobS , LandgrafW , TheobaldK , et al. Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial. Health and Quality of Life Outcomes2015;13:77. [PMID: 26055391]NCT00941369. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on oral hypoglycemic agent treatment initiating basal insulin therapy with either insulin glargine or NPH insulin. clinicaltrials.gov/ct2/show/NCT00941369 (first received 17 July 2009). ">Hermanns 2015</a>; <a href="./references#CD005613-bbs2-0002" title="BetônicoCC , TitanSM , Correa-GiannellaML , NeryM , QueirozM . Comparison of insulin glargine vs. NPH insulin in basal-bolus therapies in T2DM patients and CKD: preliminary results of a prospective, randomized, open-label trial. Diabetes2016;65:A144-5. [CENTRAL: CN-01450000] BetônicoCC , TitanSM , LiraA , PelaesTS , Correa-GiannellaML , NeryM , et al. Insulin glargine U100 improved glycemic control and reduced nocturnal hypoglycemia in patients with type 2 diabetes mellitus and chronic kidney disease stages 3 and 4. Clinical Therapeutics2019;41(10):2008-20. [PMID: 31383366]NCT02451917. Subcutaneous insulin glargine versus NPH insulin in patients with chronic kidney disease stages III and IV: randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02451917 (first received 22 May 2015). ">Betônico 2019</a>). </p> <section id="CD005613-sec-0096"> <h5 class="title">Primary outcomes</h5> <section id="CD005613-sec-0097"> <h6 class="title">Diabetes‐related complications</h6> <p>Two trials reported a total of six non‐fatal myocardial infarctions, three in people treated with glargine and three in people treated with NPH (very low‐certainty evidence) (<a href="./references#CD005613-bbs2-0019" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. PanCY , SinnassamyP , ChungKD , KimKW , Group LS . Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Research &amp; Clinical Practice2007;76(1):111-8. [PMID: 17011662]">Pan 2007</a>; <a href="./references#CD005613-bbs2-0002" title="BetônicoCC , TitanSM , Correa-GiannellaML , NeryM , QueirozM . Comparison of insulin glargine vs. NPH insulin in basal-bolus therapies in T2DM patients and CKD: preliminary results of a prospective, randomized, open-label trial. Diabetes2016;65:A144-5. [CENTRAL: CN-01450000] BetônicoCC , TitanSM , LiraA , PelaesTS , Correa-GiannellaML , NeryM , et al. Insulin glargine U100 improved glycemic control and reduced nocturnal hypoglycemia in patients with type 2 diabetes mellitus and chronic kidney disease stages 3 and 4. Clinical Therapeutics2019;41(10):2008-20. [PMID: 31383366]NCT02451917. Subcutaneous insulin glargine versus NPH insulin in patients with chronic kidney disease stages III and IV: randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02451917 (first received 22 May 2015). ">Betônico 2019</a>). </p> <p>Four trials provided information on fatal myocardial infarctions, three in people treated with glargine, and one in a person treated with NPH (very low‐certainty evidence) (<a href="./references#CD005613-bbs2-0009" title='EUCTR2007-006640-22. Superiority of insulin glargine Lantus vs NPH: "Treat to normoglycemia concept". Effect of insulin glargine in comparison to insulin NPH in insulin-naïve people with type 2 diabetes mellitus treated with at least one OAD and not adequately controlled (LANCELOT) (LANTU_C_02762 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2007-006640-22/results (last accessed 19 July 2017). HomePD , BolliGB , MathieuC , DeerochanawongC , LandgrafW , CandelasC , et al. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naive people with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2015;17(1):15-22. [PMID: 24957785]NCT00949442. Lantus versus NPH: comparison in insulin naive people not adequately controlled with at least one oral anti diabetics (OAD) treatment (LANCELOT). clinicaltrials.gov/ct2/show/NCT00949442 (first received 30 July 2009). '>Home 2015</a>; <a href="./references#CD005613-bbs2-0010" title="HsiaSH . Comparison of single-dose regimens of insulin glargine versus NPH among inner city ethnic minority type 2 diabetic patients uncontrolled on oral agents. Journal of Investigative Medicine2010;58(1):136. [EMBASE: 70981533]HsiaSH . Insulin glargine compared to NPH among insulin-naive, U.S. inner city, ethnic minority type 2 diabetic patients. Diabetes Research &amp; Clinical Practice2011;91(3):293-9. [PMID: 21146881]NCT00686712. Insulin glargine at bedtime or in AM versus NPH. clinicaltrials.gov/ct2/show/NCT00686712 (first received 7 October 2010). ">Hsia 2011</a>; <a href="./references#CD005613-bbs2-0002" title="BetônicoCC , TitanSM , Correa-GiannellaML , NeryM , QueirozM . Comparison of insulin glargine vs. NPH insulin in basal-bolus therapies in T2DM patients and CKD: preliminary results of a prospective, randomized, open-label trial. Diabetes2016;65:A144-5. [CENTRAL: CN-01450000] BetônicoCC , TitanSM , LiraA , PelaesTS , Correa-GiannellaML , NeryM , et al. Insulin glargine U100 improved glycemic control and reduced nocturnal hypoglycemia in patients with type 2 diabetes mellitus and chronic kidney disease stages 3 and 4. Clinical Therapeutics2019;41(10):2008-20. [PMID: 31383366]NCT02451917. Subcutaneous insulin glargine versus NPH insulin in patients with chronic kidney disease stages III and IV: randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02451917 (first received 22 May 2015). ">Betônico 2019</a>; <a href="./references#CD005613-bbs2-0023" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. VarewijckAJ , JanssenJA , VahataloM , HoflandLJ , LambertsSW , Yki-JarvinenH . Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. Diabetologia2012;55(4):1186-94. [PMID: 22237688]VarewijckAJ , JanssenJA , VahataloM , LambertsSW , Ki-JarvinenHY . IGF-I bioactivity decreases during insulin therapy in type 2 diabetic patients: comparison of high doses of insulin glargine and NPH insulin in the LANMET study. In: Endocrine Reviews Conference: 93rd Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 32 (3 Meeting Abstracts). 2011. [EMBASE: 70676865]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJA . Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and IGF-I receptor signaling. Diabetes2013;62(7):2539-44. [PMID: 23569175]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJAMJL . Comparison of effects of insulin glargine, its metabolites, IGF-I and human insulin on insulin-and IGF-I receptor signaling in type 2 diabetic patients. In: Endocrine Reviews Conference: 95th Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 34 (3 suppl 1). 2013. [EMBASE: 71784187]Yki-JärvinenH , Kauppinen-MakelinR , TiikkainenM , VahataloM , VirtamoH , Nikkila K et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia2006;49(3):442-51. [PMID: 10937510]">Yki‐Järvinen 2006</a>). </p> <p>One trial with 32 participants reported no strokes in either group (very low‐certainty evidence) (<a href="./references#CD005613-bbs2-0002" title="BetônicoCC , TitanSM , Correa-GiannellaML , NeryM , QueirozM . Comparison of insulin glargine vs. NPH insulin in basal-bolus therapies in T2DM patients and CKD: preliminary results of a prospective, randomized, open-label trial. Diabetes2016;65:A144-5. [CENTRAL: CN-01450000] BetônicoCC , TitanSM , LiraA , PelaesTS , Correa-GiannellaML , NeryM , et al. Insulin glargine U100 improved glycemic control and reduced nocturnal hypoglycemia in patients with type 2 diabetes mellitus and chronic kidney disease stages 3 and 4. Clinical Therapeutics2019;41(10):2008-20. [PMID: 31383366]NCT02451917. Subcutaneous insulin glargine versus NPH insulin in patients with chronic kidney disease stages III and IV: randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02451917 (first received 22 May 2015). ">Betônico 2019</a>). There were no fatal strokes in four trials with 934 participants (very low‐certainty evidence) (<a href="./references#CD005613-bbs2-0009" title='EUCTR2007-006640-22. Superiority of insulin glargine Lantus vs NPH: "Treat to normoglycemia concept". Effect of insulin glargine in comparison to insulin NPH in insulin-naïve people with type 2 diabetes mellitus treated with at least one OAD and not adequately controlled (LANCELOT) (LANTU_C_02762 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2007-006640-22/results (last accessed 19 July 2017). HomePD , BolliGB , MathieuC , DeerochanawongC , LandgrafW , CandelasC , et al. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naive people with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2015;17(1):15-22. [PMID: 24957785]NCT00949442. Lantus versus NPH: comparison in insulin naive people not adequately controlled with at least one oral anti diabetics (OAD) treatment (LANCELOT). clinicaltrials.gov/ct2/show/NCT00949442 (first received 30 July 2009). '>Home 2015</a>; <a href="./references#CD005613-bbs2-0010" title="HsiaSH . Comparison of single-dose regimens of insulin glargine versus NPH among inner city ethnic minority type 2 diabetic patients uncontrolled on oral agents. Journal of Investigative Medicine2010;58(1):136. [EMBASE: 70981533]HsiaSH . Insulin glargine compared to NPH among insulin-naive, U.S. inner city, ethnic minority type 2 diabetic patients. Diabetes Research &amp; Clinical Practice2011;91(3):293-9. [PMID: 21146881]NCT00686712. Insulin glargine at bedtime or in AM versus NPH. clinicaltrials.gov/ct2/show/NCT00686712 (first received 7 October 2010). ">Hsia 2011</a>; <a href="./references#CD005613-bbs2-0002" title="BetônicoCC , TitanSM , Correa-GiannellaML , NeryM , QueirozM . Comparison of insulin glargine vs. NPH insulin in basal-bolus therapies in T2DM patients and CKD: preliminary results of a prospective, randomized, open-label trial. Diabetes2016;65:A144-5. [CENTRAL: CN-01450000] BetônicoCC , TitanSM , LiraA , PelaesTS , Correa-GiannellaML , NeryM , et al. Insulin glargine U100 improved glycemic control and reduced nocturnal hypoglycemia in patients with type 2 diabetes mellitus and chronic kidney disease stages 3 and 4. Clinical Therapeutics2019;41(10):2008-20. [PMID: 31383366]NCT02451917. Subcutaneous insulin glargine versus NPH insulin in patients with chronic kidney disease stages III and IV: randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02451917 (first received 22 May 2015). ">Betônico 2019</a>; <a href="./references#CD005613-bbs2-0023" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. VarewijckAJ , JanssenJA , VahataloM , HoflandLJ , LambertsSW , Yki-JarvinenH . Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. Diabetologia2012;55(4):1186-94. [PMID: 22237688]VarewijckAJ , JanssenJA , VahataloM , LambertsSW , Ki-JarvinenHY . IGF-I bioactivity decreases during insulin therapy in type 2 diabetic patients: comparison of high doses of insulin glargine and NPH insulin in the LANMET study. In: Endocrine Reviews Conference: 93rd Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 32 (3 Meeting Abstracts). 2011. [EMBASE: 70676865]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJA . Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and IGF-I receptor signaling. Diabetes2013;62(7):2539-44. [PMID: 23569175]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJAMJL . Comparison of effects of insulin glargine, its metabolites, IGF-I and human insulin on insulin-and IGF-I receptor signaling in type 2 diabetic patients. In: Endocrine Reviews Conference: 95th Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 34 (3 suppl 1). 2013. [EMBASE: 71784187]Yki-JärvinenH , Kauppinen-MakelinR , TiikkainenM , VahataloM , VirtamoH , Nikkila K et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia2006;49(3):442-51. [PMID: 10937510]">Yki‐Järvinen 2006</a>). </p> <p>For end‐stage renal disease for glargine versus NPH, there were no events in either group (1 trial, 34 participants; very low‐certainty evidence; <a href="./references#CD005613-bbs2-0002" title="BetônicoCC , TitanSM , Correa-GiannellaML , NeryM , QueirozM . Comparison of insulin glargine vs. NPH insulin in basal-bolus therapies in T2DM patients and CKD: preliminary results of a prospective, randomized, open-label trial. Diabetes2016;65:A144-5. [CENTRAL: CN-01450000] BetônicoCC , TitanSM , LiraA , PelaesTS , Correa-GiannellaML , NeryM , et al. Insulin glargine U100 improved glycemic control and reduced nocturnal hypoglycemia in patients with type 2 diabetes mellitus and chronic kidney disease stages 3 and 4. Clinical Therapeutics2019;41(10):2008-20. [PMID: 31383366]NCT02451917. Subcutaneous insulin glargine versus NPH insulin in patients with chronic kidney disease stages III and IV: randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02451917 (first received 22 May 2015). ">Betônico 2019</a>). </p> <p>There was no evidence of a difference in progression of retinopathy (three steps) (RR 1.03, 95% CI 0.60 to 1.77; P = 0.90; 5 trials, 1974 participants; very low‐certainty evidence; <a href="./references#CD005613-fig-0005" title="">Analysis 1.1</a>). The 95% prediction interval ranged between 0.22 and 4.83. </p> <p>Amputations: there were no events in either group (1 trial, 34 participants; very low‐certainty evidence; <a href="./references#CD005613-bbs2-0002" title="BetônicoCC , TitanSM , Correa-GiannellaML , NeryM , QueirozM . Comparison of insulin glargine vs. NPH insulin in basal-bolus therapies in T2DM patients and CKD: preliminary results of a prospective, randomized, open-label trial. Diabetes2016;65:A144-5. [CENTRAL: CN-01450000] BetônicoCC , TitanSM , LiraA , PelaesTS , Correa-GiannellaML , NeryM , et al. Insulin glargine U100 improved glycemic control and reduced nocturnal hypoglycemia in patients with type 2 diabetes mellitus and chronic kidney disease stages 3 and 4. Clinical Therapeutics2019;41(10):2008-20. [PMID: 31383366]NCT02451917. Subcutaneous insulin glargine versus NPH insulin in patients with chronic kidney disease stages III and IV: randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02451917 (first received 22 May 2015). ">Betônico 2019</a>). </p> <p>None of the trials provided further information on late diabetic complications.</p> </section> <section id="CD005613-sec-0098"> <h6 class="title">Hypoglycaemic episodes</h6> <p>The RR for severe hypoglycaemia was 0.68 (95% CI 0.46 to 1.01 in random‐effects meta‐analysis; P = 0.06; 14 trials, 6164 participants; very low‐certainty evidence; <a href="./references#CD005613-fig-0006" title="">Analysis 1.2</a>). The 95% prediction interval ranged between 0.33 and 1.40. Fixed‐effect meta‐analysis showed a RR of 0.67 (95% CI 0.50 to 0.90; P = 0.007). </p> <p>The RR for serious hypoglycaemia was 0.75 (95% CI 0.52 to 1.09; P = 0.54; 10 trials, 4685 participants; low‐certainty evidence; <a href="./references#CD005613-fig-0007" title="">Analysis 1.3</a>). The 95% prediction interval ranged between 0.48 and 1.16. </p> <p>The RR for confirmed hypoglycaemia less than 75 mg/dL was 0.92 (95% CI 0.85 to 1.01; P = 0.08; 7 trials, 4115 participants; low‐certainty evidence; <a href="./references#CD005613-fig-0008" title="">Analysis 1.4</a>). The 95% prediction interval ranged between 0.69 and 1.22. </p> <p>The RR for confirmed hypoglycaemia less than 55 mg/dL was 0.88 in favour of glargine (95% CI 0.81 to 0.96; P = 0.005; 8 trials, 4388 participants; moderate‐certainty evidence; <a href="./references#CD005613-fig-0009" title="">Analysis 1.5</a>). The 95% prediction interval ranged between 0.79 and 0.98. </p> <p>The RR for nocturnal confirmed hypoglycaemia less than 75 mg/dL was 0.78 (95% CI 0.68 to 0.89; P &lt; 0.001; 8 trials, 4225 participants; very low‐certainty evidence; <a href="./references#CD005613-fig-0010" title="">Analysis 1.6</a>). The 95% prediction interval ranged between 0.53 and 1.14. </p> <p>The RR for nocturnal confirmed hypoglycaemia less than 55 mg/dL was 0.74 in favour of glargine (95% CI 0.64 to 0.85; P &lt; 0.001; 8 trials, 4759 participants; moderate‐certainty evidence; <a href="./references#CD005613-fig-0011" title="">Analysis 1.7</a>). The 95% prediction interval ranged between 0.62 and 0.88. </p> </section> <section id="CD005613-sec-0099"> <h6 class="title">Health‐related quality of life</h6> <p>Three trials reported health‐related quality of life (1228 participants; very low‐certainty evidence). </p> <p><a href="./references#CD005613-bbs2-0014" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. MassiBM , HumburgE , DresslerA , ZiemenM . A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Hormone &amp; Metabolic Research2003;35(3):189-96. [PMID: 12734781]Yki-JarvinenH , DresslerA , ZiemenM . Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care2000;23(8):1130-6. [EMBASE: 2006092604]">Massi 2003</a> used the Well‐being Questionnaire (W‐BQ22). The difference between trial start and trial end for total score was 1.0 (95% CI –45.0 to 32.0) for glargine and 0.0 (95% CI –25.2 to 46.2) for NPH (P = 0.40). </p> <p><a href="./references#CD005613-bbs2-0021" title="FonsecaV , BellDS , BergerS , ThomsonS , MeccaTE . A comparison of bedtime insulin glargine with bedtime neutral protamine Hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. American Journal of the Medical Sciences2004;328(5):274-80. [PMID: 15545844]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. RosenstockJ , SchwartzSL , Clark CM Jr, ParkGD , DonleyDW , EdwardsMB . Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care2001;24(4):631-6. [PMID: 11315821]">Rosenstock 2001</a> used the W‐BQ22. The difference between trial start and trial end for total score was 0.5 (95% CI –22.0 to 36.0) for glargine and 0.0 (95% CI –37.0 to 39.0) for NPH (P = 0.25). </p> <p><a href="./references#CD005613-bbs2-0007" title="EUCTR2009-010913-59. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on OHA treatment initiating basal insulin therapy with either insulin glargine or NPH insulin added to therapies with oral hypoglycemic agents (HAPPY) (LANTU_L_04079 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2009-010913-59/results (last accessed 3 May 2017). HermannsN , KulzerB , KohlmannT , JacobS , LandgrafW , TheobaldK , et al. Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial. Health and Quality of Life Outcomes2015;13:77. [PMID: 26055391]NCT00941369. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on oral hypoglycemic agent treatment initiating basal insulin therapy with either insulin glargine or NPH insulin. clinicaltrials.gov/ct2/show/NCT00941369 (first received 17 July 2009). ">Hermanns 2015</a> used the EuroQol 5 (EQ‐5) instrument. The difference between trial start and trial end for EQ‐5 descriptive was –0.009 (SD 0.1727) for glargine and 0.001 (SD 0.1606) for NPH (P = 0.62). The difference between trial start and trial end for EQ‐5 Visual Analogue Scale (VAS) was –0.0 (SD 0.1646) for glargine and 0.009 (SD 0.1655) for NPH (P = 0.64). </p> </section> </section> <section id="CD005613-sec-0100"> <h5 class="title">Secondary outcomes</h5> <section id="CD005613-sec-0101"> <h6 class="title">All‐cause mortality</h6> <p>The Peto OR for death from any cause was 1.06 (95% CI 0.62 to 1.82; P = 0.83; 14 trials, 6173 participants; low‐certainty evidence; <a href="./references#CD005613-fig-0012" title="">Analysis 1.8</a>). </p> </section> <section id="CD005613-sec-0102"> <h6 class="title">Adverse events other than hypoglycaemia</h6> <p>The RR for serious adverse events was 0.98 (95% CI 0.87 to 1.10; P = 0.74; 13 trials, 5499 participants; moderate‐certainty evidence; <a href="./references#CD005613-fig-0013" title="">Analysis 1.9</a>). The 95% prediction interval ranged between 0.86 and 1.12. </p> <p>The RR for all adverse events was 1.01 (95% CI 0.98 to 1.03; P = 0.62; 14 trials, 6170 participants; moderate‐certainty evidence; <a href="./references#CD005613-fig-0014" title="">Analysis 1.10</a>). The 95% prediction interval ranged between 0.99 and 1.03. </p> <p>The RR for adverse events leading to discontinuation of the trial was 1.21 (95% CI 0.84 to 1.76; P = 0.30; 13 trials, 6149 participants; moderate‐certainty evidence; <a href="./references#CD005613-fig-0015" title="">Analysis 1.11</a>). The 95% prediction interval ranged between 0.79 and 1.84. </p> <p>There was an increase in weight gain (BMI) in favour of NPH insulin (MD 0.12 kg/m², 95% CI 0.02 to 0.22; P = 0.02; 8 trials, 2405 participants; <a href="./references#CD005613-fig-0016" title="">Analysis 1.12</a>). The 95% prediction interval ranged between 0.06 kg/m² and 0.26 kg/m². </p> <p>The RR for adverse skin reactions was 1.06 (95% CI 0.83 to 1.35; P = 0.63; 10 trials, 4735 participants; <a href="./references#CD005613-fig-0017" title="">Analysis 1.13</a>). The 95% prediction interval ranged between 0.80 and 1.41. </p> <p>The RR for eye‐related adverse events was 1.08 (95% CI 0.86 to 1.35; P = 0.52; 9 trials, 4204 participants; <a href="./references#CD005613-fig-0018" title="">Analysis 1.14</a>). The 95% prediction interval ranged between 0.83 and 1.41. </p> </section> <section id="CD005613-sec-0103"> <h6 class="title">Socioeconomic effects</h6> <p>No study investigated socioeconomic effects.</p> </section> <section id="CD005613-sec-0104"> <h6 class="title">HbA1c</h6> <p>The MD in HbA1c was –0.07% (95% CI –0.18 to 0.03; P = 0.17; 16 trials, 5809 participants; low‐certainty evidence; <a href="./references#CD005613-fig-0019" title="">Analysis 1.15</a>). The 95% prediction interval ranged between –46% and 0.32%. </p> </section> </section> <section id="CD005613-sec-0105"> <h5 class="title">Subgroup analyses</h5> <p>We performed subgroup analyses for trials with OADs as concomitant blood glucose lowering medications versus trials with short‐acting insulin as a concomitant blood glucose lowering medication for hypoglycaemic events (severe, serious, confirmed, nocturnal confirmed) and progression of diabetic retinopathy. Interaction was only found for the outcome progression of retinopathy. Retinopathy progression (three steps) for OADs showed a RR of 0.73 (95% CI 0.38 to 1.38, P = 0.33). Retinopathy progression (three steps) for short‐acting insulin showed a RR of 2.75 (95% CI 1.10 to 6.91, P = 0.03) (test for subgroup difference: I² = 81.6%; P = 0.02). </p> <p>We performed subgroup analyses for trials with NPH administration once daily versus NPH administration more than once daily for hypoglycaemic events (severe, serious, confirmed, nocturnal confirmed) and progression of diabetic retinopathy. Interaction was only found for the outcome nocturnal confirmed hypoglycaemia less than 75 mg/dL. Nocturnal confirmed hypoglycaemia less than 75 mg/dL for NPH once daily showed a RR of 0.74 (95% CI 0.62 to 0.89; P = 0.001). Nocturnal confirmed hypoglycaemia less than 75 mg/dL for NPH more than once daily showed a RR of 0.91 (95% CI 0.82 to 1.01; P = 0.11) (test for subgroup difference: I² = 74.7%; P = 0.05). </p> <p>We did not conduct any further subgroup analyses because there were not enough trials or events to evaluate effects. </p> </section> <section id="CD005613-sec-0106"> <h5 class="title">Sensitivity analyses</h5> <p>We performed sensitivity analyses for the following factors: very long (follow‐up more than 12 months) and very large trials (more than 1000 participants). Trials did not differ enough in terms of other variables to allow meaningful sensitivity analyses. Analyses including and excluding the results from <a href="./references#CD005613-bbs2-0024" title="YokoyamaH , TadaJ , KamikawaF , KannoS , YokotaY , KuramitsuM . Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Research &amp; Clinical Practice2006;73(1):35-40. [PMID: 16513202]">Yokoyama 2006</a> were also not feasible. We investigated the robustness of the pooled results by repeating the analyses using different statistical models (fixed‐ and random‐effects). </p> <p>Nocturnal confirmed hypoglycaemia less than 75 mg/dL all studies showed a RR of 0.78 (95% CI 0.68 to 0.89; P = 0.003). Nocturnal confirmed hypoglycaemia less than 75 mg/dL for very large and very long studies only showed a RR (0.92, 95% CI 0.82 to 1.02; P = 0.11). The meta‐analyses' results remained robust for all other outcomes. </p> <p>Results also remained robust when we repeated the analyses using different statistical models. </p> </section> <section id="CD005613-sec-0107"> <h5 class="title">Assessment of reporting bias</h5> <p>We drew a funnel plot for the primary endpoint severe hypoglycaemia (14 trials; <a href="#CD005613-fig-0004">Figure 4</a>). The funnel plot did not indicate any increased risk of publication bias. </p> <div class="figure" id="CD005613-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Insulin glargine versus NPH insulin, outcome: 1.2 Severe hypoglycaemia." data-id="CD005613-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Insulin glargine versus NPH insulin, outcome: 1.2 Severe hypoglycaemia. </p> </div> </div> </div> </section> </section> <section id="CD005613-sec-0108"> <h4 class="title">Long‐acting insulin analogue detemir versus NPH insulin</h4> <section id="CD005613-sec-0109"> <h5 class="title">Primary outcomes</h5> <section id="CD005613-sec-0110"> <h6 class="title">Diabetes‐related complications</h6> <p>Three trials reported a total of three non‐fatal myocardial infarctions, two in participants treated with detemir and one in a participant treated with NPH (very low‐certainty evidence) (<a href="./references#CD005613-bbs2-0004" title="EUCTR2005-000976-42. A multi-centre, open-labelled, randomised, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime (PREDICTIVE-BMI study) – PREDICTIVE-BMI study. www.clinicaltrialsregister.eu/ctr-search/trial/2005-000976-42/ES (first received 17 May 2006). Fajardo MontañanaC , Hernandez HerreroC , Rivas FernandezM . Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabetic Medicine2008;25(8):916-23. [PMID: 18959604]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00504673. Comparison of insulin detemir versus insulin NPH on weight change in overweight and obese with type 2 diabetes (PREDICTIVE). clinicaltrials.gov/ct2/show/NCT00504673 (first received 20 July 2007). Novo Nordisk A/S. A multi-centre, open-labelled, randomized, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime. (PREDICTIVE-BMI study). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1410&amp;filename=1659-ctr-redacted.pdf (last accessed 3 November 2020). Smith-PalmerJ , Fajardo-MontananaC , PollockRF , EricssonA , ValentineWJ . Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. Journal of Medical Economics2012;15(5):977-86. [PMID: 22563742]">Fajardo Montañana 2008</a>; <a href="./references#CD005613-bbs2-0006" title="HaakT , TiengoA , DraegerE , SuntumM , WaldhauslW . Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2005;7(1):56-64. [PMID: 15642076]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Haak 2005</a>; <a href="./references#CD005613-bbs2-0018" title="EUCTR2008-003739-19. Ensayo multicéntrico, abierto, aleatorizado, de dos grupos, paralelo para comparar el cambio en la distribución de grasa en sujetos con sobrepeso y obesos con diabetes tipo 2 tras 26 semanas de tratamiento con insulina detemir una vez al día frente a insulina NPH una vez al día, ambas con insulina aspart a la hora de las comidas. www.clinicaltrialsregister.eu/ctr-search/trial/2008-003739-19/ES (first received 19 September 2008). NCT00795600. A multi-centre, open-labelled, randomised, two-group parallel trial comparing the change in fat distribution in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin apart at mealtimes. clinicaltrials.gov/ct2/show/NCT00795600 (first received 21 November 2008). Novo Nordisk A/S. A multi-centre, open-labelled, randomised, two-group parallel trial comparing the change in fat distribution in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart at mealtimes (NN304-3614 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1461&amp;filename=3614-ctr-synopsis-redacted.pdf (last accessed 3 November 2020). TinahonesFJ , Gomez-HuelgasR , Garcia-AlegriaJ , Tapia-GuerreroM , Martos-PerezF . Fat distribution, HbA1c and hypoglycaemia in overweight and obese patients with type 2 diabetes: a comparison of NPH and insulin detemir from a pilot randomised clinical trial. Diabetologia2011;54:S273. [EMBASE: 70562816]TinahonesFJ , Gomez-HuelgasR , GarciaalegriaJ , Tapia-GuerreroMJ , PerezFM . The effect of insulin detemir on fat distribution and weight parameters in overweight and obese subjects with type 2 diabetes. Diabetes2011;60:A309. [EMBASE: 70628891]">NN304‐3614</a>). </p> <p><a href="./references#CD005613-bbs2-0004" title="EUCTR2005-000976-42. A multi-centre, open-labelled, randomised, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime (PREDICTIVE-BMI study) – PREDICTIVE-BMI study. www.clinicaltrialsregister.eu/ctr-search/trial/2005-000976-42/ES (first received 17 May 2006). Fajardo MontañanaC , Hernandez HerreroC , Rivas FernandezM . Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabetic Medicine2008;25(8):916-23. [PMID: 18959604]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00504673. Comparison of insulin detemir versus insulin NPH on weight change in overweight and obese with type 2 diabetes (PREDICTIVE). clinicaltrials.gov/ct2/show/NCT00504673 (first received 20 July 2007). Novo Nordisk A/S. A multi-centre, open-labelled, randomized, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime. (PREDICTIVE-BMI study). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1410&amp;filename=1659-ctr-redacted.pdf (last accessed 3 November 2020). Smith-PalmerJ , Fajardo-MontananaC , PollockRF , EricssonA , ValentineWJ . Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. Journal of Medical Economics2012;15(5):977-86. [PMID: 22563742]">Fajardo Montañana 2008</a> reported no fatal myocardial infarctions in either group. No other trial reported on this endpoint. </p> <p>Three trials reported stroke (<a href="./references#CD005613-bbs2-0004" title="EUCTR2005-000976-42. A multi-centre, open-labelled, randomised, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime (PREDICTIVE-BMI study) – PREDICTIVE-BMI study. www.clinicaltrialsregister.eu/ctr-search/trial/2005-000976-42/ES (first received 17 May 2006). Fajardo MontañanaC , Hernandez HerreroC , Rivas FernandezM . Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabetic Medicine2008;25(8):916-23. [PMID: 18959604]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00504673. Comparison of insulin detemir versus insulin NPH on weight change in overweight and obese with type 2 diabetes (PREDICTIVE). clinicaltrials.gov/ct2/show/NCT00504673 (first received 20 July 2007). Novo Nordisk A/S. A multi-centre, open-labelled, randomized, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime. (PREDICTIVE-BMI study). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1410&amp;filename=1659-ctr-redacted.pdf (last accessed 3 November 2020). Smith-PalmerJ , Fajardo-MontananaC , PollockRF , EricssonA , ValentineWJ . Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. Journal of Medical Economics2012;15(5):977-86. [PMID: 22563742]">Fajardo Montañana 2008</a>; <a href="./references#CD005613-bbs2-0006" title="HaakT , TiengoA , DraegerE , SuntumM , WaldhauslW . Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2005;7(1):56-64. [PMID: 15642076]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Haak 2005</a>; <a href="./references#CD005613-bbs2-0016" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">NN304‐1337</a>). One trial reported no fatal strokes in any group (<a href="./references#CD005613-bbs2-0016" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">NN304‐1337</a>). The other two reported two non‐fatal events in the detemir groups and one non‐fatal event in the NPH groups. The certainty of evidence was very low. </p> <p><a href="./references#CD005613-bbs2-0004" title="EUCTR2005-000976-42. A multi-centre, open-labelled, randomised, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime (PREDICTIVE-BMI study) – PREDICTIVE-BMI study. www.clinicaltrialsregister.eu/ctr-search/trial/2005-000976-42/ES (first received 17 May 2006). Fajardo MontañanaC , Hernandez HerreroC , Rivas FernandezM . Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabetic Medicine2008;25(8):916-23. [PMID: 18959604]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00504673. Comparison of insulin detemir versus insulin NPH on weight change in overweight and obese with type 2 diabetes (PREDICTIVE). clinicaltrials.gov/ct2/show/NCT00504673 (first received 20 July 2007). Novo Nordisk A/S. A multi-centre, open-labelled, randomized, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime. (PREDICTIVE-BMI study). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1410&amp;filename=1659-ctr-redacted.pdf (last accessed 3 November 2020). Smith-PalmerJ , Fajardo-MontananaC , PollockRF , EricssonA , ValentineWJ . Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. Journal of Medical Economics2012;15(5):977-86. [PMID: 22563742]">Fajardo Montañana 2008</a> reported that no end‐stage renal disease occurred in any of the participants. No further information was available in the other trials. </p> <p>Three‐step progression of retinopathy for detemir versus NPH showed a RR of 1.50 (95% CI 0.68 to 3.32; P = 0.32; 2 trials; 972 participants; very low‐certainty evidence; <a href="./references#CD005613-fig-0020" title="">Analysis 2.1</a>). </p> <p><a href="./references#CD005613-bbs2-0004" title="EUCTR2005-000976-42. A multi-centre, open-labelled, randomised, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime (PREDICTIVE-BMI study) – PREDICTIVE-BMI study. www.clinicaltrialsregister.eu/ctr-search/trial/2005-000976-42/ES (first received 17 May 2006). Fajardo MontañanaC , Hernandez HerreroC , Rivas FernandezM . Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabetic Medicine2008;25(8):916-23. [PMID: 18959604]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00504673. Comparison of insulin detemir versus insulin NPH on weight change in overweight and obese with type 2 diabetes (PREDICTIVE). clinicaltrials.gov/ct2/show/NCT00504673 (first received 20 July 2007). Novo Nordisk A/S. A multi-centre, open-labelled, randomized, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime. (PREDICTIVE-BMI study). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1410&amp;filename=1659-ctr-redacted.pdf (last accessed 3 November 2020). Smith-PalmerJ , Fajardo-MontananaC , PollockRF , EricssonA , ValentineWJ . Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. Journal of Medical Economics2012;15(5):977-86. [PMID: 22563742]">Fajardo Montañana 2008</a> reported that no participants underwent amputations. </p> <p>No further information on diabetic late complications were available in any of the trials. </p> </section> <section id="CD005613-sec-0111"> <h6 class="title">Hypoglycaemic episodes</h6> <p>The RR for severe hypoglycaemia was 0.45 (95% CI 0.17 to 1.20, P = 0.63; 5 trials, 1804 participants; very low‐certainty evidence; <a href="./references#CD005613-fig-0021" title="">Analysis 2.2</a>). The 95% prediction interval ranged between 0.09 and 2.21. </p> <p>The Peto OR for serious hypoglycaemia was 0.16 (95% CI 0.04 to 0.61; P = 0.007; 5 trials, 1777 participants; low‐certainty evidence; <a href="./references#CD005613-fig-0022" title="">Analysis 2.3</a>). </p> <p>The RR for confirmed hypoglycaemia less than 75 mg/dL was 0.73 in favour of detemir (95% CI 0.61 to 0.86; P &lt; 0.001; 4 trials, 1718 participants; very low‐certainty evidence; <a href="./references#CD005613-fig-0023" title="">Analysis 2.4</a>). The 95% prediction interval ranged between 0.36 and 1.48. </p> <p>The RR for confirmed hypoglycaemia less than 55 mg/dL was 0.48 in favour of detemir (95% CI 0.32 to 0.71; P &lt; 0.001; 4 trials, 1718 participants; low‐certainty evidence; <a href="./references#CD005613-fig-0024" title="">Analysis 2.5</a>). The 95% prediction interval ranged between 0.20 and 1.13. </p> <p>The RR for nocturnal confirmed hypoglycaemia less than 75 mg/dL was 0.57, 95% CI 0.47 to 0.68; P &lt; 0.001; 4 trials; 1718 participants; low‐certainty evidence; <a href="./references#CD005613-fig-0025" title="">Analysis 2.6</a> in favour of detemir. The 95% prediction interval ranged between 0.39 and 0.84. </p> <p>The RR for nocturnal confirmed hypoglycaemia less than 55 mg/dL was 0.32 in favour of detemir (95% CI 0.16 to 0.63; P = 0.001; 4 trials; 1718 participants; low‐certainty evidence; <a href="./references#CD005613-fig-0026" title="">Analysis 2.7</a>). The 95% prediction interval ranged between 0.07 and 1.42. </p> </section> <section id="CD005613-sec-0112"> <h6 class="title">Health‐related quality of life</h6> <p>Three trials reported information on health‐related quality of life (<a href="./references#CD005613-bbs2-0004" title="EUCTR2005-000976-42. A multi-centre, open-labelled, randomised, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime (PREDICTIVE-BMI study) – PREDICTIVE-BMI study. www.clinicaltrialsregister.eu/ctr-search/trial/2005-000976-42/ES (first received 17 May 2006). Fajardo MontañanaC , Hernandez HerreroC , Rivas FernandezM . Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabetic Medicine2008;25(8):916-23. [PMID: 18959604]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00504673. Comparison of insulin detemir versus insulin NPH on weight change in overweight and obese with type 2 diabetes (PREDICTIVE). clinicaltrials.gov/ct2/show/NCT00504673 (first received 20 July 2007). Novo Nordisk A/S. A multi-centre, open-labelled, randomized, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime. (PREDICTIVE-BMI study). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1410&amp;filename=1659-ctr-redacted.pdf (last accessed 3 November 2020). Smith-PalmerJ , Fajardo-MontananaC , PollockRF , EricssonA , ValentineWJ . Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. Journal of Medical Economics2012;15(5):977-86. [PMID: 22563742]">Fajardo Montañana 2008</a>; <a href="./references#CD005613-bbs2-0006" title="HaakT , TiengoA , DraegerE , SuntumM , WaldhauslW . Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2005;7(1):56-64. [PMID: 15642076]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Haak 2005</a>; <a href="./references#CD005613-bbs2-0013" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KobayashiM , IwamotoY , KakuK , KawamoriR , TajimaN . Phase 3 clinical trial of insulin detemir for type 2 diabetes patients with insufficient blood sugar control in oral diabetes drug therapy. Journal of the Japan Diabetes Society2007;50(9):665-77. [DOI: 10.11213/tonyobyo.50.665]NCT00604253. Efficacy and safety of insulin detemir in type 2 diabetes inadequately controlled on OHA therapy alone. www.clinicaltrials.gov/ct2/show/results/NCT00604253 (first received 30 January 2008). Novo Nordisk A/S. A 36-week, randomised, multi-centre, open-labelled, parallel-group trial to compare the efficacy and the safety of NN304 and NPH human insulin once daily treatment as add-on to current OHA therapy in subjects with type 2 diabetes mellitus who are inadequately controlled on OHA therapy. http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1397&amp;filename=NN304_1477_ICTRSynopsis_Final_20051101.pdf (last accessed 3 November 2020). ">Kobayashi 2007 B</a>). As the trials used different instruments for measuring health‐related quality of life, a meta‐analysis was not feasible. </p> <p><a href="./references#CD005613-bbs2-0006" title="HaakT , TiengoA , DraegerE , SuntumM , WaldhauslW . Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2005;7(1):56-64. [PMID: 15642076]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Haak 2005</a> used the Diabetes Health Profile 2 (DHP‐2) questionnaire. The MD in barriers to activity for detemir compared with NPH was –0.16 (95% CI –2.45 to 2.13; P = 0.89). The MD in disinhibited eating for detemir compared with NPH was 1.34 (95% CI –1.52 to 4.20; P = 0.36). The MD in psychological distress for detemir compared with NPH was –0.19 (95% CI –2.46 to 2.09; P = 0.87). </p> <p><a href="./references#CD005613-bbs2-0004" title="EUCTR2005-000976-42. A multi-centre, open-labelled, randomised, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime (PREDICTIVE-BMI study) – PREDICTIVE-BMI study. www.clinicaltrialsregister.eu/ctr-search/trial/2005-000976-42/ES (first received 17 May 2006). Fajardo MontañanaC , Hernandez HerreroC , Rivas FernandezM . Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabetic Medicine2008;25(8):916-23. [PMID: 18959604]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00504673. Comparison of insulin detemir versus insulin NPH on weight change in overweight and obese with type 2 diabetes (PREDICTIVE). clinicaltrials.gov/ct2/show/NCT00504673 (first received 20 July 2007). Novo Nordisk A/S. A multi-centre, open-labelled, randomized, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime. (PREDICTIVE-BMI study). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1410&amp;filename=1659-ctr-redacted.pdf (last accessed 3 November 2020). Smith-PalmerJ , Fajardo-MontananaC , PollockRF , EricssonA , ValentineWJ . Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. Journal of Medical Economics2012;15(5):977-86. [PMID: 22563742]">Fajardo Montañana 2008</a> used the SF‐36 questionnaire. The MD in total score physical health for detemir compared with NPH was 2.83 (95% CI –1.56 to 7.23; P = 0.21). The MD in total score mental health for detemir compared with NPH was 4.19 (95% CI –0.22 to 8.61; P = 0.06). </p> <p><a href="./references#CD005613-bbs2-0012" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. IshiiH , IwamotoY , KakuK , KawamoriR , KobayashiM , TajimaN . Night-time QOL and treatment satisfaction in diabetes mellitus patients treated with insulin detemir used in basal-bolus therapy – randomized multicenter open-label parallel group phase 3 trial compared to NPH insulin. Journal of the Japan Diabetes Society2009;52(8):691-701. [DOI: 10.11213/tonyobyo.52.691]KobayashiM , IwamotoY , KakuK , KawamoriR , TajimaN . Phase 3 clinical trial of insulin detemir for patients with insulin-dependent diabetes during basal-bolus therapy – a study of efficacy and safety with NPH insulin as control. Journal of the Japan Diabetes Society2007;50(9):649-63. [DOI: 10.11213/tonyobyo.50.649]NCT00604344. Efficacy and the safety of insulin detemir in subjects with insulin requiring diabetes. clinicaltrials.gov/ct2/show/NCT00604344 (first received 30 January 2008). Novo Nordisk A/S. A 48-week, randomised, multi-centre, open-labelled, parallel-group trial to compare the efficacy and the safety of NN304 (insulin detemir) and NPH human insulin in subjects with insulin requiring diabetes mellitus on a basal-bolus regimen. https://s3.amazonaws.com/ctr-nvo-7271/NN304-1476/aa9b4da3-1f92-460d-af0a-cc538614c3b2/3f7ed86e-d6e7-4542-ab8f-6cad24b46593/1476-ctr-synopsis-redacted-v2.pdf (last accessed 3 November 2020). ">Kobayashi 2007 A</a> used the Insulin Therapy Related Quality Of Life At Night (ITR‐QOLN) instrument. The MD in total score for detemir compared with NPH was 1.7 (95% CI –4.4 to 7.8; P = 0.58). </p> </section> </section> <section id="CD005613-sec-0113"> <h5 class="title">Secondary outcomes</h5> <section id="CD005613-sec-0114"> <h6 class="title">All‐cause mortality</h6> <p>The Peto OR for death from any cause was 0.74 (95% CI 0.20 to 2.65; P = 0.64; 8 trials, 2328 participants; low‐certainty evidence; <a href="./references#CD005613-fig-0027" title="">Analysis 2.8</a>). </p> </section> <section id="CD005613-sec-0115"> <h6 class="title">Adverse events other than hypoglycaemia</h6> <p>The RR for serious adverse events was 0.88 (95% CI 0.64 to 1.20; P = 0.40; 8 trials, 2328 participants; moderate‐certainty evidence; <a href="./references#CD005613-fig-0028" title="">Analysis 2.9</a>). The 95% prediction interval ranged between 0.60 and 1.30. </p> <p>The RR for all adverse events was 1.03 (95% CI 0.96 to 1.11; P = 0.35; 8 trials, 2328 participants; moderate‐certainty evidence; <a href="./references#CD005613-fig-0029" title="">Analysis 2.10</a>). The 95% prediction interval ranged between 0.94 and 1.13. </p> <p>The RR for adverse events leading to discontinuation of the trial was 1.22 (95% CI 0.67 to 2.25; P = 0.52; 8 trials, 2328 participants; moderate‐certainty evidence; <a href="./references#CD005613-fig-0030" title="">Analysis 2.11</a>). The 95% prediction interval ranged between 0.57 and 2.62. </p> <p>The MD for weight gain (BMI) was –0.60 kg/m² (95% CI –0.88 to –0.32; P &lt; 0.001; 1 trial; 278 participants) (<a href="./references#CD005613-bbs2-0004" title="EUCTR2005-000976-42. A multi-centre, open-labelled, randomised, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime (PREDICTIVE-BMI study) – PREDICTIVE-BMI study. www.clinicaltrialsregister.eu/ctr-search/trial/2005-000976-42/ES (first received 17 May 2006). Fajardo MontañanaC , Hernandez HerreroC , Rivas FernandezM . Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabetic Medicine2008;25(8):916-23. [PMID: 18959604]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00504673. Comparison of insulin detemir versus insulin NPH on weight change in overweight and obese with type 2 diabetes (PREDICTIVE). clinicaltrials.gov/ct2/show/NCT00504673 (first received 20 July 2007). Novo Nordisk A/S. A multi-centre, open-labelled, randomized, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime. (PREDICTIVE-BMI study). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1410&amp;filename=1659-ctr-redacted.pdf (last accessed 3 November 2020). Smith-PalmerJ , Fajardo-MontananaC , PollockRF , EricssonA , ValentineWJ . Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. Journal of Medical Economics2012;15(5):977-86. [PMID: 22563742]">Fajardo Montañana 2008</a>). </p> <p>The RR for adverse skin reactions was 1.28 (95% CI 0.63 to 2.59; P = 0.50; 5 trials; 1777 participants; <a href="./references#CD005613-fig-0031" title="">Analysis 2.12</a>). </p> <p>The RR for eye‐related adverse events was 0.75 (95% CI 0.41 to 1.37; P = 0.34; 6 trials; 1386 participants; <a href="./references#CD005613-fig-0032" title="">Analysis 2.13</a>). </p> </section> <section id="CD005613-sec-0116"> <h6 class="title">Socioeconomic effects</h6> <p>No study investigated socioeconomic effects.</p> </section> <section id="CD005613-sec-0117"> <h6 class="title">HbA1c</h6> <p>The MD for HbA1c was 0.13% (95% CI –0.02 to 0.28; P = 0.08; 7 trials, 2233 participants; very low‐certainty evidence; <a href="./references#CD005613-fig-0033" title="">Analysis 2.14</a>). The 95% prediction interval ranged between –0.28% and 0.54%. </p> </section> </section> <section id="CD005613-sec-0118"> <h5 class="title">Subgroup analyses</h5> <p>Subgroup analyses in trials with OADs versus short‐acting insulin as concomitant blood glucose‐lowering medications either showed no substantial differences (severe, serious, confirmed and confirmed nocturnal hypoglycaemia), or were not feasible because of the low number of trials and events. This was also true for subgroup analyses involving trials administering NPH once daily versus trials administering NPH at least twice daily. </p> </section> <section id="CD005613-sec-0119"> <h5 class="title">Sensitivity analyses</h5> <p>We performed sensitivity analyses for the following factors: published or unpublished trials, and commercially or non‐commercially funded trials. Trials did not differ enough in terms of other variables to allow for meaningful additional sensitivity analyses. We also investigated the robustness of the pooled results by repeating the analyses using different statistical models (fixed‐ and random‐effects). </p> <p>Severe hypoglycaemia including all trials found an OR of 0.37 (95% CI 0.15 to 0.92; P = 0.03). Severe hypoglycaemia including published trials only found an OR of 0.43 (95% CI 0.17 to 1.13; P = 0.09). The results of the meta‐analyses remained robust for all other outcomes. </p> <p>The results of the meta‐analyses remained robust for all outcomes after exclusion of non‐commercially funded studies and following comparisons using different statistical models. </p> </section> <section id="CD005613-sec-0120"> <h5 class="title">Assessment of reporting bias</h5> <p>We did not draw funnel plots due to the limited number of trials (eight).</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD005613-sec-0121" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD005613-sec-0121"></div> <section id="CD005613-sec-0122"> <h3 class="title" id="CD005613-sec-0122">Summary of main results</h3> <p>With regard to diabetes complications information on myocardial infarction, stroke, amputations and end‐stage renal disease was available from few trials only with a small number of events. No trustworthy inferences could be drawn from these results. There were more data on retinopathy; however, meta‐analyses did not result in statistically or clinically relevant differences between treatment with glargine or detemir and NPH. </p> <p>There were no clear differences for all‐cause mortality when comparing treatment with long‐acting insulin‐analogues to NPH treatment. Information was available from almost all included trials and the number of people dying during a trial was low. </p> <p>Three trials comparing glargine to NPH and three further trials comparing detemir to NPH reported outcomes on health‐related quality of life utilising mostly different instruments. None of them found substantial differences between treatment with glargine or detemir and NPH. </p> <p>We found no substantial differences between interventions and comparators in the frequency of adverse events. </p> <p>No trial reported on socioeconomic effects.</p> <p>Treatment of people with type 2 diabetes mellitus with insulin glargine and insulin detemir compared to NPH insulin resulted in no substantial differences in hypoglycaemic episodes, HbA1c lowering was comparable between treatments. Serious hypoglycaemia was somewhat lower following insulin detemir treatment compared to NPH insulin. Both insulin glargine and insulin detemir showed lower confirmed (nocturnal) hypoglycaemia rates in comparison to NPH insulin. </p> <p>We considered no evidence to be of high certainty and all trials to have an unclear or high risk of bias in one or more risk of bias domains. </p> </section> <section id="CD005613-sec-0123"> <h3 class="title" id="CD005613-sec-0123">Overall completeness and applicability of evidence</h3> <p>This Cochrane Review is the most current and comprehensive systematic review to compare the effects of (ultra‐)long‐acting insulin analogues with those of NPH insulin. We have included 16 trials (6330 participants) comparing glargine to NPH and eight trials(2342 participants) comparing detemir to NPH. </p> <p>We conducted an extensive search for trials, included publications in all languages, and tried to obtain additional data on all trials. However, the provision of additional data was limited. We also took into consideration additional information published in a report by the German Institute for Quality and Efficiency in Health Care that was based on the original trial reports (<a href="./references#CD005613-bbs2-0102" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009.">IQWiG 2009</a>). </p> <p>The diagnostic criteria for type 2 diabetes mellitus were not specified in most of the included trials. Participants had diabetes for eight years or longer at the beginning of all trials. </p> <p>In the included trials, blood glucose targets set for insulin dose titration were comparable to those set in studies comparing the effects of a near‐normal blood glucose reduction with a less intense reduction. In some cases, they were even lower. In other words, the trials aimed to achieve a near‐normal reduction in blood glucose levels for the participants. This contrasts with the recommendations of professional associations for the individual setting of target values (<a href="./references#CD005613-bbs2-0068" title="American Diabetes Association. Introduction: standards of medical care in diabetes. Diabetes Care2020;43:S1-212.">ADA 2020</a>). For example, a more moderate therapy target is recommended for people with a long duration of illness, significant comorbidity or diabetes‐associated complications, and for people with limited life expectancy and resources (<a href="./references#CD005613-bbs2-0068" title="American Diabetes Association. Introduction: standards of medical care in diabetes. Diabetes Care2020;43:S1-212.">ADA 2020</a>). In fact, since all trial participants had the disease for a relatively long time, higher target levels may well have been more appropriate. Incidence of serious or severe hypoglycaemia is directly associated with the intensity of blood glucose lowering. From this follows that less stringent blood glucose or HbA1c target values will result in less frequent major hypoglycaemic events and absolute risk reducing effect will be lower. Therefore, results from the studies at hand are only applicable to people in whom very low blood glucose concentrations are targeted. </p> <p>However, even for those people for whom a blood glucose reduction to near normal concentrations can be considered an adequate treatment goal, the trial results provided only limited information about the different effects of insulin analogues and NPH insulin. In most studies (10/16 glargine trials and 5/8 detemir trials) limited NPH to a single injection per day. Also, an adjustment of the blood glucose‐lowering comedications (short‐acting insulin or oral glucose‐lowering agents) was not possible – both of which do not correspond to current good clinical practice. </p> <p>Because of the limited applicability of the results it remains unclear if the same effects will be observed in daily clinical practice. An indication that this is not the case is provided by the study of Lipska and colleagues, a retrospective observational study using data from a large US health management organisation (<a href="./references#CD005613-bbs2-0114" title="LipskaKJ , ParkerMM , MoffetHH , HuangES , KarterAJ . Association of initiation of basal insulin analogs vs neutral protamine Hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes. JAMA2018;320(1):53-62. [PMID: 29936529]">Lipska 2018</a>). The authors found that initiating therapy with a long‐acting insulin analogue was not associated with a reduced risk of hypoglycaemic emergency department visits, hospital admissions or improved glycaemic control compared to NPH insulin. </p> <p>We identified no trials investigating NPH insulin therapy with ultra‐long‐acting insulin analogues treatment. Data can only be derived from indirect comparisons based on the results from trials comparing long‐acting and ultra‐long‐acting insulin analogues. The results of a network meta‐analysis suggested that compared to NPH insulin ultra‐long‐acting insulin analogues reduce the risk of hypoglycaemic events s (<a href="./references#CD005613-bbs2-0115" title="MadenidouAV , PaschosP , KaragiannisT , KatsoulaA , AthanasiadouE , KitsiosK , et al. Comparative benefits and harms of basal insulin analogues for type 2 diabetes: a systematic review and network meta-analysis. Annals of Internal Medicine2018;169(3):165-74. [PMID: 29987326]">Madenidou 2018</a>). However, regarding the applicability of the results, in addition to the uncertainty of indirect comparisons, restrictions apply as again the set target titration values corresponded to a near‐normal blood glucose reduction (<a href="./references#CD005613-bbs2-0087" title="GersteinHC , BoschJ , DagenaisGR , DíazR , JungH , MaggioniAP , et al (ORIGIN Trial Investigators). Basal insulin and cardiovascular and other outcomes in dysglycemia. New England Journal of Medicine2012;367(4):319-28. [PMID: 22686416]">Gerstein 2012</a>; <a href="./references#CD005613-bbs2-0123" title="RosenstockJ , ChengA , RitzelR , BosnyakZ , DevismeC , CaliAM , et al. More similarities than differences testing insulin glargine 300 units/mL versus insulin degludec 100 units/mL in insulin-naive type 2 diabetes: the randomized head-to-head BRIGHT trial. Diabetes Care2018;41(10):2147-54. [PMID: 30104294]">Rosenstock 2018</a>). </p> </section> <section id="CD005613-sec-0124"> <h3 class="title" id="CD005613-sec-0124">Quality of the evidence</h3> <p>For most patient‐important outcomes, no or very limited information was available and only in a small number of trials. Furthermore, the reported frequency of such outcomes was low. Duration of follow‐up was 12 months or less for all studies but one, which lasted for 60 months (<a href="./references#CD005613-bbs2-0022" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00174824. Comparison of insulin glargine and NPH human insulin in progression of diabetic retinopathy in type 2 diabetic patients. clinicaltrials.gov/ct2/show/study/NCT00174824 (first received 15 September 2005). RosenstockJ , FonsecaV , DainMP , RiddleM . Estimating number-needed-to-treat to avoid hypoglycaemic episodes in people with type 2 diabetes: a post-hoc analysis of a prospective randomized controlled trial comparing once-daily insulin glargine with twice-daily NPH insulin. Canadian Journal of Diabetes2009;33(3):185-6. [EMBASE: 70031352]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia2009;52(9):1778-88. [PMID: 19526210]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia2009;52(9):1971-3. [PMID: 19609501]RosenstockJ , FonsecaV , SchinzelS , DainMP , MullinsP , RiddleM . Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: evidence from a long-term controlled trial. Journal of Diabetic Complications2014;28(5):742-9. [PMID: 24856612]">Rosenstock 2009</a>). </p> <p>None of the included 24 studies could be classified as having low risk of bias for all risk of bias domains. The major shortcoming in all included trials was that neither participants nor study personnel were blinded to the respective interventions. Although blinding of participants and personnel would have been complicated, no effort was made to at least provide for a blinded outcome assessment. While this is of lesser concern for objective outcomes such as centrally measured HbA1c or death from any cause, it means that more subjective and self‐reported outcomes such as hypoglycaemia are at high risk of bias. </p> <p>This is even more important when the bias‐prone definitions of hypoglycaemia in the included trials are taken into consideration. Patients may inappropriately deny having had severe hypoglycaemia and in this context 'third party help' is a soft and variable description of severity. More robust definitions such as 'injection of glucose or glucagon by a third person' may result in more reliable data (<a href="./references#CD005613-bbs2-0120" title="MühlhauserI , OvermannH , BenderR , BottU , BergerM . Risk factors of severe hypoglycaemia in adult patients with type 1 diabetes – a prospective population based study. Diabetologia1998;41:1274-82. [PMID: 9833933]">Mühlhauser 1998</a>). Since classification of hypoglycaemia as a serious adverse event requires the presence of specific additional criteria (<a href="./references#CD005613-bbs2-0101" title="International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Integrated addendum to ICH E6(R1): guideline for good clinical practice E6(R2). www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R2__Step_4.pdf (accessed 29 August 2017).">ICH 2016</a>), severe hypoglycaemic events, which simultaneously fulfil at least one of these criteria, are less vulnerable to bias. To minimise the risk of bias, apart from severe or serious hypoglycaemia, we only considered events for which a confirmed blood glucose measurement was available (<a href="./references#CD005613-bbs2-0067" title="Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care2005;28(5):1245-9. [PMID: 15855602]">ADA 2005</a>). But even for confirmed hypoglycaemia, the risk of bias was high as participants may have chosen not to report events or may have made mistakes when transcribing blood glucose readings. </p> <p>In addition, randomisation and allocation of concealment remained unclear in many trials. </p> <p>Pharmaceutical companies producing long‐acting insulin analogues funded most trials. Some argue that systematic bias favours products that are made by the company funding the research. Explanations include the selection of an inappropriate comparator to the product under investigation, and publication bias (<a href="./references#CD005613-bbs2-0112" title="LexchinJ , BeroLA , DjulbegovicB , ClarkO . Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ (Clinical Research Ed.)2003;326(7400):1167-70. [PMID: 12775614]">Lexchin 2003</a>). </p> <p>Major reasons for downgrading the certainty of the evidence (GRADE) were lack of blinding of participants, study personnel and outcome‐assessment, inconsistency (95% prediction intervals) and imprecision (small numbers of studies reporting on outcomes and low frequency of events). </p> </section> <section id="CD005613-sec-0125"> <h3 class="title" id="CD005613-sec-0125">Potential biases in the review process</h3> <p>As part of the original review, we contacted all authors of the available trials and producers of insulin‐analogues and requested missing data and clarification of risk when bias domains could not be adequately assessed. For this update, we contacted all authors of the additionally identified trials, unless they had been included in the IQWiG report. This was because additional data had already been provided for the IQWiG report. We again contacted the two pharmaceutical companies manufacturing insulin glargine and insulin detemir. We also sought additional data from documents available from the USA and European medical agencies and trial registries. The IQWiG report was an important source of data because it included data provided by Sanofi and Novo Nordisk. But despite these efforts, a large quantity of data were still missing, which limited our investigations of the effects of the different insulins on a large number of outcomes and influenced our assessments of risk of bias and certainty of the evidence. </p> <p>We excluded trials that lasted less than 24 weeks. While this is consistent with our effort to investigate the long‐term effects of long‐acting insulin analogues compared to NPH, especially on diabetes‐related complications, it also resulted in fewer data on outcomes such as HbA1c and hypoglycaemia. </p> <p>We were unable to draw funnel plots because of the small number of trials comparing detemir to NPH. </p> <p>It was only possible to investigate heterogeneity by conducting subgroup and sensitivity analyses for a limited number of outcomes and variables. </p> <p>Two review authors extracted the data. However, the review authors extracting the data were not blinded to the trial they were extracting data from. </p> </section> <section id="CD005613-sec-0126"> <h3 class="title" id="CD005613-sec-0126">Agreements and disagreements with other studies or reviews</h3> <p>Several other systematic reviews and meta‐analyses have investigated the effects of treatment with (ultra‐)long‐acting insulin analogues compared to treatment with NPH (<a href="./references#CD005613-bbs2-0026" title="BiY , LiX , YangD , HaoY , LiangH , ZhuD , et al. Comparative efficacy and safety of long-acting insulin analogs in patients with type 2 diabetes failing on oral therapy: systemic review and meta-analyses. Journal of Diabetes Investigation2012;3(3):283-93. [EMBASE: 364970679] [PMID: 24843578]BiY , ZhuD , YangD , WengJ . Comparative efficacy and safety of long-acting insulin analogs in patients with type 2 diabetes failing on oral therapy: systemic review and meta-analyses. Diabetes2011;60:A598-9. [EMBASE: 70629960]">Bi 2012</a>; <a href="./references#CD005613-bbs2-0030" title="FreemantleN , ChouE , FroisC , ZhuoD , LehmacherW , VlajnicA , et al. Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis. BMJ Open2016;6(2):e009421. [PMID: 26880669]">Freemantle 2016</a>; <a href="./references#CD005613-bbs2-0033" title="FrierBM , Russell-JonesD , HeiseT . A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review. Diabetes, Obesity &amp; Metabolism2013;15(11):978-86. [PMID: 23551900]">Frier 2013</a>; <a href="./references#CD005613-bbs2-0046" title="OwensDR , TraylorL , MullinsP , LandgrafW . Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy. Diabetes Research &amp; Clinical Practice2017;124:57-65. [PMID: 28092788]">Owens 2017</a>; <a href="./references#CD005613-bbs2-0052" title="RysP , WojciechowskiP , Rogoz-SitekA , NiesyczynskiG , LisJ , SytaA , et al. Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus. Acta Diabetologica2015;52(4):649-62. [PMID: 25585592]">Rys 2015</a>). However, they all differ from this Cochrane Review in several aspects: only <a href="./references#CD005613-bbs2-0026" title="BiY , LiX , YangD , HaoY , LiangH , ZhuD , et al. Comparative efficacy and safety of long-acting insulin analogs in patients with type 2 diabetes failing on oral therapy: systemic review and meta-analyses. Journal of Diabetes Investigation2012;3(3):283-93. [EMBASE: 364970679] [PMID: 24843578]BiY , ZhuD , YangD , WengJ . Comparative efficacy and safety of long-acting insulin analogs in patients with type 2 diabetes failing on oral therapy: systemic review and meta-analyses. Diabetes2011;60:A598-9. [EMBASE: 70629960]">Bi 2012</a> compared insulin glargine and insulin detemir to NPH insulin, but did not provide separate analyses and results for the two insulin‐analogues. <a href="./references#CD005613-bbs2-0046" title="OwensDR , TraylorL , MullinsP , LandgrafW . Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy. Diabetes Research &amp; Clinical Practice2017;124:57-65. [PMID: 28092788]">Owens 2017</a> only included trials comparing glargine U100 once daily in combination with OAD with treatment with NPH once daily combined with OADs. <a href="./references#CD005613-bbs2-0030" title="FreemantleN , ChouE , FroisC , ZhuoD , LehmacherW , VlajnicA , et al. Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis. BMJ Open2016;6(2):e009421. [PMID: 26880669]">Freemantle 2016</a> compared glargine U300 to other basal insulins in a network meta‐analysis. <a href="./references#CD005613-bbs2-0052" title="RysP , WojciechowskiP , Rogoz-SitekA , NiesyczynskiG , LisJ , SytaA , et al. Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus. Acta Diabetologica2015;52(4):649-62. [PMID: 25585592]">Rys 2015</a> included trials comparing NPH with glargine and <a href="./references#CD005613-bbs2-0033" title="FrierBM , Russell-JonesD , HeiseT . A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review. Diabetes, Obesity &amp; Metabolism2013;15(11):978-86. [PMID: 23551900]">Frier 2013</a> included trials comparing NPH with detemir. With the exception of <a href="./references#CD005613-bbs2-0046" title="OwensDR , TraylorL , MullinsP , LandgrafW . Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy. Diabetes Research &amp; Clinical Practice2017;124:57-65. [PMID: 28092788]">Owens 2017</a>, trials of less than 24 weeks' duration were also considered. <a href="./references#CD005613-bbs2-0033" title="FrierBM , Russell-JonesD , HeiseT . A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review. Diabetes, Obesity &amp; Metabolism2013;15(11):978-86. [PMID: 23551900]">Frier 2013</a> did not conduct any meta‐analyses. </p> <p>Despite these differences, the reported results were similar. All authors reported comparable effects of (ultra‐)long‐acting insulin analogues and NPH on HbA1c and weight gain, and they all found a lower rate of nocturnal hypoglycaemia when using long‐acting insulin‐analogues compared to NPH. <a href="./references#CD005613-bbs2-0046" title="OwensDR , TraylorL , MullinsP , LandgrafW . Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy. Diabetes Research &amp; Clinical Practice2017;124:57-65. [PMID: 28092788]">Owens 2017</a> and <a href="./references#CD005613-bbs2-0026" title="BiY , LiX , YangD , HaoY , LiangH , ZhuD , et al. Comparative efficacy and safety of long-acting insulin analogs in patients with type 2 diabetes failing on oral therapy: systemic review and meta-analyses. Journal of Diabetes Investigation2012;3(3):283-93. [EMBASE: 364970679] [PMID: 24843578]BiY , ZhuD , YangD , WengJ . Comparative efficacy and safety of long-acting insulin analogs in patients with type 2 diabetes failing on oral therapy: systemic review and meta-analyses. Diabetes2011;60:A598-9. [EMBASE: 70629960]">Bi 2012</a> also found lower rates of overall hypoglycaemia and <a href="./references#CD005613-bbs2-0052" title="RysP , WojciechowskiP , Rogoz-SitekA , NiesyczynskiG , LisJ , SytaA , et al. Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus. Acta Diabetologica2015;52(4):649-62. [PMID: 25585592]">Rys 2015</a> found less symptomatic hypoglycaemia when treating with insulin analogues. In <a href="./references#CD005613-bbs2-0046" title="OwensDR , TraylorL , MullinsP , LandgrafW . Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy. Diabetes Research &amp; Clinical Practice2017;124:57-65. [PMID: 28092788]">Owens 2017</a> and <a href="./references#CD005613-bbs2-0052" title="RysP , WojciechowskiP , Rogoz-SitekA , NiesyczynskiG , LisJ , SytaA , et al. Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus. Acta Diabetologica2015;52(4):649-62. [PMID: 25585592]">Rys 2015</a>, there were no beneficial effects of insulin analogues on severe hypoglycaemia. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD005613-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/urn:x-wiley:14651858:media:CD005613:CD005613-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Trial flow diagram; HTA: health technology assessment; RCT: randomised controlled trial." data-id="CD005613-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_t/tCD005613-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Trial flow diagram; HTA: health technology assessment; RCT: randomised controlled trial. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/full#CD005613-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005613-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/urn:x-wiley:14651858:media:CD005613:CD005613-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials (blank cells indicate that the particular outcome was not measured in some trials)." data-id="CD005613-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_t/tCD005613-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials (blank cells indicate that the particular outcome was not measured in some trials). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/full#CD005613-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005613-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/urn:x-wiley:14651858:media:CD005613:CD005613-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included trial (blank cells indicate that the particular outcome was not measured in the trial)" data-id="CD005613-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_t/tCD005613-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included trial (blank cells indicate that the particular outcome was not measured in the trial) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/full#CD005613-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005613-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/urn:x-wiley:14651858:media:CD005613:CD005613-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Insulin glargine versus NPH insulin, outcome: 1.2 Severe hypoglycaemia." data-id="CD005613-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_t/tCD005613-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Insulin glargine versus NPH insulin, outcome: 1.2 Severe hypoglycaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/full#CD005613-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005613-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/urn:x-wiley:14651858:media:CD005613:CD005613-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Insulin glargine versus NPH insulin, Outcome 1: Diabetes‐related complications (progression in retinopathy)" data-id="CD005613-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_t/tCD005613-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Insulin glargine versus NPH insulin, Outcome 1: Diabetes‐related complications (progression in retinopathy) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/references#CD005613-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005613-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/urn:x-wiley:14651858:media:CD005613:CD005613-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Insulin glargine versus NPH insulin, Outcome 2: Severe hypoglycaemia" data-id="CD005613-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_t/tCD005613-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Insulin glargine versus NPH insulin, Outcome 2: Severe hypoglycaemia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/references#CD005613-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005613-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/urn:x-wiley:14651858:media:CD005613:CD005613-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Insulin glargine versus NPH insulin, Outcome 3: Serious hypoglycaemia" data-id="CD005613-fig-0007" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_t/tCD005613-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Insulin glargine versus NPH insulin, Outcome 3: Serious hypoglycaemia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/references#CD005613-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005613-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/urn:x-wiley:14651858:media:CD005613:CD005613-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Insulin glargine versus NPH insulin, Outcome 4: Confirmed hypoglycaemia (blood glucose (BG) &lt; 75 mg/dL)" data-id="CD005613-fig-0008" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_t/tCD005613-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Insulin glargine versus NPH insulin, Outcome 4: Confirmed hypoglycaemia (blood glucose (BG) &lt; 75 mg/dL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/references#CD005613-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005613-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/urn:x-wiley:14651858:media:CD005613:CD005613-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Insulin glargine versus NPH insulin, Outcome 5: Confirmed hypoglycaemia (BG &lt; 55 mg/dL)" data-id="CD005613-fig-0009" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_t/tCD005613-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Insulin glargine versus NPH insulin, Outcome 5: Confirmed hypoglycaemia (BG &lt; 55 mg/dL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/references#CD005613-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005613-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/urn:x-wiley:14651858:media:CD005613:CD005613-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Insulin glargine versus NPH insulin, Outcome 6: Confirmed nocturnal hypoglycaemia (BG &lt; 75 mg/dL)" data-id="CD005613-fig-0010" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_t/tCD005613-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Insulin glargine versus NPH insulin, Outcome 6: Confirmed nocturnal hypoglycaemia (BG &lt; 75 mg/dL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/references#CD005613-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005613-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/urn:x-wiley:14651858:media:CD005613:CD005613-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Insulin glargine versus NPH insulin, Outcome 7: Confirmed nocturnal hypoglycaemia (BG &lt; 55 mg/dL)" data-id="CD005613-fig-0011" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_t/tCD005613-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Insulin glargine versus NPH insulin, Outcome 7: Confirmed nocturnal hypoglycaemia (BG &lt; 55 mg/dL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/references#CD005613-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005613-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/urn:x-wiley:14651858:media:CD005613:CD005613-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Insulin glargine versus NPH insulin, Outcome 8: All‐cause mortality" data-id="CD005613-fig-0012" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_t/tCD005613-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Insulin glargine versus NPH insulin, Outcome 8: All‐cause mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/references#CD005613-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005613-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/urn:x-wiley:14651858:media:CD005613:CD005613-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Insulin glargine versus NPH insulin, Outcome 9: Adverse events other than hypoglycaemia (serious adverse effects)" data-id="CD005613-fig-0013" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_t/tCD005613-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Insulin glargine versus NPH insulin, Outcome 9: Adverse events other than hypoglycaemia (serious adverse effects) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/references#CD005613-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005613-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/urn:x-wiley:14651858:media:CD005613:CD005613-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Insulin glargine versus NPH insulin, Outcome 10: Adverse events other than hypoglycaemia (all adverse events (AE))" data-id="CD005613-fig-0014" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_t/tCD005613-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Insulin glargine versus NPH insulin, Outcome 10: Adverse events other than hypoglycaemia (all adverse events (AE)) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/references#CD005613-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005613-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/urn:x-wiley:14651858:media:CD005613:CD005613-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Insulin glargine versus NPH insulin, Outcome 11: Adverse events other than hypoglycaemia (AEs leading to discontinuation)" data-id="CD005613-fig-0015" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_t/tCD005613-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Insulin glargine versus NPH insulin, Outcome 11: Adverse events other than hypoglycaemia (AEs leading to discontinuation) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/references#CD005613-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005613-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/urn:x-wiley:14651858:media:CD005613:CD005613-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Insulin glargine versus NPH insulin, Outcome 12: Adverse events other than hypoglycaemia (weight gain)" data-id="CD005613-fig-0016" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_t/tCD005613-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Insulin glargine versus NPH insulin, Outcome 12: Adverse events other than hypoglycaemia (weight gain) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/references#CD005613-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005613-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/urn:x-wiley:14651858:media:CD005613:CD005613-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Insulin glargine versus NPH insulin, Outcome 13: Adverse events other than hypoglycaemia (skin reactions)" data-id="CD005613-fig-0017" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_t/tCD005613-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Insulin glargine versus NPH insulin, Outcome 13: Adverse events other than hypoglycaemia (skin reactions) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/references#CD005613-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005613-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/urn:x-wiley:14651858:media:CD005613:CD005613-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Insulin glargine versus NPH insulin, Outcome 14: Adverse events other than hypoglycaemia (eye related AEs)" data-id="CD005613-fig-0018" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_t/tCD005613-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Insulin glargine versus NPH insulin, Outcome 14: Adverse events other than hypoglycaemia (eye related AEs) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/references#CD005613-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005613-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/urn:x-wiley:14651858:media:CD005613:CD005613-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Insulin glargine versus NPH insulin, Outcome 15: Glycosylated haemoglobin (HbA1c)" data-id="CD005613-fig-0019" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_t/tCD005613-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Insulin glargine versus NPH insulin, Outcome 15: Glycosylated haemoglobin (HbA1c) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/references#CD005613-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005613-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/urn:x-wiley:14651858:media:CD005613:CD005613-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Insulin detemir vs NPH insulin, Outcome 1: Diabetes‐related complications (progression in retinopathy)" data-id="CD005613-fig-0020" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_t/tCD005613-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Insulin detemir vs NPH insulin, Outcome 1: Diabetes‐related complications (progression in retinopathy) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/references#CD005613-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005613-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/urn:x-wiley:14651858:media:CD005613:CD005613-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Insulin detemir vs NPH insulin, Outcome 2: Severe hypoglycaemia" data-id="CD005613-fig-0021" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_t/tCD005613-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Insulin detemir vs NPH insulin, Outcome 2: Severe hypoglycaemia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/references#CD005613-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005613-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/urn:x-wiley:14651858:media:CD005613:CD005613-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Insulin detemir vs NPH insulin, Outcome 3: Serious hypoglycaemia" data-id="CD005613-fig-0022" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_t/tCD005613-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Insulin detemir vs NPH insulin, Outcome 3: Serious hypoglycaemia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/references#CD005613-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005613-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/urn:x-wiley:14651858:media:CD005613:CD005613-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Insulin detemir vs NPH insulin, Outcome 4: Confirmed hypoglycaemia (blood glucose (BG) &lt; 75 mg/dL)" data-id="CD005613-fig-0023" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_t/tCD005613-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Insulin detemir vs NPH insulin, Outcome 4: Confirmed hypoglycaemia (blood glucose (BG) &lt; 75 mg/dL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/references#CD005613-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005613-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/urn:x-wiley:14651858:media:CD005613:CD005613-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Insulin detemir vs NPH insulin, Outcome 5: Confirmed hypoglycaemia (BG &lt; 55 mg/dL)" data-id="CD005613-fig-0024" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_t/tCD005613-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Insulin detemir vs NPH insulin, Outcome 5: Confirmed hypoglycaemia (BG &lt; 55 mg/dL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/references#CD005613-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005613-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/urn:x-wiley:14651858:media:CD005613:CD005613-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Insulin detemir vs NPH insulin, Outcome 6: Confirmed nocturnal hypoglycaemia (BG &lt; 75 mg/dL)" data-id="CD005613-fig-0025" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_t/tCD005613-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Insulin detemir vs NPH insulin, Outcome 6: Confirmed nocturnal hypoglycaemia (BG &lt; 75 mg/dL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/references#CD005613-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005613-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/urn:x-wiley:14651858:media:CD005613:CD005613-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Insulin detemir vs NPH insulin, Outcome 7: Confirmed nocturnal hypoglycaemia (BG &lt; 55 mg/dL)" data-id="CD005613-fig-0026" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_t/tCD005613-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Insulin detemir vs NPH insulin, Outcome 7: Confirmed nocturnal hypoglycaemia (BG &lt; 55 mg/dL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/references#CD005613-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005613-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/urn:x-wiley:14651858:media:CD005613:CD005613-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Insulin detemir vs NPH insulin, Outcome 8: All‐cause mortality" data-id="CD005613-fig-0027" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_t/tCD005613-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Insulin detemir vs NPH insulin, Outcome 8: All‐cause mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/references#CD005613-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005613-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/urn:x-wiley:14651858:media:CD005613:CD005613-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Insulin detemir vs NPH insulin, Outcome 9: Adverse events other than hypoglycaemia (serious adverse events)" data-id="CD005613-fig-0028" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_t/tCD005613-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Insulin detemir vs NPH insulin, Outcome 9: Adverse events other than hypoglycaemia (serious adverse events) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/references#CD005613-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005613-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/urn:x-wiley:14651858:media:CD005613:CD005613-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Insulin detemir vs NPH insulin, Outcome 10: Adverse events other than hypoglycaemia (all adverse events (AE))" data-id="CD005613-fig-0029" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_t/tCD005613-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Insulin detemir vs NPH insulin, Outcome 10: Adverse events other than hypoglycaemia (all adverse events (AE)) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/references#CD005613-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005613-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/urn:x-wiley:14651858:media:CD005613:CD005613-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Insulin detemir vs NPH insulin, Outcome 11: Adverse events other than hypoglycaemia (AEs leading to discontinuation)" data-id="CD005613-fig-0030" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_t/tCD005613-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: Insulin detemir vs NPH insulin, Outcome 11: Adverse events other than hypoglycaemia (AEs leading to discontinuation) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/references#CD005613-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005613-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/urn:x-wiley:14651858:media:CD005613:CD005613-CMP-002.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Insulin detemir vs NPH insulin, Outcome 12: Adverse events other than hypoglycaemia (skin reactions)" data-id="CD005613-fig-0031" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-002.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_t/tCD005613-CMP-002.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2: Insulin detemir vs NPH insulin, Outcome 12: Adverse events other than hypoglycaemia (skin reactions) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/references#CD005613-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-002.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005613-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/urn:x-wiley:14651858:media:CD005613:CD005613-CMP-002.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Insulin detemir vs NPH insulin, Outcome 13: Adverse events other than hypoglycaemia (eye‐related AEs)" data-id="CD005613-fig-0032" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-002.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_t/tCD005613-CMP-002.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2: Insulin detemir vs NPH insulin, Outcome 13: Adverse events other than hypoglycaemia (eye‐related AEs) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/references#CD005613-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-002.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005613-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/urn:x-wiley:14651858:media:CD005613:CD005613-CMP-002.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Insulin detemir vs NPH insulin, Outcome 14: Glycosylated haemoglobin (HbA1c)" data-id="CD005613-fig-0033" src="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-002.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_t/tCD005613-CMP-002.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2: Insulin detemir vs NPH insulin, Outcome 14: Glycosylated haemoglobin (HbA1c) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/references#CD005613-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/media/CDSR/CD005613/image_n/nCD005613-CMP-002.14.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD005613-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Insulin glargine versus NPH insulin for type 2 diabetes mellitus</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Insulin glargine vs NPH insulin for type 2 diabetes mellitus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient:</b> participants with type 2 diabetes mellitus </p> <p><b>Intervention:</b> insulin glargine </p> <p><b>Comparison:</b> NPH insulin (human isophane insulin) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk for NPH insulin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk for insulin glargine</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diabetes‐related complications</b> </p> <p>(1) Fatal MI</p> <p>(2) Fatal stroke</p> <p>(3) Progression in retinopathy</p> <p>(4) Amputations</p> <p>(5) ESRD</p> <p>Follow‐up: 6 months to 36 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>(1) See comment</p> <p>(2) See comment</p> <p><b>(3) 101 per 1000</b> </p> <p>(4) See comment</p> <p>(5) See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>(1) See comment</p> <p>(2) See comment</p> <p><b>(3) 104 per 1000</b> (60 to 178) </p> <p>(4) See comment</p> <p>(5) See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) + (2) See comment</p> <p>(3) <b>RR 1.03</b> </p> <p>(0.60 to 1.77)</p> <p>(4) + (5) See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) 934 (4 RCTs)</p> <p>(2) 934 (4 RCTs)</p> <p>(3) 1947 (5 RCTs)</p> <p>(4) 34 (1 RCT)</p> <p>(5) 34 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) + (2)</p> <p>⊕⊝⊝⊝<br/><b>Very low<sup>a</sup> </b> </p> <p>(3) ⊕⊝⊝⊝<br/><b>Very</b> <b>low<sup>b</sup> </b> </p> <p>(4) + (5) ⊕⊝⊝⊝<br/><b>Very low<sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) 1 trial reported 3/352 participants in the glargine 100 IU group vs 0/349 participants in the NPH group experienced fatal MI; 3 additional trials with 233 participants reported that no fatal MI occurred. </p> <p>(2) No fatal strokes occurred.</p> <p>(3) The 95% prediction interval ranged between 0.22 and 4.83.</p> <p>(4) + (5) 1 trial reported that no amputation or ESRD occurred.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypoglycaemic episodes</b><br/>(1) Severe hypoglycaemia </p> <p>(2) Serious hypoglycaemia</p> <p>(3) Confirmed hypoglycaemia (BG &lt; 75 mg/dL)</p> <p>(4) Confirmed hypoglycaemia (BG &lt; 55 mg/dL)</p> <p>(5) Confirmed nocturnal hypoglycaemia (BG &lt; 75 mg/dL)</p> <p>(6) Confirmed nocturnal hypoglycaemia (BG &lt; 55 mg/dL)</p> <p>Follow‐up: 24 weeks to 5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>(1) <b>37 per 1000</b> </p> <p>(2) <b>27 per 1000</b> </p> <p>(3) <b>572 per 1000</b> </p> <p>(4) <b>180 per 1000</b> </p> <p>(5) <b>351 per 1000</b> </p> <p>(6) <b>115 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>(1) <b>25 per 1000</b> (17 to 37) </p> <p>(2) <b>20 per 1000</b> (14 to 29) </p> <p>(3) <b>526 per 1000</b> (486 to 578) </p> <p>(4) <b>159 per 1000</b> (146 to 173) </p> <p>(5) <b>274 per 1000</b> (239 to 312) </p> <p>(6) <b>85 per 1000</b> (74 to 98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) <b>RR 0.68</b> (0.46 to 1.01) </p> <p>(2) <b>RR 0.75</b> (0.52 to 1.09) </p> <p>(3) <b>RR 0.92</b> (0.85 to 1.01) </p> <p>(4) <b>RR 0.88</b> (0.81 to 0.96) </p> <p>(5) <b>RR 0.78</b> (0.68 to 0.89) </p> <p>(6) <b>RR 0.74</b> (0.64 to 0.85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) 6164 (14 RCTs)</p> <p>(2) 4685 (10 RCTs)</p> <p>(3) 4115 (7 RCTs)</p> <p>(4) 4388 (8 RCTs)</p> <p>(5) 4225 (8 RCTs)</p> <p>(6) 4759 (8 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) ⊕⊝⊝⊝<br/><b>Very low<sup>d</sup> </b> </p> <p>(2) ⊕⊕⊝⊝<br/><b>Low<sup>e</sup> </b> </p> <p>(3) ⊕⊝⊝⊝<br/><b>Very low<sup>f</sup> </b> </p> <p>(4) ⊕⊕⊕⊝<br/><b>Moderate<sup>g</sup> </b> </p> <p>(5) ⊕⊝⊝⊝<br/><b>Very low<sup>f</sup> </b> </p> <p>(6) ⊕⊕⊕⊝<br/><b>Moderate<sup>g</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) The 95% prediction interval ranged between 0.33 and 1.40.</p> <p>(2) The 95% prediction interval ranged between 0.48 and 1.16.</p> <p>(3) The 95% prediction interval ranged between 0.69 and 1.22.</p> <p>(4) The 95% prediction interval ranged between 0.79 and 0.98.</p> <p>(5) The 95% prediction interval ranged between 0.53 and 1.14.</p> <p>(6) The 95% prediction interval ranged between 0.62 and 0.88.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HRQoL</b> </p> <p>Follow‐up: 28 weeks to 48 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1228 (3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>h</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 trials reported no statically significant differences between glargine groups and NPH groups in HRQoL total scores (W‐BQ22; EQ‐5) or any subscales. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 24 weeks to 5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b> (5 to 15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Peto OR 1.06</b> (0.62 to 1.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6173 (14 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>i</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AEs other than hypoglycaemia</b> </p> <p>(1) SAE</p> <p>(2) Overall AE</p> <p>(3) AE leading to discontinuation</p> <p>Follow‐up: 24 weeks to 5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>(1) <b>135 per 1000</b> </p> <p>(2)<b>662 per 1000</b> </p> <p>(3) <b>17 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>(1) <b>132 per 1000</b> (117 to 148) </p> <p>(2) <b>669 per 1000</b> (649 to 682) </p> <p>(3)<b>20 per 1000</b> (14 to 30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) <b>RR 0.98</b> (0.87 to 1.10) </p> <p>(2) <b>RR 1.01</b> (0.98 to 1.03) </p> <p>(3) <b>RR 1.21</b> (0.84 to 1.76) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) 5499 (13 RCTs)</p> <p>(2) 6170 (14 RCTs)</p> <p>(3) 6149 (13 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) + (2) (+3) ⊕⊕⊕⊝<br/><b>Moderate<sup>j</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) The 95% prediction interval ranged between 0.86 and 1.12.</p> <p>(2) The 95% prediction interval ranged between 0.99 and 1.03.</p> <p>(3) The 95% prediction interval ranged between 0.79 and 1.84.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Socioeconomic effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c</b> </p> <p>Follow‐up: 24 weeks to 5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in HbA1c ranged across control groups from –2.12% to +0.1%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in HbA1c in the intervention groups was <b>0.07% lower</b> </p> <p>(0.18% lower to 0.03% higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5809 (16 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>k</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The 95% prediction interval ranged between –46% and 0.32%.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>AE:</b> adverse event; <b>BG:</b> blood glucose; <b>CI:</b> confidence interval; <b>EQ‐5(D):</b> EuroQol 5 (Dimension); <b>ESRD:</b> end‐stage renal disease; <b>HbA1c:</b> glycosylated haemoglobin A1c; <b>HRQoL:</b> health‐related quality of life; <b>MD:</b> mean difference; <b>MI:</b> myocardial infarction; <b>NPH:</b> neutral protamine Hagedorn; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SAE:</b> serious adverse event; <b>W‐BQ22:</b> Well‐Being Questionnaire (22 items). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded three levels because of risk of bias and serious imprecision (very sparse data) – see <a href="./appendices#CD005613-sec-0133">Appendix 1</a>.<br/><sup>b</sup>Downgraded three levels because of risk of bias, inconsistency and imprecision – see <a href="./appendices#CD005613-sec-0133">Appendix 1</a>.<br/><sup>c</sup>Downgraded three levels because of indirectness and serious imprecision (very sparse data) – see <a href="./appendices#CD005613-sec-0133">Appendix 1</a>.<br/><sup>d</sup>Downgraded three levels because of risk of bias, imprecision and inconsistency – see <a href="./appendices#CD005613-sec-0133">Appendix 1</a>.<br/><sup>e</sup>Downgraded two levels because of risk of bias and imprecision – see <a href="./appendices#CD005613-sec-0133">Appendix 1</a>.<br/><sup>f</sup>Downgraded three levels because of risk of bias, inconsistency and imprecision – see <a href="./appendices#CD005613-sec-0133">Appendix 1</a>.<br/><sup>g</sup>Downgraded one level because of risk of bias – see <a href="./appendices#CD005613-sec-0133">Appendix 1</a>.<br/><sup>h</sup>Downgraded three levels because of risk of bias and serious imprecision – see <a href="./appendices#CD005613-sec-0133">Appendix 1</a>.<br/><sup>i</sup>Downgraded two levels because of risk of bias and imprecision – see <a href="./appendices#CD005613-sec-0133">Appendix 1</a>.<br/><sup>j</sup>Downgraded one level because of imprecision – see <a href="./appendices#CD005613-sec-0133">Appendix 1</a>.<br/><sup>k</sup>Downgraded two levels because of inconsistency and imprecision – see <a href="./appendices#CD005613-sec-0133">Appendix 1</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Insulin glargine versus NPH insulin for type 2 diabetes mellitus</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/full#CD005613-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005613-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Insulin detemir versus NPH insulin for type 2 diabetes mellitus</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Insulin detemir vs NPH insulin for type 2 diabetes mellitus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient:</b> participants with type 2 diabetes mellitus </p> <p><b>Intervention:</b> insulin detemir </p> <p><b>Comparison:</b> NPH insulin (human isophane insulin) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk for NPH insulin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk for insulin detemir</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diabetes‐related complications</b> </p> <p>(1) Fatal MI</p> <p>(2) Fatal stroke</p> <p>(3) Progression in retinopathy</p> <p>(4) Amputations</p> <p>(5) ESRD</p> <p>Follow‐up: 24 weeks to 26 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>(1) + (2) See comment</p> <p><b>(3) 25 per 1000</b> </p> <p>(4) + (5) See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>(1) + (2) See comment</p> <p><b>(3) 37 per 1000</b> (17 to 82) </p> <p>(4) + (5) See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) + (2) See comment</p> <p>(3) <b>RR 1.50</b> </p> <p>(0.68 to 3.32)</p> <p>(4) + (5) See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) + (2) 271 (1 RCT)</p> <p>(3) 972 (2 RCTs)</p> <p>(4) + (5) 271 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) + (2) + (3) + (4) + (5) ⊕⊝⊝⊝<br/><b>Very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) + (2) 1 trial reported that no fatal MI or fatal stroke occurred.</p> <p>(3) –</p> <p>(4) + (5) 1 trial reported that no amputation or ESRD occurred.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypoglycaemic episodes</b> </p> <p>(1) Severe hypoglycaemia</p> <p>(2) Serious hypoglycaemia</p> <p>(3) Confirmed hypoglycaemia (BG &lt; 75 mg/dL)</p> <p>(4) Confirmed hypoglycaemia (BG &lt; 55 mg/dL)</p> <p>(5) Confirmed nocturnal hypoglycaemia (BG &lt; 75 mg/dL)</p> <p>(6) Confirmed nocturnal hypoglycaemia (BG &lt; 55 mg/dL)</p> <p>Follow‐up: 24 weeks to 7 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>(1) <b>17 per 1000</b> </p> <p>(2) <b>11 per 1000</b> </p> <p>(3) <b>562 per 1000</b> </p> <p>(4) <b>493 per 1000</b> </p> <p>(5) <b>309 per 1000</b> </p> <p>(6) <b>40 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>(1) <b>8 per 1000</b> (3 to 21) </p> <p>(2) <b>2 per 1000</b> (0 to 7) </p> <p>(3) <b>410 per 1000</b> (343 to 484) </p> <p>(4) <b>237 per 1000</b> (158 to 350) </p> <p>(5) <b>176 per 1000</b> (145 to 210) </p> <p>(6) <b>13 per 1000</b> (6 to 25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) <b>RR 0.45</b> (0.17 to 1.20) </p> <p>(2) <b>Peto OR 0.16</b> (0.04 to 0.61) </p> <p>(3) <b>RR 0.73</b> (0.61 to 0.86) </p> <p>(4) <b>RR 0.48</b> (0.32 to 0.71) </p> <p>(5) <b>RR 0.57</b> (0.47 to 0.68) </p> <p>(6) <b>RR 0.32</b> (0.16 to 0.63) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) 1804 (5 RCTs)</p> <p>(2) 1777 (5 RCTs)</p> <p>(3) 1718 (4 RCTs)</p> <p>(4) 1718 (4 RCTs)</p> <p>(5) 1718 (4 RCTs)</p> <p>(6) 1718 (4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) ⊕⊝⊝⊝<br/><b>Very low<sup>b</sup> </b> </p> <p>(2) ⊕⊕⊝⊝<br/><b>Low<sup>c</sup> </b> </p> <p>(3) ⊕⊕⊝⊝<br/><b>Low<sup>d</sup> </b> </p> <p>(4) + (5) + (6)<br/>⊕⊕⊝⊝<br/><b>Low<sup>e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) The 95% prediction interval ranged between 0.09 and 2.21.</p> <p>(2) –</p> <p>(3) The 95% prediction interval ranged between 0.36 and 1.48.</p> <p>(4) The 95% prediction interval ranged between 0.20 and 1.13.</p> <p>(5) The 95% prediction interval ranged between 0.39 and 0.84.</p> <p>(6) The 95% prediction interval ranged between 0.07 and 1.42.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> <p>Follow‐up: 26 weeks to 36 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>873 (3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 trials reported no statically significant difference between detemir groups and NPH groups in HRQoL total scores (ITR‐QOLN; DHP‐2; SF‐36) or any subscales. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 24 weeks to 48 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> (1 to 13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Peto OR 0.74</b> (0.20 to 2.65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2328 (8 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>L<b>ow<sup>f</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AEs other than hypoglycaemia</b> </p> <p>(1) SAE</p> <p>(2) Overall AE</p> <p>(3) AE leading to discontinuation</p> <p>Follow‐up: 24 weeks to 48 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>(1) <b>71 per 1000</b> </p> <p>(2)<b>611 per 1000</b> </p> <p>(3) <b>18 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>(1) <b>62 per 1000</b> (45 to 85) </p> <p>(2) <b>629 per 1000</b> (586 to 678) </p> <p>(3)<b>22 per 1000</b> (12 to 40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) <b>RR 0.88</b> </p> <p>(0.64 to 1.20)</p> <p>(2) <b>RR 1.03</b> (0.96 to 1.11) </p> <p>(3) <b>RR 1.22</b> (0.67 to 2.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) 2328 (8 RCTs)</p> <p>(2) 2328 (8 RCTs)</p> <p>(3) 2328 (8 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) + (2) (+3)</p> <p>⊕⊝⊝⊝<br/><b>Moderate<sup>g</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) The 95% prediction interval ranged between 0.60 and 1.30.</p> <p>(2) The 95% prediction interval ranged between 0.94 and 1.13.</p> <p>(3) The 95% prediction interval ranged between 0.57 and 2.62.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Socioeconomic effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c</b> </p> <p>Follow‐up:</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in HbA1c ranged across control groups from –1.9% to –0.32%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in HbA1c in the intervention groups was <b>0.13% higher</b> </p> <p>(0.02% lower to 0.28% higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2233 (7 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>h</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The 95% prediction interval ranged between –0.28% and 0.54%.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>AE:</b> adverse event; <b>BG:</b> blood glucose; <b>CI:</b> confidence interval; <b>DHP‐2:</b> Diabetes Health Profile 2; <b>ESRD: e</b> nd‐stage renal disease; <b>HbA1c:</b> glycosylated haemoglobin A1c; <b>HRQoL:</b> health‐related quality of life; <b>ITR‐QOLN:</b> insulin therapy‐related quality of life at night; <b>MD:</b> mean difference; <b>MI:</b> myocardial infarction; <b>NPH:</b> neutral protamine Hagedorn; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio; <b>SAE:</b> serious adverse event; <b>SF‐36:</b> 36‐item Short Form Health Survey. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded three levels because of risk of bias and serious imprecision (very sparse data) – see <a href="./appendices#CD005613-sec-0134">Appendix 2</a>.<br/><sup>b</sup>Downgraded three levels because of risk of bias and serious imprecision – see <a href="./appendices#CD005613-sec-0134">Appendix 2</a>.<br/><sup>c</sup>Downgraded two levels because of risk of bias and imprecision – see <a href="./appendices#CD005613-sec-0134">Appendix 2</a>.<br/><sup>d</sup>Downgraded two levels because of risk of bias and inconsistency – see <a href="./appendices#CD005613-sec-0134">Appendix 2</a>.<br/><sup>e</sup>Downgraded two levels because risk of bias and imprecision – see <a href="./appendices#CD005613-sec-0134">Appendix 2</a>.<br/><sup>f</sup>Downgraded two levels because of serious imprecision – see <a href="./appendices#CD005613-sec-0134">Appendix 2</a>.<br/><sup>g</sup>Downgraded one level because of imprecision – see <a href="./appendices#CD005613-sec-0134">Appendix 2</a>.<br/><sup>h</sup>Downgraded two levels because of inconsistency and imprecision – see <a href="./appendices#CD005613-sec-0134">Appendix 2</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Insulin detemir versus NPH insulin for type 2 diabetes mellitus</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/full#CD005613-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005613-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of trial populations</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Trial ID</b> </p> <p><b>(study design)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention(s) and comparator(s)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Description of power and sample size calculation</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Screened/eligible<br/>(n)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Randomised<br/>(n)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>ITT<br/>(n)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Analysed<br/>(n)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Finishing trial<br/>(n)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Randomised finishing trial<br/>(%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Follow‐up<br/>(extended follow‐up)<sup>a</sup> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0001" title="BerardL , CameronB , WooV , StewartJ . Replacing insulin glargine with neutral protamine Hagedorn (NPH) insulin in a subpopulation of study subjects in the action to control cardiovascular risk in diabetes (ACCORD): effects on blood glucose levels, hypoglycemia and patient satisfaction. Canadian Journal of Diabetes2015;39(4):296-301. [PMID: 25819531]BerardLD , WooVC . Safety and efficacy of NPH after switching from insulin glargine in Canadian patients. Diabetologia2011;54:S430. [EMBASE: 70563203]">Berard 2015</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin glargine once‐daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin once daily or twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>66</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0003" title="EliaschewitzFG , CalvoC , ValbuenaH , RuizM , AschnerP , VillenaJ , et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Archives of Medical Research2006;37(4):495-501. [PMID: 16715577]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Eliaschewitz 2006</a> </p> <p>(parallel RCT, equivalence design)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin glargine at bedtime + glimepiride 4 mg/day in the morning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Based on an equivalence region of 0.5% and an SD of 2.0% for the differences in HbA1c between the groups, equivalence can be demonstrated with a statistical power of 80% with 199 participants per group, based on a 1‐sided α = 0.05. A 1:1 randomisation would require 199 evaluable participants in each group. Based on an expectation that 20% of the participants would not be evaluable, the study required the enrolment of 240 in each group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>918/—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy: 218</p> <p>Safety: 231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>24 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin at bedtime + glimepiride 4 mg/day in the morning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy: 244</p> <p>Safety: 250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>528</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>481</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Efficacy: 462</b> </p> <p><b>Safety: 481</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>462</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>87.5</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0004" title="EUCTR2005-000976-42. A multi-centre, open-labelled, randomised, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime (PREDICTIVE-BMI study) – PREDICTIVE-BMI study. www.clinicaltrialsregister.eu/ctr-search/trial/2005-000976-42/ES (first received 17 May 2006). Fajardo MontañanaC , Hernandez HerreroC , Rivas FernandezM . Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabetic Medicine2008;25(8):916-23. [PMID: 18959604]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00504673. Comparison of insulin detemir versus insulin NPH on weight change in overweight and obese with type 2 diabetes (PREDICTIVE). clinicaltrials.gov/ct2/show/NCT00504673 (first received 20 July 2007). Novo Nordisk A/S. A multi-centre, open-labelled, randomized, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime. (PREDICTIVE-BMI study). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1410&amp;filename=1659-ctr-redacted.pdf (last accessed 3 November 2020). Smith-PalmerJ , Fajardo-MontananaC , PollockRF , EricssonA , ValentineWJ . Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. Journal of Medical Economics2012;15(5):977-86. [PMID: 22563742]">Fajardo Montañana 2008</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin detemir at bedtime</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>272 participants (230 evaluable) were required to detect a difference in weight change of 1.5 kg (SD 4.0) between groups after 26 weeks, using a 2‐sided test with a 0.05 significance level. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>345/293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>26 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin at bedtime</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92.1</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>277</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>271</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>271</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>252</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>91.0</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD005613-bbs2-0005" title="FritscheA , SchweitzerMA , HaringHU , Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Annals of Internal Medicine2003;138(12):952-9. [PMID: 12809451]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Fritsche 2003</a> </p> <p>(parallel RCT, non‐inferiority design)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: insulin glargine in the morning + glimepiride 3 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Based on the assumption of an SD of σ = 2.0%, a difference of Δ = 0.5% for HbA1c reductions among treatment groups can be detected with an α‐error of 0.05 and a β‐error of 0.2. This equates to a statistical power of 80% with 199 participants per group. With use of a 1:1:1 randomisation, 597 participants would be required for this study. Assuming a non‐evaluable rate of 20%, 720 participants (240 per group) would need to be enrolled in this study. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>938/752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>24 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: insulin glargine at bedtime + glimepiride 3 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin at bedtime + glimepiride 3 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.6</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>700</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>695</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>695</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>640</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>91.4</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0006" title="HaakT , TiengoA , DraegerE , SuntumM , WaldhauslW . Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2005;7(1):56-64. [PMID: 15642076]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">Haak 2005</a> </p> <p>(parallel RCT, non‐inferiority design)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: detemir once daily at bedtime or twice daily in the morning and at bedtime + mealtime insulin aspart </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The study had sufficient power (85%) to detect a mean difference of 0.4% in HbA1c between groups. A 95% 2‐sided CI was constructed for the difference between the group means (insulin detemir NPH insulin); insulin detemir was deemed non‐inferior if the upper limit of the 95% CI was &lt; 0.4% (absolute). Treatments were considered comparable if the non‐inferiority criterion was fulfilled. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—/—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>26 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: detemir once daily at bedtime or twice daily in the morning and at bedtime + mealtime insulin aspart </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.1</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>505</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>505</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>505</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>471</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>93.3</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0007" title="EUCTR2009-010913-59. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on OHA treatment initiating basal insulin therapy with either insulin glargine or NPH insulin added to therapies with oral hypoglycemic agents (HAPPY) (LANTU_L_04079 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2009-010913-59/results (last accessed 3 May 2017). HermannsN , KulzerB , KohlmannT , JacobS , LandgrafW , TheobaldK , et al. Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial. Health and Quality of Life Outcomes2015;13:77. [PMID: 26055391]NCT00941369. Health assessment, patient treatment satisfaction and quality-of-life in insulin-naive type 2 diabetes patients uncontrolled on oral hypoglycemic agent treatment initiating basal insulin therapy with either insulin glargine or NPH insulin. clinicaltrials.gov/ct2/show/NCT00941369 (first received 17 July 2009). ">Hermanns 2015</a> </p> <p>(cross‐over RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin glargine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>In a previous cross‐sectional study, different effect sizes of insulin glargine compared to NPH insulin in terms of SF‐12 (d = 0.10), PAID (d = 0.22), and ITEQ (d = 0.29) scores were observed. The mean effect size of all 3 scales was d = 0.166. Since the present study had a cross‐over design, in which each participant served as his/her own control, an effect size on the primary endpoint DRQoL of d = 0.20 was expected. Such an effect can be detected with 90% power using a paired t‐test with a significance level of 5% and with 265 participants. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>460/—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>343;<br/>sequence A: 176,<br/>sequence B: 167 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>339;</p> <p>sequence A: 175,<br/>sequence B: 164 </p> <p>229<sup>b</sup>; sequence A: 118,<br/>sequence B: 111 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>296;</p> <p>sequence A: 151,<br/>sequence B: 145 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>86.3;</p> <p>sequence A: 85.8,<br/>sequence B: 86.8 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>48 weeks (efficacy)<br/>49 weeks (safety) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH basal insulin</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>343</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>339</b> </p> <p><b>229<sup>b</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>296</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>86.3</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0008" title="DaileyG , StrangeP , RiddleM . Reconsideration of severe hypoglycemic events in the treat-to-target trial. Diabetes Technology &amp; Therapeutics2009;11(8):477-9. [PMID: 19698059]DaviesMJ , DerezinskiT , PedersenCB , ClausonP . Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Diabetes Technology &amp; Therapeutics2008;10(4):273-7. [PMID: 18715200]HermansenK , DaviesM , DerezinskiT , Martinez RavnG , ClausonP , HomeP . Erratum: A 26-week randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people wih type 2 diabetes (Diabetes Care (2006) 29, (1269-1274)). Diabetes Care2007;30(4):1035. [EMBASE: 46556609]HermansenK , DaviesM , DerezinskiT , MartinezRG , ClausonP , HomeP . A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care2006;29(6):1269-74. [PMID: 16732007]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00604396. Safety and efficacy of insulin detemir in combination with OAD in type 2 diabetes. clinicaltrials.gov/ct2/show/results/NCT00604396 (first received 30 January 2008). ">Hermansen 2006</a> </p> <p>(parallel RCT, non‐inferiority design)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: detemir in the morning and evening</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>A non‐inferiority criterion, defined as a &lt; 0.4% difference in HbA1c, was calculated to require 198 completers per arm for 95% power with a 5% significance level and with a maximum baseline‐adjusted SD of 1.1% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>735/490</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>24 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin in the morning and evening</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.1</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>476</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>475</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>475</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>452</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>95.0</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0009" title='EUCTR2007-006640-22. Superiority of insulin glargine Lantus vs NPH: "Treat to normoglycemia concept". Effect of insulin glargine in comparison to insulin NPH in insulin-naïve people with type 2 diabetes mellitus treated with at least one OAD and not adequately controlled (LANCELOT) (LANTU_C_02762 trial report). www.clinicaltrialsregister.eu/ctr-search/trial/2007-006640-22/results (last accessed 19 July 2017). HomePD , BolliGB , MathieuC , DeerochanawongC , LandgrafW , CandelasC , et al. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naive people with type 2 diabetes. Diabetes, Obesity &amp; Metabolism2015;17(1):15-22. [PMID: 24957785]NCT00949442. Lantus versus NPH: comparison in insulin naive people not adequately controlled with at least one oral anti diabetics (OAD) treatment (LANCELOT). clinicaltrials.gov/ct2/show/NCT00949442 (first received 30 July 2009). '>Home 2015</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin glargine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>It was estimated that at least 568 evaluable participants (670 were randomised with 15% not assessable) needed to be randomised to detect a difference in change of HbA1c of 0.3% (3.3 mmol/mol) at the 5% significance level with 90% power.This assumes an SD of change of HbA1c of 1.1% (12 mmol/mol) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1102/—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>36 weeks (efficacy)<br/>37 weeks (safety) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>328</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92.9</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>708</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>701</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>701</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>663</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>93.6</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD005613-bbs2-0010" title="HsiaSH . Comparison of single-dose regimens of insulin glargine versus NPH among inner city ethnic minority type 2 diabetic patients uncontrolled on oral agents. Journal of Investigative Medicine2010;58(1):136. [EMBASE: 70981533]HsiaSH . Insulin glargine compared to NPH among insulin-naive, U.S. inner city, ethnic minority type 2 diabetic patients. Diabetes Research &amp; Clinical Practice2011;91(3):293-9. [PMID: 21146881]NCT00686712. Insulin glargine at bedtime or in AM versus NPH. clinicaltrials.gov/ct2/show/NCT00686712 (first received 7 October 2010). ">Hsia 2011</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: insulin glargine at bedtime</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Based on previously published HbA1c levels in oral agent‐treated participants from the study centre, enrolment of 24 in each of the 3 treatment arms (72 total) would provide 95% power to detect an HbA1c difference of 0.8%, at a 5% significance level. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—/108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.7<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>26 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I2: insulin glargine in the morning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.0<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin at bedtime</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.7<sup>c</sup> </p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>85</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>85</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>85</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>51</b><sup>c</sup> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>60.0</b><sup>c</sup> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0011" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KawamoriR , IwamotoY , KadowakiT , IwasakiM . Efficacy and safety of insulin glargine in concurrent use with oral hypoglycemic agents for the treatment of type 2 diabetes patients. Rinshoiyaku2003;19(5):445-64. ">Kawamori 2003</a> </p> <p>(parallel RCT, non‐inferiority design)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin glargine once in the morning + OAD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—/400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy: 141</p> <p>Safety: 158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>28 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin once in the morning + OAD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy: 134</p> <p>Safety: 159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79.8</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>335</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>317</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Efficacy: 275</b> </p> <p><b>Safety: 317</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>275</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>82.1</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0012" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. IshiiH , IwamotoY , KakuK , KawamoriR , KobayashiM , TajimaN . Night-time QOL and treatment satisfaction in diabetes mellitus patients treated with insulin detemir used in basal-bolus therapy – randomized multicenter open-label parallel group phase 3 trial compared to NPH insulin. Journal of the Japan Diabetes Society2009;52(8):691-701. [DOI: 10.11213/tonyobyo.52.691]KobayashiM , IwamotoY , KakuK , KawamoriR , TajimaN . Phase 3 clinical trial of insulin detemir for patients with insulin-dependent diabetes during basal-bolus therapy – a study of efficacy and safety with NPH insulin as control. Journal of the Japan Diabetes Society2007;50(9):649-63. [DOI: 10.11213/tonyobyo.50.649]NCT00604344. Efficacy and the safety of insulin detemir in subjects with insulin requiring diabetes. clinicaltrials.gov/ct2/show/NCT00604344 (first received 30 January 2008). Novo Nordisk A/S. A 48-week, randomised, multi-centre, open-labelled, parallel-group trial to compare the efficacy and the safety of NN304 (insulin detemir) and NPH human insulin in subjects with insulin requiring diabetes mellitus on a basal-bolus regimen. https://s3.amazonaws.com/ctr-nvo-7271/NN304-1476/aa9b4da3-1f92-460d-af0a-cc538614c3b2/3f7ed86e-d6e7-4542-ab8f-6cad24b46593/1476-ctr-synopsis-redacted-v2.pdf (last accessed 3 November 2020). ">Kobayashi 2007 A</a> </p> <p>(parallel RCT, non‐inferiority design)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin detemir once daily at bedtime or twice daily in the morning and at bedtime + mealtime insulin aspart </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>454/401<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>48 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin once daily at bedtime or twice daily in the morning and at bedtime + mealtime insulin aspart </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.4</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>105</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>102</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>102</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>97</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>92.4</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0013" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. KobayashiM , IwamotoY , KakuK , KawamoriR , TajimaN . Phase 3 clinical trial of insulin detemir for type 2 diabetes patients with insufficient blood sugar control in oral diabetes drug therapy. Journal of the Japan Diabetes Society2007;50(9):665-77. [DOI: 10.11213/tonyobyo.50.665]NCT00604253. Efficacy and safety of insulin detemir in type 2 diabetes inadequately controlled on OHA therapy alone. www.clinicaltrials.gov/ct2/show/results/NCT00604253 (first received 30 January 2008). Novo Nordisk A/S. A 36-week, randomised, multi-centre, open-labelled, parallel-group trial to compare the efficacy and the safety of NN304 and NPH human insulin once daily treatment as add-on to current OHA therapy in subjects with type 2 diabetes mellitus who are inadequately controlled on OHA therapy. http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1397&amp;filename=NN304_1477_ICTRSynopsis_Final_20051101.pdf (last accessed 3 November 2020). ">Kobayashi 2007 B</a> </p> <p>(parallel RCT, non‐inferiority design)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin detemir at bedtime + OAD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>437/371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>36 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin at bedtime + OAD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97.5</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>371</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>363</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>363</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>332</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>89.5</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0014" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. MassiBM , HumburgE , DresslerA , ZiemenM . A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Hormone &amp; Metabolic Research2003;35(3):189-96. [PMID: 12734781]Yki-JarvinenH , DresslerA , ZiemenM . Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care2000;23(8):1130-6. [EMBASE: 2006092604]">Massi 2003</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin glargine once daily at bedtime + OAD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Based on 1:1 randomisation and using a t‐test, a total number of 384 participants (192 for each group) was required to detect a mean difference of 0.5% glycated haemoglobin between insulin glargine and NPH insulin with a significance level of α = 5% and a statistical power of 90%. It was estimated that a total of 480 participants were to be enrolled to have 384 participants evaluable for efficacy analysis, </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>687/—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>52 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin once daily at bedtime + OAD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.4</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>578</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>570</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>570</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>529</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>91.5</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0015" title="NCT00687453. The utility of insulin glargine (Lantus) compared to NPH in ethnic minority type 2 diabetic subjects on combination insulin-oral agent therapy. clinicaltrials.gov/ct2/show/NCT00687453 (first received 30 May 2008). ">NCT00687453</a> </p> <p>(parallel RCT, non‐inferiority design)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin glargine at bedtime</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>27/24 <sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin in the morning and at bedtime</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54<sup>c</sup> </p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>24</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>24</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>24</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>15</b><sup>c</sup> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>62.5</b><sup>c</sup> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0016" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. ">NN304‐1337</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin detemir once daily at bedtime + metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>24 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin once daily at bedtime + metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.6</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>467</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>467</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>467</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>406</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>86.9</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0017" title="DoucetJ , Le FlochJ , HanaireH , CourregesJ , AlexandreB , BauduceauB . Comparison of safety between detemir and neutral protamine Hagedorn (NPH) in ageing subjects: the '3 L study'. Fundamental and Clinical Pharmacology2011;25:82. [EMBASE: 70653089]EUCTR2006-006589-41-FR. Levemir® in ageing patients with type 2 diabetes A seven-month open-labelled randomised multi-centre two-group parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in the morning in ageing subjects with type 2 diabetes. The 3L Study (Levemir in Late Life) Trial Phase: 4. www.clinicaltrialsregister.eu/ctr-search/trial/2006-006589-41/FR (first received 27 March 2007). NCT00506662. The effect of insulin detemir on glucose control in ageing subjects with type 2 diabetes. clinicaltrials.gov/ct2/show/study/NCT00506662 (first received 25 July 2007). Novo Nordisk A/S. A seven-month, open-labelled, randomised, multicentre, two-group, parallel trial comparing administration of insulin detemir once daily in the morning versus NPH insulin once daily in ageing patients with type 2 diabetes: The 3L Study (Levemir in Later Life) (NN304-1808 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1426&amp;filename=1808-ctr-redacted.pdf (last accessed 3 November 2020). ">NN304‐1808</a> </p> <p>(parallel RCT, non‐inferiority design)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin detemir once daily before breakfast ± metformin at optimal dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>For 80% power and 5% significance level with a baseline‐adjusted SD of 1.1, a total of 238 completers (119 per group) was required. Owing to a 20% maximal expected frequency of participants lost for follow‐up, 286 were to have been included, 143 in each group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>124/—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.3<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>7 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin once daily before breakfast ± metformin at optimal dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.7<sup>c</sup> </p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>86</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>86</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>86</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>41</b><sup>c</sup> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>47.7</b><sup>c</sup> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0018" title="EUCTR2008-003739-19. Ensayo multicéntrico, abierto, aleatorizado, de dos grupos, paralelo para comparar el cambio en la distribución de grasa en sujetos con sobrepeso y obesos con diabetes tipo 2 tras 26 semanas de tratamiento con insulina detemir una vez al día frente a insulina NPH una vez al día, ambas con insulina aspart a la hora de las comidas. www.clinicaltrialsregister.eu/ctr-search/trial/2008-003739-19/ES (first received 19 September 2008). NCT00795600. A multi-centre, open-labelled, randomised, two-group parallel trial comparing the change in fat distribution in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin apart at mealtimes. clinicaltrials.gov/ct2/show/NCT00795600 (first received 21 November 2008). Novo Nordisk A/S. A multi-centre, open-labelled, randomised, two-group parallel trial comparing the change in fat distribution in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart at mealtimes (NN304-3614 Clinical Trial Report). http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_NVO_7271&amp;studyid=1461&amp;filename=3614-ctr-synopsis-redacted.pdf (last accessed 3 November 2020). TinahonesFJ , Gomez-HuelgasR , Garcia-AlegriaJ , Tapia-GuerreroM , Martos-PerezF . Fat distribution, HbA1c and hypoglycaemia in overweight and obese patients with type 2 diabetes: a comparison of NPH and insulin detemir from a pilot randomised clinical trial. Diabetologia2011;54:S273. [EMBASE: 70562816]TinahonesFJ , Gomez-HuelgasR , GarciaalegriaJ , Tapia-GuerreroMJ , PerezFM . The effect of insulin detemir on fat distribution and weight parameters in overweight and obese subjects with type 2 diabetes. Diabetes2011;60:A309. [EMBASE: 70628891]">NN304‐3614</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin detemir in the evening + insulin aspart each meal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>As the primary objective was to demonstrate a difference of 5% in the primary endpoint, using an analysis of covariance model with 3 factors and 1 covariate and with an SD of 5%, the number of participants needed would be of 23 per group. Assuming a withdrawal rate of 20%, the total number of randomised participants would be 58. With a planned screening failure of 20%, the total number of participants planned would be 73. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>81/—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>26 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin in the evening + insulin aspart each meal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.6</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>60</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>59</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>59</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>52</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>86.7</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0019" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. PanCY , SinnassamyP , ChungKD , KimKW , Group LS . Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Research &amp; Clinical Practice2007;76(1):111-8. [PMID: 17011662]">Pan 2007</a> </p> <p>(parallel RCT, non‐inferiority design)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin glargine in the evening + glimepiride 3 mg in the morning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Assuming an SD of 1.6% for the changes from baseline in HbA1c in the 2 groups, and a maximum difference between the groups to be equivalent to 0.4%, the sample size per group was calculated to provide 80% power. The sample size was adjusted for an evaluation rate of 90%, and a total of 440 participants (220 per group) was thus targeted for randomisation. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>24 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin in the evening + glimepiride 3 mg in the morning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>223<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.5</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>448</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>443</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>443</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>425</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>94.9</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0002" title="BetônicoCC , TitanSM , Correa-GiannellaML , NeryM , QueirozM . Comparison of insulin glargine vs. NPH insulin in basal-bolus therapies in T2DM patients and CKD: preliminary results of a prospective, randomized, open-label trial. Diabetes2016;65:A144-5. [CENTRAL: CN-01450000] BetônicoCC , TitanSM , LiraA , PelaesTS , Correa-GiannellaML , NeryM , et al. Insulin glargine U100 improved glycemic control and reduced nocturnal hypoglycemia in patients with type 2 diabetes mellitus and chronic kidney disease stages 3 and 4. Clinical Therapeutics2019;41(10):2008-20. [PMID: 31383366]NCT02451917. Subcutaneous insulin glargine versus NPH insulin in patients with chronic kidney disease stages III and IV: randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02451917 (first received 22 May 2015). ">Betônico 2019</a> </p> <p>(cross‐over RCT, non‐inferiority design)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin glargine in the morning + insulin lispro at mealtime</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>A sample size of 34 participants provided 90% power to detect a mean difference of 0.7% (7.7 mmol/mol) in the primary endpoint (HbA1c), considering a 15% dropout rate and assuming an SD of 0.85% and a type I error of 5%. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>193/40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Period 1 – glargine/period 2 – NPH: 16</p> <p>Period 1 – NPH/period 2 – glargine: 18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After period 1: 16</p> <p>After period 2: 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After period 1: 16</p> <p>After period 2: 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Period 1 – glargine/period 2 – NPH: 14</p> <p>Period 1 – NPH/period 2 – glargine: 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Period 1 – glargine/period 2 – NPH: 87.5</p> <p>Period 1 – NPH/period 2 – glargine: 83.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Cross‐over trial, 6 months per period</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin 3 times daily + insulin lispro at mealtime</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After period 1: 18</p> <p>After period 2: 14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After period 1: 18</p> <p>After period 2: 14</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>34</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>After period 1: 34</b> </p> <p><b>After period 2: 29</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>After period 1: 34</b> </p> <p><b>After period 2: 29</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>29</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>85.3</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0020" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00653341. Effect of insulin glargine in insulin naïve subjects with type 2 diabetes on oral hypoglycemic agent(s). www.clinicaltrials.gov/ct2/show/results/NCT00653341 (first received 4 April 2008). RiddleMC , RosenstockJ , GerichJ , InsulinG . The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care2003;26(11):3080-6. [PMID: 14578243]">Riddle 2003</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin glargine once at bedtime + OAD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Based on previous data, randomisation of 750 participants had the power to provide an 85% chance of detecting, with α = 5%, a 10% treatment effect for the primary outcome measure </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1381/764</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>372</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>367</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>367</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>334</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>24 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin once at bedtime + OAD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>392</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>389</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>389</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>357</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.1</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>764</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>756</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>756</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>691</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>90.4</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0021" title="FonsecaV , BellDS , BergerS , ThomsonS , MeccaTE . A comparison of bedtime insulin glargine with bedtime neutral protamine Hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. American Journal of the Medical Sciences2004;328(5):274-80. [PMID: 15545844]Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. RosenstockJ , SchwartzSL , Clark CM Jr, ParkGD , DonleyDW , EdwardsMB . Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care2001;24(4):631-6. [PMID: 11315821]">Rosenstock 2001</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin glargine once daily at bedtime + premeal regular insulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The study was designed to provide 90% power to detect a mean difference of 0.5% in HbA1c between treatment groups </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>846<sup>g</sup>/— </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>28 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin once at bedtime or twice daily in the morning and at bedtime + premeal regular insulin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.2</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>521</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>518</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>518</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>469</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>90.0</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0022" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. NCT00174824. Comparison of insulin glargine and NPH human insulin in progression of diabetic retinopathy in type 2 diabetic patients. clinicaltrials.gov/ct2/show/study/NCT00174824 (first received 15 September 2005). RosenstockJ , FonsecaV , DainMP , RiddleM . Estimating number-needed-to-treat to avoid hypoglycaemic episodes in people with type 2 diabetes: a post-hoc analysis of a prospective randomized controlled trial comparing once-daily insulin glargine with twice-daily NPH insulin. Canadian Journal of Diabetes2009;33(3):185-6. [EMBASE: 70031352]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia2009;52(9):1778-88. [PMID: 19526210]RosenstockJ , FonsecaV , McGillJB , RiddleM , HalleJP , HramiakI , et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia2009;52(9):1971-3. [PMID: 19609501]RosenstockJ , FonsecaV , SchinzelS , DainMP , MullinsP , RiddleM . Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: evidence from a long-term controlled trial. Journal of Diabetic Complications2014;28(5):742-9. [PMID: 24856612]">Rosenstock 2009</a> </p> <p>(parallel RCT, non‐inferiority design)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin glargine once daily, generally at bedtime</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Sample size was calculated assuming a 20% 5‐year event rate for a ≥ 3 step progression in diabetic retinopathy on the Early Treatment of Diabetic Retinopathy Study scale from baseline to end of study (based on data from the Diabetes Control and Complications Trial), and a non‐inferiority margin of 10% (half of the expected background rate of 20%) was chosen. Assuming that approximately 40% of the randomised participants would not be evaluable, a sample size of 840 randomised participants (420 per group) was calculated to provide at least 80% power for declaring non‐inferiority </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1413/—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>515</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>513</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>513 (ITT); 514<sup>h</sup> (safety population) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>374</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>5 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin twice daily, generally in the morning and at bedtime</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>509</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>504</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>504 (ITT); 503<sup>h</sup> (safety population) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>364</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.5</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>1024</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>1017</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>1017</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>738</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>72.1</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0023" title="Institute for Quality and Efficiency in Health Care (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 2 (IQWiG Reports – Commission No. A05-03). Cologne: Institute for Quality and Efficiency in Health Care (IQWiG), 2009. VarewijckAJ , JanssenJA , VahataloM , HoflandLJ , LambertsSW , Yki-JarvinenH . Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. Diabetologia2012;55(4):1186-94. [PMID: 22237688]VarewijckAJ , JanssenJA , VahataloM , LambertsSW , Ki-JarvinenHY . IGF-I bioactivity decreases during insulin therapy in type 2 diabetic patients: comparison of high doses of insulin glargine and NPH insulin in the LANMET study. In: Endocrine Reviews Conference: 93rd Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 32 (3 Meeting Abstracts). 2011. [EMBASE: 70676865]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJA . Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and IGF-I receptor signaling. Diabetes2013;62(7):2539-44. [PMID: 23569175]VarewijckAJ , Yki-JarvinenH , SchmidtR , TennagelsN , JanssenJAMJL . Comparison of effects of insulin glargine, its metabolites, IGF-I and human insulin on insulin-and IGF-I receptor signaling in type 2 diabetic patients. In: Endocrine Reviews Conference: 95th Annual Meeting and Expo of the Endocrine Society, ENDO. Vol. 34 (3 suppl 1). 2013. [EMBASE: 71784187]Yki-JärvinenH , Kauppinen-MakelinR , TiikkainenM , VahataloM , VirtamoH , Nikkila K et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia2006;49(3):442-51. [PMID: 10937510]">Yki‐Järvinen 2006</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin glargine at bedtime + metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The sample size calculation was based on differences observed in a previous study between 11 insulin‐naive participants treated with NPH and metformin and 12 participants treated with glargine and metformin for 1 year in Helsinki. In this study, HbA1c differed by 0.5% at the end of 1 year; the SDs for the groups were not different and averaged 0.87. The mean HbA1c change for the NPH + metformin group was −0.8 (SE 0.2%) (11 participants), and for the glargine + metformin group it was −1.3 (SE 0.3%) (12 participants) at the end of 1 year. Assuming α = 0.05 and 80% power, the required number of participants per group to observe a difference of 0.5% is 50. To allow for a 10% dropout rate, 110 participants were randomised </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>157/110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>36 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin at bedtime + metformin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98.0</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>110</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>110</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>110</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>108</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>98.2</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD005613-bbs2-0024" title="YokoyamaH , TadaJ , KamikawaF , KannoS , YokotaY , KuramitsuM . Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Research &amp; Clinical Practice2006;73(1):35-40. [PMID: 16513202]">Yokoyama 2006</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: insulin glargine once at breakfast + aspart/lispro at each meal with or without OADs </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—/—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: NPH insulin daily at bedtime + aspart/lispro at each meal with or without OADs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>62</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Overall total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All comparators</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All interventions and comparators</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8677</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>— denotes not reported.</p> <p><sup>a</sup>Follow‐up under randomised conditions until end of trial or if not available, duration of intervention; extended follow‐up refers to follow‐up of participants once the original study was terminated as specified in the power calculation.<br/><sup>b</sup>Modified ITT set for primary endpoint evaluation (including randomised participants with valid values for DRQoL for both treatment periods).<br/><sup>c</sup>Study prematurely discontinued.<br/><sup>d</sup>Participants with type 1 and type 2 diabetes.<br/><sup>e</sup>3 participants not randomised due to protocol violations.<br/><sup>f</sup>Safety population: 444 participants.<br/><sup>g</sup>According to European Medical Agency report.<br/><sup>h</sup>1 participant who was randomised to receive NPH insulin received insulin glargine throughout the study, and was consequently counted in the ITT population as an NPH participant, but in the safety population as an insulin glargine participant, leading to a discrepancy in the numbers for the ITT and safety populations in both the insulin glargine and NPH insulin arms. </p> <p>C: comparator; CI: confidence interval; DRQoL: diabetes‐related quality of life; HbA1c: glycosylated haemoglobin A1c; I: intervention; ITEQ: Insulin Therapy Experience Questionnaire; ITT: intention‐to‐treat; n: number of participants; NPH: neutral protamine Hagedorn; OAD: oral antihyperglycaemic drug; PAID: Problem Areas In Diabetes; RCT: randomised controlled trial; SD: standard deviation; SE: standard error; SF‐12: 12‐item Short Form Health Survey. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of trial populations</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/full#CD005613-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005613-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Insulin glargine versus NPH insulin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Diabetes‐related complications (progression in retinopathy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1947</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.60, 1.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Severe hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.46, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Serious hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4685</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.52, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Confirmed hypoglycaemia (blood glucose (BG) &lt; 75 mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.85, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Confirmed hypoglycaemia (BG &lt; 55 mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.81, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Confirmed nocturnal hypoglycaemia (BG &lt; 75 mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.68, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Confirmed nocturnal hypoglycaemia (BG &lt; 55 mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.64, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.62, 1.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Adverse events other than hypoglycaemia (serious adverse effects) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.87, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Adverse events other than hypoglycaemia (all adverse events (AE)) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.98, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Adverse events other than hypoglycaemia (AEs leading to discontinuation) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.84, 1.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Adverse events other than hypoglycaemia (weight gain) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2405</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.02, 0.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Adverse events other than hypoglycaemia (skin reactions) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4735</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.83, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Adverse events other than hypoglycaemia (eye related AEs) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.86, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Glycosylated haemoglobin (HbA1c) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5809</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.18, 0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Insulin glargine versus NPH insulin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/references#CD005613-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005613-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Insulin detemir vs NPH insulin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Diabetes‐related complications (progression in retinopathy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>972</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.68, 3.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Severe hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1804</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.17, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Serious hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1777</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.04, 0.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Confirmed hypoglycaemia (blood glucose (BG) &lt; 75 mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.61, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Confirmed hypoglycaemia (BG &lt; 55 mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.32, 0.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Confirmed nocturnal hypoglycaemia (BG &lt; 75 mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.47, 0.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Confirmed nocturnal hypoglycaemia (BG &lt; 55 mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.16, 0.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2328</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.20, 2.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Adverse events other than hypoglycaemia (serious adverse events) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2328</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.64, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Adverse events other than hypoglycaemia (all adverse events (AE)) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2328</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.96, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Adverse events other than hypoglycaemia (AEs leading to discontinuation) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2328</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.67, 2.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.12 Adverse events other than hypoglycaemia (skin reactions) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1777</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.63, 2.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.13 Adverse events other than hypoglycaemia (eye‐related AEs) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.41, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.14 Glycosylated haemoglobin (HbA1c) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [‐0.02, 0.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Insulin detemir vs NPH insulin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005613.pub4/references#CD005613-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD005613.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD005613-note-0008">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD005613-note-0014">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD005613-note-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD005613-note-0013">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD005613-note-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="th#CD005613-note-0010">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD005613-note-0009">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005613\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005613\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005613\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005613\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005613\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005613\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005613\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005613\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005613\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005613\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005613\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005613\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005613\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005613\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005613\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005613\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005613\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005613\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=eLIOL3Be&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005613.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005613.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD005613.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD005613.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005613.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714814750"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005613.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714814754"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005613.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d77dc699b937d',t:'MTc0MDcxNDgxOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 